<SEC-DOCUMENT>0001193125-18-207818.txt : 20180628
<SEC-HEADER>0001193125-18-207818.hdr.sgml : 20180628
<ACCEPTANCE-DATETIME>20180628171126
ACCESSION NUMBER:		0001193125-18-207818
CONFORMED SUBMISSION TYPE:	DEF 14A
PUBLIC DOCUMENT COUNT:		5
CONFORMED PERIOD OF REPORT:	20180807
FILED AS OF DATE:		20180628
DATE AS OF CHANGE:		20180628
EFFECTIVENESS DATE:		20180628

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Wave Life Sciences Ltd.
		CENTRAL INDEX KEY:			0001631574
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				000000000
		STATE OF INCORPORATION:			U0
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		DEF 14A
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-37627
		FILM NUMBER:		18926242

	BUSINESS ADDRESS:	
		STREET 1:		7 STRAITS VIEW
		STREET 2:		#12-00, MARINA ONE EAST TOWER
		CITY:			SINGAPORE
		STATE:			U0
		ZIP:			018936
		BUSINESS PHONE:		617-949-2900

	MAIL ADDRESS:	
		STREET 1:		733 CONCORD AVENUE
		CITY:			CAMBRIDGE
		STATE:			MA
		ZIP:			02138

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	WAVE Life Sciences Ltd.
		DATE OF NAME CHANGE:	20170516

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	Wave Life Sciences Ltd.
		DATE OF NAME CHANGE:	20151106

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	Wave Life Sciences LTD.
		DATE OF NAME CHANGE:	20151106
</SEC-HEADER>
<DOCUMENT>
<TYPE>DEF 14A
<SEQUENCE>1
<FILENAME>d589845ddef14a.htm
<DESCRIPTION>DEF 14A
<TEXT>
<HTML><HEAD>
<TITLE>DEF 14A</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="margin-top:3pt; margin-bottom:0pt; font-size:16pt; font-family:Times New Roman" ALIGN="center"><B>UNITED STATES </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:16pt; font-family:Times New Roman" ALIGN="center"><B>SECURITIES AND EXCHANGE COMMISSION </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>WASHINGTON, D.C. 20549 </B></P> <P STYLE="font-size:5pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:5pt; margin-bottom:0pt; font-size:16pt; font-family:Times New Roman" ALIGN="center"><B>SCHEDULE 14A
</B></P> <P STYLE="margin-top:5pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Proxy Statement Pursuant to Section&nbsp;14(a) of the </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Securities Exchange Act of 1934 </B></P> <P STYLE="font-size:5pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:5pt; margin-bottom:0pt; font-size:9pt; font-family:Times New Roman">Filed by the
Registrant&nbsp;&nbsp;&#9746;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Filed by a Party other than the
Registrant&nbsp;&nbsp;&#9744; </P> <P STYLE="margin-top:5pt; margin-bottom:0pt; font-size:9pt; font-family:Times New Roman">Check the appropriate box: </P> <P STYLE="font-size:5pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="4%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="95%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top"><FONT STYLE="font-size:10pt">&#9744;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Preliminary Proxy Statement</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top"><FONT STYLE="font-size:10pt">&#9744;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>Confidential, for Use of the Commission Only (as permitted by Rule <FONT STYLE="white-space:nowrap">14a-6(e)(2))</FONT></B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top"><FONT STYLE="font-size:10pt">&#9746;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Definitive Proxy Statement</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top"><FONT STYLE="font-size:10pt">&#9744;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Definitive Additional Materials</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top"><FONT STYLE="font-size:10pt">&#9744;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Soliciting Material Under Rule <FONT STYLE="white-space:nowrap">14a-12</FONT></TD></TR>
</TABLE> <P STYLE="margin-top:5pt; margin-bottom:0pt; font-size:20pt; font-family:Times New Roman" ALIGN="center"><B>WAVE LIFE SCIENCES LTD. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:Times New Roman" ALIGN="center"><B>(Name of Registrant as Specified In Its Charter) </B></P> <P STYLE="font-size:5pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(Name of Person(s) Filing Proxy Statement, if other than the Registrant) </B></P>
<P STYLE="margin-top:5pt; margin-bottom:0pt; font-size:9pt; font-family:Times New Roman">Payment of Filing Fee (Check the appropriate box): </P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:9pt" ALIGN="center">


<TR>
<TD WIDTH="4%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="4%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="90%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"><FONT STYLE="font-size:9pt">&#9746;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" COLSPAN="3"><FONT STYLE="font-size:9pt">No fee required.</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"><FONT STYLE="font-size:9pt">&#9744;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" COLSPAN="3"><FONT STYLE="font-size:9pt">Fee computed on table below per Exchange Act Rules <FONT STYLE="white-space:nowrap">14a-6(i)(1)</FONT> and <FONT STYLE="white-space:nowrap">0-11.</FONT></FONT></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"><FONT STYLE="font-size:10pt">1)</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:Times New Roman">Title of each class of securities to which transaction applies:</P> <P STYLE="font-size:3pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:9pt; font-family:Times New Roman">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"><FONT STYLE="font-size:10pt">2)</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:Times New Roman">Aggregate number of securities to which transaction applies:</P> <P STYLE="font-size:3pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:9pt; font-family:Times New Roman">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"><FONT STYLE="font-size:10pt">3)</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:Times New Roman">Per unit price or other underlying value of transaction computed pursuant to Exchange Act Rule <FONT STYLE="white-space:nowrap">0-11</FONT>
(set forth the amount on which the filing fee is calculated and state how it was determined):</P> <P STYLE="font-size:3pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:9pt; font-family:Times New Roman">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"><FONT STYLE="font-size:10pt">4)</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:Times New Roman">Proposed maximum aggregate value of transaction:</P> <P STYLE="font-size:3pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:9pt; font-family:Times New Roman">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"><FONT STYLE="font-size:10pt">5)</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:Times New Roman">Total fee paid:</P> <P STYLE="font-size:3pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:9pt; font-family:Times New Roman">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top"><FONT STYLE="font-size:10pt">&#9744;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" COLSPAN="3">Fee paid previously with preliminary materials.</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top"><FONT STYLE="font-size:10pt">&#9744;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" COLSPAN="3">Check box if any part of the fee is offset as provided by Exchange Act Rule <FONT STYLE="white-space:nowrap">0-11(a)(2)</FONT> and identify the filing for which the offsetting fee was paid previously. Identify the
previous filing by registration statement number, or the Form or Schedule and the date of its filing:</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"><FONT STYLE="font-size:10pt">1)</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:Times New Roman">Amount previously paid:</P> <P STYLE="font-size:3pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:9pt; font-family:Times New Roman">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"><FONT STYLE="font-size:10pt">2)</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:Times New Roman">Form, Schedule or Registration Statement No:</P> <P STYLE="font-size:3pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:9pt; font-family:Times New Roman">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"><FONT STYLE="font-size:10pt">3)</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:Times New Roman">Filing party:</P> <P STYLE="font-size:3pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:9pt; font-family:Times New Roman">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"><FONT STYLE="font-size:10pt">4)</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:Times New Roman">Date Filed:</P> <P STYLE="font-size:3pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:9pt; font-family:Times New Roman">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</P></TD></TR>
</TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>WAVE LIFE SCIENCES LTD. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(Incorporated in the Republic of Singapore) </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(Company Registration Number 201218209G) </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>NOTICE OF 2018 ANNUAL GENERAL MEETING OF SHAREHOLDERS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>TIME</B>: 11:00 a.m., Eastern Time </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>DATE</B>:
August&nbsp;7, 2018 </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>PLACE</B>: Wave Life Sciences Ltd., 733 Concord Avenue, Cambridge, MA 02138 </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">To Our Shareholders: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">You are cordially invited
to attend the 2018 Annual General Meeting of Shareholders of Wave Life Sciences Ltd. to be held at 11:00 a.m., Eastern Time, on Tuesday, August&nbsp;7, 2018 at 733 Concord Avenue, Cambridge, MA 02138. In this Notice, we refer to the 2018 Annual
General Meeting of Shareholders as the &#147;2018 AGM&#148; and we refer to Wave Life Sciences Ltd. as the &#147;Company,&#148; &#147;we,&#148; &#147;us&#148; and &#147;our.&#148; Details regarding the 2018 AGM, the business to be conducted at the
2018 AGM, and information about Wave Life Sciences Ltd. that you should consider when you vote your shares are described in the attached proxy statement. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The 2018 AGM will be held for the following purposes: </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><U>As Special Business </U></B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">1.</TD>
<TD ALIGN="left" VALIGN="top">(a)&nbsp;&nbsp;&nbsp;To elect Paul B. Bolno, M.D. to serve on the Board of Directors; <B> </B></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>(Ordinary Resolution 1(a)) </B></P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(b)</TD>
<TD ALIGN="left" VALIGN="top">To elect Christian Henry to serve on the Board of Directors; <B> </B></TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>(Ordinary Resolution
1(b)) </B></P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(c)</TD>
<TD ALIGN="left" VALIGN="top">To elect Peter&nbsp;Kolchinsky, Ph.D. to serve on the Board of Directors; <B> </B></TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>(Ordinary
Resolution 1(c)) </B></P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(d)</TD>
<TD ALIGN="left" VALIGN="top">To elect Koji Miura to serve on the Board of Directors; <B> </B></TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>(Ordinary Resolution 1(d))
</B></P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(e)</TD>
<TD ALIGN="left" VALIGN="top">To elect Adrian Rawcliffe to serve on the Board of Directors; <B> </B></TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>(Ordinary Resolution
1(e)) </B></P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(f)</TD>
<TD ALIGN="left" VALIGN="top">To elect Ken Takanashi to serve on the Board of Directors; <B> </B></TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>(Ordinary Resolution 1(f))
</B></P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(g)</TD>
<TD ALIGN="left" VALIGN="top">To elect Gregory L. Verdine, Ph.D. to serve on the Board of Directors; <B> </B></TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>(Ordinary
Resolution 1(g)) </B></P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><U>As Ordinary Business </U></B></P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">2.</TD>
<TD ALIGN="left" VALIGN="top">To approve the <FONT STYLE="white-space:nowrap">re-appointment</FONT> of KPMG LLP to serve as our independent registered public accounting firm and independent Singapore auditor for the year ending December&nbsp;31,
2018, and to authorize the Audit Committee of the Board of Directors to fix KPMG LLP&#146;s remuneration for services provided through the date of our 2019 Annual General Meeting of Shareholders; <B> </B></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>(Ordinary Resolution 2) </B></P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">3.</TD>
<TD ALIGN="left" VALIGN="top">To approve the Company&#146;s payment of cash and equity-based compensation to <FONT STYLE="white-space:nowrap">non-employee</FONT> directors for service on the Board and its committees, in the manner and on the basis
as set forth under &#147;Proposal&nbsp;3: <FONT STYLE="white-space:nowrap">Non-Employee</FONT> Directors&#146; Compensation&#148; in the attached proxy statement; <B> </B></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>(Ordinary Resolution 3) </B></P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><U>As Special Business </U></B></P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">4.</TD>
<TD ALIGN="left" VALIGN="top">Pursuant to the provisions of Section&nbsp;161 of the Singapore Companies Act (the &#147;Singapore Companies Act&#148;), Chapter 50, and also subject to the provisions of the Singapore Companies Act and our
Constitution, authority be, and hereby is, given to our Board of Directors: </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(a)</TD>
<TD ALIGN="left" VALIGN="top">to: </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="13%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(i)</TD>
<TD ALIGN="left" VALIGN="top">allot and issue ordinary shares in our capital; and/or </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="13%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(ii)</TD>
<TD ALIGN="left" VALIGN="top">make or grant offers, agreements, options or other instruments (including the grant of awards or options pursuant to our equity-based incentive plans and agreements in effect from time to time) that might or would
require ordinary shares to be allotted and issued, whether such allotment or issuance would occur during or after the expiration of this authority (including but not limited to, the creation and issuance of warrants, rights, units, purchase
contracts, debentures or other instruments (including debt instruments) convertible into or exercisable for ordinary shares), </TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:8%; font-size:10pt; font-family:Times New Roman">at any time to and/or with such persons and upon such terms and conditions, for such purposes and for consideration as our directors may in
their sole discretion deem fit, and with such rights or restrictions as our directors may think fit to impose and as are set forth in our Constitution; and </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(b)</TD>
<TD ALIGN="left" VALIGN="top">to allot and issue ordinary shares in our capital pursuant to any offer, agreement, option or other agreement made, granted or authorized by our directors while this resolution was in effect, regardless of whether the
authority conferred by this resolution may have ceased to be in effect at the time of the allotment and issuance, </TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:8%; font-size:10pt; font-family:Times New Roman">and that
such authority, if approved by our shareholders, shall continue in effect until the earlier of the conclusion of our 2019 Annual General Meeting of Shareholders or the expiration of the period within which our 2019 Annual General Meeting of
Shareholders is required by law to be held; and &nbsp;&nbsp;&nbsp;&nbsp; </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>(Ordinary Resolution 4) </B></P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">5.</TD>
<TD ALIGN="left" VALIGN="top">To transact such other business as may properly come before the 2018 AGM and all adjournments or postponements thereof. </TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Board of Directors recommends the approval of each of the first four proposals. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">All of the above proposals should be read in conjunction with the attached proxy statement, which sets out the specific parameters of the
proposals. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Each of the matters to be voted on at the 2018 AGM may be passed by ordinary resolution pursuant to our Constitution. </P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><U>Notes About the Annual General Meeting of Shareholders </U></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Eligibility to Vote at 2018 AGM</I>. The Board of Directors has fixed the close of business on June&nbsp;22, 2018 as the record date for
determining those shareholders who will be entitled to receive copies of this Notice and the attached proxy statement. However, under Singapore law, only registered holders of our ordinary shares (i.e., persons whose names appear on the Register of
Members of the Company maintained in accordance with Section&nbsp;190 of the Singapore Companies Act), or &#147;shareholders of record,&#148; on the date of the 2018 AGM, August&nbsp;7, 2018, will be entitled to vote at the 2018 AGM. If you have
sold or transferred any of your ordinary shares after June&nbsp;22, 2018 and prior to the 2018 AGM, you should immediately forward this Notice and the attached proxy statement and proxy card to the purchaser or transferee of such shares, or to the
bank, broker or agent through whom the sale of such shares was effected, for onward transmission to the purchaser or transferee. If you hold shares other than in registered form as a shareholder of record, and instead hold your shares as, or
through, a participant in DTC (i.e., in &#147;street name&#148;), we understand that in order for your vote to be counted at the 2018 AGM, you must also have been a holder of shares at, and with effect from, June&nbsp;22, 2018. As of
June&nbsp;15,&nbsp;2018, we had 29,293,050 ordinary shares issued and outstanding. </P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Proxies</I>. All shareholders of record as of the date of the 2018 AGM are cordially invited
to attend the 2018 AGM or appoint a proxy to attend and vote in their place (referred to as a &#147;legal proxy&#148;). A legal proxy need not also be a shareholder of record. <B>Whether you plan to attend the 2018 AGM or not, we urge you to vote
and submit your proxy card by mail in order to ensure the presence of a quorum.</B> A proxy card must be received by Vote Processing, c/o Broadridge, 51 Mercedes Way, Edgewood, NY 11717 not less than 48 hours before the time appointed for holding
the 2018 AGM or within such other time as may be required by the Singapore Companies Act. Completion and submission of the proxy card shall not preclude a shareholder of record from attending and voting at the 2018 AGM. Any appointment of a legal
proxy or proxies will be revoked if a shareholder of record attends and votes in person at the 2018 AGM, and in such event, we reserve the right to refuse to admit any person or persons appointed under the instrument of proxy or proxies to the
meeting. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">For the avoidance of doubt, the reference to &#147;proxy&#148; in this Notice does not mean a &#147;legal proxy&#148; entitled
under Singapore law to attend and vote on behalf of a shareholder of record. The reference to &#147;soliciting your proxy&#148; means that a shareholder of record may appoint the persons identified on the proxy card as such shareholder&#146;s legal
proxies to vote in accordance with such shareholder&#146;s instructions given via proxy or to authorize such persons to vote freely. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Beneficial or &#147;Street Name&#148; Holders</I>. If your shares are held in &#147;street name&#148; (i.e., in the name of a bank, broker
or other shareholder of record), you will receive instructions from the shareholder of record. You must follow the instructions of the shareholder of record in order for your shares to be voted. If your shares are not registered in your own name and
you plan to vote your shares in person at the 2018 AGM, you should contact your broker or agent to obtain a legal proxy or broker&#146;s proxy card and bring it to the 2018 AGM in order to vote as a legal proxy. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Singapore Audited Accounts</I>. At the 2018 AGM, our shareholders will have the opportunity to discuss and ask questions regarding our
Singapore audited accounts for the fiscal year ended December&nbsp;31, 2017, together with the directors&#146; statement and independent auditors&#146; report thereon, in compliance with the laws of Singapore. Shareholder approval of our Singapore
audited accounts is not being sought by the attached proxy statement and will not be sought at the 2018 AGM. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">When you have finished
reading the attached proxy statement, you are urged to vote in accordance with the instructions set forth in the proxy statement. We encourage you to vote by proxy so that your shares will be represented and voted at the 2018 AGM, whether or not you
can attend. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Thank you for your continued support of Wave Life Sciences Ltd. </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>
<TD WIDTH="46%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="5%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="47%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">BY ORDER OF THE BOARD OF DIRECTORS</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">


<IMG SRC="g589845g65t06.jpg" ALT="LOGO">
</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"><FONT STYLE="font-size:10pt">June&nbsp;28, 2018</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:10pt">Paul B. Bolno, M.D.</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Director, President and Chief Executive Officer</TD></TR>
</TABLE>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><U><A NAME="toc"></A>TABLE OF CONTENTS </U></B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="93%"></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>PAGE</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc589845_1">Important Information About the Annual General Meeting of Shareholders and Voting
</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc589845_2">Security Ownership of Certain Beneficial Owners and Management</A></P></TD>

<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">8</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc589845_3">Management and Corporate Governance</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">11</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc589845_4">Executive Officer and Director Compensation</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">19</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc589845_5">Equity Compensation Plan Information</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">25</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc589845_6">Report of Audit Committee</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">26</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc589845_7">Section&nbsp;16(a) Beneficial Ownership Reporting Compliance</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">27</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc589845_8">Certain Relationships and Related Person Transactions</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">27</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc589845_9">Proposal 1: Election of Directors</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">31</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc589845_10">Proposal 2: Independent Registered Public Accounting Firm and Independent Singapore
 Auditor and Auditor Remuneration</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">32</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc589845_11">Proposal 3: <FONT STYLE="white-space:nowrap">Non-Employee</FONT> Directors&#146;
 Compensation</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">34</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc589845_12">Proposal 4: Ordinary Share Allotments and Issuances</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">36</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc589845_13">Code of Business Conduct and Ethics</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">38</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc589845_14">Other Matters</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">38</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc589845_15">Shareholder Proposals and Nominations For Director</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">38</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"><B><U>Appendices</U></B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"><A HREF="#toc589845_16">Appendix A &#150; Singapore Statutory Financial Statements for the year ended December&nbsp;31, 2017 </A></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">A-1</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">i </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>IMPORTANT NOTICE REGARDING THE AVAILABILITY OF PROXY MATERIALS </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>FOR THE ANNUAL GENERAL MEETING OF SHAREHOLDERS </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>TO BE HELD ON AUGUST&nbsp;7, 2018 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>The Notice, this proxy statement and our 2017 annual report to shareholders are available for viewing, printing and downloading
at&nbsp;https://materials.proxyvote.com/. You can elect to receive distributions of our proxy statements and annual reports to shareholders for future annual general meetings by electronic delivery. For specific instructions on making such an
election, please refer to the instructions on the proxy card or voting instruction form. </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">At no charge, we are providing each person
from whom a proxy is solicited a copy of, and access to, our Annual Report on Form <FONT STYLE="white-space:nowrap">10-K</FONT> for the fiscal year ended December&nbsp;31, 2017, as amended, or our &#147;2017 Form
<FONT STYLE="white-space:nowrap">10-K.&#148;</FONT> Additionally, you can find a copy of our 2017 Form <FONT STYLE="white-space:nowrap">10-K</FONT> on the website of the Securities and Exchange Commission, or the &#147;SEC,&#148; at www.sec.gov, or
in the &#147;For Investors&nbsp;&amp; Media&#148; section of our website at http://ir.wavelifesciences.com/ under the heading &#147;Financial Information.&#148; You may also obtain a printed copy of our 2017 Form
<FONT STYLE="white-space:nowrap">10-K,</FONT> free of charge, from us by sending a written request to Investor Relations, Wave Life Sciences Ltd., 733 Concord Avenue, Cambridge, MA 02138 or by email to&nbsp;IR@wavelifesci.com. Exhibits to our 2017
Form <FONT STYLE="white-space:nowrap">10-K</FONT> will be provided upon written request and payment of an appropriate processing fee. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The
information provided on our website (www.wavelifesciences.com) is referenced in this proxy statement for information purposes only. The information on our website shall not be deemed to be a part of or incorporated by reference into this proxy
statement or any other filings we make with the SEC or any solicitation of proxies by us. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">ii </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>WAVE LIFE SCIENCES LTD. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>733 CONCORD AVENUE </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>CAMBRIDGE, MA 02138 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>PROXY STATEMENT FOR THE WAVE LIFE SCIENCES LTD. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>2018 ANNUAL GENERAL MEETING OF SHAREHOLDERS </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>TO BE HELD ON AUGUST&nbsp;7, 2018 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This proxy statement, along with the accompanying Notice of 2018 Annual General Meeting of Shareholders, or the &#147;Notice,&#148; contains
information about the 2018 Annual General Meeting of Shareholders of Wave Life Sciences Ltd. (including any adjournments or postponements thereof), which we refer to in this proxy statement as the &#147;2018 AGM.&#148; We are holding the 2018 AGM at
11:00 a.m., Eastern Time, on Tuesday, August&nbsp;7, 2018, at 733 Concord Avenue, Cambridge, MA 02138. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In this proxy statement, we refer
to Wave Life Sciences Ltd. as the &#147;Company,&#148; &#147;we,&#148; &#147;us&#148; and &#147;our.&#148; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This proxy statement relates
to the solicitation of proxies by our Board of Directors for use at the 2018 AGM. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On or about July&nbsp;2, 2018, we began sending this
proxy statement, the Notice and the enclosed proxy card to shareholders of record as of June&nbsp;22, 2018. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Although not part of this
proxy statement, we are also sending, along with this proxy statement, our 2017 annual report to shareholders, which includes our financial statements for the fiscal year ended December&nbsp;31, 2017. Except as otherwise stated herein, all monetary
amounts in this proxy statement have been presented in U.S. dollars. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">1 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc589845_1"></A>IMPORTANT INFORMATION ABOUT THE </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ANNUAL GENERAL MEETING OF SHAREHOLDERS AND VOTING </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Why is the Company Soliciting My Proxy? </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Board of Directors of Wave Life Sciences Ltd. is soliciting your proxy to vote at the 2018 Annual General Meeting of Shareholders to be
held at 733 Concord Avenue, Cambridge, MA 02138 on Tuesday, August&nbsp;7, 2018, at 11:00 a.m., Eastern Time, and any adjournments or postponements of the 2018 AGM. This proxy statement, along with the Notice, summarizes the purposes of the meeting
and the information you need to know to vote at the 2018 AGM. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We have made available to you on the Internet or have sent you this proxy
statement, the Notice, the proxy card, and our 2017 annual report to shareholders because you owned ordinary shares of Wave Life Sciences Ltd. on the record date for determining those shareholders who will be entitled to receive copies of the Notice
and this proxy statement. We began distributing the proxy materials to shareholders on or about July&nbsp;2, 2018. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">For the avoidance of
doubt, the reference to &#147;proxy&#148; in this proxy statement does not mean a &#147;legal proxy&#148; entitled under Singapore law to attend and vote on behalf of a shareholder of record. The reference to &#147;soliciting your proxy&#148; means
that a shareholder of record may appoint the persons identified on the proxy card as such shareholder&#146;s legal proxy to vote in accordance with such shareholder&#146;s instructions given via proxy or to authorize such persons to vote freely.
</P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Who Can Vote? </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Board of
Directors has fixed the close of business on June&nbsp;22, 2018 as the record date for determining those shareholders who will be entitled to receive copies of the Notice and this proxy statement. However, under Singapore law, only registered
holders of our ordinary shares, or &#147;shareholders of record,&#148; on the date of the 2018 AGM, August&nbsp;7, 2018, will be entitled to vote at the 2018 AGM. If you have sold or transferred any of your ordinary shares after the record date of
June&nbsp;22,&nbsp;2018 and prior to the 2018 AGM, you should immediately forward the Notice, this proxy statement and the proxy card to the purchaser or transferee of such shares, or to the bank, broker or agent through whom the sale of such shares
was effected, for onward transmission to the purchaser or transferee. If you hold shares other than in registered form as a shareholder of record, and instead hold your shares as, or through, a participant in DTC (i.e., in &#147;street name&#148;),
we understand that in order for your vote to be counted at the 2018 AGM (represented by a shareholder of record), you must also have been a holder of shares at, and with effect from, June&nbsp;22, 2018 through the date of the 2018 AGM. As of
June&nbsp;15, 2018, we had 29,293,050 ordinary shares issued and outstanding. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">All shareholders of record as of the date of the 2018 AGM
are cordially invited to attend the 2018 AGM or appoint a legal proxy to attend and vote in their place. A legal proxy need not also be a shareholder of record. <B>Whether you plan to attend the 2018 AGM or not, we urge you to vote and submit your
proxy card by mail in order to ensure the presence of a quorum. </B>A proxy card must be received by Vote Processing, c/o Broadridge, 51 Mercedes Way, Edgewood, NY 11717 not less than 48 hours before the time appointed for holding the 2018 AGM or
within such other time as may be required by the Singapore Companies Act. Completion and submission of the proxy card shall not preclude a shareholder of record from attending and voting at the 2018 AGM. Any appointment of a legal proxy or proxies
will be revoked if a shareholder of record attends the 2018 AGM in person, and in such event, we reserve the right to refuse to admit any person or persons appointed under the instrument of proxy or proxies to the meeting. Shareholders of record may
change or revoke their legal proxies at any time before their shares are voted at the 2018 AGM. For instructions on how to change or revoke your legal proxy, see &#147;May I Change or Revoke My Proxy?&#148; below. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>How Many Votes Do I Have? </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Each ordinary
share that you own or represent as a legal proxy entitles you to one vote at the 2018 AGM. The Series A preferred shares of the Company are not entitled to vote on any of the matters being proposed at the 2018 AGM. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">2 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>How Do I Vote? </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If you are not planning to attend the 2018 AGM, we urge you to vote by proxy. All shares represented by valid proxies that we receive through
this solicitation, and that are not revoked, will be voted in accordance with your instructions on the proxy card. You may specify whether your shares should be voted for, against or abstain for each nominee for director, and whether your shares
should be voted for, against or abstain with respect to each of the other proposals. If you properly submit a proxy card without giving specific voting instructions, your shares will be voted in accordance with the Board&#146;s recommendations as
noted below, except as described under &#147;Will My Shares be Voted if I Do Not Vote or Provide Voting Instructions?&#148; Voting by proxy will not affect your right to attend the 2018 AGM. If you are a shareholder of record such that your shares
are registered directly in your name through our transfer agent, Computershare Trust Company, N.A., or you have share certificates registered in your name, you may vote: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"><B>By mail.</B> If you received a proxy card by mail, you can vote by mail by completing, signing, dating and returning the proxy card as instructed on the card. If you sign the proxy card but do not specify how you
want your shares voted, they will be voted in accordance with the Board&#146;s recommendations as noted below. </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"><B>In person at the meeting.</B> If you attend the meeting, you may vote by completing a ballot, which will be available at the meeting. </TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">A proxy card must be received by Vote Processing, c/o Broadridge, 51 Mercedes Way, Edgewood, NY 11717 not less than 48 hours before the time
appointed for holding the 2018 AGM or within such other time as may be required by the Singapore Companies Act. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If your shares are held
in &#147;street name&#148; (i.e., in the name of a bank, broker or other shareholder of record), you will receive instructions from the shareholder of record. You must follow the instructions of the shareholder of record in order for your shares to
be voted. If your shares are not registered in your own name and you plan to vote your shares in person at the 2018 AGM, you should contact your broker or agent to obtain a legal proxy or broker&#146;s proxy card and bring it to the 2018 AGM in
order to vote. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>How Does the Board of Directors Recommend That I Vote on the Proposals? </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Board of Directors recommends that you vote as follows: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">&#147;<B><U>FOR</U></B>&#148; each of the resolutions for the election of the nominees for director; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">&#147;<B><U>FOR</U></B>&#148; the approval of the <FONT STYLE="white-space:nowrap">re-appointment</FONT> of KPMG LLP as our independent registered public accounting firm and independent Singapore auditor for the year
ending December&nbsp;31, 2018 and the authorization of the Audit Committee of the Board of Directors to fix KPMG LLP&#146;s remuneration for services provided through the date of our 2019 Annual General Meeting of Shareholders; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">&#147;<B><U>FOR</U></B>&#148; the approval of cash and equity-based compensation to be paid to the <FONT STYLE="white-space:nowrap">non-employee</FONT> members of the Board of Directors for service on the Board and its
committees, as described under &#147;Proposal 3: <FONT STYLE="white-space:nowrap">Non-Employee</FONT> Directors&#146; Compensation&#148;; and </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">&#147;<B><U>FOR</U></B>&#148; the authorization of the Board of Directors to allot and issue ordinary shares of the Company. </TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If any other matter is presented at the 2018 AGM, your proxy card provides that your shares will be voted by the proxy holder listed in the
proxy card in accordance with his or her judgment. At the time this proxy statement was first made available, we knew of no matters that needed to be acted on at the 2018 AGM, other than those discussed in this proxy statement. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">3 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>May I Change or Revoke My Proxy? </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If you give us your proxy, you may change or revoke it at any time before the 2018 AGM in any one of the following ways: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">if you received a proxy card, by signing and submitting a new proxy card with a date later than your previously delivered proxy card, which must be received by Vote Processing, c/o Broadridge, 51 Mercedes Way, Edgewood,
NY 11717 not less than 48 hours before the time appointed for holding the 2018 AGM or within such other time as may be required by the Singapore Companies Act; or </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">by attending the 2018 AGM in person and voting in person. Attending the 2018 AGM in person will not in and of itself revoke a previously submitted proxy. You must specifically request at the 2018 AGM that your
previously submitted proxy be revoked. </TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Your most current vote is the one that will be counted. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>What if I Receive More Than One Proxy Card? </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">You may receive more than one proxy card if you hold any of our ordinary shares in more than one account, which may be in registered form or
held in street name. Please vote in the manner described above under &#147;How Do I Vote?&#148; for each account to ensure that all of your shares are voted. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Will My Shares be Voted if I Do Not Vote or Provide Voting Instructions? </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If your shares are registered in your name or if you have share certificates, they will not be counted if you do not vote as described above
under &#147;How Do I Vote?&#148; If your shares are held in street name and you do not provide voting instructions to the bank, broker or other nominee that holds your shares as described above, the bank, broker or other nominee that holds your
shares has the authority to vote your unvoted shares without receiving instructions from you on all of the proposals to be voted on at the 2018 AGM, other than the election of directors (Proposal&nbsp;1), and the approval of <FONT
STYLE="white-space:nowrap">non-employee</FONT> directors&#146; compensation (Proposal&nbsp;3). We encourage you to provide voting instructions to your bank, broker or other nominee to ensure your shares will be voted at the 2018 AGM and in the
manner you desire. A &#147;broker <FONT STYLE="white-space:nowrap">non-vote&#148;</FONT> will occur if your broker cannot vote your shares on a particular matter because it has not received instructions from you and does not have discretionary
voting authority on that matter or because your broker chooses not to vote on a matter for which it does have discretionary voting authority. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>What
Vote is Required to Approve Each Proposal and How are Votes Counted? </B></P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR VALIGN="TOP">
<TD WIDTH="38%"> <P STYLE=" margin-top:0pt; margin-bottom:1pt; margin-left:2%; text-indent:0%; font-size:10pt; font-family:Times New Roman"><B>Proposal 1: Elect Directors</B> </P></TD>
<TD>Each nominee for director who receives the affirmative vote of a majority of the votes cast by the holders of ordinary shares voting either in person or by proxy at the 2018 AGM will be elected to serve until the next annual general meeting of
shareholders (meaning the number of shares voted &#147;for&#148; a nominee must exceed the number of shares voted &#147;against&#148; such nominee). </TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="38%">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">You may vote either &#147;for&#148; or &#147;against&#148; each of the nominees, or you may &#147;abstain&#148; from voting for one or more nominees. If you &#147;abstain&#148; from voting with respect to one or more
nominees, your vote will have no effect on the election of such nominees. Brokerage firms do not have authority to vote customers&#146; unvoted shares held by the firms in street name with respect to this proposal. As a result, any shares not voted
by a customer will be treated as a broker <FONT STYLE="white-space:nowrap">non-vote.</FONT> Such broker <FONT STYLE="white-space:nowrap">non-votes</FONT> will have no effect on the results of this vote. </TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">4 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR VALIGN="TOP">
<TD WIDTH="38%"> <P STYLE=" margin-top:0pt; margin-bottom:1pt; margin-left:2%; text-indent:0%; font-size:10pt; font-family:Times New Roman"><B>Proposal 2: Approve the <FONT STYLE="white-space:nowrap">Re-Appointment</FONT> of Independent Registered
Public Accounting Firm and Independent Singapore Auditor and Authorize the Auditor&#146;s Remuneration </B></P></TD>
<TD>The affirmative vote of a majority of the votes cast by holders of ordinary shares voting in person or by proxy at the 2018 AGM is required to approve the <FONT STYLE="white-space:nowrap">re-appointment</FONT> of KPMG LLP as our independent
registered public accounting firm and our independent Singapore auditor and to authorize the Audit Committee to fix the auditor&#146;s remuneration (meaning the number of shares voted &#147;for&#148; the proposal must exceed the number of shares
voted &#147;against&#148; the proposal). </TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="38%">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">You may vote either &#147;for&#148; or &#147;against&#148; or &#147;abstain&#148; from voting on this proposal. Abstentions will have no effect on the results of this vote. Brokerage firms have authority to vote
customers&#146; unvoted shares held by the firms in street name on this proposal. If a broker does not exercise this authority, such broker <FONT STYLE="white-space:nowrap">non-votes</FONT> will have no effect on the results of this vote.
</TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR VALIGN="TOP">
<TD WIDTH="38%"> <P STYLE=" margin-top:0pt; margin-bottom:1pt; margin-left:2%; text-indent:0%; font-size:10pt; font-family:Times New Roman"><B>Proposal 3: Approve the <FONT STYLE="white-space:nowrap">Non-Employee</FONT> Directors&#146;
Compensation</B> </P></TD>
<TD>The affirmative vote of a majority of the votes cast by holders of ordinary shares voting in person or by proxy at the 2018 AGM is required to approve the <FONT STYLE="white-space:nowrap">non-employee</FONT> directors&#146; compensation (meaning
the number of shares voted &#147;for&#148; the proposal must exceed the number of shares voted &#147;against&#148; the proposal). </TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="38%">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">You may vote either &#147;for&#148; or &#147;against&#148; or &#147;abstain&#148; from voting on this proposal. Abstentions will have no effect on the results of this vote. Brokerage firms do not have authority to vote
customers&#146; unvoted shares held by the firms in street name with respect to this proposal. As a result, any shares not voted by a customer will be treated as a broker <FONT STYLE="white-space:nowrap">non-vote.</FONT> Such broker <FONT
STYLE="white-space:nowrap">non-votes</FONT> will have no effect on the results of this vote. </TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR VALIGN="TOP">
<TD WIDTH="38%"> <P STYLE=" margin-top:0pt; margin-bottom:1pt; margin-left:2%; text-indent:0%; font-size:10pt; font-family:Times New Roman"><B>Proposal 4: Authorize the Board to Allot and Issue Ordinary Shares of the Company</B> </P></TD>
<TD>The affirmative vote of a majority of the votes cast by holders of ordinary shares voting in person or by proxy at the 2018 AGM is required to authorize the Board of Directors to allot and issue ordinary shares of the Company (meaning the number
of shares voted &#147;for&#148; the proposal must exceed the number of shares voted &#147;against&#148; the proposal). </TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="38%">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">You may vote either &#147;for&#148; or &#147;against&#148; or &#147;abstain&#148; from voting on this proposal. Abstentions will have no effect on the results of this vote. Brokerage firms have authority to vote
customers&#146; unvoted shares held by the firms in street name on this proposal. If a broker does not exercise this authority, such broker <FONT STYLE="white-space:nowrap">non-votes</FONT> will have no effect on the results of this vote.
</TD></TR></TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Is Voting Confidential? </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We will keep all the proxies, ballots and voting tabulations private. We only let our Inspector of Elections, a representative of Broadridge,
examine these documents. Management will not know how you voted on a specific proposal unless it is necessary to meet legal requirements. However, Broadridge will forward to management any written comments you make, either on the proxy card or that
you otherwise provide. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">5 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Where Can I Find the Voting Results of the 2018 AGM? </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The preliminary voting results will be announced at the 2018 AGM, and we will publish preliminary results, or final results if available, in a
Current Report on Form <FONT STYLE="white-space:nowrap">8-K</FONT> within four business days after the 2018 AGM. If final results are unavailable at the time we file the Form <FONT STYLE="white-space:nowrap">8-K,</FONT> then we will file an amended
report on Form <FONT STYLE="white-space:nowrap">8-K</FONT> to disclose the final voting results within four business days after the final voting results are known. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>What Are the Costs of Soliciting these Proxies? </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We will pay all of the costs of soliciting these proxies. Our directors and employees may solicit proxies in person or by telephone, fax or
email. We will pay these employees and directors no additional compensation for these services. We will ask banks, brokers and other institutions, nominees and fiduciaries to forward these proxy materials to their principals and to obtain authority
to execute proxies. We will then reimburse them for their expenses. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>What Constitutes a Quorum for the 2018 AGM? </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In order to hold the meeting, there must be a quorum. The presence, in person or by proxy, of at least two shareholders holding in aggregate at
least a majority of all issued and outstanding ordinary shares entitled to vote at the 2018 AGM is necessary to constitute a quorum at the 2018 AGM. Votes of shareholders of record who are present in person or represented by proxy at the 2018 AGM,
abstentions and broker <FONT STYLE="white-space:nowrap">non-votes</FONT> are counted for purposes of determining whether a quorum exists. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Attending
the 2018 AGM </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The 2018 AGM will be held at 11:00 a.m., Eastern Time, on Tuesday, August&nbsp;7, 2018 at 733 Concord Avenue, Cambridge,
MA 02138. When you arrive, signs will direct you to the appropriate meeting rooms. You need not attend the 2018 AGM in person in order to vote, provided that your proxy is present to represent your vote. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Singapore Statutory Financial Statements </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our Singapore audited accounts for the fiscal year ended December&nbsp;31, 2017, prepared in conformity with the provisions of the laws of
Singapore, and the accompanying directors&#146; statement and the independent auditors&#146; report thereon are required under Singapore law and our Constitution to be provided to shareholders for discussion at the 2018 AGM. We refer to such
materials herein collectively as the &#147;Singapore Statutory Financial Statements.&#148; The Singapore Statutory Financial Statements are provided as <U>Appendix A</U> to this proxy statement solely to satisfy this requirement. At the 2018 AGM,
our shareholders will have the opportunity to discuss and ask questions regarding the Singapore Statutory Financial Statements. Shareholder approval of the Singapore Statutory Financial Statements is not being sought by this proxy statement for the
2018 AGM and will not be sought at the 2018 AGM. The Singapore Statutory Financial Statements shall not be deemed to be &#147;soliciting material&#148; or to be &#147;filed&#148; with the Securities and Exchange Commission, or SEC, nor shall such
information be incorporated by reference into any filings under the Securities Act of 1933, as amended, or the Securities Act, or under the Securities Exchange Act of 1934, as amended, or the Exchange Act, or be subject to the liabilities of
Section&nbsp;18 of the Exchange Act, except to the extent that we specifically incorporate this information by reference into any such filing. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">6 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Emerging Growth Company </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We are an &#147;emerging growth company,&#148; as defined under the Jumpstart Our Business Startups Act of 2012, or the &#147;JOBS Act.&#148;
As an emerging growth company, we have taken advantage of, and may continue to take advantage of, specified reduced disclosure and other requirements that are otherwise applicable generally to public companies. These provisions include: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">reduced disclosure about our executive compensation arrangements; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">exemptions from the requirements to obtain a <FONT STYLE="white-space:nowrap">non-binding</FONT> advisory vote on executive compensation or a shareholder approval of any golden parachute arrangements; and
</TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">an exemption from compliance with the auditor attestation requirement on the effectiveness of our internal control over financial reporting. </TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We have taken advantage of certain of the exemptions provided under the JOBS Act. We may continue to take advantage of exemptions under the
JOBS Act until the fifth anniversary of our initial public offering or such earlier time that we are no longer an emerging growth company. We would cease to be an emerging growth company if we have more than $1&nbsp;billion in annual revenues, we
have more than $700&nbsp;million in market value of our shares held by <FONT STYLE="white-space:nowrap">non-affiliates,</FONT> or we issue more than $1&nbsp;billion of <FONT STYLE="white-space:nowrap">non-convertible</FONT> debt over a three-year
period. Under the JOBS Act, we may choose to take advantage of some but not all of these reduced disclosure requirements. We have taken advantage of these reduced disclosure requirements in this proxy statement, and may continue to do so in future
filings. Therefore, the information contained herein may be different than the information you receive from other public companies in which you hold stock. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">7 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc589845_2"></A>SECURITY OWNERSHIP OF </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>CERTAIN BENEFICIAL OWNERS AND MANAGEMENT </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following table sets forth certain information with respect to the beneficial ownership of our ordinary shares as of June&nbsp;15, 2018
for (i)&nbsp;the executive officers named in the Summary Compensation Table appearing elsewhere in this proxy statement, (ii)&nbsp;each of our directors and director nominees, (iii)&nbsp;all of our current directors and executive officers as a
group, and (iv)&nbsp;each shareholder known by us to own beneficially more than 5% of our ordinary shares. Beneficial ownership is determined in accordance with the rules of the SEC and includes voting or investment power with respect to the
securities. We deem ordinary shares that may be acquired by an individual or group within 60 days of June&nbsp;15, 2018 pursuant to the exercise of options, vesting of restricted share units and the conversion of our outstanding Series A preferred
shares into ordinary shares to be outstanding for the purpose of computing the percentage ownership of such individual or group, but are not deemed to be outstanding for the purpose of computing the percentage ownership of any other person shown in
the table. Except as indicated in footnotes to this table, we believe that the shareholders named in this table have sole voting and investment power with respect to all ordinary shares shown to be beneficially owned by them based on information
provided to us by these shareholders. Percentage ownership is based on 29,293,050 ordinary shares outstanding on June&nbsp;15, 2018. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="76%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="72%"></TD>
<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Ordinary&nbsp;Shares<BR>Beneficially&nbsp;Owned</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; width:20.00pt; display:inline; font-size:8pt; font-family:Times New Roman; "><B>Name</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Shares</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Percent</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><I>5% Beneficial Owners</I></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">RA Capital Management, LLC<SUP STYLE="font-size:85%; vertical-align:top">(1)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7,512,049</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">25.6</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Shin Nippon Biomedical Laboratories,
Ltd.<SUP STYLE="font-size:85%; vertical-align:top">(2)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5,885,478</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">17.7</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Kagoshima Sinsangyo Sousei Investment Limited Partnership<SUP
STYLE="font-size:85%; vertical-align:top">(3)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,494,865</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">8.5</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Redmile Group, LLC<SUP STYLE="font-size:85%; vertical-align:top">(4)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,209,107</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7.5</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Pfizer Inc.<SUP STYLE="font-size:85%; vertical-align:top">(5)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,875,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6.4</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">T. Rowe Price Associates, Inc.<SUP STYLE="font-size:85%; vertical-align:top">(6)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,726,956</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5.9</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="4"></TD>
<TD HEIGHT="16" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><I>Directors and Named Executive Officers</I></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Paul B. Bolno, M.D.<SUP STYLE="font-size:85%; vertical-align:top">(7)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">846,479</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2.8</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Christopher Francis, Ph.D.<SUP STYLE="font-size:85%; vertical-align:top">(8)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">106,204</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">*</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Chandra Vargeese, Ph.D.<SUP STYLE="font-size:85%; vertical-align:top">(9)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">251,588</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">*</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Christian Henry<SUP STYLE="font-size:85%; vertical-align:top">(10)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">16,874</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">*</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Peter Kolchinsky, Ph.D.<SUP STYLE="font-size:85%; vertical-align:top">(11)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7,530,049</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">25.7</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Koji Miura<SUP STYLE="font-size:85%; vertical-align:top">(12)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">18,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">*</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Adrian Rawcliffe<SUP STYLE="font-size:85%; vertical-align:top">(13)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">15,749</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">*</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Ken Takanashi<SUP STYLE="font-size:85%; vertical-align:top">(14)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5,903,478</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">17.8</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Gregory L. Verdine, Ph.D.<SUP STYLE="font-size:85%; vertical-align:top">(15)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">625,842</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2.1</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><I>All current directors and executive officers as a <BR>group (11 individuals)<SUP
STYLE="font-size:85%; vertical-align:top">(16)</SUP></I></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">15,459,345</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">44.2</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
</TABLE> <P STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:10%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">*</TD>
<TD ALIGN="left" VALIGN="top">Represents less than 1% of ordinary shares outstanding on June&nbsp;15, 2018. </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(1)</TD>
<TD ALIGN="left" VALIGN="top">Based on information reported by RA Capital Management, LLC, or RA Capital, on Schedule 13D/A filed with the SEC on November&nbsp;15, 2017. Such shares are held by RA Capital Healthcare Fund, L.P., or the Fund, and in a
separately managed account, or the Account. RA Capital is the general partner of the Fund and serves as investment advisor for the Account. Peter Kolchinsky, Ph.D., a member of our Board of Directors, is the manager of RA Capital. RA Capital and
Dr.&nbsp;Kolchinsky share voting and dispositive power with respect to such shares and may be deemed to beneficially own such shares. The Fund and the Account have pledged an aggregate of 2,298,398 ordinary shares which are held on margin in
respective Fidelity prime brokerage accounts. The address of RA Capital is 20 Park Plaza, Suite 1200, Boston, MA 02116. </TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">8 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(2)</TD>
<TD ALIGN="left" VALIGN="top">Based on information reported by Shin Nippon Biomedical Laboratories, Ltd., or SNBL, on Schedule 13D/A filed with the SEC on April&nbsp;26, 2018. Consists of (i) 1,697,467 ordinary shares held by SNBL; (ii) 286,663
ordinary shares held by SNBL USA, Ltd., or SNBL USA; (iii) 1,801,348 Series A preferred shares held by SNBL; and (iv) 2,100,000 Series A preferred shares held by SNBL USA. The Series A preferred shares can be converted at any time on a <FONT
STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">one-for-one</FONT></FONT> basis into ordinary shares at the discretion of the holder. SNBL USA has pledged 286,663 ordinary shares for the benefit of The Kagoshima Bank, Ltd., or Kagoshima
Bank, in order to secure the obligations of SNBL under a loan agreement, dated December&nbsp;28, 2016, between SNBL and Kagoshima Bank. SNBL has pledged 915,464 ordinary shares for the benefit of Kagoshima Bank in order to secure the obligations of
SNBL under a loan agreement, dated September&nbsp;23, 2016, between SNBL and Kagoshima Bank. SNBL has pledged 720,063 ordinary shares for the benefit of Kagoshima Bank and certain other lenders in order to secure the obligations of SNBL under a loan
agreement, dated September&nbsp;15, 2017, between SNBL, Kagoshima Bank and certain other lenders. Ken Takanashi, a member of our Board of Directors, is a director and executive officer of SNBL and a director of SNBL USA. SNBL and Mr.&nbsp;Takanashi
share voting and dispositive power with respect to such shares and may be deemed to beneficially own such shares.&nbsp;The address of SNBL is St. Luke&#146;s Tower <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">28F,&nbsp;8-1,&nbsp;Akashi-cho,&nbsp;Chuo-ku,&nbsp;Tokyo&nbsp;104-0044,&nbsp;Japan.</FONT></FONT></FONT></FONT> </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(3)</TD>
<TD ALIGN="left" VALIGN="top">Based on information reported by Kagoshima Shinsangyo Sousei Investment Limited Partnership, or KSS, on Schedule 13D/A filed with the SEC on March&nbsp;22, 2018. Kagoshima Development Co. Ltd., or Kagoshima Development,
is the general partner of KSS. KSS and Kagoshima Development share voting and dispositive power with respect to such shares, and Kagoshima Development may be deemed to beneficially own such shares. The address of KSS is <FONT
STYLE="white-space:nowrap">1-10</FONT> <FONT STYLE="white-space:nowrap">Yamanokuchi-cho,</FONT> Kagoshima City, Kagoshima, <FONT STYLE="white-space:nowrap">892-0844,</FONT> Japan. </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(4)</TD>
<TD ALIGN="left" VALIGN="top">Based on information reported by Redmile Group, LLC on Schedule 13G filed with the SEC on February&nbsp;14, 2018, such shares are held by Redmile Group, LLC or its direct or indirect subsidiaries. Jeremy C. Green is
managing member of Redmile Group, LLC and may be deemed to beneficially own such shares. The address of Redmile Group, LLC is One Letterman Drive, Building D, Suite <FONT STYLE="white-space:nowrap">D3-300,</FONT> San Francisco, CA 94129.
</TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(5)</TD>
<TD ALIGN="left" VALIGN="top">Based on information reported by Pfizer Inc., on Schedule 13G filed with the SEC on May&nbsp;12, 2016. Such shares are held by C.P. Pharmaceuticals International C.V., or the Shareholder, a Netherlands limited
partnership. Pfizer Production LLC and Pfizer Manufacturing LLC, or the General Partners, are the general partners for C.P. Pharmaceuticals International C.V. Pfizer Inc. may be deemed to have beneficial ownership over such shares since the
Shareholder and the General Partners are indirect wholly-owned subsidiaries of Pfizer Inc. The General Partners may be deemed to have beneficial ownership over such shares as the general partners of the Shareholder. The address of Pfizer Inc., the
General Partners and the Shareholder is 235 E. 42nd Street, New York, NY 10017. </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(6)</TD>
<TD ALIGN="left" VALIGN="top">Based on information reported by T. Rowe Price Associates, Inc., or T. Rowe Price, on Schedule 13G filed with the SEC on February&nbsp;14, 2018. T. Rowe Price does not serve as custodian of the assets of any of its
clients. Accordingly, in each instance only the client or the client&#146;s custodian or trustee bank has the right to receive dividends paid with respect to, and proceeds from the sale of, such securities. The ultimate power to direct the receipt
of dividends paid with respect to, and the proceeds from the sale of, such securities, is vested in the individual and institutional clients which T. Rowe Price serves as investment adviser. Any and all discretionary authority which has been
delegated to T. Rowe Price may be revoked in whole or in part at any time. The address of T. Rowe Price is 100 E. Pratt Street, Baltimore, MD 21202. </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(7)</TD>
<TD ALIGN="left" VALIGN="top">Consists of (i) 197,217 ordinary shares held by Dr.&nbsp;Bolno and (ii) 649,262 ordinary shares underlying options exercisable within 60 days of June&nbsp;15, 2018. </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(8)</TD>
<TD ALIGN="left" VALIGN="top">Consists of (i) 1,727 ordinary shares held by Dr.&nbsp;Francis and (ii) 104,477 ordinary shares underlying options exercisable within 60 days of June&nbsp;15, 2018. </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(9)</TD>
<TD ALIGN="left" VALIGN="top">Consists of (i) 2,450 ordinary shares held by Dr.&nbsp;Vargeese and (ii) 249,138 ordinary shares underlying options exercisable within 60 days of June&nbsp;15, 2018. </TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">9 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(10)</TD>
<TD ALIGN="left" VALIGN="top">Consists of ordinary shares underlying options exercisable within 60 days of June&nbsp;15, 2018 held by Mr.&nbsp;Henry. </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(11)</TD>
<TD ALIGN="left" VALIGN="top">See Footnote (1)&nbsp;above. Also consists of 18,000 ordinary shares underlying options exercisable within 60 days of June&nbsp;15, 2018 held by Dr.&nbsp;Kolchinsky. </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(12)</TD>
<TD ALIGN="left" VALIGN="top">Consists of ordinary shares underlying options exercisable within 60 days of June&nbsp;15, 2018 held by Mr.&nbsp;Miura. </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(13)</TD>
<TD ALIGN="left" VALIGN="top">Consists of ordinary shares underlying options exercisable within 60 days of June&nbsp;15, 2018 held by Mr.&nbsp;Rawcliffe. </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(14)</TD>
<TD ALIGN="left" VALIGN="top">See Footnote (2) above. Also consists of 18,000 ordinary shares underlying options exercisable within 60 days of June&nbsp;15, 2018 held by Mr. Takanashi. </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(15)</TD>
<TD ALIGN="left" VALIGN="top">Consists of (i) 75,039 ordinary shares held by Dr.&nbsp;Verdine and (ii) 550,803 ordinary shares underlying options exercisable within 60 days of June&nbsp;15, 2018. </TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(16)</TD>
<TD ALIGN="left" VALIGN="top">Consists of (i) 1,768,076 ordinary shares underlying options exercisable within 60 days of June&nbsp;15, 2018, held by our directors and executive officers, (ii) 9,789,921 outstanding ordinary shares beneficially owned
by our directors and executive officers and entities affiliated with certain of our directors, and (iii) 3,901,348 Series A preferred shares, which can be converted at any time on
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">a&nbsp;one-for-one&nbsp;basis</FONT></FONT> into ordinary shares at the discretion of the holder, held by entities affiliated with one of our directors. </TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">10 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc589845_3"></A>MANAGEMENT AND CORPORATE GOVERNANCE </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Board of Directors </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Pursuant to our
Constitution, there is no maximum number of directors that may hold office at any time. Our Board currently consists of seven members and each of our directors is elected annually. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On June&nbsp;27, 2018, our Board of Directors accepted the recommendation of the Nominating and Corporate Governance Committee and voted to
nominate Paul B. Bolno, M.D., Christian Henry, Peter Kolchinsky, Ph.D., Koji Miura, Adrian Rawcliffe, Ken Takanashi, and Gregory L. Verdine, Ph.D., each currently a director of the Company, for election at the 2018 AGM. If each such nominee is
elected, he will serve on our Board of Directors until our 2019 Annual General Meeting of Shareholders and until his successor has been elected and qualified. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Set forth below are the names of the directors and persons nominated as directors, their ages as of June&nbsp;15, 2018, their offices in the
Company, if any, their principal occupations or employment for at least the past five years, the length of their tenure as directors and the names of other public companies in which such persons hold or have held directorships during the past five
years. Additionally, information about the specific experience, qualifications, attributes or skills that led to our Board of Directors&#146; conclusion at the time of filing of this proxy statement that each person listed below should serve as a
director is set forth below. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="76%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="31%"></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD WIDTH="57%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; width:20.00pt; display:inline; font-size:8pt; font-family:Times New Roman; "><B>Name</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Age</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; width:45.65pt; display:inline; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>Position/Title</B></P></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Paul B. Bolno, M.D.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">44</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">President,&nbsp;Chief&nbsp;Executive&nbsp;Officer&nbsp;and&nbsp;Director</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Christian Henry</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">50</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Chairman of the Board of Directors</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Peter&nbsp;Kolchinsky,&nbsp;Ph.D.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">41</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Director</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Koji Miura</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">69</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Director</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Adrian Rawcliffe</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">46</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Director</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Ken Takanashi</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">54</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Director</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Gregory&nbsp;L.&nbsp;Verdine,&nbsp;Ph.D.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">59</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Director</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our Board of Directors has reviewed the materiality of any relationship that each of our directors has with
the Company, either directly or indirectly. Based upon this review, our Board has determined that the following members of the Board are &#147;independent directors&#148; as defined by the Nasdaq Stock Market: Dr.&nbsp;Kolchinsky and Messrs. Henry,
Miura, Rawcliffe and Takanashi. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B><I>Paul B. Bolno, M.D.</I></B> has served as our President and Chief Executive Officer and as a
director since December 2013. Prior to joining us, he served at GlaxoSmithKline from 2009 to 2013 in various roles, including Vice President, Worldwide Business Development&#151;Head of Asia BD and Investments, Head of Global Neuroscience BD, a
director of Glaxo Welcome Manufacturing, Pte. Ltd. in Singapore and Vice President, Business Development for the Oncology Business Unit, where he helped establish GlaxoSmithKline&#146;s global oncology business and served as a member of the Oncology
Executive Team, Oncology Commercial Board and Cancer Research Executive Team. Prior to GlaxoSmithKline, he served as director of Research at Two River LLC, a health care private equity firm from 2004 to 2009. Dr.&nbsp;Bolno earned a medical degree
from <FONT STYLE="white-space:nowrap">MCP-Hahnemann</FONT> School of Medicine and an M.B.A. from Drexel University. He was a general surgery resident and cardiothoracic surgery postdoctoral research fellow at Drexel University College of Medicine.
We believe that Dr.&nbsp;Bolno&#146;s experience serving as our President and Chief Executive Officer and a member of our Board of Directors and his experience leading biopharmaceutical companies qualify him to serve on our Board of Directors. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B><I>Christian Henry </I></B>has served as a director since November 2016, and as Chairman of our Board of Directors since October 2017.
Mr.&nbsp;Henry served as Executive Vice President&nbsp;&amp; Chief Commercial Officer of Illumina, Inc. from 2015 through January 2017, and previously served as Senior Vice President&nbsp;&amp; Chief Commercial Officer from 2014 to 2015, Senior Vice
President&nbsp;&amp; General Manager Genomic Solutions from 2012 to 2014, Senior Vice President, Chief Financial Officer&nbsp;&amp; General Manager Life Sciences from 2010 to 2012, Senior Vice </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">11 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
President, Corporate Development&nbsp;&amp; Chief Financial Officer from 2009 to 2010, Senior Vice President&nbsp;&amp; Chief Financial Officer from 2007 to 2009, and Vice President&nbsp;&amp;
Chief Financial Officer from 2005 to 2006. Prior to joining Illumina, Inc., Mr.&nbsp;Henry served as the Chief Financial Officer of Tickets.com, Inc. from 2003 to 2005. From 1999 to 2003, Mr.&nbsp;Henry served as Vice President, Finance&nbsp;&amp;
Corporate Controller of Affymetrix, Inc. (acquired by Thermo Fisher Scientific in 2016). In 1997, Mr.&nbsp;Henry joined Nektar Therapeutics (formerly Inhale Therapeutic Systems, Inc.), as Corporate Controller, and later as its Chief Accounting
Officer from 1997 to 1999. In 1996, Mr.&nbsp;Henry served as General Accounting Manager of Sugen, Inc. Mr.&nbsp;Henry began his career in 1992 at Ernst&nbsp;&amp; Young LLP, where he was a Senior Accountant through 1996. Mr.&nbsp;Henry earned his
B.A. in biochemistry and cell biology from the University of California, San Diego, and his M.B.A., with a concentration in finance, from the University of California, Irvine. We believe he is qualified to serve on our Board of Directors because of
his strengths in corporate strategy, finance and operations, along with his extensive experience leading various functions at one of the largest and most innovative genetic healthcare companies. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B><I>Peter Kolchinsky, Ph.D.</I></B> has served as a director since January 2015. Dr.&nbsp;Kolchinsky is a founder, Portfolio Manager, and
Managing Director of RA Capital Management, LLC, a multi-stage investment manager which is dedicated to evidence-based investing in healthcare and life science companies, where he has worked since 2001. RA Capital Management, LLC is the general
partner of RA Capital Healthcare Fund, L.P. He serves as a member of the Board of Directors of Dicerna Pharmaceuticals, as well as a number of private companies. Dr.&nbsp;Kolchinsky authored &#147;Entrepreneur&#146;s Guide to a Biotech Startup&#148;
and served on the Board of Global Science and Technology for the National Academics of Sciences from 2009 to 2012. Dr.&nbsp;Kolchinsky earned his Ph.D. in virology from Harvard University and earned his bachelor&#146;s degree in Biology from Cornell
University. We believe Dr.&nbsp;Kolchinsky is qualified to serve on our Board of Directors because of his business experience including his experience as an institutional investor and his experience serving on the boards of various healthcare and
life science companies. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B><I>Koji Miura</I></B> has served as a director since October 2012. Mr.&nbsp;Miura is the founder and Managing
Director of Miura&nbsp;&amp; Associates Management Consultants Pte. Ltd. and serves on the boards of directors of Azeus Systems Holdings Ltd., Marine Tec Tachibana Pte. Ltd., Matsuura Singapore Pte. Ltd., Mercury Investment Holding Pte. Ltd.,
Sunmoon Pte. Ltd., and Triple Farm Singapore Pte. Ltd. Mr.&nbsp;Miura holds a bachelor&#146;s degree in Business Administration from the University of Aoyama Gakuin, Tokyo, Japan. We believe he is qualified to serve on our Board of Directors because
of his broad business experience including his diverse background serving on the board of directors of various companies, both private and publicly-held, across multiple industries. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B><I>Adrian Rawcliffe</I></B> has served as a director since February 2017. Mr.&nbsp;Rawcliffe currently serves as Chief Financial Officer of
Adaptimmune Therapeutics plc, where he has worked since 2015. Prior to joining Adaptimmune, Mr.&nbsp;Rawcliffe served in various roles at GlaxoSmithKline plc, including Senior Vice President Finance, North America Pharmaceuticals and Global
Franchises from 2011 to 2015; Senior Vice President, Worldwide Business Development and R&amp;D Finance from 2006 to 2011; Vice President, Worldwide Business Development Transactions and Ventures from 2003 to 2005; and Vice President, Deal
Structuring from 2001 to 2003. From 2005 to 2006, Mr.&nbsp;Rawcliffe served as the President and Managing Partner of SR One Ltd. Mr.&nbsp;Rawcliffe began his career as a supervisor at Coopers&nbsp;&amp; Lybrand (now PricewaterhouseCoopers) from 1993
to 1997. Mr.&nbsp;Rawcliffe received his B.Sc. in Natural Sciences from the University of Durham, England. Mr.&nbsp;Rawcliffe also received Chartered Accountancy training through The Institute of Chartered Accountants in England and Wales (ICAEW).
We believe he is qualified to serve on our Board of Directors because of his global expertise, along with extensive business and operating experience at one of the world&#146;s largest global healthcare companies. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B><I>Ken Takanashi</I></B> has served as a director since July 2012. Since 2002, Mr.&nbsp;Takanashi has served in various executive
management and director roles at Shin Nippon Biomedical Laboratories Ltd., or SNBL, and its affiliates and currently serves as its Executive Vice President, Chief Operating Officer. Mr.&nbsp;Takanashi was the Chief Financial Officer of SNBL USA,
Ltd., a subsidiary of Shin Nippon Biomedical Laboratories, from 2012 to 2014. Mr.&nbsp;Takanashi earned an M.B.A. from the University of Warwick and received his bachelor&#146;s degree from </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">12 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
the University of Tokyo and is a Chartered Public Accountant. We believe he is qualified to serve on our Board of Directors because of his extensive experience leading research and development
for biopharmaceutical companies and his business, financial and accounting credentials. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B><I>Gregory L. Verdine, Ph.D.</I></B>, is one
of our founders and has served as a director since July 2013. He was our President, Chief Executive Officer and Chief Scientific Officer from our inception through December 2013 and served as Chairman of our Board of Directors from July 2013 through
September 2017. Since 1989, Dr.&nbsp;Verdine has served as the Erving Professor of Chemistry in the Department of Stem Cell and Regenerative Biology and the Department of Chemistry and Chemical Biology at Harvard University and Harvard Medical
School. Dr.&nbsp;Verdine <FONT STYLE="white-space:nowrap">co-founded</FONT> the <FONT STYLE="white-space:nowrap">non-profit</FONT> Gloucester Marine Genomics Institute and Gloucester Biotechnology Academy in 2013 and served as the Founding President
until 2016. He is the <FONT STYLE="white-space:nowrap">co-founder</FONT> of Fog Pharmaceuticals Inc. and LifeMine Therapeutics Inc. and serves as Chairman, President, Chief Executive Officer and Chief Scientific Officer for both companies. He is
also the founder of Warp Drive Bio and has served in various roles, from Chief Scientific Officer to Chief Executive Officer, from the company&#146;s inception in 2012 until April 2016. Dr.&nbsp;Verdine founded Enanta Pharmaceuticals and served as a
member of the Board of from 1990 through its initial public offering in 2013. He is a Venture Partner at WuXi Healthcare Ventures, and has previously served as Venture Partner at AppleTree Ventures, TPG Biotech and Third Rock Ventures. He has served
on the Board of Scientific Counsellors of the National Cancer Institute, and is on the Board of Scientific Consultants of the Memorial Sloan Kettering Cancer Center, and he is a Senior Advisor to Shin Nippon Biomedical Laboratories Ltd.
Dr.&nbsp;Verdine is also the <FONT STYLE="white-space:nowrap">co-founder</FONT> of Eleven Biotherapeutics, Tokai Therapeutics, Aileron Therapeutics, and Gloucester Pharmaceuticals (acquired by Celgene in 2010). He has also served as a director of
the Chemical Biology Initiative and the Program in Cancer Chemical Biology at the Dana-Farber Cancer Institute. Dr.&nbsp;Verdine received his Ph.D. in Chemistry from Columbia University and completed postdoctoral work in Molecular Biology at the
Massachusetts Institute of Technology and Harvard Medical School. We believe he is qualified to serve on our Board of Directors because of his expertise and deep knowledge of our company, its technology and our industry and his long track record of
creating and advising successful biopharmaceutical companies. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Pursuant to the Singapore Companies Act, Chapter 50, or the &#147;Singapore
Companies Act,&#148; and our Constitution, our Board must have at least one director who is ordinarily resident in Singapore. Mr.&nbsp;Miura is our Singapore resident director. Due to the Singapore Companies Act requirement that we have at least one
director who is ordinarily resident in Singapore in office at all times and the sole resident director cannot resign or step down unless there is at least one other resident director, in the event that Mr.&nbsp;Miura is not elected at the 2018 AGM,
he will continue in office after the 2018 AGM as a member of our Board until his qualifying successor (i.e., a Singapore resident director) is appointed. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Committees of the Board of Directors and Meetings </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B><I>Meeting Attendance</I></B>. During the fiscal year ended December&nbsp;31, 2017, there were six meetings of our Board of Directors, and
the various committees of the Board met a total of 12 times. No director, with the exception of Masaharu Tanaka, who served as a director from January&nbsp;1, 2017 through August&nbsp;10, 2017, the date of our 2017 Annual General Meeting of
Shareholders, attended fewer than 75% of the total number of meetings of the Board and of committees of the Board on which he served during 2017. The Board has adopted a policy under which our directors are encouraged to attend our annual general
meetings of shareholders. One director attended our 2017 Annual General Meeting of Shareholders, which was held on August&nbsp;10, 2017. As a Singapore company, we are required to prepare annual Singapore statutory audited financial statements (our
&#147;second annual audit&#148;) and to deliver them to our shareholders in connection with our annual general meetings of shareholders. Our second annual audit can only be conducted following our first annual audit, which requires our preparation
and filing of annual U.S. GAAP audited consolidated financial statements with the SEC. As a result, these multiple audits do not allow us to schedule our quarterly board meetings at the same time as our annual general meetings of shareholders. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B><I>Audit Committee</I></B><I>.</I> Our Audit Committee held four meetings during the fiscal year ended December&nbsp;31, 2017. Our Audit
Committee currently has three members: Mr.&nbsp;Henry (Chairman) and Messrs. Miura and </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">13 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
Rawcliffe. On February&nbsp;1, 2017, Mr.&nbsp;Rawcliffe replaced Masaharu Tanaka, who served as a director of our Board during 2017 from January&nbsp;1, 2017 through August&nbsp;10, 2017, the
date of our 2017 Annual General Meeting of Shareholders, as a member of our Audit Committee. Our Audit Committee&#146;s role and responsibilities are set forth in the Audit Committee&#146;s written charter and include the responsibility to retain
and terminate the services of our independent registered public accounting firm. In addition, the Audit Committee reviews annual financial statements, considers matters relating to accounting policy and internal controls and reviews the scope of
annual audits. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Messrs. Henry, Miura and Rawcliffe satisfy the current independence standards promulgated by the SEC and by the Nasdaq
Stock Market, as such standards apply specifically to members of audit committees. The Board has determined that each member of the Audit Committee meets the financial literacy requirements of the Nasdaq Stock Market Rules and that each of Messrs.
Henry and Rawcliffe qualifies an &#147;audit committee financial expert,&#148; as the SEC has defined that term in Item 407 of Regulation <FONT STYLE="white-space:nowrap">S-K.</FONT> </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">A copy of the Audit Committee&#146;s written charter is publicly available on our website at www.wavelifesciences.com. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B><I>Compensation Committee</I></B><I>.</I> Our Compensation Committee met four times during the fiscal year ended December&nbsp;31, 2017.
The Compensation Committee currently has three members: Mr.&nbsp;Henry (Chairman), Dr.&nbsp;Kolchinsky and Mr.&nbsp;Takanashi. On March&nbsp;9, 2017, Mr.&nbsp;Henry joined as a member of our Compensation Committee and, on December&nbsp;12, 2017,
replaced Dr.&nbsp;Kolchinsky as the Chairman of our Compensation Committee. During the period of January&nbsp;1, 2017 through March&nbsp;9, 2017, our Compensation Committee was comprised of two members, Dr.&nbsp;Kolchinsky (Chairman) and
Mr.&nbsp;Takanashi. Our Compensation Committee&#146;s role and responsibilities are set forth in the Compensation Committee&#146;s written charter and includes reviewing, approving and making recommendations regarding our compensation policies,
practices and procedures to ensure that legal and fiduciary responsibilities of the Board of Directors are carried out and that such policies, practices and procedures contribute to our success. Our Compensation Committee also administers our 2014
Equity Incentive Plan, as amended (the &#147;2014 Equity Incentive Plan&#148;). The Compensation Committee is responsible for determining the compensation of our executive officers. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Each member of the Compensation Committee qualifies as independent under the definition promulgated by the Nasdaq Stock Market. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">A copy of the Compensation Committee&#146;s written charter is publicly available on our website at www.wavelifesciences.com. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B><I>Nominating and Corporate Governance Committee</I></B><I>.</I> Our Nominating and Corporate Governance Committee met four times during
the fiscal year ended December&nbsp;31, 2017. The Nominating and Corporate Governance Committee currently has three members: Mr.&nbsp;Henry (Chairman), Mr.&nbsp;Takanashi and Dr.&nbsp;Kolchinsky. On March&nbsp;9, 2017, Mr.&nbsp;Henry joined as a
member of our Nominating and Corporate Governance Committee and, on December&nbsp;12, 2017, replaced Mr.&nbsp;Takanashi as the Chairman of our Nominating and Corporate Governance Committee. During the period of January&nbsp;1, 2017 through
March&nbsp;9, 2017, our Nominating and Corporate Governance Committee was comprised of two members, Mr.&nbsp;Takanashi (Chairman) and Dr.&nbsp;Kolchinsky. The Nominating and Corporate Governance Committee&#146;s role and responsibilities are set
forth in the Nominating and Corporate Governance Committee&#146;s written charter and include evaluating and making recommendations to the full Board as to the size and composition of the Board and its committees, evaluating and making
recommendations as to potential candidates, and evaluating current Board members&#146; performance. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Each member of the Nominating and
Corporate Governance Committee qualifies as independent under the definition promulgated by the Nasdaq Stock Market. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">14 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Nominating and Corporate Governance Committee is responsible for identifying individuals
qualified to serve as directors, consistent with criteria approved by the Board, and recommending the persons to be nominated for election as directors, except where we are legally required by contract, law or otherwise to provide third parties with
the right to nominate. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The process followed by the Nominating and Corporate Governance Committee to identify and evaluate director
candidates includes making requests to Board members and others for recommendations, holding meetings from time to time to evaluate biographical information and reviewing background material relating to potential candidates and interviews of
selected candidates by members of the committee and the Board. The qualifications, qualities and skills that the committee believes must be met by a committee-recommended nominee for a position on our Board of Directors are as follows: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Nominees should have a reputation for integrity, honesty and adherence to high ethical standards. </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Nominees should have demonstrated business acumen, experience and ability to exercise sound judgments in matters that relate to the Company&#146;s current and long-term objectives and should be willing and able to
contribute positively to the Company&#146;s decision-making process. </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Nominees should have a commitment to understand the Company and its industry and to regularly attend and participate in meetings of the Board and its committees. </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Nominees should have the interest and ability to understand the sometimes conflicting interests of our various constituencies, which include shareholders, employees, customers, governmental units, creditors and the
general public, and to act in the interests of all shareholders. </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Nominees should not have, nor appear to have, a conflict of interest that would impair the nominee&#146;s ability to represent the interests of all of our shareholders and to fulfill the responsibilities of a director.
</TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Nominees shall not be discriminated against on the basis of race, religion, national origin, sex, sexual orientation, disability or any other basis proscribed by law. The value of diversity on the Board is considered.
</TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Nominees should normally be able to serve for at least five years before reaching the age of 70. </TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Nominating and Corporate Governance Committee considers issues of diversity among its members in identifying and considering nominees for
director, and strives where appropriate to achieve a diverse balance of backgrounds, perspectives, experience, age, gender, ethnicity and country of citizenship on the Board and its committees. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">A copy of the Nominating and Corporate Governance Committee&#146;s written charter is publicly available on our website at
www.wavelifesciences.com. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Procedures by which Shareholders may Nominate Directors </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Nominating and Corporate Governance Committee shall review and evaluate information available to it regarding candidates proposed by
shareholders and shall apply the same criteria, and shall follow substantially the same process in considering them, as it does in considering other candidates. The factors generally considered by the Nominating and Corporate Governance Committee
are set out in our Corporate Governance Guidelines, which are publicly available on the &#147;For Investors&nbsp;&amp; Media&#148; section of our website at http://ir.wavelifesciences.com/ under the heading &#147;Corporate Governance.&#148; If a
shareholder wishes to nominate a candidate to be considered by the Nominating and Corporate Governance Committee for election as a director at the 2019 Annual General Meeting of Shareholders, it must give timely notice of the nomination in writing
to our General Counsel not less than 45 days prior to the date that is one year from the date on which we first mail our proxy statement relating to our 2018 AGM of Shareholders. All shareholder proposals should be marked for the attention of
General Counsel, Wave Life Sciences Ltd., 733 Concord Avenue, Cambridge, MA 02138. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">15 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Compensation Committee Interlocks and Insider Participation </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">During 2017, the members of our Compensation Committee were Dr.&nbsp;Kolchinsky and Messrs. Henry and&nbsp;Takanashi. Dr.&nbsp;Kolchinsky is
the managing member of RA Capital Management, LLC, the general partner of RA Capital Healthcare Fund, L.P., one of our shareholders. Mr.&nbsp;Takanashi is a director and executive officer of Shin Nippon Biomedical Laboratories Ltd. and its
affiliates, one of our shareholders. We have entered into certain transactions with affiliates of RA Capital Healthcare Fund, L.P. and Shin Nippon Biomedical Laboratories Ltd., as further described under &#147;Certain Relationships and Related
Person Transactions&#148; below. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">No officer or employee has served as a member of the Compensation Committee.&nbsp;None of our executive
officers serve as a member of the board of directors or compensation committee of any entity that has one or more executive officers serving on our Board of Directors or Compensation Committee. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Familial Relationships </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">There are no
familial relationships between any of our executive officers and directors. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Board Leadership Structure and Role in Risk Oversight </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The positions of Chairman of the Board and Chief Executive Officer are presently separated at the Company. We believe that separating these
positions allows our Chief Executive Officer to focus on our <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">day-to-day</FONT></FONT> business, while allowing our Chairman of the Board to lead the Board of Directors in its
fundamental role of providing advice to, and independent oversight of, management. Our Board of Directors recognizes the time, effort and energy that the Chief Executive Officer is required to devote to his position in the current business
environment, as well as the commitment required to serve as our Chairman, particularly as the Board of Directors&#146; oversight responsibilities continue to grow. Our Board of Directors also believes that this structure ensures a greater role for
the independent directors in the oversight of our Company and active participation of the independent directors in setting agendas and establishing priorities and procedures for the work of our Board of Directors. The Board retains the authority to
modify this leadership structure as and when appropriate to best address the Company&#146;s unique circumstances at any given time and to serve the best interests of our shareholders. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our Board of Directors oversees the risk management activities designed and implemented by our management. Our Board of Directors executes its
oversight responsibility for risk management both directly and through its committees. Our Board of Directors also considers specific risk topics, including risks associated with our strategic plan, business operations and capital structure. In
addition, our Board of Directors receives detailed regular reports from members of our management team and other personnel that include assessments and potential mitigation of the risks and exposures involved with their respective areas of
responsibility. Our Board of Directors may delegate to the Audit Committee oversight of our risk management process. Our other Board committees will also consider and address risk as they perform their respective committee responsibilities.
Specifically, the Audit Committee receives regular reports from members of senior management on areas of material risk to the Company, including operational, financial, legal, regulatory, strategic and reputational risks. As part of its charter, our
Audit Committee regularly discusses with management our major risk exposures, their potential financial impact on our Company and the steps we take to manage them. Our Compensation Committee assists the Board in fulfilling its oversight
responsibilities with respect to the management and risks arising from our compensation policies and programs. Our Nominating and Corporate Governance Committee assists the Board in fulfilling its oversight responsibilities with respect to the
management of risks associated with Board organization, membership and structure, succession planning for our directors and executive officers and corporate governance. All committees report to the full Board of Directors as appropriate, including
when a matter rises to the level of a material or enterprise level risk. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">16 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Shareholder Communications to the Board </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Generally, shareholders who have questions or concerns or who wish to address questions regarding our business directly with the Board of
Directors, or any individual director, should direct his or her questions in writing to IR@wavelifesci.com.&nbsp;Communications will be distributed to the Board, or to any individual director or directors as appropriate, depending on the facts and
circumstances outlined in the communications.&nbsp;Items that are unrelated to the duties and responsibilities of the Board may be excluded, such as junk mail and mass mailings, resumes and other forms of job inquiries, surveys and solicitations or
advertisements.&nbsp;In addition, any material that is unduly hostile, threatening, or illegal in nature may be excluded, provided that any communication that is filtered out will be made available to any outside director upon request. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Executive Officers </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Set forth below is
information as of June&nbsp;15, 2018 regarding our executive officers who are not also directors. We have employment agreements with certain of our executive officers and all of our executive officers are generally
<FONT STYLE="white-space:nowrap">at-will</FONT> employees. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="76%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="34%"></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD WIDTH="56%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; width:20.00pt; display:inline; font-size:8pt; font-family:Times New Roman; "><B>Name</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Age</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; width:15.95pt; display:inline; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>Title</B></P></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Christopher&nbsp;Francis,&nbsp;Ph.D.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">40</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Senior&nbsp;Vice&nbsp;President,&nbsp;Corporate&nbsp;Development, Head of Emerging Areas</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Michael&nbsp;Panzara,&nbsp;M.D.,&nbsp;MPH</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">51</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Franchise Lead, Neurology</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Keith C. Regnante</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">48</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Chief Financial Officer</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Chandra Vargeese, Ph.D.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">57</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Senior&nbsp;Vice&nbsp;President,&nbsp;Drug&nbsp;Discovery</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B><I>Christopher Francis, Ph.D.</I></B> has served as our Senior Vice President, Corporate Development, Head
of Emerging Areas since May 2017. During the period January 2017 to May 2017, Dr.&nbsp;Francis served as our Senior Vice President, Corporate Development&nbsp;&amp; Portfolio Management. Prior to that, Dr.&nbsp;Francis served as our Vice President,
Head of Business Development since April 2014. Prior to joining us, Dr.&nbsp;Francis held senior operational, strategic and business development roles within GlaxoSmithKline Oncology from 2009 to 2014 and was a member of the team that established
GlaxoSmithKline&#146;s Rare Disease Unit. Before GlaxoSmithKline, Dr.&nbsp;Francis was a health care private equity associate at Two River LLC from 2008 to 2009. He began his career in pharmaceutical pricing and reimbursement consulting at IMS
Health. Dr.&nbsp;Francis earned undergraduate and graduate degrees in Biochemistry and Molecular Biology from the University of Melbourne and was a doctoral research associate at the University of Cambridge. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B><I>Michael Panzara, M.D., MPH </I></B>joined us as our Franchise Lead, Neurology in July 2016. Prior to joining us, Dr.&nbsp;Panzara served
in various roles at Sanofi Genzyme (and Genzyme Corporation before its merger with Sanofi in 2011) from 2009 to July 2016, most recently serving as Head of the Multiple Sclerosis, Neurology and Ophthalmology Therapeutic Area for Global Development
and prior to that, serving as Group Vice President, Therapeutic Area Head, Multiple Sclerosis and Neurology. Prior to joining Genzyme, Dr.&nbsp;Panzara served in roles of increasing responsibility at Biogen, including Vice President, Chief Medical
Officer, Neurology from 2006 to 2009 and in various roles in the Medical Research group from 2001 to 2006. In addition, from 1999 to 2011, Dr.&nbsp;Panzara was an Instructor in Neurology at Harvard Medical School and an Assistant in Neurology at
Massachusetts General Hospital (MGH). He trained in neurology at MGH from 1994 to 1998, and completed his post-doctoral training in immunology and rheumatology at Brigham and Women&#146;s Hospital. Dr.&nbsp;Panzara holds a bachelor&#146;s degree
from the University of Pennsylvania, a medical degree from Stanford University School of Medicine, and a master&#146;s degree in public health from the Harvard School of Public Health. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B><I>Keith C. Regnante</I></B> has served as our Chief Financial Officer since August 2016. Prior to joining us, from February 2014 to August
2016, Mr.&nbsp;Regnante served as Vice President of Finance at Shire Pharmaceuticals, a global biopharmaceutical company. Mr.&nbsp;Regnante also served on the Financial Leadership Team and the R&amp;D Leadership Team while he was at Shire. From
September 2013 to February 2014, he served as Head of R&amp;D </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">17 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
Finance for ARIAD Pharmaceuticals, Inc. From January 1999 to August 2013, Mr.&nbsp;Regnante held multiple positions within finance for Biogen Inc., including Senior Director of Corporate Finance
from 2011 to 2013, Senior Director of Worldwide R&amp;D Finance from 2008 to 2011, and several other positions dating back to 1999. Prior to joining finance organizations for biotechnology companies, Mr.&nbsp;Regnante worked as a consultant at The
Boston Consulting Group. He holds a B.A. in Economics from Tufts University and an M.B.A. from the MIT Sloan School of Management. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B><I>Chandra Vargeese, Ph.D.</I></B> has served as our Senior Vice President, Head of Drug Discovery since August 2014. Before joining us,
Dr.&nbsp;Vargeese served as Novartis&#146; Executive Director and Head of RNA Chemistry and Delivery, a position she held from 2008 to 2014. Prior to joining Novartis, Dr.&nbsp;Vargeese led siRNA delivery in the RNA Therapeutics division at
Merck&nbsp;&amp; Co., where she served as Senior Director and Head of RNA Chemistry and Delivery. Dr.&nbsp;Vargeese joined Merck through its acquisition of Sirna Therapeutics, where she was Vice President of Chemistry. Before Sirna,
Dr.&nbsp;Vargeese served as Associate Director of Chemistry at NeXstar Pharmaceuticals and is the <FONT STYLE="white-space:nowrap">co-inventor</FONT> of Macugen (pegaptanib), an approved therapy for treating wet AMD. Dr.&nbsp;Vargeese earned a Ph.D.
in Organic Chemistry at the Indian Institute of Science, Bangalore, India and completed post-doctoral work at the University of Rhode Island. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">18 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc589845_4"></A>EXECUTIVE OFFICER AND DIRECTOR COMPENSATION </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Summary Compensation Table </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following
table shows the total compensation paid or accrued during the last two fiscal years ended December&nbsp;31, 2017 and 2016 to our President and Chief Executive Officer and our two next most highly compensated executive officers who earned more than
$100,000 during the fiscal year ended December&nbsp;31, 2017 and were serving as executive officers as of such date. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="37%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; width:97.90pt; display:inline; font-size:8pt; font-family:Times New Roman; "><B>Name and Principal Position</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Year</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Salary<BR>($)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Bonus<BR>($)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Share<BR>Awards<BR>($)<SUP STYLE="font-size:85%; vertical-align:top">(1)</SUP></B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Option<BR>Awards<BR>($)<SUP STYLE="font-size:85%; vertical-align:top">(2)</SUP></B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B><FONT STYLE="white-space:nowrap">Non-Equity</FONT><BR>Incentive&nbsp;Plan<BR>Compensation<BR>($)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>All Other<BR>Compensation<BR>($)<SUP STYLE="font-size:85%; vertical-align:top">(3)</SUP></B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Total ($)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Paul B. Bolno, M.D.</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2017</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">515,300</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,054,515</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,342,902</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">283,400</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">528</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,196,645</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><I>President and Chief<BR>Executive Officer</I></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2016</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">490,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">329,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,505,377</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">245,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">25,486</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,594,863</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Christopher Francis, Ph.D.</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2017</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">330,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">284,690</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">361,194</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">127,100</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">528</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,103,512</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><I>Senior Vice President, Corporate Development, Head of Emerging Areas</I></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Chandra Vargeese, Ph.D.</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2017</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">350,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">284,690</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">361,194</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">154,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7,380</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,157,264</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><I>Senior Vice President, Drug Discovery</I></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
</TABLE> <P STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:10%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(1)</TD>
<TD ALIGN="left" VALIGN="top">Amount represents the aggregate grant date fair value for the share awards identified, computed in accordance with FASB ASC Topic 718. A discussion of the assumptions used in determining grant date fair value may be
found in Note 7 to the financial statements included in our Annual Report on Form <FONT STYLE="white-space:nowrap">10-K</FONT> for the year ended December&nbsp;31, 2017. </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(2)</TD>
<TD ALIGN="left" VALIGN="top">Amounts represent the aggregate grant date fair value for the option awards identified, computed in accordance with FASB ASC Topic 718. A discussion of the assumptions used in determining grant date fair value may be
found in Note 7 to the financial statements included in our Annual Report on Form <FONT STYLE="white-space:nowrap">10-K</FONT> for the year ended December&nbsp;31, 2017. </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(3)</TD>
<TD ALIGN="left" VALIGN="top">Amounts include 401(k) matching contributions made to Dr.&nbsp;Vargeese and the value of annual premiums paid by us with respect to a life insurance policy for the benefit of each of the named executive officers. For
2016, amounts for Dr.&nbsp;Bolno also include reimbursement of relocation expenses of $15,461 and the related tax gross up of $8,500 as well as certain commuting expenses. </TD></TR></TABLE>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Narrative to Summary Compensation Table </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our Compensation Committee reviews and discusses our executive officers&#146; proposed compensation with the Chief Executive Officer for all
executives other than the Chief Executive Officer. The Chief Executive Officer&#146;s compensation is determined by the Compensation Committee. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Employment Agreements </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B><I>Paul B.
Bolno, M.D.</I></B> Effective as of January&nbsp;1, 2016, Dr.&nbsp;Bolno&#146;s annual base salary was increased to $490,000 and his annual target bonus percentage for his 2016 bonus was increased to 50%. Effective as of January&nbsp;1, 2017,
Dr.&nbsp;Bolno&#146;s annual base salary was increased to $515,300, and effective as of January&nbsp;1, 2018, his annual base salary was increased to $541,100. In January 2018, in recognition of his 2017 performance supporting the achievement of our
corporate goals discussed below, Dr.&nbsp;Bolno received a cash bonus of $283,400 that was equal to 110% of his target bonus of 50%. He also received an option to purchase 109,000 of our ordinary shares and 54,500 restricted share units under our
2014 Equity Incentive Plan as long-term incentive plan awards. In addition, effective as of January&nbsp;1, 2018, Dr.&nbsp;Bolno&#146;s annual target bonus percentage was increased to 55%. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">19 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B><I>Christopher Francis, Ph.D. </I></B>In March 2014, we entered into an offer letter with
Dr.&nbsp;Francis pursuant to which he served as our Vice President, Head of Business Development, and now serves as our Senior Vice President, Corporate Development, Head of Emerging Areas. Effective as of January&nbsp;1, 2017,
Dr.&nbsp;Francis&#146;s annual base salary was increased to $330,000, and effective as of January&nbsp;1, 2018, his annual base salary was increased to $363,000. In January 2018, in recognition of his 2017 performance supporting the achievement of
our corporate goals discussed below, Dr.&nbsp;Francis received a cash bonus of $127,100 that was equal to 110% of his annual target bonus percentage of 35%. In addition, he received an option to purchase 26,000 of our ordinary shares and 13,000
restricted share units under our 2014 Equity Incentive Plan as long-term incentive plan awards. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B><I>Chandra Vargeese, Ph.D. </I></B>In
July 2014, we entered into an offer letter with Dr.&nbsp;Vargeese pursuant to which she served as our Senior Vice President, Drug Discovery. Effective as of January&nbsp;1, 2017, Dr.&nbsp;Vargeese&#146;s annual base salary was increased to $350,000,
and effective as of January&nbsp;1, 2018, her annual base salary was increased to $400,000. In January 2018, in recognition of her 2017 performance supporting the achievement of our corporate goals discussed below, Dr.&nbsp;Vargeese received a cash
bonus of $154,000 that was equal to 110% of her annual target bonus percentage of 40%. In addition, she received an option to purchase 35,000 of our ordinary shares and 17,500 restricted share units under our 2014 Equity Incentive Plan as long-term
incentive plan awards. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our named executive officers are also entitled to certain benefits in connection with a termination of employment
or a change of control, which are discussed below under &#147;&#151;Potential Payments upon Termination or <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">Change-In-Control.&#148;</FONT></FONT> </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition, as a condition of their employment, each of our named executive officers has entered into a
<FONT STYLE="white-space:nowrap">non-competition</FONT> and <FONT STYLE="white-space:nowrap">non-solicitation</FONT> agreement pursuant to which he or she has agreed not to compete with us for a period of 12&nbsp;months following the termination of
his or her employment.&nbsp;All agreements generally provide for <FONT STYLE="white-space:nowrap">at-will</FONT> employment and that our named executive officers are eligible to participate in employee benefit plans of general applicability to other
senior executives, which we maintain from time to time. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>2017 <FONT STYLE="white-space:nowrap">Non-Equity</FONT> Incentive Plan Compensation </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Each of our named executive officers is eligible to receive an annual cash bonus calculated based on a target percentage of base salary,
subject to the achievement of annual performance goals as determined by our Board of Directors in its sole discretion. Performance goals considered by our Board of Directors to determine bonuses for 2017 included advancing our pipeline by initiating
three clinical programs in neurology and identifying clinical candidates outside of neurology; investing in platform technologies to enhance our discovery engine; and establishing internal cGMP manufacturing capabilities to meet our clinical
deliverables. In recognition of these achievements, each of our named executive officers received their annual bonuses at 110% of their target bonus percentage. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>2014 Equity Incentive Plan </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our 2014
Equity Incentive Plan was amended on August&nbsp;10, 2017 (the &#147;2014 Equity Incentive Plan&#148;), following shareholder approval at our 2017 Annual General Meeting. Accordingly, our Board of Directors and shareholders have authorized 6,064,544
ordinary shares for the granting of incentive options, <FONT STYLE="white-space:nowrap">non-qualified</FONT> options, or NQSOs, share appreciation rights and restricted share unit awards, plus annual increases on the first day of July 2018, 2019 and
2020 equal to the lesser of (A)&nbsp;3% of the ordinary shares outstanding on the day prior to the increase; and (B)&nbsp;such lesser number of ordinary shares as determined by the Board; provided that no more than 10,000,000 ordinary shares may be
issued upon the exercise of incentive share options.&nbsp;The maximum number of ordinary shares with respect to awards which may be granted to any participant in any fiscal year under the 2014 Equity Incentive Plan is 600,000 shares. In the event of
a share dividend, split, recapitalization or reorganization or other change in capital structure, our Board of Directors will make appropriate adjustments to these amounts. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">20 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Any shares subject to an award that is canceled, forfeited or expires prior to exercise or
realization, either in full or in part, will again become available for issuance under the 2014 Equity Incentive Plan. However, shares subject to an award under the 2014 Equity Incentive Plan will not again be made available for issuance or delivery
under the 2014 Equity Incentive Plan if such shares are (a)&nbsp;shares tendered in payment of an option; (b)&nbsp;shares delivered or withheld by us to satisfy any tax withholding obligation; or (c)&nbsp;shares covered by a share-settled share
appreciation right or other awards that were not issued upon the settlement of the award. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If we are acquired, our Board of Directors (or
Compensation Committee) will with respect to options and share appreciation rights: (i)&nbsp;make appropriate provision for the continuation of the option or share appreciation right by substituting on an equitable basis for the ordinary shares then
subject to such option or share appreciation right either the consideration payable with respect to the outstanding ordinary shares in connection with the corporate transaction or securities of any successor or acquiring entity; (ii)&nbsp;cancel or
arrange for the cancellation of the options or share appreciation rights, to the extent not vested or exercised prior to the effective time of the transaction, in exchange for a payment in cash or ordinary shares as determined by the Board of
Directors, in an amount equal to the amount by which the then-fair market value of the ordinary shares subject to such vested option or share appreciation right exceeds the exercise price; or (iii)&nbsp;after giving holders an opportunity to
exercise to the extent vested their outstanding options or share appreciation rights, terminate any or all unexercised options and share appreciation rights at such time as the Board of Directors deems appropriate. If we are acquired, our Board of
Directors (or Compensation Committee) will with respect to outstanding restricted awards make appropriate provision for the continuation of such restricted awards on the same terms and conditions by substituting on an equitable basis for the
ordinary shares then subject to such restricted awards either the consideration payable with respect to the outstanding ordinary shares in connection with the transaction or securities of any successor or acquiring entity. In lieu of the foregoing,
if we are acquired, the Board of Directors may provide that, upon consummation of the acquisition, each outstanding restricted award shall be terminated in exchange for payment of an amount equal to the consideration payable upon consummation of
such transaction to a holder of the number of ordinary shares comprising such restricted award to the extent then vested. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">21 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Outstanding Equity Awards at 2017 Fiscal <FONT STYLE="white-space:nowrap">Year-End</FONT> </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following table shows grants of options and grants of unvested restricted share unit awards outstanding on the last day of the fiscal year
ended December&nbsp;31, 2017 to each of the executive officers named in the Summary Compensation Table. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="38%"></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="14" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Option Awards</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Share Awards</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; width:20.00pt; display:inline; font-size:8pt; font-family:Times New Roman; "><B>Name</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Number of<BR>Securities<BR>Underlying<BR>Unexercised<BR>Options<BR>(#)<BR>Exercisable</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Number of<BR>Securities<BR>Underlying<BR>Unexercised<BR>Options<BR>(#)<BR>Unexercisable</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Option<BR>Exercise<BR>Price&nbsp;($)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Option<BR>Expiration<BR>Date</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Number of<BR>Shares&nbsp;or&nbsp;Share<BR>Units That<BR>Have Not<BR>Vested (#)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Market&nbsp;Value&nbsp;of<BR>Shares or Share<BR>Units&nbsp;That&nbsp;Have<BR>Not Vested ($)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Paul B. Bolno, M.D.</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">544,025</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">2.48</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3/10/2025</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">88,650</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><SUP STYLE="font-size:85%; vertical-align:top"></SUP>&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">147,750<SUP STYLE="font-size:85%; vertical-align:top"></SUP></TD>
<TD NOWRAP VALIGN="bottom"><SUP STYLE="font-size:85%; vertical-align:top">(1)</SUP>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">18.79</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6/16/2026</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><SUP STYLE="font-size:85%; vertical-align:top"></SUP>&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">72,500<SUP STYLE="font-size:85%; vertical-align:top"></SUP></TD>
<TD NOWRAP VALIGN="bottom"><SUP STYLE="font-size:85%; vertical-align:top">(2)</SUP>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">29.05</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1/25/2027</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><SUP STYLE="font-size:85%; vertical-align:top"></SUP>&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">36,300<SUP STYLE="font-size:85%; vertical-align:top"></SUP></TD>
<TD NOWRAP VALIGN="bottom"><SUP STYLE="font-size:85%; vertical-align:top">(3)</SUP>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1,274,130</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Christopher Francis, Ph.D.</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">134,726</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><SUP STYLE="font-size:85%; vertical-align:top"></SUP>&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">12,250<SUP STYLE="font-size:85%; vertical-align:top"></SUP></TD>
<TD NOWRAP VALIGN="bottom"><SUP STYLE="font-size:85%; vertical-align:top">(4)</SUP>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">2.48</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3/10/2025</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">13,913</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><SUP STYLE="font-size:85%; vertical-align:top"></SUP>&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">23,187<SUP STYLE="font-size:85%; vertical-align:top"></SUP></TD>
<TD NOWRAP VALIGN="bottom"><SUP STYLE="font-size:85%; vertical-align:top">(1)</SUP>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">18.79</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6/16/2026</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><SUP STYLE="font-size:85%; vertical-align:top"></SUP>&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">19,500<SUP STYLE="font-size:85%; vertical-align:top"></SUP></TD>
<TD NOWRAP VALIGN="bottom"><SUP STYLE="font-size:85%; vertical-align:top">(2)</SUP>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">29.05</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1/25/2027</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><SUP STYLE="font-size:85%; vertical-align:top"></SUP>&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">9,800<SUP STYLE="font-size:85%; vertical-align:top"></SUP></TD>
<TD NOWRAP VALIGN="bottom"><SUP STYLE="font-size:85%; vertical-align:top">(3)</SUP>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">343,980</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Chandra Vargeese, Ph.D.</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">182,220</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><SUP STYLE="font-size:85%; vertical-align:top"></SUP>&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">36,744<SUP STYLE="font-size:85%; vertical-align:top"></SUP></TD>
<TD NOWRAP VALIGN="bottom"><SUP STYLE="font-size:85%; vertical-align:top">(5)</SUP>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">2.48</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3/10/2025</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">18,598</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><SUP STYLE="font-size:85%; vertical-align:top"></SUP>&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">31,002<SUP STYLE="font-size:85%; vertical-align:top"></SUP></TD>
<TD NOWRAP VALIGN="bottom"><SUP STYLE="font-size:85%; vertical-align:top">(1)</SUP>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">18.79</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6/16/2026</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><SUP STYLE="font-size:85%; vertical-align:top"></SUP>&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">19,500<SUP STYLE="font-size:85%; vertical-align:top"></SUP></TD>
<TD NOWRAP VALIGN="bottom"><SUP STYLE="font-size:85%; vertical-align:top">(2)</SUP>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">29.05</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1/25/2027</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><SUP STYLE="font-size:85%; vertical-align:top"></SUP>&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">9,800<SUP STYLE="font-size:85%; vertical-align:top"></SUP></TD>
<TD NOWRAP VALIGN="bottom"><SUP STYLE="font-size:85%; vertical-align:top">(3)</SUP>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">343,980</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE> <P STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:10%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(1)</TD>
<TD ALIGN="left" VALIGN="top">Vests in equal monthly installments over 36 months, commencing on June&nbsp;16, 2017, subject to such officer&#146;s continued service with us on each such vesting date. The option shall become fully vested upon a
change of control. </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(2)</TD>
<TD ALIGN="left" VALIGN="top">25% vests on February&nbsp;15, 2018 and the remainder of the option vests in equal monthly installments over 36 months, subject to such officer&#146;s continued service with us on each such vesting date. The option
shall become fully vested upon a change of control. </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(3)</TD>
<TD ALIGN="left" VALIGN="top">25% vests on February&nbsp;15, 2018 and the remainder of the award vests in equal annual installments over 3 years, subject to such officer&#146;s continued service with us on each such vesting date. The award shall
become fully vested upon a change of control. </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(4)</TD>
<TD ALIGN="left" VALIGN="top">Vests in equal monthly installments over 36 months, commencing on April&nbsp;15, 2015, subject to such officer&#146;s continued service with us on each such vesting date. The option shall become fully vested upon a
change of control. </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(5)</TD>
<TD ALIGN="left" VALIGN="top">Vests in equal monthly installments over 36 months, commencing on August&nbsp;1, 2015, subject to such officer&#146;s continued service with us on each such vesting date. The option shall become fully vested upon a
change of control. </TD></TR></TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>401(k) Plan </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We maintain a 401(k) plan that is intended to qualify under Section&nbsp;401(k) of the Internal Revenue Service Code of 1986, as amended. In
general, all of our employees, including our named executive officers, are eligible to participate in the 401(k) plan. Under the 401(k) plan, employees may elect to reduce their current compensation by up to the statutorily prescribed annual limit,
equal to $18,000 in 2017, and to have the amount of such reduction contributed to the 401(k) plan. We currently match 50% of an employee&#146;s 401(k) contributions up to a maximum of 6% of the participant&#146;s compensation. Matching contributions
are 100% vested upon completion of one year of service with the Company. Matching contributions made to each of our named executive officers are included in the &#147;Summary Compensation Table&#148; above. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">22 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Potential Payments upon Termination or
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">Change-In-Control</FONT></FONT> </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Pursuant to applicable equity
agreements with each of Drs. Bolno, Francis and Vargeese, all unvested shares underlying outstanding options and restricted share units that were granted through December&nbsp;31, 2017 will become fully vested upon a change of control which is
defined as follows: (A)&nbsp;a merger or consolidation of the Company whether or not approved by the Board of Directors, other than a merger or consolidation which would result in the voting securities of the Company outstanding immediately prior
thereto continuing to represent (either by remaining outstanding or by being converted into voting securities of the surviving entity or the parent of such corporation) more than 50% of the total voting power represented by the voting securities of
the Company or such surviving entity&nbsp;or parent of such corporation, as the case may be, outstanding immediately after such merger or consolidation; or (B)&nbsp;the sale or disposition by the Company of all or substantially all of the
Company&#146;s assets in a transaction requiring shareholder approval. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Pursuant to applicable equity agreements with each of Drs. Bolno,
Francis and Vargeese, all unvested shares underlying outstanding options and restricted share units that are granted after December&nbsp;31, 2017 will become fully vested upon termination without cause or for good reason within 12 months following a
change of control, as defined above. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition, if we terminate Dr.&nbsp;Bolno&#146;s employment without cause, then he will be
entitled to receive as of the date of termination continued payment of his base salary for 12&nbsp;months. Drs. Francis and Vargeese do not have any severance arrangements with the Company. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Director Compensation </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following
table shows the total compensation paid or accrued during the fiscal year ended December&nbsp;31, 2017 to each of our <FONT STYLE="white-space:nowrap">non-employee</FONT> directors.&nbsp;Directors who are also employees are not compensated for their
service on our Board of Directors. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="92%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="35%"></TD>
<TD VALIGN="bottom" WIDTH="10%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="10%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="10%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="9%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; width:20.00pt; display:inline; font-size:8pt; font-family:Times New Roman; "><B>Name</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Fees&nbsp;Earned&nbsp;or<BR>Paid&nbsp;in&nbsp;Cash&nbsp;
($)<SUP STYLE="font-size:85%; vertical-align:top"></SUP><SUP STYLE="font-size:85%; vertical-align:top">(1)</SUP></B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Option&nbsp;Awards&nbsp;($)<SUP STYLE="font-size:85%; vertical-align:top"></SUP><SUP STYLE="font-size:85%; vertical-align:top">(2)</SUP></B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>All Other<BR>Compensation&nbsp;($)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Total ($)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Christian Henry</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">63,431</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">78,241</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">141,672</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Peter Kolchinsky, Ph.D.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">49,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">78,241</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">127,241</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Koji Miura</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">42,500</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">78,241</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">120,741</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Adrian Rawcliffe</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">38,745</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">408,167</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">446,912</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Ken Takanashi</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">48,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">78,241</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">126,241</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Masaharu Tanaka</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">22,069</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">22,069</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Gregory Verdine, Ph.D.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">53,886</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">78,241</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><SUP STYLE="font-size:85%; vertical-align:top"></SUP>&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">150,000<SUP STYLE="font-size:85%; vertical-align:top"></SUP></TD>
<TD NOWRAP VALIGN="bottom"><SUP STYLE="font-size:85%; vertical-align:top">(3)</SUP>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">282,127</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Takeshi Wada, Ph.D.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,973</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><SUP STYLE="font-size:85%; vertical-align:top"></SUP>&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">26,290<SUP STYLE="font-size:85%; vertical-align:top"></SUP></TD>
<TD NOWRAP VALIGN="bottom"><SUP STYLE="font-size:85%; vertical-align:top">(4)</SUP>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">29,263</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE> <P STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:10%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(1)</TD>
<TD ALIGN="left" VALIGN="top">Amounts represent fees earned during 2017 under our <FONT STYLE="white-space:nowrap">Non-Employee</FONT> Director Compensation Policy. </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(2)</TD>
<TD ALIGN="left" VALIGN="top">Amount represents the aggregate grant date fair value for the option awards identified, computed in accordance with FASB ASC Topic 718. A discussion of the assumptions used in determining grant date fair value may be
found in Note 7 to the financial statements included in our Annual Report on Form <FONT STYLE="white-space:nowrap">10-K</FONT> for the year ended December&nbsp;31, 2017. </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(3)</TD>
<TD ALIGN="left" VALIGN="top">Amount paid pursuant to a consulting agreement between the Company and Dr. Verdine. </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(4)</TD>
<TD ALIGN="left" VALIGN="top">Amount paid as a fee for the provision of scientific advisory services to Wave Life Sciences Japan, Inc., or Wave Japan, our wholly owned subsidiary, and reflects the converted to U.S. dollar value of &yen;2,935,000 at
an average conversion rate for 2017 of 112.50 yen per U.S. dollar. </TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following is a description of the standard
compensation arrangements under which our directors are compensated for their service as directors, including as members of the various committees of our Board of Directors. In 2016, our Board of Directors and our shareholders approved a
compensation policy for our </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">23 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
<FONT STYLE="white-space:nowrap">non-employee</FONT> directors, or the <FONT STYLE="white-space:nowrap">Non-Employee</FONT> Director Compensation Policy, which took effect on November&nbsp;10,
2016. At the 2017 Annual General Meeting of Shareholders, our shareholders approved the extension of the term of our <FONT STYLE="white-space:nowrap">Non-Employee</FONT> Director Compensation Policy through the date on which our 2018 AGM is held.
The approval of Proposal 3 would extend the term of our <FONT STYLE="white-space:nowrap">Non-Employee</FONT> Director Compensation Policy through the date on which our 2019 Annual General Meeting of Shareholders is held and amend the terms of the
compensation payable thereunder as set forth in Proposal 3. On August&nbsp;10, 2017, our shareholders approved the following <FONT STYLE="white-space:nowrap">non-employee</FONT> director compensation be paid to our
<FONT STYLE="white-space:nowrap">non-employee</FONT> directors from the date of our 2017 AGM through the date of the 2018 AGM: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Annual cash compensation of $35,000 to each <FONT STYLE="white-space:nowrap">non-employee</FONT> director, other than the Chairman of the Board, and cash compensation of $60,000 to the
<FONT STYLE="white-space:nowrap">non-employee</FONT> Chairman of the Board. </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Additional annual cash compensation of $15,000 to the Chairman of the Audit Committee and $7,500 to each member of the Audit Committee other than the Chairman, in each case provided that such person is an independent
director. </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Additional annual cash compensation of $10,000 to the Chairman of the Compensation Committee and $5,000 to each member of the Compensation Committee other than the Chairman, in each case provided that such person is an
independent director. </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Additional annual cash compensation of $8,000 to the Chairman of the Nominating and Corporate Governance Committee and $4,000 to each member of the Nominating and Corporate Governance Committee other than the Chairman,
in each case provided that such person is an independent director. </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="white-space:nowrap">One-time</FONT> equity grant upon initial appointment or election to the Board of an option to purchase 18,000 ordinary shares, 25% of which shall vest on the first anniversary of the
grant and the remaining 75% of which shall vest monthly thereafter for three years. </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Annual equity grant of an option to purchase 9,000 ordinary shares, all of which shall vest on the first anniversary of the grant. </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Additional pro rata cash compensation of the annual cash compensation amounts set forth above shall be made, as applicable, to (i)&nbsp;any director who ceases to be a director, Chairman of the Board or member or
chairman of any committee of the Board and (ii)&nbsp;any new <FONT STYLE="white-space:nowrap">non-employee</FONT> director who is appointed by the Board, any independent director who is appointed to the position of Chairman of the Board or chairman
of any such committee of the Board or any independent director who is appointed to serve on any such committee of the Board, for their services rendered as a director and/or committee member. </TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">24 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc589845_5"></A>EQUITY COMPENSATION PLAN INFORMATION </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following table provides certain information with respect to our 2014 Equity Incentive Plan, which was our only equity compensation plan
in effect as of December&nbsp;31, 2017. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="84%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="34%"></TD>
<TD VALIGN="bottom" WIDTH="15%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="14%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="14%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; width:49.10pt; display:inline; font-size:8pt; font-family:Times New Roman; "><B>Plan Category</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Number&nbsp;of&nbsp;Securities<BR>to be Issued upon<BR>Exercise of<BR>Outstanding&nbsp;Options,<BR>Warrants and Rights</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Weighted-Average<BR>Exercise Price of<BR>Outstanding<BR>Options,&nbsp;Warrants<BR>and Rights</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Number of<BR>Securities<BR>Remaining<BR>Available&nbsp;for&nbsp;Future<BR>Issuance under<BR>Equity<BR>Compensation Plans</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Equity compensation plans approved by security holders</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><SUP STYLE="font-size:85%; vertical-align:top"></SUP>&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,921,589<SUP STYLE="font-size:85%; vertical-align:top"></SUP></TD>
<TD NOWRAP VALIGN="bottom"><SUP STYLE="font-size:85%; vertical-align:top">(1)</SUP>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$<SUP STYLE="font-size:85%; vertical-align:top"></SUP></TD>
<TD VALIGN="bottom" ALIGN="right">12.69<SUP STYLE="font-size:85%; vertical-align:top"></SUP></TD>
<TD NOWRAP VALIGN="bottom"><SUP STYLE="font-size:85%; vertical-align:top">(2)</SUP>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,716,110</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Equity compensation plans not approved by security holders</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><SUP STYLE="font-size:85%; vertical-align:top"></SUP>&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,921,589<SUP STYLE="font-size:85%; vertical-align:top"></SUP></TD>
<TD NOWRAP VALIGN="bottom"><SUP STYLE="font-size:85%; vertical-align:top">(1)</SUP>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$<SUP STYLE="font-size:85%; vertical-align:top"></SUP></TD>
<TD VALIGN="bottom" ALIGN="right">12.69<SUP STYLE="font-size:85%; vertical-align:top"></SUP></TD>
<TD NOWRAP VALIGN="bottom"><SUP STYLE="font-size:85%; vertical-align:top">(2)</SUP>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,716,110</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:10%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(1)</TD>
<TD ALIGN="left" VALIGN="top">Consists of options to purchase 3,767,130 of our ordinary shares outstanding under the 2014 Equity Incentive Plan and 154,459 of our ordinary shares subject to RSUs outstanding under the 2014 Equity Incentive Plan.
</TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(2)</TD>
<TD ALIGN="left" VALIGN="top">Reflects the weighted average exercise price of the options to purchase 3,767,130 of our ordinary shares outstanding under the 2014 Equity Incentive Plan. </TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">25 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc589845_6"></A>REPORT OF AUDIT COMMITTEE </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Audit Committee of the Board of Directors has furnished the following report: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Audit Committee assists the Board in overseeing and monitoring the integrity of our financial reporting process, compliance with legal and
regulatory requirements and the quality of internal and external audit processes. The committee&#146;s role and responsibilities are set forth in the Audit Committee charter adopted by the Board, which is available on our website at
www.wavelifesciences.com. This committee reviews and reassesses our charter annually and recommends any changes to the Board for approval. The Audit Committee is responsible for overseeing our overall financial reporting process, and for the
appointment, compensation, retention, and oversight of the work of KPMG LLP. In fulfilling its responsibilities for the financial statements for the fiscal year ended December&nbsp;31, 2017, the Audit Committee took the following actions: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Reviewed and discussed the audited financial statements for the fiscal year ended December&nbsp;31, 2017 with management and KPMG LLP, our independent registered public accounting firm; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Discussed with KPMG LLP the matters required to be discussed in accordance with Auditing Standard No.&nbsp;1301 &#150; <I>Communications with Audit Committees</I>; and </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Received written disclosures and the letter from KPMG LLP regarding its independence as required by applicable requirements of the Public Company Accounting Oversight Board regarding KPMG LLP communications with the
Audit Committee and the Audit Committee further discussed with KPMG LLP their independence. The Audit Committee also considered the status of pending litigation, taxation matters and other areas of oversight relating to the financial reporting and
audit process that the committee determined appropriate. </TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Based on the Audit Committee&#146;s review of the audited
financial statements and discussions with management and KPMG LLP, the Audit Committee recommended to the Board that the audited financial statements be included in our Annual Report on Form <FONT STYLE="white-space:nowrap">10-K</FONT> for the
fiscal year ended December&nbsp;31, 2017 for filing with the SEC. </P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>
<TD WIDTH="100%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"><B>Members of the Audit Committee</B></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">Christian Henry, Chair</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">Koji Miura</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">Adrian Rawcliffe</TD></TR>
</TABLE></DIV>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">26 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc589845_7"></A>SECTION 16(A) BENEFICIAL OWNERSHIP REPORTING COMPLIANCE </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">With the exception of Form 4s required to report the receipt of annual option grants to each of our
<FONT STYLE="white-space:nowrap">non-employee</FONT> directors, Drs. Kolchinsky and Verdine, and Messrs. Henry, Miura, Rawcliffe, and Takanashi, on August&nbsp;10, 2017, the date of our 2017 Annual General Meeting of Shareholders, pursuant to our
publicly filed <FONT STYLE="white-space:nowrap">non-employee</FONT> director compensation policy, which were filed on August&nbsp;17, 2017 (but were due on August&nbsp;14, 2017), our records reflect that all reports that were required to be filed
pursuant to Section&nbsp;16(a) of the Exchange Act were filed on a timely basis. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc589845_8"></A>CERTAIN RELATIONSHIPS AND
RELATED PERSON TRANSACTIONS </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following includes a summary of transactions since January&nbsp;1, 2017 to which we have been a
party, in which the amount involved in the transaction exceeded $120,000, and in which any of our directors, executive officers or beneficial owners of more than 5% of our ordinary shares, on an <FONT STYLE="white-space:nowrap">as-converted</FONT>
basis, or any member of the immediate family of any of the foregoing persons had or will have a direct or indirect material interest, other than equity and other compensation, termination, change in control and other arrangements, which are
described under &#147;Executive Officer and Director Compensation.&#148; We refer to such transactions as &#147;related party transactions&#148; and such persons as &#147;related parties.&#148; With the approval of our Board of Directors, we have
engaged in the related party transactions described below. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Related Party Transaction Policy </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our Board of Directors has adopted a written policy that requires our management to identify proposed related party transactions and present
information about the proposed related party transaction to our Audit Committee, or if Audit Committee approval would be inappropriate, to another independent body of our Board of Directors, for review and, if deemed appropriate, for approval by the
committee.&nbsp;In approving or rejecting such proposed related party transaction, the committee is required to consider relevant facts and circumstances.&nbsp;The committee approves only those transactions that, in light of known circumstances, are
deemed to be in our best interests.&nbsp;In the event that any member of the committee is not a disinterested person with respect to the related party transaction under review, that member is excluded from the review and approval or rejection of
such related party transaction; provided, however, that such committee member may be counted in determining the presence of a quorum at the meeting of the committee at which such transaction is considered.&nbsp;If we become aware of an existing
related party transaction which has not been approved under the policy, the matter will be referred to the committee.&nbsp;The committee evaluates all options available, including ratification, revision or termination of such transaction.&nbsp;In
the event that management determines that it is impractical or undesirable to wait until a meeting of the committee to consummate a related party transaction, the chair of the committee may approve such transaction in accordance with the related
person transaction approval policy.&nbsp;Any such approval must be reported to the committee at the next regularly scheduled meeting. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Indemnification
Agreements with Officers and Directors </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We have entered into deeds of indemnity with our directors and our executive
officers.&nbsp;These agreements will require us to indemnify these individuals to the fullest extent permitted under Singapore law against liabilities that may arise by reason of their service to us as a result of any proceeding against them as to
which they could be indemnified.&nbsp;These indemnification rights shall not be exclusive of any other right which an indemnified person may have or hereafter acquire under any statute, provision of our Constitution, agreement, vote of shareholders
or disinterested directors or otherwise if he or she is subsequently found to have been negligent or otherwise have breached his or her trust or fiduciary duties or to be in default thereof, or where the Singapore courts have declined to grant
relief. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">27 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Registration Rights </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B><I>Registration Rights Under Our Investors&#146; Rights Agreement </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As of June&nbsp;15, 2018, the holders of approximately 7.3&nbsp;million of our ordinary shares are entitled to rights with respect to the
registration of these shares under the Securities Act pursuant to the terms of the Investors&#146; Rights Agreement dated as of August&nbsp;14, 2015 between us and the holders of these shares. The rights include demand registration rights, Form <FONT
STYLE="white-space:nowrap">S-3</FONT> registration rights and piggyback registration rights. We are generally required to bear all registration expenses incurred in connection with the demand, Form <FONT STYLE="white-space:nowrap">S-3</FONT> and
piggyback registrations described below, other than underwriting commissions and discounts, and will pay the reasonable fees and expenses, not to exceed $25,000, of one special counsel to represent all participating shareholders in a registration.
The holders of registration rights as of June&nbsp;15, 2018 under the Investors&#146; Rights Agreement include the following related parties: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="68%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="82%"></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; width:20.00pt; display:inline; font-size:8pt; font-family:Times New Roman; "><B>Name</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Securities</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Entities affiliated with Shin Nippon Biomedical Laboratories, Ltd.<SUP
STYLE="font-size:85%; vertical-align:top">(1)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,859,130</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Entities affiliated with RA Capital Healthcare Fund, L.P.<SUP
STYLE="font-size:85%; vertical-align:top">(2)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5,213,651</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Gregory&nbsp;L. Verdine, Ph.D.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">75,039</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Paul B. Bolno, M.D.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">190,856</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE> <P STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:10%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(1)</TD>
<TD ALIGN="left" VALIGN="top">Consists of (i) 1,697,467 ordinary shares held by SNBL and (ii) 161,663 ordinary shares held by SNBL USA, an affiliate of SNBL. </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(2)</TD>
<TD ALIGN="left" VALIGN="top">Consists of (i) 5,012,057 ordinary shares held by RA Capital and (ii) 201,594 shares held in a separately managed account for which RA Capital Management, LLC, the general partner of RA Capital, is investment advisor.
</TD></TR></TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Demand Registration Rights </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Under the terms of the Investors&#146; Rights Agreement, we will be required, upon the request of holders of at least 50% of the
then-outstanding shares of Registrable Securities, as such term is defined in the Investors&#146; Rights Agreement, requesting registration of at least 50% of the then-outstanding shares of Registrable Securities having an anticipated aggregate
offering price of at least $25.0&nbsp;million, net of selling expenses, to effect the registration of such shares on Form <FONT STYLE="white-space:nowrap">S-1</FONT> for public resale. We are required to effect only one registration pursuant to this
provision of the Investors&#146; Rights Agreement. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I><FONT STYLE="white-space:nowrap">Form&nbsp;S-3</FONT> Registration Rights </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">At any time that we are entitled under the Securities Act to register our shares on <FONT STYLE="white-space:nowrap">Form&nbsp;S-3</FONT> and
the holders of at least 30% of the then-outstanding Registrable Securities request that we register their shares for public resale on <FONT STYLE="white-space:nowrap">Form&nbsp;S-3</FONT> with an aggregate offering price of the shares to be
registered of at least $5.0&nbsp;million, net of selling expenses, we will be required to effect such registration. If, however, our Chief Executive Officer certifies that, in the good faith judgment of our Board of Directors, it would be materially
detrimental to us and our shareholders for such registration to become or remain effective because such action would (i)&nbsp;materially interfere with a significant acquisition, corporate reorganization or similar transaction involving us,
(ii)&nbsp;require premature disclosure of material information that we have a bona fide business purpose for preserving as confidential, or (iii)&nbsp;render us unable to comply with requirements under the Securities Act or Exchange Act, then we
will have the right to defer the registration for up to 120 days. We are only obligated to effect up to one registration on <FONT STYLE="white-space:nowrap">Form&nbsp;S-3</FONT> within any <FONT STYLE="white-space:nowrap">12-month</FONT> period.
</P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Piggyback Registration Rights </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If we
register any of our securities either for our own account or for the account of other shareholders, the holders of these shares are entitled to include their shares in the registration. Subject to certain exceptions, we
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">28 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
and the underwriters may limit the number of shares included in the underwritten offering if the underwriters believe that including these shares would adversely affect the offering. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Indemnification </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our Investors&#146;
Rights Agreement contains customary cross-indemnification provisions, under which we are obligated to indemnify holders of Registrable Securities in the event of material misstatements or omissions in the registration statement attributable to us,
and they are obligated to indemnify us for material misstatements or omissions attributable to them. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Termination of Registration Rights </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The registration rights granted under the Investors&#146; Rights Agreement will terminate on the third anniversary of the closing of our
initial public offering (November 16, 2018) or, with respect to any holder of Registrable Securities, such earlier time as all such Registrable Securities held by such holder are available for resale without limitation during a three-month period
without registration, pursuant to Rule&nbsp;144 or another similar exemption under the Securities Act. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Registration Rights under our Share Purchase
Agreement </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Under the terms of the Pfizer Equity Agreement (defined below), the 1,875,000 ordinary shares that the Pfizer Affiliate
purchased from us under the Pfizer Equity Agreement (the &#147;Pfizer Shares&#148;) were subject to a <FONT STYLE="white-space:nowrap">lock-up</FONT> restriction, such that the Pfizer Affiliate agreed not to, nor cause its affiliates to, without our
prior approval, sell, transfer or otherwise dispose of the Pfizer Shares until certain specified periods of time after the effective date of the Pfizer Equity Agreement. For a certain period following the expiration of the <FONT
STYLE="white-space:nowrap">lock-up</FONT> period, subject to certain conditions and limitations, we agreed to provide certain demand registration rights to the Pfizer Affiliate in order to register all or a portion of the Pfizer Shares purchased by
the Pfizer Affiliate. We also provided the Pfizer Affiliate with certain &#147;piggyback&#148; registration rights for a certain period following the expiration of the <FONT STYLE="white-space:nowrap">lock-up</FONT> period, subject to certain
conditions and limitations, such that when we propose to register our ordinary shares for our account, the Pfizer Affiliate will have the right to include some or all of the Pfizer Shares in such registration. The Pfizer Equity Agreement also
contains other customary terms and conditions of the parties with respect to the registration of the Pfizer Shares. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Consulting Agreement with
Gregory&nbsp;L. Verdine, Ph.D. </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Gregory&nbsp;L. Verdine, Ph.D., a member of our Board of Directors, entered into a consulting agreement
with Wave Life Sciences USA, Inc., or Wave USA, our wholly owned subsidiary, dated as of April&nbsp;1, 2012, pursuant to which Dr.&nbsp;Verdine serves as a scientific advisor. The consulting agreement does not have a specified term and may be
terminated by either party upon 14 days&#146; prior written notice. Wave USA pays Dr.&nbsp;Verdine $12,500 per month and, in 2017, Dr.&nbsp;Verdine was paid an aggregate of $150,000 under this agreement. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Scientific Advisory Arrangement with Takeshi Wada, Ph.D. </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Takeshi Wada, Ph.D., elected to step down from our Board of Directors, effective January&nbsp;31, 2017, and is continuing to work with us as a
scientific advisor. During 2017, Dr.&nbsp;Wada continued to provide scientific advisory services to Wave Life Sciences Japan, Inc., our wholly-owned subsidiary. In January 2017, he was compensated under a
<FONT STYLE="white-space:nowrap">pre-existing</FONT> arrangement that entitled him to &yen;250,000&nbsp;per month, which amounted to approximately $2,000 per month. For the remainder of 2017, Dr.&nbsp;Wada was compensated under a new scientific
advisory services agreement, which entitled him to &yen;335,000&nbsp;per month, and amounted to approximately $3,000 per month. In 2017, we paid Dr.&nbsp;Wada approximately $26,290 in the aggregate for these scientific advisory services. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">29 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Agreements with SNBL </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Ken Takanashi, a member of our Board of Directors, is a director and executive officer of SNBL and its affiliates.&nbsp;Previously, we leased
our corporate office space in Boston, Massachusetts under a <FONT STYLE="white-space:nowrap">non-cancellable</FONT> operating sublease with SNBL, a related party. On September&nbsp;22, 2015, we terminated our sublease with SNBL and exited the
premises on October&nbsp;2, 2015. In connection with the termination, we agreed to guarantee SNBL certain obligations of an unrelated third party who entered into a sublease agreement with SNBL effective October&nbsp;2, 2015. The guarantee provides
that in the event the <FONT STYLE="white-space:nowrap">sub-lessee</FONT> does not meet its lease obligations to SNBL, we will make the required payments. The guarantee agreement is effective through August 2019, when the final lease payments are
due, and coincides with the original expiration of the lease. We simultaneously entered into an indemnification agreement with the <FONT STYLE="white-space:nowrap">sub-lessee</FONT> to indemnify us for any costs incurred under the guaranty made by
us to SNBL. The maximum amount of the guarantee over the three-year and <FONT STYLE="white-space:nowrap">six-month</FONT> sublease period is $0.6&nbsp;million, exclusive of any indemnification from the
<FONT STYLE="white-space:nowrap">sub-lessee.</FONT> </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition, pursuant to the terms of certain service agreements we have with SNBL,
in 2017, we paid SNBL $0.5&nbsp;million for contract research services provided to us and our affiliates. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Banking Relationship with KSS </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Masaharu Tanaka, a member of our Board of Directors through August 2017, served as the President of Kagoshima Development Co. Ltd., the general
partner of KSS, from June 2014 to March 2017. We maintained depository accounts at Kagoshima Bank, Ltd. during 2017, an affiliate of KSS, where we held certain of our cash balances. These accounts were closed in 2018. During the year ended
December&nbsp;31, 2017, we had <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">end-of-quarter</FONT></FONT> cash balances of up to approximately $127&nbsp;thousand in these depository accounts. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Agreements with Pfizer and its Affiliate </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On May&nbsp;5, 2016, we entered into a Research, License and Option Agreement with Pfizer Inc., which we refer to herein as the &#147;Pfizer
Collaboration Agreement.&#148; Simultaneously with the entry into the Pfizer Collaboration Agreement, on May&nbsp;5, 2016, we entered into a Share Purchase Agreement, or the &#147;Pfizer Equity Agreement,&#148; with C.P. Pharmaceuticals
International C.V., an affiliate of Pfizer, or the &#147;Pfizer Affiliate.&#148; We refer to the Pfizer Collaboration Agreement and the Pfizer Equity Agreement herein collectively as the &#147;Pfizer Agreements.&#148; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Pursuant to the terms of the Pfizer Collaboration Agreement, we and Pfizer have agreed to collaborate on the discovery, development and
commercialization of stereopure oligonucleotide therapeutics for up to five programs (each, a &#147;Pfizer Program&#148;), each directed at a genetically-defined hepatic target selected by Pfizer. Under the Pfizer Collaboration Agreement, the
parties agreed to collaborate during a four-year research term. The term of the Pfizer Collaboration Agreement runs from the effective date until the date of the last to expire payment obligations with respect to each Pfizer Program and with respect
to each Company program, and expires on a <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">program-by-program</FONT></FONT> basis accordingly. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Under the terms of the Pfizer Agreements, Pfizer paid us $40.0&nbsp;million upfront, $30.0&nbsp;million of which was in the form of an equity
investment in our ordinary shares. Subject to option exercises by Pfizer, assuming five potential products are successfully developed and commercialized, we may earn potential research, development and commercial milestone payments, plus royalties,
tiered up to low double-digits, on sales of any products that may result from the collaboration pursuant to the Pfizer Collaboration Agreement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Under the Pfizer Equity Agreement, we issued 1,875,000 ordinary shares, or the &#147;Pfizer Shares,&#148; to the Pfizer Affiliate at a
purchase price of $16.00 per share, for an aggregate purchase price of $30.0&nbsp;million. Under the terms of the Pfizer Equity Agreement, the Pfizer Shares were subject to a <FONT STYLE="white-space:nowrap">lock-up</FONT> restriction, such that the
Pfizer Affiliate agreed not to, nor cause its affiliates to, without our prior approval, sell, transfer or otherwise dispose of the Pfizer Shares until certain specified periods of time after the effective date of the Pfizer Equity Agreement. We
also agreed to provide the Pfizer Affiliate with registration rights, as described under &#147;Registration Rights&#148; above. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">30 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc589845_9"></A>PROPOSAL 1: ELECTION OF DIRECTORS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our Constitution requires that each of our directors retire at each annual general meeting of our shareholders, and each retiring director is
then eligible for <FONT STYLE="white-space:nowrap">re-election.</FONT> The Board of Directors, acting on the recommendation of the Nominating and Corporate Governance Committee, has nominated each of Paul B. Bolno, M.D., Christian Henry, Peter
Kolchinsky, Ph.D., Koji Miura, Adrian Rawcliffe, Ken Takanashi, and Gregory L. Verdine, Ph.D. for election at the 2018 AGM. Voting on the election of each nominee will be done separately. If each such nominee is elected, he will serve on our Board
of Directors until our 2019 Annual General Meeting of Shareholders and until his successor has been elected and qualified. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Pursuant to
the Singapore Companies Act and our Constitution, our Board must have at least one director who is ordinarily resident in Singapore. Mr.&nbsp;Miura is our Singapore resident director. Due to the Singapore Companies Act requirement that we have at
least one director who is ordinarily resident in Singapore in office at all times and the sole resident director cannot resign or step down unless there is at least one other resident director, in the event that Mr.&nbsp;Miura is not elected at the
2018 AGM, he will continue in office after the 2018 AGM as a member of our Board until his qualifying successor (i.e., a Singapore resident director) is appointed. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Each of the nominees is presently a director, and each has indicated a willingness to continue to serve as director, if elected. We have no
reason to believe that any nominee will be unable or unwilling to serve as a director. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Each nominee for director who receives the
affirmative vote of a majority of the votes cast by the holders of ordinary shares voting either in person or by proxy at the 2018 AGM will be elected (meaning the number of shares voted &#147;for&#148; a nominee must exceed the number of shares
voted &#147;against&#148; such nominee). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>THE BOARD OF DIRECTORS RECOMMENDS A VOTE &#147;<U>FOR</U>&#148; THE ELECTION OF PAUL B.
BOLNO, M.D., CHRISTIAN HENRY, PETER KOLCHINSKY, PH.D., KOJI MIURA, ADRIAN RAWCLIFFE, KEN TAKANASHI AND GREGORY L. VERDINE, PH.D. AS DIRECTORS, AND PROXIES SOLICITED BY THE BOARD WILL BE VOTED IN FAVOR THEREOF UNLESS A SHAREHOLDER HAS INDICATED
OTHERWISE ON THE PROXY CARD. </B></P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">31 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc589845_10"></A>PROPOSAL 2: INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM AND
</B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>INDEPENDENT SINGAPORE AUDITOR AND </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>AUDITOR REMUNERATION </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The
Audit Committee has appointed KPMG LLP as our independent registered public accounting firm and independent Singapore auditor to audit our financial statements for the fiscal year ending December&nbsp;31, 2018. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">For the fiscal year ended December&nbsp;31, 2017, KPMG LLP was our independent registered public accounting firm and the independent Singapore
auditor of our Singapore Statutory Financial Statements. Pursuant to Section&nbsp;205(2) and 205(4) of the Singapore Companies Act, any <FONT STYLE="white-space:nowrap">re-appointment</FONT> after the initial appointment of our independent Singapore
auditor, or its subsequent removal, requires the approval of our shareholders. The Board proposes that the shareholders approve the <FONT STYLE="white-space:nowrap">re-appointment</FONT> of KPMG LLP as our independent registered public accounting
firm and the independent Singapore auditor of our Singapore Statutory Financial Statements. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We expect that representatives of KPMG LLP
will be present at the 2018 AGM, will be able to make a statement if they so desire, and will be available to respond to appropriate questions. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Pursuant to Section&nbsp;205(16) of the Singapore Companies Act, the remuneration of a company&#146;s auditor shall be fixed by the
shareholders in a general meeting or the shareholders may authorize directors to fix the remuneration. Our Board believes that it is appropriate for the Audit Committee, as part of its oversight responsibilities, to fix the auditor&#146;s
remuneration. Our Board therefore also proposes that the shareholders authorize the Audit Committee to fix KPMG LLP&#146;s remuneration for services rendered as our independent registered public accounting firm and independent Singapore auditor
through the date of our 2019 Annual General Meeting of Shareholders. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In deciding to <FONT STYLE="white-space:nowrap">re-appoint</FONT>
KPMG LLP, the Audit Committee reviewed auditor independence issues and existing commercial relationships with KPMG LLP and concluded that KPMG LLP has no commercial relationship with the Company that would impair its independence for the fiscal year
ending December&nbsp;31, 2018. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Principal Accounting Fees and Services </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following table presents fees for professional audit services rendered by KPMG LLP, our independent registered public accounting firm and
independent Singapore auditor, for the services described in the table. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="76%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="68%"></TD>
<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2017</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2016</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Audit fees<SUP STYLE="font-size:85%; vertical-align:top">(1)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1,143,931</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">633,671</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Audit-related fees<SUP STYLE="font-size:85%; vertical-align:top">(2)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Tax fees<SUP STYLE="font-size:85%; vertical-align:top">(2)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">All other fees<SUP STYLE="font-size:85%; vertical-align:top">(2)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:10%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(1)</TD>
<TD ALIGN="left" VALIGN="top">Audit fees consisted of audit work performed in the preparation of financial statements, as well as work generally only the independent registered public accounting firm can reasonably be expected to provide, such as
statutory audits and the provision of consents in connection with the filing of registration statements and related amendments, as well as other filings. </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(2)</TD>
<TD ALIGN="left" VALIGN="top">There were no audit-related, tax or other fees in 2016 or 2017. </TD></TR></TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Policy on Audit Committee <FONT
STYLE="white-space:nowrap">Pre-Approval</FONT> of Audit and Permissible <FONT STYLE="white-space:nowrap">Non-Audit</FONT> Services of Independent Public Accountant and Independent Singapore Auditor </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In connection with our initial public offering, we adopted a policy under which the Audit Committee must
<FONT STYLE="white-space:nowrap">pre-approve</FONT> all audit and permissible <FONT STYLE="white-space:nowrap">non-audit</FONT> services to be provided by the independent registered public </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">32 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
accounting firm.&nbsp;As part of its review, the Audit Committee also considers whether the categories of <FONT STYLE="white-space:nowrap">pre-approved</FONT> services are consistent with the
rules on accountant independence of the SEC and the Public Company Accounting Oversight Board.&nbsp;The Audit Committee <FONT STYLE="white-space:nowrap">pre-approved</FONT> all services performed since the
<FONT STYLE="white-space:nowrap">pre-approval</FONT> policy was adopted. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Prior to engagement of an independent registered public
accounting firm and independent Singapore auditor for the next year&#146;s audit, management will submit an aggregate of services expected to be rendered during that year for each of four categories of services to the Audit Committee for approval.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">1. <B><I>Audit </I></B>services include audit work performed in the preparation of financial statements, as well as work that generally
only an independent registered public accounting firm can reasonably be expected to provide, including comfort letters, statutory audits, and attest services and consultation regarding financial accounting and/or reporting standards. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">2. <B><I>Audit-related</I></B> services are for assurance and related services that are traditionally performed by an independent registered
public accounting firm, including due diligence related to mergers and acquisitions, employee benefit plan audits, and special procedures required to meet certain regulatory requirements. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">3. <B><I>Tax</I></B> services include all services performed by an independent registered public accounting firm&#146;s tax personnel except
those services specifically related to the audit of the financial statements, and includes fees in the areas of tax compliance, tax planning, and tax advice. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">4. <B><I>Other fees</I></B> are those associated with services not captured in the other categories.&nbsp;The Company generally does not
request such services from our independent registered public accounting firm. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Prior to engagement, the Audit Committee <FONT
STYLE="white-space:nowrap">pre-approves</FONT> these services by category of service. During the year, circumstances may arise when it may become necessary to engage our independent registered public accounting firm and independent Singapore auditor
for additional services not contemplated in the original <FONT STYLE="white-space:nowrap">pre-approval.</FONT> In those instances, the Audit Committee requires specific <FONT STYLE="white-space:nowrap">pre-approval</FONT> before engaging our
independent registered public accounting firm and independent Singapore auditor. The Audit Committee may delegate <FONT STYLE="white-space:nowrap">pre-approval</FONT> authority to one or more of its members. The member to whom such authority is
delegated must report, for informational purposes only, any <FONT STYLE="white-space:nowrap">pre-approval</FONT> decisions to the Audit Committee at its next scheduled meeting. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The affirmative vote of a majority of the votes cast by holders of ordinary shares voting in person or by proxy at the 2018 AGM is required to
approve the <FONT STYLE="white-space:nowrap">re-appointment</FONT> of our independent registered public accounting firm and our independent Singapore auditor and to authorize the Audit Committee to fix the auditor&#146;s remuneration (meaning the
number of shares voted &#147;for&#148; the proposal must exceed the number of shares voted &#147;against&#148; the proposal). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>THE
BOARD OF DIRECTORS RECOMMENDS A VOTE </B>&#147;<B><U>FOR</U></B>&#148;<B> THE APPROVAL OF THE <FONT STYLE="white-space:nowrap">RE-APPOINTMENT</FONT> OF KPMG LLP AS OUR INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM AND INDEPENDENT SINGAPORE AUDITOR
FOR THE YEAR ENDING DECEMBER</B><B></B><B>&nbsp;31, 2018 AND THE AUTHORIZATION OF THE AUDIT COMMITTEE TO FIX KPMG LLP&#146;S REMUNERATION FOR SUCH SERVICES, AND PROXIES SOLICITED BY THE BOARD WILL BE VOTED IN FAVOR OF SUCH APPROVAL AND AUTHORIZATION
UNLESS A SHAREHOLDER INDICATES OTHERWISE ON THE PROXY CARD. </B> </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">33 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc589845_11"></A>PROPOSAL 3: <FONT STYLE="white-space:nowrap">NON-EMPLOYEE</FONT>
DIRECTORS&#146; COMPENSATION </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Under the laws of Singapore, our shareholders must approve all cash and equity-based compensation paid
by us to our directors for services rendered in their capacity as directors. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In 2016, our Board of Directors and our shareholders
approved a compensation policy for our <FONT STYLE="white-space:nowrap">non-employee</FONT> directors, or the <FONT STYLE="white-space:nowrap">Non-Employee</FONT> Director Compensation Policy, which took effect on November&nbsp;10, 2016 and remains
in effect through the date of the 2018 AGM. Proposal 3 would extend the term of our <FONT STYLE="white-space:nowrap">Non-Employee</FONT> Director Compensation Policy through the date on which our 2019 Annual General Meeting of Shareholders is held
and amend the terms of the compensation payable thereunder such that the resulting compensation will be as described below. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Accordingly,
we are seeking shareholder approval to provide payment of the following compensation pursuant to such policy to our <FONT STYLE="white-space:nowrap">non-employee</FONT> directors for service on the Board and its committees during the period from the
2018 AGM through and including the date on which our 2019&nbsp;Annual General Meeting of Shareholders is held: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Annual cash compensation of $40,000 to each <FONT STYLE="white-space:nowrap">non-employee</FONT> director, an increase from the current annual cash compensation of $35,000, other than the Chairman of the Board, and cash
compensation of $65,000 to the <FONT STYLE="white-space:nowrap">non-employee</FONT> Chairman of the Board, an increase from the current annual cash compensation of $60,000. </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Additional annual cash compensation of $15,000 to the Chairman of the Audit Committee and $7,500 to each member of the Audit Committee other than the Chairman, in each case provided that such person is an independent
director. </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Additional annual cash compensation of $10,000 to the Chairman of the Compensation Committee and $5,000 to each member of the Compensation Committee other than the Chairman, in each case provided that such person is an
independent director. </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Additional annual cash compensation of $8,000 to the Chairman of the Nominating and Corporate Governance Committee and $4,000 to each member of the Nominating and Corporate Governance Committee other than the Chairman,
in each case provided that such person is an independent director. </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="white-space:nowrap">One-time</FONT> equity grant upon initial appointment or election to the Board of an option to purchase 18,000 ordinary shares, 25% of which shall vest on the first anniversary of the
grant and the remaining 75% of which shall vest quarterly thereafter for three years. This quarterly vesting represents a change from our prior monthly vesting, which we made to our company-wide standard vesting schedule. </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Annual equity grant of an option to purchase 9,000 ordinary shares, all of which shall vest on the first anniversary of the grant. </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Additional pro rata cash compensation of the annual cash compensation amounts set forth above shall be made, as applicable, to (i)&nbsp;any director who ceases to be a director, Chairman of the Board or member or
chairman of any committee of the Board and (ii)&nbsp;any new <FONT STYLE="white-space:nowrap">non-employee</FONT> director who is appointed by the Board, any independent director who is appointed to the position of Chairman of the Board or chairman
of any such committee of the Board or any independent director who is appointed to serve on any such committee of the Board, for their services rendered as a director and/or committee member. </TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Directors who are employed by us are ineligible to receive compensation from us for services rendered in their capacity as directors. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We believe the authorization requested in this Proposal 3 will benefit our shareholders by enabling us to attract and retain qualified
individuals to serve as members of our Board and to continue to provide leadership to the Company. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">34 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The affirmative vote of a majority of the votes cast by holders of ordinary shares voting in
person or by proxy at the 2018 AGM is required to approve the <FONT STYLE="white-space:nowrap">non-employee</FONT> directors&#146; compensation (meaning the number of shares voted &#147;for&#148; the proposal must exceed the number of shares voted
&#147;against&#148; the proposal). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>THE BOARD OF DIRECTORS RECOMMENDS A VOTE &#147;<U>FOR</U>&#148; THE APPROVAL OF THE NON-EMPLOYEE DIRECTORS&#146;
COMPENSATION AND PROXIES SOLICITED BY THE BOARD WILL BE VOTED IN FAVOR THEREOF UNLESS A SHAREHOLDER HAS INDICATED OTHERWISE ON THE PROXY CARD. </B></P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">35 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc589845_12"></A>PROPOSAL 4: ORDINARY SHARE ALLOTMENTS AND ISSUANCES </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We are incorporated in the Republic of Singapore. Under the laws of Singapore, our directors may issue ordinary shares and make offers or
agreements or grant options that might or would require the issuance of ordinary shares only with the prior approval of our shareholders. We are submitting this proposal to authorize our Board (or a committee thereof) to allot and issue our ordinary
shares from time to time, as set forth below, because we are required to do so under the laws of Singapore before we can issue any ordinary shares in connection with our equity compensation plans, possible future strategic transactions, or public
and private offerings. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If this proposal is approved, the authorization would be effective from the date of the 2018 AGM and continue
until the earlier of (i)&nbsp;the conclusion of our 2019 Annual General Meeting of Shareholders or (ii)&nbsp;the expiration of the period within which our 2019 Annual General Meeting of Shareholders is required by the laws of Singapore to be held.
Our 2019 Annual General Meeting of Shareholders is required to be held no later than 15 months after the date of the 2018 AGM or within six months from the financial year end, whichever is earlier.<B><I> </I></B>The laws of Singapore allow for an
application to be made to the Singapore Accounting and Corporate Regulatory Authority to extend the deadline for holding an annual general meeting for an additional maximum of two months, which may be granted in the discretion of that authority.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our Board believes that it is advisable and in the best interests of our shareholders for our shareholders to authorize the directors to
issue ordinary shares and to make, enter into or grant offers, agreements or options that might or would require the issuance of ordinary shares. In the future, the directors may need to issue ordinary shares or make agreements that would require
the allotment and issuance of new ordinary shares. For example, we may issue ordinary shares: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">in connection with strategic transactions and acquisitions; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">pursuant to public and private offerings of our ordinary shares, as well as instruments (including debt instruments) convertible into our ordinary shares; or </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">in connection with our equity compensation plans and arrangements. </TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Notwithstanding this
general authorization to allot and issue our ordinary shares, we will be required to seek shareholder approval with respect to future issuances of ordinary shares, where required under the Nasdaq Stock Market rules, such as if we were to propose an
issuance of ordinary shares that would result in a change in control of the Company or in connection with certain transactions involving the issuance of ordinary shares representing 20% or more of our outstanding ordinary shares. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We expect that we will continue to issue ordinary shares and grant share options and other equity-based awards in the future under
circumstances similar to those in the past. As of the date of this proxy statement, other than issuances of ordinary shares or agreements that would require the issuance of new ordinary shares in connection with our equity compensation plans and
arrangements, including any equity compensation plans and awards we have assumed or may assume as a result of any acquisitions we may make, we have no specific plans, agreements or commitments to issue any ordinary shares for which approval of this
proposal is required. Nevertheless, our Board believes that it is advisable and in the best interests of our shareholders for our shareholders to provide this general authorization in order to avoid the delay and expense of obtaining shareholder
approval at a later date, and to provide us with greater flexibility to pursue strategic transactions and acquisitions and raise additional capital through public and private offerings of our ordinary shares, as well as instruments convertible into
our ordinary shares. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If this proposal is approved, our directors would be authorized to allot and issue ordinary shares, during the
period described above, subject to our Constitution, applicable Singapore laws and the Nasdaq Stock Market rules. The issuance of a large number of ordinary shares (or instruments convertible into ordinary shares) could
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">36 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
be dilutive to existing shareholders or reduce the trading price of our ordinary shares on the Nasdaq Global Market. If this proposal is not approved, we would not be permitted to issue ordinary
shares (other than shares issuable on exercise or settlement of outstanding options and other instruments convertible into or exercisable for ordinary shares or the like, which were previously granted). If we are unable to rely upon equity as a
component of compensation, we would have to review our compensation practices, and would likely have to substantially increase cash compensation to retain key personnel. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Accordingly, our Board seeks shareholder approval of Ordinary Resolution 4 as set out in the Notice. The affirmative vote of a majority of the
ordinary shares held by the shareholders present in person or represented by proxy at the 2018 AGM and entitled to vote on the proposal is required to authorize the Board of Directors to allot and issue ordinary shares of the Company (meaning the
number of shares voted &#147;for&#148; the proposal must exceed the number of shares voted &#147;against&#148; the proposal). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>THE BOARD OF DIRECTORS
RECOMMENDS A VOTE &#147;<U>FOR</U>&#148; THE AUTHORIZATION OF ORDINARY SHARE ALLOTMENTS AND ISSUANCES AND PROXIES SOLICITED BY THE BOARD WILL BE VOTED IN FAVOR THEREOF UNLESS A SHAREHOLDER HAS INDICATED OTHERWISE ON THE PROXY CARD. </B></P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">37 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc589845_13"></A>CODE OF BUSINESS CONDUCT AND ETHICS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We have adopted a code of business conduct and ethics that applies to all of our employees. The text of the code of conduct and ethics is
posted on our website at www.wavelifesciences.com. Disclosure regarding any amendments to, or waivers from, provisions of the code of conduct and ethics that apply to our directors, principal executive officer or principal financial officer will be
included in a Current Report on Form <FONT STYLE="white-space:nowrap">8-K</FONT> filed with the SEC within four business days following the date of the amendment or waiver, unless website posting or the issuance of a press release of such amendments
or waivers is then permitted by the rules of the Nasdaq Stock Market. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc589845_14"></A>OTHER MATTERS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Board of Directors knows of no other business which will be presented at the 2018 AGM. If any other business is properly brought before
the 2018 AGM, proxies will be voted in accordance with the judgment of the persons named therein. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc589845_15"></A>SHAREHOLDER PROPOSALS AND NOMINATIONS FOR DIRECTOR </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">To be considered for inclusion in the proxy statement relating to our 2019 Annual General Meeting of Shareholders, we must receive shareholder
proposals (other than for director nominations) no later than March&nbsp;4, 2019. To be considered for presentation at our 2019 Annual General Meeting of Shareholders, although not included in the proxy statement, proposals (including director
nominations that are not requested to be included in our proxy statement) must be received no later than May&nbsp;18, 2019. Shareholder proposals are also subject to the requirements of the Singapore Companies Act as described in the paragraph
below. Proposals that are not received in a timely manner will not be voted on at our 2019 Annual General Meeting of Shareholders. If a proposal is received on time, the proxies that management solicits for the meeting may still exercise
discretionary voting authority on the proposal under circumstances consistent with the proxy rules of the SEC. All shareholder proposals should be marked for the attention of General Counsel, Wave Life Sciences Ltd., 733 Concord Avenue, Cambridge,
MA 02138. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition, under Section&nbsp;183 of the Singapore Companies Act, only registered shareholders representing not less than 5%
of the total voting rights or registered shareholders representing not fewer than 100 registered shareholders having an average paid up sum of at least S$500 (Singapore dollars) each may, at their expense, request that we include and give notice of
their proposal for our 2019 Annual General Meeting of Shareholders. Subject to satisfaction of the requirements of Section&nbsp;183 of the Singapore Companies Act, any such requisition must be signed by all the shareholders making the request and be
deposited at our registered office in Singapore, 7 Straits View <FONT STYLE="white-space:nowrap">#12-00,</FONT> Marina One East Tower, Singapore 018936, at least six weeks prior to the date of our 2019 Annual General Meeting of Shareholders in the
case of a request requiring notice of a resolution, or at least one week prior to the date of our 2019 Annual General Meeting of Shareholders in the case of any other request. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Cambridge, Massachusetts </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>June&nbsp;28, 2018 </B></P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">38 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B><U><A NAME="toc589845_16"></A>Appendix A </U></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Wave Life Sciences Ltd. and its Subsidiaries </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Registration Number: 201218209G </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Singapore Statutory Financial Statements </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Year ended December&nbsp;31, 2017 </P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B></B><B><I>Wave Life Sciences Ltd. and its Subsidiaries</I></B><B> </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B></B><B><I>Singapore Statutory Financial Statements</I></B><B> </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B></B><B><I>Year ended December&nbsp;31, 2017</I></B><B> </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="index"></A>Index </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="94%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Page</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#appa589845_1">Directors&#146; Statements</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#appa589845_2">Independent Auditors&#146; Report to the Members of Wave Life Sciences Ltd.
</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#appa589845_3">Consolidated Financial Statements of Wave Life Sciences Ltd. and its Subsidiaries
</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="white-space:nowrap">F-1</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#appa589845_4">Supplementary Financial Information of Wave Life Sciences Ltd. (Parent Company)
</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">F-33</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">2 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B></B><B><I>Wave Life Sciences Ltd. and its Subsidiaries</I></B><B> </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B></B><B><I>Directors&#146; Statements</I></B><B> </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B></B><B><I>Year ended December&nbsp;31, 2017</I></B><B> </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><A NAME="appa589845_1"></A>Directors&#146; Statements </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The directors are pleased to submit this annual report to the members of Wave Life Sciences Ltd. (&#147;the Parent&#148;), together with these directors&#146;
statements, the audited financial statements for the financial year ended December&nbsp;31, 2017 and the auditors&#146; report thereon. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In our opinion:
</P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">a)</TD>
<TD ALIGN="left" VALIGN="top">other than as discussed in the Investment in Subsidiaries paragraph in Note 2 to the supplementary financial information, the consolidated financial statements of Wave Life Sciences Ltd. and its subsidiaries (together
&#147;the Company&#148;) and the supplementary financial information of the Parent set out on pages <FONT STYLE="white-space:nowrap">F-1</FONT> to F-40 are drawn up so as to give a true and fair view of the financial position of the Company and of
the Parent as at December&nbsp;31, 2017, the financial performance, changes in equity and cash flows of the Company for the year ended on that date in accordance with the provisions of the Singapore Companies Act, Chapter 50 and accounting
principles generally accepted in the United&nbsp;States of America; and </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">b)</TD>
<TD ALIGN="left" VALIGN="top">at the date of this statement, there are reasonable grounds to believe that Wave Life Sciences Ltd. will be able to pay its debts as and when they fall due. </TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The board of directors has, on the date of this statement, authorized these financial statements for issue. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Directors </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The directors in office at the date of this
statement are as follows: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="17%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="81%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Paul&nbsp;B.&nbsp;Bolno</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Chief Executive Officer</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Christian&nbsp;O.&nbsp;Henry</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Peter&nbsp;Kolchinsky</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Koji Miura</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Adrian&nbsp;Rawcliffe</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(Appointed on February&nbsp;1, 2017)</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Ken Takanashi</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Gregory&nbsp;L.&nbsp;Verdine</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">3 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B></B><B><I>Wave Life Sciences Ltd. and its Subsidiaries</I></B><B> </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B></B><B><I>Directors&#146; Statements</I></B><B> </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B></B><B><I>Year ended December&nbsp;31, 2017</I></B><B> </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Directors&#146; Interests </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">According to the register kept by Wave Life Sciences Ltd. for the purposes of Section&nbsp;164 of the Companies Act, Chapter 50 (&#147;the Act&#148;) and the
Wave Life Sciences Ltd. option ledger, particulars of interests of directors who held office at the end of the financial year (including those held by their spouses and infant children) in shares, debentures, warrants and share options of Wave Life
Sciences Ltd. or in related corporations (other than wholly-owned subsidiaries) are as follows: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="92%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="72%"></TD>
<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; width:207.10pt; display:inline; font-size:8pt; font-family:Times New Roman; "><B>Name of director and corporation in which interests are
held</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Holdings&nbsp;as&nbsp;of<BR>January&nbsp;1,<BR>2017 or<BR>date&nbsp;of<BR>appointment,<BR>if later</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Holdings&nbsp;as&nbsp;of<BR>December&nbsp;31,<BR>2017</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Paul B. Bolno</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Wave Life Sciences Ltd.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">- Ordinary shares</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">190,856</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">190,856</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">- Options to purchase ordinary shares at:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">- US$2.48 between March&nbsp;10, 2015 and March&nbsp;10, 2025</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">544,025</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">544,025</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">- US$18.79 between June&nbsp;16, 2016 and June&nbsp;16, 2026</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">236,400</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">236,400</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">- US$29.05 between January&nbsp;25, 2017 and January&nbsp;25, 2027</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">72,500</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">- Restricted share units</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">36,300</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Christian O. Henry</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Wave Life Sciences Ltd.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">- Options to purchase ordinary shares at:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">- US$36.43 between November&nbsp;10, 2016 and November&nbsp;10, 2021</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">18,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">18,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">- US$18.10 between August&nbsp;10, 2017 and August&nbsp;10, 2022</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">9,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Peter Kolchinsky</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Wave Life Sciences Ltd.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">- Options to purchase ordinary shares at:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">- US$36.43 between November&nbsp;10, 2016 and November&nbsp;10, 2021</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">9,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">9,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">- US$18.10 between August&nbsp;10, 2017 and August&nbsp;10, 2022</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">9,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Koji Miura</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Wave Life Sciences Ltd.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">- Options to purchase ordinary shares at:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">- US$36.43 between November&nbsp;10, 2016 and November&nbsp;10, 2021</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">9,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">9,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">- US$18.10 between August&nbsp;10, 2017 and August&nbsp;10, 2022</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">9,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Adrian Rawcliffe</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Wave Life Sciences Ltd.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">- Options to purchase ordinary shares at:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">- US$28.80 between February&nbsp;1, 2017 and February&nbsp;1, 2022</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">18,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">- US$18.10 between August&nbsp;10, 2017 and August&nbsp;10, 2022</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">9,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Ken Takanashi</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Wave Life Sciences Ltd.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">- Options to purchase ordinary shares at:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">- US$36.43 between November&nbsp;10, 2016 and November&nbsp;10, 2021</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">9,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">9,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">- US$18.10 between August&nbsp;10, 2017 and August&nbsp;10, 2022</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">9,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">4 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B></B><B><I>Wave Life Sciences Ltd. and its Subsidiaries</I></B><B> </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B></B><B><I>Directors&#146; Statements</I></B><B> </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B></B><B><I>Year ended December&nbsp;31, 2017</I></B><B> </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="92%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="72%"></TD>
<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>

<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; width:207.10pt; display:inline; font-size:8pt; font-family:Times New Roman; "><B>Name of director and corporation in which interests are
held</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Holdings&nbsp;as&nbsp;of<BR>January&nbsp;1,<BR>2017 or<BR>date&nbsp;of<BR>appointment,<BR>if later</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Holdings&nbsp;as&nbsp;of<BR>December&nbsp;31,<BR>2017</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Gregory L. Verdine</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Wave Life Sciences Ltd.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">- Ordinary shares</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">150,079</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">75,039</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">- Ordinary shares<SUP STYLE="font-size:85%; vertical-align:top">(1)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">75,040</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">- Restricted share units<SUP STYLE="font-size:85%; vertical-align:top">(1)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">500</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">- Options to purchase ordinary shares at:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">- US$2.48 between March&nbsp;10, 2015 and March&nbsp;10, 2025</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">532,803</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">532,803</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">- US$2.48 between March&nbsp;10, 2015 and March&nbsp;10, 2025<SUP
STYLE="font-size:85%; vertical-align:top">(1)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">14,699</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">823</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">- US$36.43 between November&nbsp;10, 2016 and November&nbsp;10, 2021</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">9,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">9,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">- US$18.10 between August&nbsp;10, 2017 and August&nbsp;10, 2022</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">9,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE> <P STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:10%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><SUP STYLE="font-size:85%; vertical-align:top">(1)</SUP></TD>
<TD ALIGN="left" VALIGN="top"><SUP STYLE="font-size:85%; vertical-align:top"></SUP>These are held by Kasumi Verdine, Gregory L. Verdine&#146;s spouse. The restricted share units and options were granted to Kasumi Verdine as a part of her
compensation as an employee of Wave Life Sciences USA, Inc., a subsidiary of Wave Life Sciences Ltd. </TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Except as disclosed in this statement,
no director who held office at the end of the financial year had interests in shares, debentures, warrants or share options of Wave Life Sciences Ltd., or of its related corporations, either at the beginning of the financial year, or date of his/her
appointment to this board of directors, if later. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Except as disclosed in Note 7 to the consolidated financial statements, there were no unissued shares
of Wave Life Sciences Ltd. or its subsidiaries under options granted by Wave Life Sciences Ltd. or its subsidiaries as of the end of the financial year. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Auditors </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">KPMG LLP were
<FONT STYLE="white-space:nowrap">re-appointed</FONT> as auditors of Wave Life Sciences Ltd. on August&nbsp;10, 2017. The auditors, KPMG&nbsp;LLP, have indicated their willingness to accept <FONT STYLE="white-space:nowrap">re-appointment.</FONT> </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On behalf of the board of directors, </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>
<TD WIDTH="100%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">/s/ Christian O. Henry</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">&nbsp;&nbsp;Christian O. Henry</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">&nbsp;&nbsp;Director</P></TD></TR>
</TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>
<TD WIDTH="100%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">/s/ Paul B. Bolno</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">&nbsp;&nbsp;Paul B. Bolno, M.D.</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">&nbsp;&nbsp;Director</P></TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">5 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt;margin-bottom:0pt">


<IMG SRC="g589845g51v37.jpg" ALT="LOGO">
 </P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" ALIGN="center">


<TR>
<TD WIDTH="34%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="34%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="30%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman"><B>KPMG LLP</B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman">16 Raffles Quay #22-00</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman">Hong Leong Building</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman">Singapore 048581</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman">Telephone +65 6213 3388</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman">Fax +65 6225 0984</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman">Internet www.kpmg.com.sg</P></TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><A NAME="appa589845_2"></A>Independent auditors&#146; report </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Members of the Company </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Wave Life Sciences Ltd. and its
subsidiaries </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Report on the audit of the financial statements </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Qualified opinion </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We have audited the accompanying
consolidated financial statements of Wave Life Sciences Ltd. and its subsidiaries (the &#147;Company&#148;) and the supplementary financial information of Wave Life Sciences Ltd. (the &#147;Parent&#148;), which comprise the balance sheets of the
Company and Parent as at December&nbsp;31, 2017, consolidated statements of operations, consolidated statements of comprehensive loss, consolidated statements of series A preferred shares and shareholders&#146; equity, and consolidated statements of
cash flows of the Company for the year then ended, and notes to the financial statements, including a summary of significant accounting policies, as set out on pages <FONT STYLE="white-space:nowrap">F-1</FONT> to F-40 (collectively, the
&#147;financial statements&#148;). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In our opinion, except for the effects of the matter described in the &#147;<I>Basis for qualified opinion</I>&#148;
section of our report, the consolidated financial statements of the Company and the balance sheet of the Parent are properly drawn up in accordance with the provisions of the Companies Act, Chapter 50 (the &#147;Act&#148;) and accounting principles
generally accepted in the United States of America (the use of which is approved by the Accounting and Corporate Regulatory Authority of Singapore) so as to give a true and fair view of the financial position of the Company and of the Parent as at
December&nbsp;31, 2017 and of the financial performance, changes in equity and cash flows of the Company for the year ended on that date. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Basis for
qualified opinion </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Accounting principles generally accepted in the United States of America require that the investments in subsidiaries be
consolidated. For the purposes of the supplementary financial information provided as a part of the Singapore Statutory Financial Statements, the Parent did not consolidate the investments in subsidiaries and reported these investments and the
balances with subsidiaries as separate lines in the Parent&#146;s standalone balance sheet. The Parent&#146;s investments in subsidiaries are accounted for by either increasing its initial investment in each subsidiary by that subsidiary&#146;s net
income for each financial year or by decreasing its initial investment in each subsidiary by that subsidiary&#146;s net loss for each financial year to the extent of the initial investment of the subsidiary. Our audit opinion on the financial
statements for the year ended December&nbsp;31, 2016 dated June&nbsp;28, 2017 also included a modification on the same matter. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We conducted our audit in
accordance with Singapore Standards on Auditing (&#147;SSAs&#148;). Our responsibilities under those standards are further described in the &#147;<I>Auditors&#146; responsibilities for the audit of the financial statements&#148; </I>section of our
report. We are independent of the Company in accordance with the Accounting and Corporate Regulatory Authority <I>Code of Professional Conduct and Ethics for Public Accountants and Accounting Entities</I> (&#147;ACRA Code&#148;) together with the
ethical requirements that are relevant to our audit of the financial statements in Singapore, and we have fulfilled our other ethical responsibilities in accordance with these requirements and the ACRA Code. We believe that the audit evidence we
have obtained is sufficient and appropriate to provide a basis for our qualified opinion. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">6 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="51%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="47%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">


<IMG SRC="g589845g51v37.jpg" ALT="LOGO">
</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B></B><B><I>Wave Life Sciences Ltd. and its Subsidiaries</I></B><B></B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B></B><B><I>Independent Auditors&#146; Report</I></B><B></B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B></B><B><I>Year ended December&nbsp;31, 2017</I></B><B></B></P></TD></TR>
</TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Key audit matters </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Key
audit matters are those matters that, in our professional judgement, were of most significance in our audit of the financial statements of the current period. These matters were addressed in the context of our audit of the financial statements as a
whole, and in forming our opinion thereon, and we do not provide a separate opinion on these matters. In addition to the matter described in the &#147;<I>Basis for qualified opinion</I>&#148; section, we have determined the matter described below to
be the key audit matter to be communicated in our report. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="51%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="47%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Revenue recognition under the Pfizer Collaboration Agreement</P>
<P STYLE="font-size:12pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">Refer to Note 5 Pfizer Collaboration and Share Purchase Agreement and the accounting
policy note on revenue recognition</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"><B>The key audit matter</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><B>How the matter was addressed in our audit</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In May 2016, the Company entered into a Research, License and Option Agreement (the &#147;Pfizer Collaboration Agreement&#148;) with Pfizer
Inc. (&#147;Pfizer&#148;). Under the agreement, the Company and Pfizer agreed to collaborate on up to five Pfizer programs over a four year research term, the target nomination period for Pfizer to identify the five Pzifer programs
(&#147;targets&#148;) is eighteen months ended November&nbsp;5, 2017. Pfizer declared two of the five targets upon initiation of the agreement. In 2016, the Company received a $10.0&nbsp;million payment as an upfront license fee under the agreement
and an additional payment following Pfizer&#146;s nomination of the third target in August 2016.</P> <P STYLE="font-size:12pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">During 2017, the Pfizer Collaboration Agreement was amended to extend the target nomination period from November&nbsp;5, 2017 to May&nbsp;5, 2018.
Additionally, a milestone was achieved in November 2017 and the revenue related to this milestone was recognized in full during the year.</P> <P STYLE="font-size:12pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Revenue of $3.7&nbsp;million has been recognized as of December&nbsp;31, 2017. Amounts received prior to satisfaction of revenue criteria have been recorded as
deferred revenue, amounting to $8.3&nbsp;million as of December&nbsp;31, 2017.</P> <P STYLE="font-size:12pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">There is judgement required in assessing the deliverables of the arrangement with Pfizer, whether these deliverables are a separate unit of accounting,
determining the allocable consideration to be allocated to each unit of accounting, and period over which revenue is recognized. These areas are a key audit focus.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our audit procedures include:</P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:1.50em; text-indent:-1.50em; font-size:10pt; font-family:Times New Roman">&#149;&#8195;&#8202;Assessing the Pfizer Collaboration Agreement in accordance to revenue recognition accounting
literature for multi-element arrangements to conclude on the identification of separation unit of accounting, determination of allocation consideration, and the period of recognition.</P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:1.50em; text-indent:-1.50em; font-size:10pt; font-family:Times New Roman">&#149;&#8195;&#8202;Understanding
management&#146;s process to develop the estimated period over which the research and development services are fulfilled and assessed management&#146;s memorandum on performance period change.</P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:1.50em; text-indent:-1.50em; font-size:10pt; font-family:Times New Roman">&#149;&#8195;&#8202;Reading the amendment to
Pfizer Collaboration Agreement to extend the target nomination period to ascertain that the amendment has no impact on the current revenue recognition.</P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:1.50em; text-indent:-1.50em; font-size:10pt; font-family:Times New Roman">&#149;&#8195;&#8202;Agreed invoices issued to and payments received from Pfizer.</P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:1.50em; text-indent:-1.50em; font-size:10pt; font-family:Times New Roman">&#149;&#8195;&#8202;Performing management
enquiries and reading project minutes to identify program changes impacting the timeline.</P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; margin-left:1.50em; text-indent:-1.50em; font-size:10pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap">&#149;&#8195;&#8202;Re-computing</FONT> the revenue and deferred
revenue.</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="font-size:12pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:11pt; font-family:Times New Roman"><B>Findings:</B></P>
<P STYLE="font-size:6pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">We found the assessment of the deliverables in the arrangement, the allocation of
consideration to each unit of accounting, and the revenue recognition period to be reasonable.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">7 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">

<TR>
<TD WIDTH="49%"></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD WIDTH="48%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">


<IMG SRC="g589845g51v37.jpg" ALT="LOGO">
</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B><I>Wave Life Sciences Ltd. and its Subsidiaries</I></B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B><I>Independent Auditors&#146; Report</I></B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B><I>Year ended December&nbsp;31, 2017</I></B></P></TD></TR></TABLE> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The above key audit matter applies to both the consolidated financial statements and the supplementary balance sheet. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Other information </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Management is responsible for the
other information contained in the Singapore Statutory Financial Statements. Other information is defined as all information in the Singapore Statutory Financial Statements other than the financial statements and our auditors&#146; report thereon.
We have obtained all other information prior to the date of this auditors&#146; report. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our opinion on the financial statements does not cover the other
information and we do not express any form of assurance conclusion thereon. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In connection with our audit of the financial statements, our responsibility
is to read the other information and, in doing so, consider whether the other information is materially inconsistent with the financial statements or our knowledge obtained in the audit or otherwise appears to be materially misstated. If, based on
the work we have performed, we conclude that there is a material misstatement of this other information, we are required to report that fact. We have nothing to report in this regard. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Responsibilities of management and directors for the financial statements </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Management is responsible for the preparation of financial statements that give a true and fair view in accordance with the provisions of the Act and
accounting principles generally accepted in the United States of America, and for devising and maintaining a system of internal accounting controls sufficient to provide a reasonable assurance that assets are safeguarded against loss from
unauthorised use or disposition; and transactions are properly authorised and that they are recorded as necessary to permit the preparation of true and fair financial statements and to maintain accountability of assets. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In preparing the financial statements, management is responsible for evaluating whether there are conditions and events, considered in the aggregate, that
raise substantial doubt about the Company&#146;s ability to continue as a going concern within one year after the date the financial statements are issued. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The directors&#146; responsibilities include overseeing the Company&#146;s financial reporting process. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Auditors&#146; responsibilities for the audit of the financial statements </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our objectives are to obtain reasonable assurance about whether the financial statements as a whole are free from material misstatement, whether due to fraud
or error, and to issue an auditors&#146; report that includes our opinion. Reasonable assurance is a high level of assurance, but is not a guarantee that an audit conducted in accordance with SSAs will always detect a material misstatement when it
exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of these financial statements.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As part of an audit in accordance with SSAs, we exercise professional judgement and maintain professional skepticism throughout the audit. We also: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Identify and assess the risks of material misstatement of the financial statements, whether due to fraud or
error, design and perform audit procedures responsive to those risks, and obtain audit evidence that </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">8 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">

<TR>
<TD WIDTH="49%"></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD WIDTH="48%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">


<IMG SRC="g589845g51v37.jpg" ALT="LOGO">
</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B><I>Wave Life Sciences Ltd. and its Subsidiaries</I></B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B><I>Independent Auditors&#146; Report</I></B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B><I>Year ended December&nbsp;31, 2017</I></B></P></TD></TR></TABLE> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">
is sufficient and appropriate to provide a basis for our opinion. The risk of not detecting a material misstatement resulting from fraud is higher than for one resulting from error, as fraud may
involve collusion, forgery, intentional omissions, misrepresentations, or the override of internal controls. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Obtain an understanding of internal controls relevant to the audit in order to design audit procedures that are appropriate in the circumstances, but not for the purpose of expressing an opinion on the effectiveness of
the Company&#146;s internal controls. </TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Evaluate the appropriateness of accounting policies used and the reasonableness of accounting estimates and related disclosures made by management. </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Conclude on the appropriateness of management&#146;s use of the going concern basis of accounting and, based on the audit evidence obtained, whether a material uncertainty exists related to events or conditions that may
cast significant doubt on the Company&#146;s ability to continue as a going concern. If we conclude that a material uncertainty exists, we are required to draw attention in our auditors&#146; report to the related disclosures in the financial
statements or, if such disclosures are inadequate, to modify our opinion. Our conclusions are based on the audit evidence obtained up to the date of our auditors&#146; report. However, future events or conditions may cause the Company to cease to
continue as a going concern. </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Evaluate the overall presentation, structure and content of the financial statements, including the disclosures, and whether the financial statements represent the underlying transactions and events in a manner that
achieves fair presentation. </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Obtain sufficient appropriate audit evidence regarding the financial information of the entities or business activities within the Company to express an opinion on the consolidated financial statements. We are
responsible for the direction, supervision and performance of the company audit. We remain solely responsible for our audit opinion. </TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We
communicate with the directors regarding, among other matters, the planned scope and timing of the audit and significant audit findings, including any significant deficiencies in internal controls that we identify during our audit. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We also provide the directors with a statement that we have complied with relevant ethical requirements regarding independence, and communicate with them all
relationships and other matters that may reasonably be thought to bear on our independence, and where applicable, related safeguards. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">From the matters
communicated with the directors, we determine those matters that were of most significance in the audit of the financial statements of the current period and are therefore the key audit matters. We describe these matters in our auditors&#146; report
unless the law or regulations preclude public disclosure about the matter or when, in extremely rare circumstances, we determine that a matter should not be communicated in our report because the adverse consequences of doing so would reasonably be
expected to outweigh the public interest benefits of such communication. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">9 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">

<TR>
<TD WIDTH="49%"></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD WIDTH="48%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">


<IMG SRC="g589845g51v37.jpg" ALT="LOGO">
</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B><I>Wave Life Sciences Ltd. and its Subsidiaries</I></B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B><I>Independent Auditors&#146; Report</I></B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B><I>Year ended December&nbsp;31, 2017</I></B></P></TD></TR></TABLE> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Report on other legal and regulatory requirements </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In our
opinion, the accounting and other records required by the Act to be kept by the Parent have been properly kept in accordance with the provisions of the Act. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The engagement partner on the audit resulting in this independent auditors&#146; report is Chu Sook Fun. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">/s/ KPMG </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>KPMG LLP </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Public Accountants and </I></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Chartered Accountants </I></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Singapore </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">June&nbsp;27, 2018 </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">10 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B><I>Wave Life Sciences Ltd. and its Subsidiaries </I></B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B><I>Consolidated Financial Statements </I></B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B><I>Year ended December&nbsp;31, 2017 </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="appa589845_3"></A>WAVE LIFE SCIENCES LTD. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>CONSOLIDATED BALANCE SHEETS </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><I>(In thousands, except share amounts) </I></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="78%"></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>December&nbsp;31,<BR>2017</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>December&nbsp;31,<BR>2016</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Assets</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Current assets:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Cash and cash equivalents</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">142,503</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">150,293</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Prepaid expenses and other current assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7,985</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,483</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Deferred tax assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">214</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total current assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">150,488</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">151,990</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Long-term assets:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Property and equipment, net</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">27,334</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">8,607</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Deferred tax assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">560</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Restricted cash</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,610</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,601</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">411</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">53</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total long-term assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">31,355</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">12,821</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">181,843</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">164,811</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Liabilities, Series A preferred shares and shareholders&#146; equity</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Current liabilities:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Accounts payable</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">7,598</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">4,943</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Accrued expenses and other current liabilities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">8,898</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,434</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Current portion of capital lease obligation</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">16</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">62</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Current portion of deferred rent</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">60</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Current portion of deferred revenue</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,705</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,705</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Current portion of lease incentive obligation</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">344</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">11</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total current liabilities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">19,621</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">12,155</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Long-term liabilities:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Capital lease obligation, net of current portion</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">16</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Deferred rent, net of current portion</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,214</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">680</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Deferred revenue, net of current portion</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5,607</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">8,311</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Lease incentive obligation, net of current portion</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,094</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">116</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other liabilities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,619</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">796</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total long-term liabilities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">14,534</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">9,919</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total liabilities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">34,155</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">22,074</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Series A preferred shares, no par value; 3,901,348 shares issued and outstanding</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">7,874</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">7,874</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Shareholders&#146; equity:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Ordinary shares, no par value; 27,829,079 and 23,502,169 shares issued and outstanding at
December&nbsp;31, 2017 and 2016, respectively</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">310,038</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">215,602</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Additional <FONT STYLE="white-space:nowrap">paid-in</FONT> capital</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">22,172</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">10,029</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Accumulated other comprehensive income (loss)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">116</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(291</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Accumulated deficit</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(192,512</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(90,477</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total shareholders&#146; equity</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">139,814</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">134,863</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total liabilities, Series A preferred shares and shareholders&#146; equity</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">181,843</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">164,811</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><I>The accompanying notes are an integral part of the consolidated financial statements. </I></P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-1 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B><I>Wave Life Sciences Ltd. and its Subsidiaries </I></B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B><I>Consolidated Financial Statements </I></B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B><I>Year ended December&nbsp;31, 2017 </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>WAVE LIFE SCIENCES LTD. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>CONSOLIDATED STATEMENTS OF OPERATIONS </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><I>(In thousands, except share and per share amounts) </I></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="65%"></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="10" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>For the Year Ended December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2017</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2016</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2015</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Revenue</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">3,704</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1,485</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">152</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Operating expenses:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Research and development</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">79,309</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">40,818</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">9,057</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">General and administrative</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">26,975</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">15,994</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">10,393</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total operating expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">106,284</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">56,812</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">19,450</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Loss from operations</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(102,580</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(55,327</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(19,298</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other income (expense), net:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Dividend income</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,578</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">255</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Interest income (expense), net</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">337</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">86</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other income (expense), net</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(331</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(50</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">56</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total other income (expense), net</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,253</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">542</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">142</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Loss before income taxes</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(101,327</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(54,785</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(19,156</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Income tax provision</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(708</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(616</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(44</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net loss</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(102,035</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(55,401</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(19,200</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net loss per share attributable to ordinary shareholders&#151;basic and diluted</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(3.85</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(2.43</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(1.83</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Weighted-average ordinary shares used in computing net loss per share attributable to ordinary
shareholders&#151;basic and diluted</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">26,513,382</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">22,800,628</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">10,501,455</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><I>The accompanying notes are an integral part of the consolidated financial statements. </I></P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-2 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B><I>Wave Life Sciences Ltd. and its Subsidiaries </I></B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B><I>Consolidated Financial Statements </I></B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B><I>Year ended December&nbsp;31, 2017 </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>WAVE LIFE SCIENCES LTD. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>CONSOLIDATED STATEMENTS OF COMPREHENSIVE LOSS </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><I>(In thousands, except share and per share amounts) </I></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="71%"></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="10" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>For the Year Ended December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2017</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2016</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2015</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net loss</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(102,035</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(55,401</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(19,200</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other comprehensive loss:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Foreign currency translation</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">407</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(332</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(15</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Comprehensive loss</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(101,628</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(55,733</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(19,215</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><I>The accompanying notes are an integral part of the consolidated financial statements. </I></P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-3 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B><I>Wave Life Sciences Ltd. and its Subsidiaries </I></B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B><I>Consolidated Financial Statements </I></B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B><I>Year ended December&nbsp;31, 2017 </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>WAVE LIFE SCIENCES LTD. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>CONSOLIDATED STATEMENTS OF SERIES A PREFERRED SHARES AND SHAREHOLDERS&#146; EQUITY </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><I>(In thousands, except share amounts) </I></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" ALIGN="center">


<TR>
<TD WIDTH="38%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom"></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Series A</B><br><B>Preferred Shares</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Series B</B><br><B>Preferred Shares</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-RIGHT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Series A</B><br><B>Preferred Shares</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Ordinary Shares</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ROWSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Additional</B><br><B><FONT STYLE="white-space:nowrap">Paid-In-</FONT></B><br><B>Capital</B></TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ROWSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Accumulated</B><br><B>Other</B><br><B>Comprehensive</B><br><B>Income&nbsp;(Loss)</B></TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ROWSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Accumulated</B><br><B>Deficit</B></TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ROWSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Total</B><br><B>Shareholders&#146;</B><br><B>Equity</B></TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Shares</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Amount</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Shares</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Amount</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-RIGHT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Shares</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Amount</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Shares</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Amount</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman"><B>Balance as of December&nbsp;31, 2014</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,901,348</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">7,874</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,263,472</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">9,973</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">56</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(15,876</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">2,027</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Issuance of ordinary shares, net of issuance costs of $169</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,769,077</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">11,631</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">11,631</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Share-based compensation</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">190,856</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">842</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,182</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,024</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Issuance of Series B preferred, net of issuance costs of $3,468</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5,334,892</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">62,532</TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Reclassification of Series A preferred shares</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,901,348</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7,874</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(3,901,348</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(7,874</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(7,874</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Issuance of ordinary shares upon initial public offering, net of issuance costs of $3,702</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6,993,126</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">100,366</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">100,366</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Conversion of Series B preferred shares into ordinary shares upon initial public offering</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(5,334,892</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(62,532</TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5,334,892</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">62,532</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">62,532</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Other comprehensive loss</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(15</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(15</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Net loss</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(19,200</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(19,200</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman"><B>Balance at December&nbsp;31, 2015</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,901,348</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">7,874</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">21,551,423</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">185,344</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">3,182</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">41</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(35,076</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">153,491</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Issuance of ordinary shares</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,875,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">30,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">30,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Share-based compensation</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6,847</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6,847</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Option exercises</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">75,746</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">258</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">258</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Other comprehensive loss</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(332</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(332</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Net loss</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(55,401</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(55,401</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman"><B>Balance at December&nbsp;31, 2016</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,901,348</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">7,874</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">23,502,169</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">215,602</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">10,029</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(291</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(90,477</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">134,863</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Issuance of ordinary shares, net of issuance costs of $491</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,166,667</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">93,509</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">93,509</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Share-based compensation</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">12,143</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">12,143</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Vesting of RSUs</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">22,750</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Option exercises</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">137,493</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">927</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">927</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Other comprehensive loss</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">407</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">407</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Net loss</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(102,035</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(102,035</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman"><B>Balance at December&nbsp;31, 2017</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,901,348</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">7,874</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">27,829,079</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">310,038</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">22,172</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">116</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(192,512</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">139,814</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><I>The accompanying notes are an integral part of the consolidated financial statements. </I></P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-4 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B><I>Wave Life Sciences Ltd. and its Subsidiaries </I></B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B><I>Consolidated Financial Statements </I></B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B><I>Year ended December&nbsp;31, 2017 </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>WAVE LIFE SCIENCES LTD. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>CONSOLIDATED STATEMENTS OF CASH FLOWS </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><I>(In thousands) </I></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:9pt" ALIGN="center">


<TR>
<TD WIDTH="78%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:7pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="10" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>For the Year Ended December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:7pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2017</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2016</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2015</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman"><B>Cash flows from operating activities</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">Net loss</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(102,035</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(55,401</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(19,200</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">Adjustments to reconcile net loss to net cash flows used in operating activities:</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">Amortization of lease incentive obligation</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(208</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">Depreciation and amortization</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,155</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">784</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">594</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">Share-based compensation expense</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">12,143</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6,847</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,024</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">Deferred rent</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,594</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">565</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">88</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">Loss on disposal of property and equipment</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">205</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">Deferred income taxes</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">774</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(564</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">36</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">Tax benefit related to share-based compensation</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(310</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">Changes in operating assets and liabilities:</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">Prepaid expenses and other current assets</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(6,502</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(1,337</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">130</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">Other <FONT STYLE="white-space:nowrap">non-current</FONT> assets</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(358</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">Accounts payable</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,892</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,369</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,648</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">Accrued expenses and other current liabilities</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,550</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,296</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">267</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">Deferred revenue</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(2,704</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">11,015</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(152</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">Other <FONT STYLE="white-space:nowrap">non-current</FONT> liabilities</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">823</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">864</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">38</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">Net cash used in operating activities</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(83,671</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(31,872</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(12,527</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman"><B>Cash flows from investing activities</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">Increase in restricted cash</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(9</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(2,599</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(1,055</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">Proceeds from government grant reimbursements for property and equipment</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">Proceeds from the sale of property and equipment</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">Purchases of property and equipment</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(18,887</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(5,567</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(1,857</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">Net cash used in investing activities</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(18,896</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(8,162</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(2,909</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman"><B>Cash flows from financing activities</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">Proceeds from initial public offering, net of offering costs and underwriter commissions</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">101,444</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">Costs associated with initial public offering</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(1,075</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">Proceeds from issuance of ordinary shares, net of offering costs</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">93,509</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">30,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">11,631</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">Proceeds from issuance of Series B preferred shares, net of offering costs</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">62,532</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">Proceeds from government grant</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">112</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">Payments on capital lease obligation</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(62</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(62</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(126</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">Proceeds from the exercise of share options</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">927</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">258</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">Net cash provided by financing activities</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">94,374</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">29,121</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">175,593</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">Effect of foreign exchange rates on cash</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">403</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(14</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">15</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">Net increase (decrease) in cash and cash equivalents</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(7,790</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(10,927</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">160,172</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">Cash and cash equivalents at beginning of period</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">150,293</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">161,220</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,048</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">Cash and cash equivalents at end of period</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">142,503</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">150,293</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">161,220</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman"><B>Supplemental disclosure of cash flow information:</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">Deferred offering costs in accounts payable and accrued expenses at period end</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1,075</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">Cash paid for interest</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">37</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">29</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">Cash paid for taxes, net of refunds</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(11</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">554</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">Equipment acquired for capital lease obligation</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">268</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">Property and equipment purchases in accounts payable and accrued expenses at period end</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">339</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1,653</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">306</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">Tenant improvements paid for by the landlord during the period</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">2,774</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">128</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">Tenant improvements to be reimbursed by the landlord</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">745</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><I>The accompanying notes are an integral part of the consolidated financial statements. </I></P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-5 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B><I>Wave Life Sciences Ltd. and its Subsidiaries </I></B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B><I>Consolidated Financial Statements </I></B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B><I>Year ended December&nbsp;31, 2017 </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Wave Life Sciences Ltd. </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Notes to Consolidated Financial Statements </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>1. THE COMPANY </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Organization </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Wave Life Sciences Ltd. (together with its subsidiaries, &#147;Wave&#148; or the &#147;Company&#148;) is a biotechnology company with an innovative and
proprietary synthetic chemistry drug development platform that the Company is using to rationally design, develop and commercialize a broad pipeline of <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">first-in-class</FONT></FONT> or
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">best-in-class</FONT></FONT> nucleic acid therapeutic candidates for genetically defined diseases. Nucleic acid therapeutics are a growing and innovative class of drugs that have the
potential to address diseases that have historically been difficult to treat with small molecule drugs or biologics. Nucleic acid therapeutics, or oligonucleotides, are comprised of a sequence of nucleotides that are linked together by a backbone of
chemical bonds. The Company is initially developing oligonucleotides that target genetic defects to either reduce the expression of disease-promoting proteins or transform the production of dysfunctional mutant proteins into the production of
functional proteins. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company was incorporated in Singapore on July&nbsp;23, 2012 and has its principal U.S. office in Cambridge, Massachusetts. The
Company was incorporated with the purpose of combining two commonly held companies, Wave Life Sciences USA, Inc. (&#147;Wave USA&#148;), a Delaware corporation (formerly Ontorii, Inc.), and Wave Life Sciences Japan, Inc. (&#147;Wave Japan&#148;), a
company organized under the laws of Japan (formerly Chiralgen., Ltd.), which occurred on September&nbsp;13, 2012. On May&nbsp;31, 2016, Wave Life Sciences Ireland Limited (&#147;Wave Ireland&#148;) was formed as a wholly<B>-</B>owned subsidiary of
Wave Life Sciences Ltd. On April&nbsp;3, 2017, Wave Life Sciences UK Limited (&#147;Wave UK&#148;) was formed as a wholly<B>-</B>owned subsidiary of Wave Life Sciences Ltd. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company&#146;s primary activities since inception have been developing an innovative and proprietary synthetic chemistry drug development platform to
design, develop and commercialize nucleic acid therapeutic programs, advancing the Company&#146;s neurology franchise, expanding the Company&#146;s research and development activities into additional therapeutic areas including ophthalmology and
hepatic, advancing programs into the clinic, furthering clinical development of such clinical-stage programs, building the Company&#146;s intellectual property, recruiting personnel and assuring adequate capital to support these activities. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Risks and Uncertainties </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company is subject to
risks common to companies in the biotechnology industry including, but not limited to, new technological innovations, protection of proprietary technology, developing internal manufacturing capabilities, dependence on key personnel, compliance with
government regulations and the need to obtain additional financing. The Company&#146;s therapeutic programs will require significant additional research and development efforts, including extensive preclinical and clinical testing and regulatory
approval, prior to commercialization of any product candidates. These efforts require significant amounts of additional capital, adequate personnel infrastructure and extensive compliance-reporting capabilities. There can be no assurance that the
Company&#146;s research and development will be successfully completed, that adequate protection for the Company&#146;s intellectual property will be obtained, that any products developed will obtain necessary government regulatory approval or that
any approved products will be commercially viable. Even if the Company&#146;s product development efforts are successful, it is uncertain when, if ever, the Company will generate significant revenue from product sales. The Company operates in an
environment of rapid change in technology and substantial competition from pharmaceutical and biotechnology companies. In addition, the Company is dependent upon the services of its employees and consultants. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-6 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B><I>Wave Life Sciences Ltd. and its Subsidiaries </I></B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B><I>Consolidated Financial Statements </I></B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B><I>Year ended December&nbsp;31, 2017 </I></B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company has never been profitable, and since its inception has incurred recurring operating losses. The
Company expects to incur significant expenses and increasing operating losses for the foreseeable future. To date, the Company has primarily funded its operations through private placements of debt and equity securities, public offerings of its
ordinary shares and collaborations with third parties. As of December&nbsp;31, 2017, the Company has received an aggregate of approximately $323.2&nbsp;million in net proceeds from these transactions. The Company received $89.3&nbsp;million in net
proceeds from private placements of its debt and equity securities, $100.4&nbsp;million in net proceeds ($111.9&nbsp;million gross proceeds) from its initial public offering, inclusive of the over-allotment exercise, $40.0&nbsp;million under the
Pfizer Agreements, including $10.0&nbsp;million as an upfront payment under the Pfizer Collaboration Agreement and $30.0&nbsp;million in the form of an equity investment, and $93.5&nbsp;million in net proceeds ($100.0&nbsp;million gross proceeds)
from its April 2017 <FONT STYLE="white-space:nowrap">follow-on</FONT> underwritten public offering. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Basis of Presentation </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company has prepared the accompanying consolidated financial statements in conformity with generally accepted accounting principles in the United States of
America (&#147;U.S. GAAP&#148;) and in U.S. dollars. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>2. SIGNIFICANT ACCOUNTING POLICIES </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Cash Equivalents </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company considers all highly
liquid securities with original final maturities of three months or less from the date of purchase to be cash equivalents. Cash equivalents are comprised of funds in money market accounts. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Principles of Consolidation </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company&#146;s
consolidated financial statements include the accounts of the Company and its wholly-owned subsidiaries. All significant intercompany balances and transactions have been eliminated in consolidation. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Use of Estimates </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The preparation of financial
statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, the disclosure of contingent assets and liabilities at the date of the consolidated financial
statements and the reported amounts of expenses during the reporting periods. Significant estimates and assumptions reflected in these consolidated financial statements include the valuation of the Company&#146;s Series A preferred shares on
conversion of the related party notes payable, the valuation of the Company&#146;s ordinary shares prior to the initial public offering in November 2015, the assumptions used to determine the fair value of share-based awards, the period over which
revenue is recognized under the Pfizer Collaboration Agreement (as defined in Note 5), the evaluation of progress to completion of external research and development costs which can result in prepaid or accrued expenses related to the Company&#146;s
contract research organizations and contract manufacturing organizations and the valuation allowance required for the Company&#146;s deferred tax assets and determining uncertain tax positions and the related liabilities. Estimates are periodically
reviewed in light of changes in circumstances, facts and experience. Actual results could differ from the Company&#146;s estimates. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Segment Data
</I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company manages its operations as a single segment for the purposes of assessing performance and making operating decisions. The
Company&#146;s singular focus is on developing its proprietary synthetic chemistry platform to develop and commercialize a broad pipeline of nucleic acid-based therapeutics. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-7 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B><I>Wave Life Sciences Ltd. and its Subsidiaries </I></B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B><I>Consolidated Financial Statements </I></B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B><I>Year ended December&nbsp;31, 2017 </I></B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Foreign Currency Translation </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The functional currency is the U.S. dollar for all of the Company&#146;s entities aside from Wave Japan, which has the Japanese Yen as its functional currency.
Assets and liabilities of Wave Japan are translated at period end exchange rates while revenues and expenses are translated at average exchange rates for the period. Prior to 2017, Wave Japan had intercompany loans payable to Wave that were not
expected to be settled in the foreseeable future which were therefore translated at the historical rate for the date of each capital transaction. In 2017, Wave Japan repaid the intercompany loans which resulted in a foreign exchange loss which is
included in the consolidated statements of operations within other income (expense), net. Net unrealized gains and losses from foreign currency translation are reflected as accumulated other comprehensive (loss) income within Series A preferred
shares and shareholders&#146; equity and consolidated statements of comprehensive loss. Gains and losses on foreign currency transactions are included in the consolidated statements of operations within other income (expenses), net. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Fair Value of Financial Instruments </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company
is required to disclose information on all assets and liabilities reported at fair value that enables an assessment of the inputs used in determining the reported fair values. The fair value hierarchy is a hierarchy of inputs used in measuring fair
value that maximizes the use of observable inputs and minimizes the use of unobservable inputs by requiring that the observable inputs be used when available. Observable inputs are inputs that market participants would use in pricing the financial
instrument based on market data obtained from sources independent of the Company. Unobservable inputs are inputs that reflect the Company&#146;s assumptions about the inputs that market participants would use in pricing the financial instrument and
are developed based on the information available in the circumstances. The fair value hierarchy applies only to the valuation inputs used in determining the reported fair value of the investments and is not a measure of the investment credit
quality. The hierarchy defines three levels of valuation inputs: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">Level 1&#151;Unadjusted quoted prices in active markets that are
accessible at the measurement date of identical, unrestricted assets. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">Level 2&#151;Quoted prices for similar assets, or inputs that are
observable, either directly or indirectly, for substantially the full term through corroboration with observable market data. Level&nbsp;2 includes investments valued at quoted prices adjusted for legal or contractual restrictions specific to the
security. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">Level 3&#151;Pricing inputs are unobservable for the asset, that is, inputs that reflect the reporting entity&#146;s own
assumptions about the assumptions market participants would use in pricing the asset. Level&nbsp;3 includes private investments that are supported by little or no market activity. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Cash and cash equivalents are Level&nbsp;1 assets which are comprised of funds held in readily available checking and money market accounts. Cash and cash
equivalents were recorded at fair value as of December&nbsp;31, 2017 and 2016, totaling $142.5&nbsp;million and $150.3&nbsp;million, respectively. The carrying amounts of accounts receivable, accounts payable and accrued expenses approximate their
fair values due to their short-term maturities. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Concentration of Credit Risk </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Cash and cash equivalents are financial instruments that potentially subject the Company to concentration of credit risk. The Company uses several financial
institutions to maintain its cash and cash equivalents, all of which are high quality, accredited financial institutions and, accordingly, such funds are subject to minimal credit risk. The Company has not experienced any losses in such accounts and
management believes that the Company is not exposed to significant credit risk due to the financial position of the depository institutions in which those deposits are held. The Company has no financial instruments with <FONT
STYLE="white-space:nowrap">off-balance</FONT> sheet risk of loss. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-8 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B><I>Wave Life Sciences Ltd. and its Subsidiaries </I></B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B><I>Consolidated Financial Statements </I></B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B><I>Year ended December&nbsp;31, 2017 </I></B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Restricted Cash </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Restricted cash consists primarily of cash placed in separate restricted bank accounts as required under the terms of the Company&#146;s lease agreements for
its Cambridge, Massachusetts and Lexington, Massachusetts facilities (refer to Note 8). As of December&nbsp;31, 2017 and 2016, the Company had $3.6&nbsp;million of restricted cash, of which $2.6&nbsp;million related to the Lexington facility and the
remaining $1.0&nbsp;million related to the Cambridge facility.</P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Property and Equipment </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Property and equipment, which consists of furniture and equipment and leasehold improvements are stated at cost less accumulated depreciation and amortization.
Depreciation is calculated on a straight-line basis over the following estimated useful lives of the assets: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="76%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="53%"></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Equipment, Furniture and Software</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="white-space:nowrap">3-7&nbsp;years</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Leasehold Improvements</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Shorter&nbsp;of&nbsp;life&nbsp;of&nbsp;lease&nbsp;or&nbsp;useful&nbsp;life</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Depreciation and amortization begins at the time the asset is placed in service. Maintenance and repairs are charged to
operations as incurred. Upon retirement or sale, the cost of the disposed asset and the related accumulated depreciation are removed from the accounts and any resulting gain or loss is reflected in the consolidated statements of operations. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Impairment of Long-Lived Assets </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Long-lived assets
consist of property and equipment. Long-lived assets are reviewed for impairment whenever events or other changes in circumstances indicate that the carrying amount may not be recoverable. Certain factors may exist or events may occur that indicate
that impairment exists including, but not limited to, the following: significant underperformance relative to historical or projected future operating results; significant changes in the manner of use of the underlying assets; and significant
adverse industry or market economic trends. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">When performing the impairment assessment for long-lived assets, the Company compares the carrying value of
such assets to the estimated undiscounted future net cash flows expected from the use of the assets and their eventual disposition. In the event that the carrying value of the assets is determined to be unrecoverable, the Company would estimate the
fair value of the assets and record an impairment charge for the excess of the carrying value over the fair value. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Through December&nbsp;31, 2017, the
Company has not recognized any impairment charges. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Revenue Recognition </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As of December&nbsp;31, 2017, the Company&#146;s only significant source of revenue is derived from the Pfizer Collaboration Agreement (as defined in Note 5),
pursuant to which the Company and Pfizer (as defined in Note 5) have agreed to collaborate on the discovery, development and commercialization of stereopure oligonucleotide therapeutics for the Pfizer Programs (as defined in Note 5), each directed
at a genetically-defined hepatic target selected by Pfizer. The Company entered into the Pfizer Collaboration Agreement in May 2016. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company presents
revenue from the Pfizer Collaboration Agreement under Financial Accounting Standards Board (&#147;FASB&#148;), Accounting Standards Codification (&#147;ASC&#148;) Topic 808,&nbsp;Collaborative Arrangements (&#147;ASC
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-9 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B><I>Wave Life Sciences Ltd. and its Subsidiaries </I></B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B><I>Consolidated Financial Statements </I></B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B><I>Year ended December&nbsp;31, 2017 </I></B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
808&#148;).&nbsp;In addition, the Company recognizes revenue in accordance with ASC Topic 605, Revenue Recognition&nbsp;(&#147;ASC 605&#148;). Accordingly, revenue is recognized for each unit of
accounting when all of the following criteria are met: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">persuasive evidence of an arrangement exists; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">delivery has occurred or services have been rendered; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the seller&#146;s price to the buyer is fixed or determinable; and </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">collectability is reasonably assured. </TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Amounts received prior to satisfying the revenue recognition criteria
are recorded as deferred revenue. Amounts expected to be recognized as revenue within the 12&nbsp;months following the balance sheet date are classified as current portion of deferred revenue in the accompanying consolidated balance sheets. Amounts
not expected to be recognized as revenue within the 12&nbsp;months following the balance sheet date are classified as deferred revenue, net of current portion. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Pursuant to the accounting guidance in ASC <FONT STYLE="white-space:nowrap">605-25,</FONT> the Company evaluates
<FONT STYLE="white-space:nowrap">multiple-element</FONT> arrangements to determine (1)&nbsp;the deliverables included in the arrangement and (2)&nbsp;whether the individual deliverables represent separate units of accounting or whether they must be
accounted for as a combined unit of accounting. This evaluation involves subjective determinations and requires the Company to make judgments about the individual deliverables and whether such deliverables are separable from the other aspects of the
contractual relationship. Deliverables are considered separate units of accounting provided that the delivered item has value to the customer on a standalone basis and, if the arrangement includes a general right of return relative to the delivered
item, delivery or performance of the undelivered item is considered probable and substantially in the Company&#146;s control. In assessing whether an item has standalone value, the Company considers factors such as the research, development,
manufacturing and commercialization capabilities of the collaboration partner and the availability of the associated expertise in the general marketplace. In addition, the Company considers whether the collaboration partner can use a deliverable for
its intended purpose without the receipt of the remaining deliverable, whether the value of the deliverable is dependent on the undelivered item and whether there are other vendors that can provide the undelivered items. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Under the Pfizer Collaboration Agreement, the Company and Pfizer agreed to collaborate on the discovery, development and commercialization of up to five
Pfizer Programs, two of the five targets were declared upon initiation of the agreement in May 2016.&nbsp;The Pfizer Collaboration Agreement provides Pfizer with certain options to nominate up to three remaining programs and the Company is required
to consider whether such options are substantive.&nbsp;Options are considered substantive if, at the inception of the arrangement, the Company is at risk as to whether the collaboration partner will choose to exercise the option. Factors that the
Company considers in evaluating whether an option is substantive include whether the optional elements are essential to the functionality of other programs nominated, whether economic factors compel Pfizer to purchase the optional elements, the cost
to exercise the option, the overall objective of the arrangement and, the benefit Pfizer might obtain from the arrangement without exercising the option. In August 2016, Pfizer nominated the third hepatic target under the Collaboration and pursuant
to the terms of the Pfizer Collaboration Agreement, Pfizer had the option to nominate two additional targets by November&nbsp;5, 2017. On November&nbsp;5, 2017, the Company amended its Pfizer Collaboration Agreement to extend the target nomination
period from November&nbsp;5, 2017 to May&nbsp;5, 2018. This amendment provides Pfizer with an additional six months to nominate the two remaining hepatic targets under the Pfizer Collaboration Agreement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">When an option is considered substantive and there is no significant incremental discount, the option is not considered a deliverable in the arrangement and
no consideration is allocated to it. Conversely, when an option is </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-10 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B><I>Wave Life Sciences Ltd. and its Subsidiaries </I></B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B><I>Consolidated Financial Statements </I></B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B><I>Year ended December&nbsp;31, 2017 </I></B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
not considered substantive or it is considered substantive but is priced at an incremental discount, it is analyzed to determine if it should be combined with other deliverables in the
arrangement. Options that are substantive and priced at a significant and incremental discount are further assessed to determine whether a portion of the upfront payment should be allocated to the option and other deliverables in the arrangement.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">At the inception of an arrangement that includes milestone payments, the Company evaluates whether each milestone is substantive and at risk to both
parties on the basis of the contingent nature of the milestone. This evaluation includes an assessment of whether: (1)&nbsp;the consideration is commensurate with either the Company&#146;s performance to achieve the milestone or the enhancement of
the value of the delivered item(s) as a result of a specific outcome resulting from its performance to achieve the milestone, (2)&nbsp;the consideration relates solely to past performance and (3)&nbsp;the consideration is reasonable relative to all
of the deliverables and payment terms within the arrangement. The Company evaluates factors such as the scientific, clinical, regulatory, commercial, and other risks that must be overcome to achieve the particular milestone and the level of effort
and investment required to achieve the particular milestone in making this assessment. There is considerable judgment involved in determining whether a milestone satisfies all of the criteria required to conclude that a milestone is substantive.
Revenue from substantive milestones will be recognized in its entirety upon successful accomplishment of the milestone. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Aside from the program nomination
payments, which relate to the options described above, the remaining milestone payments required under the Pfizer Collaboration Agreement are contingent upon the Company&#146;s performance under the Pfizer Collaboration Agreement, including in
certain instances, regulatory approval.&nbsp;The Company views these milestones as substantive and has excluded the amounts as allocable consideration at the outset of the arrangement. All commercial milestones will be accounted for in the same
manner as royalties and recorded as revenue upon achievement of the milestone, assuming all other revenue recognition criteria are met. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company
recognizes arrangement consideration allocated to each unit of accounting when all of the revenue recognition criteria in ASC 605 are satisfied for that particular unit of accounting. In the event that a deliverable does not represent a separate
unit of accounting, the Company recognizes revenue from the combined unit of accounting over the Company&#146;s contractual or estimated performance period for the undelivered elements, which is typically the term of the Company&#146;s research and
development obligations. If there is no discernible pattern of performance or objectively measurable performance measures do not exist, then the Company recognizes revenue under the arrangement on a
<FONT STYLE="white-space:nowrap">straight-line</FONT> basis over the period the Company is expected to complete its performance obligations. Conversely, if the pattern of performance in which the service is provided to the customer can be determined
and objectively measurable performance measures exist, then the Company recognizes revenue under the arrangement using the proportional performance method. Revenue recognized is limited to the lesser of the cumulative amount of payments received or
the cumulative amount of revenue earned, as determined using the <FONT STYLE="white-space:nowrap">straight-line</FONT> method or proportional performance method, as applicable, as of the period ending date. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company has concluded that the deliverables under the Pfizer Collaboration Agreement relate primarily to the research and development required by the
Company for each of the programs nominated by Pfizer.&nbsp;The remaining deliverables, including sample supplies provided by each party to fulfill its obligation as a licensee, participation on a joint steering committee to oversee the research and
development activities, and regulatory responsibilities related to filings and obtaining approvals related to the products that may result from each program do not represent separate units of accounting based on their dependence on the research and
development efforts. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Because there is no discernible pattern of performance given the nature of the research and development efforts, the Company
recognizes the allocated revenue for each deliverable under the Pfizer Collaboration Agreement on </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-11 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B><I>Wave Life Sciences Ltd. and its Subsidiaries </I></B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B><I>Consolidated Financial Statements </I></B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B><I>Year ended December&nbsp;31, 2017 </I></B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
a straight<B><FONT STYLE="white-space:nowrap">-</FONT></B>line basis over the period the Company is expected to complete its performance obligations for each deliverable, or unit of accounting.
For the first two Pfizer Programs, this period is expected to be from the initiation date of the Pfizer Collaboration Agreement, which was May&nbsp;5, 2016, and for the other Pfizer Programs, the period is expected to be from the date that work
commences on those programs through the earlier of (a)&nbsp;the termination of the research and development performance obligations under the Pfizer Collaboration Agreement, which is May&nbsp;5, 2020 (the &#147;Research Term&#148;), or (b)&nbsp;the
estimated date the Company expects to meet its research and development performance obligations under the Pfizer Collaboration Agreement. Given the uncertainty as to when the research and development performance obligations will be completed, the
Company has used the Research Term for purposes of applying the straight-line method for revenue recognition for the year ended December&nbsp;31, 2017. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Product Revenue </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company has had no product
revenue to date. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Net Loss per Share </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Basic
net loss per share is computed using the weighted-average number of ordinary shares outstanding during the period. Diluted net loss per share is computed using the sum of the weighted-average number of ordinary shares outstanding during the period
and, if dilutive, the weighted-average number of potential ordinary shares, including the assumed exercise of share options. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company applies the <FONT
STYLE="white-space:nowrap">two-class</FONT> method to calculate its basic and diluted net loss per share attributable to ordinary shareholders, as its Series A preferred shares are participating securities. The
<FONT STYLE="white-space:nowrap">two-class</FONT> method is an earnings allocation formula that treats a participating security as having rights to earnings that otherwise would have been available to ordinary shareholders. However, for the periods
presented, the <FONT STYLE="white-space:nowrap">two-class</FONT> method does not impact the net loss per ordinary share as the Company was in a net loss position for each of the periods presented and holders of Series A preferred shares do not
participate in losses. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company&#146;s Series A preferred shares contractually entitle the holders of such shares to participate in dividends but do
not contractually require the holders of such shares to participate in losses of the Company. Accordingly, for periods in which the Company reports a net loss attributable to ordinary shareholders, diluted net loss per share attributable to ordinary
shareholders is the same as basic net loss per share attributable to ordinary shareholders, since dilutive ordinary shares are not assumed to have been issued if their effect is anti-dilutive. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>License Agreements and Patent Costs </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Costs
associated with licenses of technology and patent costs are expensed as incurred and are generally included in research and development expense in the consolidated statements of operations. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Share-Based Compensation </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company measures and
recognizes share-based compensation expense, for both employee and director option awards, based on the grant date fair value of the awards. The Company calculates the fair value of restricted share unit awards based on the grant date fair value of
the underlying ordinary shares. The Company recognizes share-based compensation expense on a straight-line basis over the requisite service period of the awards, which is generally the vesting period. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-12 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B><I>Wave Life Sciences Ltd. and its Subsidiaries </I></B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B><I>Consolidated Financial Statements </I></B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B><I>Year ended December&nbsp;31, 2017 </I></B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company determines the fair value of share-based awards granted to
<FONT STYLE="white-space:nowrap">non-employees</FONT> as either the fair value of the consideration received or the fair value of the equity instruments issued, whichever is more reliably measurable. All issuances of equity instruments issued to <FONT
STYLE="white-space:nowrap">non-employees</FONT> as consideration for goods or services received by the Company are accounted for based on the fair value of the equity instruments issued. These awards are recorded in expense and additional <FONT
STYLE="white-space:nowrap">paid-in</FONT> capital in shareholders&#146; equity over the applicable service periods based on the fair value of the options at the end of each period. The Company accounts for the expense from share-based awards to <FONT
STYLE="white-space:nowrap">non-employees</FONT> by <FONT STYLE="white-space:nowrap">re-measuring</FONT> the awards at fair value over the vesting period. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company classifies share-based compensation expense in its consolidated statements of operations in the same manner in which the award recipient&#146;s
payroll costs are classified or in which the award recipients&#146; service payments are classified. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Prior to the Company&#146;s initial public offering
(&#147;IPO&#148;) in November 2015, the fair value of the ordinary shares underlying its share-based awards was estimated on each grant date by the board of directors. The board of directors determined the estimated per share fair value of the
Company&#146;s ordinary shares at various dates considering contemporaneous and retrospective valuations performed in accordance with the guidance outlined in the American Institute of Certified Public Accountants Practice Aid, <I>Valuation of
Privately-Held Company Equity Securities Issued as Compensation</I> (&#147;the Practice Aid&#148;). After the closing of the Company&#146;s IPO, the fair value of the ordinary shares underlying the Company&#146;s share-based awards is based on the
closing price of the Company&#146;s ordinary shares as reported by the Nasdaq Global Market on the date of grant. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The fair value of each share option
grant was determined using the methods and assumptions discussed below. Each of these inputs is subjective and generally requires significant judgment and estimation by management. </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"><I>Fair Value of Ordinary Shares</I>. As discussed above, prior to the Company&#146;s IPO, the fair value of the Company&#146;s ordinary shares underlying the Company&#146;s share options was historically determined by
the board of directors. Because prior to the Company&#146;s IPO, there was no public market for the Company&#146;s ordinary shares, the board of directors determined the fair value of the Company&#146;s ordinary shares at the time of grant of the
option by considering a number of objective and subjective factors, including valuations of comparable companies, sales of its shares to unrelated third parties, operating and financial performance and general and industry specific economic outlook.
Following the completion of the Company&#146;s IPO, the fair value of the ordinary shares underlying the Company&#146;s share-based awards is based on the closing price of the Company&#146;s ordinary shares as reported by the Nasdaq Global Market on
the date of grant. </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"><I>Expected Term</I>. The expected term of share options represents the weighted-average period that the share options are expected to remain outstanding. The Company estimated the expected term using the simplified
method, which is an average of the contractual term of the option and the vesting period. </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"><I>Expected Volatility</I>. Since there is limited historical data for the Company&#146;s ordinary shares and limited company-specific historical volatility, it has determined the share price volatility for options
granted based on an analysis of the volatility used by a peer group of publicly traded companies. In evaluating similarity, the Company considers factors such as industry, stage of life cycle and size. </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"><I>Risk-free Interest Rate</I>. The risk-free interest rate is based on the U.S. Treasury yield in effect at the time of the grant for <FONT STYLE="white-space:nowrap">zero-coupon</FONT> U.S. Treasury notes with
remaining terms similar to the expected term of the options. </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"><I>Dividend Rate</I>. The expected dividend was assumed to be zero as the Company has never paid dividends and has no current plans to do so. </TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-13 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B><I>Wave Life Sciences Ltd. and its Subsidiaries </I></B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B><I>Consolidated Financial Statements </I></B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B><I>Year ended December&nbsp;31, 2017 </I></B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Income Taxes </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company accounts for income taxes using an asset and liability approach, which requires recognition of deferred tax assets and liabilities for the expected
future tax consequences of events that have been recognized in the consolidated financial statements, but have not been reflected in taxable income. A valuation allowance is established to reduce deferred tax assets to their estimated realizable
value. Therefore, the Company provides a valuation allowance to the extent that it is more likely than not that all or a portion of the deferred tax assets will not be realized in the future. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company accounts for uncertainty in income taxes recognized in the financial statements by applying a <FONT STYLE="white-space:nowrap">two-step</FONT>
process to determine the amount of tax benefit to be recognized. First, the tax position must be evaluated to determine the likelihood that it will be sustained upon external examination by the taxing authorities. If the tax position is deemed <FONT
STYLE="white-space:nowrap">more-likely-than-not</FONT> to be sustained, the tax position is then assessed to determine the amount of benefit to recognize in the financial statements. The amount of the benefit that may be recognized is the largest
amount that has a greater than 50% likelihood of being realized upon ultimate settlement. The provision for income taxes includes the effects of any resulting tax reserves, or unrecognized tax benefits, that are considered appropriate as well as the
related net interest and penalties. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company recognizes interest and penalties related to uncertain tax positions in the income tax provision on the
consolidated statements of operations. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company has certain service arrangements in place between its U.S., Japan, UK and Singapore entities, which
include transfer pricing assumptions.&nbsp;The determination of the appropriate level of transfer pricing requires judgment based on transfer pricing analyses of comparable companies.&nbsp;The Company monitors the nature of its service arrangements
for changes in its operations as well as economic conditions.&nbsp;The Company also periodically reviews the transfer pricing analyses for changes in the composition in the pool of comparable companies as well the related ongoing results of the
comparable companies. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Recently Issued Accounting Pronouncements </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In May 2014, the FASB issued Accounting Standards Update (&#147;ASU&#148;) <FONT STYLE="white-space:nowrap">No.&nbsp;2014-09,</FONT> Revenue from Contracts
with Customers (Topic 606) (&#147;ASU <FONT STYLE="white-space:nowrap">2014-09&#148;),</FONT> which supersedes the revenue recognition requirements in ASC <FONT STYLE="white-space:nowrap">605-25,</FONT><I>&nbsp;Multiple-Element
Arrangements</I>&nbsp;and most industry-specific guidance. In addition, the FASB recently issued ASUs <FONT STYLE="white-space:nowrap">2016-10</FONT> and <FONT STYLE="white-space:nowrap">2016-12,</FONT> which provide clarifying amendments to ASU <FONT
STYLE="white-space:nowrap">2014-09.</FONT> ASU <FONT STYLE="white-space:nowrap">2014-09</FONT> and its related amendments will be effective for the Company for interim and annual periods beginning after December&nbsp;15, 2017. The new standard
requires that an entity recognize revenue to depict the transfer of promised goods or services to customers in an amount that reflects the consideration to which the company expects to be entitled in exchange for those goods or services. The update
also requires additional disclosure about the nature, amount, timing and uncertainty of revenue and cash flows arising from customer contracts, including significant judgments and changes in judgments and assets recognized from costs incurred to
obtain or fulfill a contract. Companies have the option of applying this new guidance retrospectively to each prior reporting period presented (the full retrospective method) or retrospectively with the cumulative effect of initially applying this
update recognized at the date of initial application (the modified retrospective method). The Company will adopt the new standard effective January&nbsp;1, 2018 under the full retrospective method. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Under ASC 606, an entity recognizes revenue when its customer obtains control of promised goods or services, in an amount that reflects the consideration
which the entity expects to receive in exchange for those goods or services. To determine revenue recognition for arrangements that an entity determines are within the scope of </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-14 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B><I>Wave Life Sciences Ltd. and its Subsidiaries </I></B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B><I>Consolidated Financial Statements </I></B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B><I>Year ended December&nbsp;31, 2017 </I></B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
ASC 606, the entity performs the following five steps: (i)&nbsp;identify the contract(s) with a customer; (ii)&nbsp;identify the performance obligations in the contract; (iii)&nbsp;determine the
transaction price; (iv)&nbsp;allocate the transaction price to the performance obligations in the contract; and (v)&nbsp;recognize revenue when (or as) the entity satisfies a performance obligation. ASC 606 also impacts certain other areas, such as
the accounting for costs to obtain or fulfill a contract. The standard also requires disclosure of the nature, amount, timing, and uncertainty of revenue and cash flows arising from contracts with customers. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company is assessing but has not yet completed its assessment of the impact of the adoption of this standard on its consolidated financial statements.
Therefore, the Company does not know and cannot reasonably estimate the impact that adoption of ASC 606 is expected to have on the consolidated financial statements. Currently, the Company anticipates a potential impact on the revenue recognition
method used to recognize revenue for the identified performance obligations under the Pfizer Collaboration Agreement as well as the recognition of milestone revenue prior to achievement. The expected impact is further described below. Estimated
impacts from the adoption of this standard could differ upon the final adoption and implementation of the standard. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">With respect to the Pfizer
Collaboration Agreement, the Company currently expects the five performance obligations identified under the provisions of ASC 606 will be consistent with the five units of accounting identified under the provisions of ASC 605. However, as
previously described, it currently expects that the timing and pattern of revenue recognition under step (v)&nbsp;above will differ from the pattern of revenue recognition under ASC 605. Under ASC 606, the revenues will be recognized over time. As
of December&nbsp;31, 2017, the Company had recognized $5.2&nbsp;million of revenue under the Pfizer Collaboration Agreement. Deferred revenue related to the Pfizer Collaboration Agreement amounted to $8.3&nbsp;million as of December&nbsp;31, 2017,
of which $2.7&nbsp;million is included in current liabilities. The Company expects a change in the timing and pattern of revenue recognition upon adoption of ASC 606 to impact the Company&#146;s revenue, deferred revenue and net loss. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company expects the accounting for contingent milestone payments under its collaboration agreements to change under ASC 606. ASC 606 does not contain
guidance specific to milestone payments, thereby requiring contingent milestone payments to be considered in accordance with the overall model of ASC 606. Revenue from contingent milestone payments may be recognized earlier under ASC 606 than under
ASC 605, based on an assessment of the probability of achievement of the milestone event and the likelihood of a significant reversal of such milestone revenue at each reporting date. This assessment may result in the recognition of revenue related
to a contingent milestone payment before the milestone event has been achieved. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">ASC 606 requires more robust disclosures than required by previous
guidance, including disclosures related to disaggregation of revenue into appropriate categories, performance obligations, the judgments made in revenue recognition determinations, adjustments to revenue which relate to activities from previous
quarters or years, any significant reversals of revenue, and costs to obtain or fulfill contracts. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In connection with the adoption of these standards,
the Company is implementing several new internal controls, including controls to monitor the probability of achievement of contingent milestone payments and the timing and pattern of performance of the performance obligation. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In February 2016, the FASB issued Accounting Standards Update <FONT STYLE="white-space:nowrap">No.&nbsp;2016-02,&nbsp;Leases</FONT><I></I>&nbsp;(&#147;ASU <FONT
STYLE="white-space:nowrap">2016-02&#148;)</FONT><I>,</I>&nbsp;which requires a lessee to recognize assets and liabilities on the balance sheet for operating leases and changes many key definitions, including the definition of a lease.&nbsp;The
update includes a short-term lease exception for leases with a term of 12 months or less, in which a lessee can make an accounting policy election not to recognize lease assets and lease liabilities. Lessees will continue to differentiate between
finance leases (previously referred to as capital leases) and operating leases, using classification criteria that are substantially similar to the previous </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-15 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B><I>Wave Life Sciences Ltd. and its Subsidiaries </I></B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B><I>Consolidated Financial Statements </I></B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B><I>Year ended December&nbsp;31, 2017 </I></B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
guidance.&nbsp;For lessees, the recognition, measurement, and presentation of expenses and cash flows arising from a lease have not significantly changed from previous U.S. GAAP.&nbsp;Lessees and
lessors are required to recognize and measure leases at the beginning of the earliest period presented using a modified retrospective approach. The modified retrospective approach includes a number of optional practical expedients that entities may
elect to apply as well as transition guidance specific to nonstandard leasing transactions. ASU <FONT STYLE="white-space:nowrap">2016-02</FONT> is effective for fiscal years beginning after December&nbsp;15, 2018, and interim periods within those
fiscal years. The Company is currently evaluating the potential impact that the adoption of ASU <FONT STYLE="white-space:nowrap">2016-02</FONT> may have on its consolidated financial statements. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In October 2016, the FASB issued Accounting Standards Update <FONT STYLE="white-space:nowrap">No.&nbsp;2016-16,</FONT> Income Taxes (Topic 740): Intra-Entity
Transfers of Assets Other Than Inventory (&#147;ASU <FONT STYLE="white-space:nowrap">2016-16&#148;),</FONT> which requires an entity to recognize the income tax consequences of an intra-entity transfer of an asset, other than inventory, when the
transfer occurs, even though the <FONT STYLE="white-space:nowrap">pre-tax</FONT> effects of that transaction are eliminated in consolidation. The amendments are effective for fiscal years, and interim periods within those fiscal years, beginning
after December&nbsp;15, 2017. These amendments should be applied on a modified retrospective basis through a cumulative-effect adjustment directly to retained earnings at the beginning of the period adopted. The Company will adopt ASU <FONT
STYLE="white-space:nowrap">2016-16</FONT> in the first quarter of 2018 and the Company estimates that there will be a cumulative-effect increase of approximately $0.4&nbsp;million to the Company&#146;s accumulated deficit. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In November 2016, the FASB issued Accounting Standards Update <FONT STYLE="white-space:nowrap">No.&nbsp;2016-18,</FONT> Statement of Cash Flows (Topic 230):
Restricted Cash (&#147;ASU <FONT STYLE="white-space:nowrap">2016-18&#148;).</FONT> The ASU requires an entity to explain the changes in the total of cash, cash equivalents, restricted cash, and restricted cash equivalents on the statement of cash
flows and to provide a reconciliation of the totals in that statement to the related captions in the balance sheet when the cash, cash equivalents, restricted cash, and restricted cash equivalents are presented in more than one line item on the
balance sheet. This ASU is effective for annual and interim periods beginning after December&nbsp;15, 2017, and is required to be adopted using a retrospective approach, with early adoption permitted. The Company is currently evaluating the
potential impact that the adoption of ASU <FONT STYLE="white-space:nowrap">2016-18</FONT> may have on its consolidated financial statements. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Other
accounting standards that have been issued or proposed by the FASB or other standards-setting bodies that do not require adoption until a future date are not expected to have a material impact on the Company&#146;s consolidated financial statements
upon adoption. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Recently Adopted Accounting Pronouncements </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In November 2015, the&nbsp;FASB&nbsp;issued Accounting Standards Update No. <FONT STYLE="white-space:nowrap">2015-17,&nbsp;Balance</FONT> Sheet Classification
of Deferred Taxes <FONT STYLE="white-space:nowrap">(&#147;ASU&nbsp;2015-17&#148;),&nbsp;which</FONT> requires entities to present deferred tax assets and liabilities, along with any related valuation allowance, as noncurrent on the balance sheet.
The new standard is effective for annual and interim periods beginning after December&nbsp;15, 2016. During the three months ended March&nbsp;31, 2017, the Company elected to adopt ASU <FONT STYLE="white-space:nowrap">2015-17</FONT> on a prospective
basis. The adoption of this standard resulted in the reclassification of short-term deferred tax assets to long-term deferred tax assets. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-16 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B><I>Wave Life Sciences Ltd. and its Subsidiaries </I></B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B><I>Consolidated Financial Statements </I></B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B><I>Year ended December&nbsp;31, 2017 </I></B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>3. PROPERTY AND EQUIPMENT, NET </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Property and equipment, net, consists of the following </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="76%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="74%"></TD>
<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2017</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2016</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center">(in thousands)</TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Furniture and equipment</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">13,626</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">7,231</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Software</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">108</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">43</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Leasehold improvements</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">16,029</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,964</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Fixed assets in progress</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,988</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,863</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">31,751</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">11,101</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Less accumulated depreciation and amortization</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(4,417</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(2,494</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Property and equipment, net</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">27,334</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">8,607</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Leasehold improvements made during the years ended December&nbsp;31, 2017 and 2016 consisted of costs related to the
Company&#146;s leased facilities in Cambridge, Massachusetts and Lexington, Massachusetts. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Depreciation and amortization expense was $2.2&nbsp;million,
$0.8&nbsp;million and $0.6&nbsp;million for the years ended December&nbsp;31, 2017, 2016 and 2015, respectively. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>4. ACCRUED EXPENSES AND OTHER CURRENT
LIABILITIES </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Accrued expenses and other current liabilities consist of the following: </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="76%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="76%"></TD>
<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2017</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2016</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center">(in thousands)</TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Accrued compensation</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">5,428</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">2,480</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Accrued professional fees</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,281</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">417</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Accrued vacation</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">33</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">589</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other current liabilities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">156</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">948</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total accrued expenses and other current liabilities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">8,898</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">4,434</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>5. PFIZER COLLABORATION AND SHARE PURCHASE AGREEMENT </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On May&nbsp;5, 2016, the Company entered into a Research, License and Option Agreement (the &#147;Pfizer Collaboration Agreement&#148;) with Pfizer Inc.
(&#147;Pfizer&#148;).&nbsp;Pursuant to the terms of the Pfizer Collaboration Agreement, the Company and Pfizer agreed to collaborate on the discovery, development and commercialization of stereopure oligonucleotide therapeutics for up to five
programs (the &#147;Pfizer Programs&#148;), each directed at a genetically-defined hepatic target selected by Pfizer (the &#147;Pfizer Collaboration&#148;).&nbsp;The Company received $10.0&nbsp;million as an upfront license fee under the Pfizer
Collaboration Agreement.&nbsp;Subject to option exercises by Pfizer, the Company may earn potential research, development and commercial milestone payments, plus royalties, tiered up to low double-digits, on sales of any products that may result
from the Pfizer Collaboration. None of the payments under the Pfizer Collaboration Agreement are refundable. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Simultaneously with the entry into the
Pfizer Collaboration Agreement, the Company entered into a Share Purchase Agreement (the &#147;Pfizer Equity Agreement,&#148; and together with the Pfizer Collaboration Agreement, the </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-17 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B><I>Wave Life Sciences Ltd. and its Subsidiaries </I></B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B><I>Consolidated Financial Statements </I></B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B><I>Year ended December&nbsp;31, 2017 </I></B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
&#147;Pfizer Agreements&#148;) with C.P. Pharmaceuticals International C.V., an affiliate of Pfizer (the &#147;Pfizer Affiliate&#148;). Pursuant to the terms of the Pfizer Equity Agreement, the
Pfizer Affiliate purchased 1,875,000 of the Company&#146;s ordinary shares (the &#147;Shares&#148;) at a purchase price of $16.00 per share, for an aggregate purchase price of $30.0&nbsp;million. The Company did not incur any material costs in
connection with the issuance of the Shares. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Under the Pfizer Collaboration Agreement, the parties agreed to collaborate during the four-year Research
Term. During the Research Term, the Company is responsible to use its commercially reasonable efforts to advance up to five programs through to the selection of clinical candidates. At that stage, Pfizer may elect to license any of these Pfizer
Programs exclusively and to have exclusive rights to undertake the clinical development of the resulting clinical candidates into products and the potential commercialization of any such products thereafter. In addition, the Company receives a <FONT
STYLE="white-space:nowrap">non-exclusive,</FONT> royalty-bearing sublicenseable license to use Pfizer&#146;s hepatic targeting technology in any of the Company&#146;s own hepatic programs that are outside the scope of the Pfizer Collaboration (the
&#147;Wave Programs&#148;). If the Company uses this technology on the Wave Programs, Pfizer is eligible to receive potential development and commercial milestone payments from the Company. Pfizer is also eligible to receive tiered royalties on
sales of any products that include Pfizer&#146;s hepatic targeting technology. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Pfizer nominated two hepatic targets upon entry into the Pfizer
Collaboration in May 2016. In August 2016, Pfizer nominated the third hepatic target under the Pfizer Collaboration for which the Company received a $2.5&nbsp;million milestone payment in 2016. On November&nbsp;5, 2017, the Company amended its
Pfizer Collaboration Agreement to extend the target nomination period from November&nbsp;5, 2017 to May&nbsp;5, 2018. This amendment provides Pfizer with an additional six months to nominate the two remaining hepatic targets under the Pfizer
Collaboration Agreement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company has determined that the options held by Pfizer under the Pfizer Collaboration Agreement are substantive and priced
at a significant incremental discount. Accordingly, $3.0&nbsp;million of the upfront payment was allocated to the options to nominate the three remaining targets upon inception. The amount allocated to the three options will be recognized as the
research and development services are provided commencing from the date that Pfizer exercises each respective option, or immediately as each option expires unexercised. The portion of the upfront payment allocated to the initial two targets was
$7.0&nbsp;million and will be recognized as the research and development services are provided from the inception of the arrangement. Subsequently, in 2016, Pfizer exercised its option to nominate a third program. The Company will recognize
$3.5&nbsp;million of revenue (which is comprised of $1.0&nbsp;million allocated to the option at inception of the arrangement and $2.5&nbsp;million paid by Pfizer at the time of exercising the option) as the research and development services are
provided. In November 2017, the Company achieved a milestone under the Pfizer Collaboration Agreement, the revenue related to this milestone was recognized in full during the year ended December&nbsp;31, 2017.</P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Pfizer Collaboration is managed by a joint steering committee in which both parties are represented equally, which will oversee the scientific progression
of each Pfizer Program up to the clinical candidate stage. During the four-year Research Term and for a period of two years thereafter, the Company has agreed to work exclusively with Pfizer with respect to using any of the Company&#146;s stereopure
oligonucleotide technology that is specific for the applicable hepatic target which is the basis of any Pfizer Program.</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The stated term of the Pfizer
Collaboration Agreement commenced on May&nbsp;5, 2016 and terminates on the date of the last to expire payment obligation with respect to each Pfizer Program and with respect to each Wave Program, expires on a <FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap">program-by-program</FONT></FONT> basis accordingly.&nbsp;Pfizer may terminate its rights related to a Pfizer Program under the Pfizer Collaboration Agreement at its own convenience upon 90 days&#146; notice to the Company.
The Company may also terminate its rights related to a Wave Program at its own convenience upon 90 days&#146; notice to Pfizer.&nbsp;The Pfizer Collaboration Agreement may also be terminated by either party in the event of an uncured material breach
of the Pfizer Collaboration Agreement by the other party. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-18 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B><I>Wave Life Sciences Ltd. and its Subsidiaries </I></B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B><I>Consolidated Financial Statements </I></B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B><I>Year ended December&nbsp;31, 2017 </I></B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">During the year ended December&nbsp;31, 2017, the Company recognized&nbsp;revenue of $3.7&nbsp;million under
the Pfizer Collaboration Agreement. Deferred revenue amounted to $8.3 million&nbsp;as of December&nbsp;31, 2017, of which $2.7&nbsp;million is included in current liabilities.</P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>6. SHARE CAPITAL </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><U>Ordinary Shares </U></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The following represents the historical ordinary share transactions of the Company from December&nbsp;31, 2013 through December&nbsp;31, 2017: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">In February 2014, the Company issued 2,263,291 ordinary shares to a third-party investor at $2.47 per share for net proceeds of $5.6&nbsp;million. In connection with this financing, holders of $9.6&nbsp;million of
related party notes payable agreed to convert such notes into 2,365,139 Series A preferred shares and 1,515,596 ordinary shares. </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">In January 2015, the Company issued 4,769,077 ordinary shares to a third-party investor and an existing investor at $2.47 per share for net proceeds of $11.6&nbsp;million. </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">In March 2015, the Company granted 190,856 fully-vested ordinary shares to an executive of the Company. </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">In November 2015, the Company completed an initial public offering of its ordinary shares, in which the Company issued and sold 6,375,000 ordinary shares at a price to the public of $16.00 per share. In December 2015,
the Company issued an additional 618,126 ordinary shares at a price of $16.00 per share pursuant to a partial exercise of the underwriters&#146; over-allotment option. The aggregate net proceeds to the Company from the initial public offering,
inclusive of the over-allotment exercise, were $100.4&nbsp;million after deducting underwriting discounts and commissions and estimated offering expenses payable by the Company. In connection with this financing, the Company&#146;s 5,334,892 Series
B preferred shares automatically converted into 5,334,892 of the Company&#146;s ordinary shares. </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">In May 2016, the Company granted 1,875,000 ordinary shares to Pfizer under the Pfizer Agreements (Note 5) at a purchase price of $16.00 per share, for an aggregate purchase price of $30.0&nbsp;million.
</TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">In April 2017, the Company closed a <FONT STYLE="white-space:nowrap">follow-on</FONT> underwritten public offering of 4,166,667 ordinary shares for gross proceeds of $100.0&nbsp;million.&nbsp;The net proceeds from this
issuance were $93.5&nbsp;million after deducting underwriting discounts and commissions and other estimated offering expenses. </TD></TR></TABLE>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Features of the Ordinary Shares </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The ordinary
shares have no par value and there is no concept of authorized share capital under Singapore law. The rights, preferences, and privileges of ordinary shares are as follows: </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>New Share Offering </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Prior to the closing of the
Company&#146;s initial public offering, any new ordinary shares or securities convertible into ordinary shares were required to be offered in the first instance to all the then holders of any class of shares, other than the Series A preferred
shares, prior to issuance and each shareholder had the right of <FONT STYLE="white-space:nowrap">pre-emption</FONT> with respect to any issuance of new ordinary shares or securities convertible into ordinary shares. This right of <FONT
STYLE="white-space:nowrap">pre-emption</FONT> did not apply to shares sold in the Company&#146;s initial public offering and terminated immediately prior to the closing of the Company&#146;s initial public offering. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-19 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B><I>Wave Life Sciences Ltd. and its Subsidiaries </I></B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B><I>Consolidated Financial Statements </I></B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B><I>Year ended December&nbsp;31, 2017 </I></B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Voting </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The holders of ordinary shares are entitled to one vote for each ordinary share held at all meetings of shareholders and written actions in lieu of meetings.
</P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Dividends </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">All dividends, if any, shall be
declared and paid pro rata according to the number of shares held by each member entitled to receive dividends. The Company&#146;s board of directors may deduct from any dividend all sums of money presently payable by the member to the Company on
account of calls. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Liquidation </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In the event
of a liquidation, dissolution or winding up of, or a return of capital by the Company, the ordinary shares will rank equally with the Series A preferred shares after the payment of the liquidation preference of $10.00 for Series A preferred shares.
</P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><U>Series A Preferred Shares </U></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The following
represent the Series A preferred share transactions of the Company from December&nbsp;31, 2013 through December&nbsp;31, 2017: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">In February 2014, holders of $9.6&nbsp;million of related party notes payable agreed to convert such notes into 2,365,139 Series A preferred shares and 1,515,596 ordinary shares. </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">In connection with the private placement of Series B preferred shares on August&nbsp;14, 2015, holders of the Company&#146;s preference shares agreed to rename the existing &#147;preference shares&#148; as &#147;Series
A preferred shares.&#148; In addition, as further described below, the terms of the Series A preferred shares were amended to remove their right of first refusal and to provide for their right to convert on a <FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap">one-for-one</FONT></FONT> basis into an aggregate of 3,901,348 ordinary shares at any time at the election of the holder. The rights of the Series A preferred shares are identical to the ordinary shares except that the
Series A preferred shares have: (1)&nbsp;no voting rights other than in limited circumstances, (2)&nbsp;the right to a <FONT STYLE="white-space:nowrap">non-cumulative</FONT> dividend if and when declared by the Company&#146;s board of directors and
(3)&nbsp;the right to convert the Series A preferred shares at any time on a <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">one-for-one</FONT></FONT> basis into ordinary shares at the discretion of the holder. The Company&#146;s
shareholders, including holders of Series A preferred shares, entered into an investors&#146; rights agreement and a voting agreement with the Company in connection with the private placement. Pursuant to the terms of the voting agreement, which
terminated in connection with the Company&#146;s IPO, investors who held at least 1,212,477 shares of registerable securities, including holders of Series A preferred shares and Series B preferred shares, had a right to purchase certain new
securities offered by the Company. Additionally, in the event of the sale of 50% or more of the voting power of the Company or a deemed liquidation event, if the holders of at least a majority of the ordinary shares and the holders of 56% of the
Series B preferred shares had voted for a sale of the Company, they had the right to force the other shareholders, including the holders of Series A preferred shares, to agree to such a sale. </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">In September 2015, the terms of the Series A preferred shares were further amended to provide that, upon the mandatory conversion of Series B preferred shares, which occurred on the completion of the initial public
offering, the existing right of Series A preferred shares to a <FONT STYLE="white-space:nowrap">non-cumulative</FONT> dividend if and when declared by our board of directors ceased and was replaced by a liquidation preference consisting of $0.002
per Series A preferred share, or an aggregate of $10.00 based on the number of Series A preferred shares outstanding at the date of the amendment. </TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-20 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B><I>Wave Life Sciences Ltd. and its Subsidiaries </I></B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B><I>Consolidated Financial Statements </I></B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B><I>Year ended December&nbsp;31, 2017 </I></B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company has accounted for the September 2015 amendment to the Series A preferred shares as a modification
of the preferred shares based on upon a qualitative assessment of the amendment. The Company has not adjusted the carrying value of the Series A preferred shares since the fair value of the Series A preferred shares immediately prior and subsequent
to the modification date resulted in an immaterial change in fair value. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The addition of the liquidation preference to the Series A preferred shares,
however, resulted in the reclassification of the Series A preferred shares from permanent shareholders&#146; equity to temporary shareholders&#146; equity since the holders of the Series A preferred shares are entitled to a liquidation preference
upon a deemed liquidation event, which is outside the control of the Company. In the event a deemed liquidation event were to occur, the Company would adjust the carrying value of the Series A preferred shares to their liquidation value, which
amounts to $10.00 in the aggregate. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Series A preferred shares have no par value and there is no concept of authorized share capital under Singapore
law. The Series A preferred shares are not redeemable. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><U>Series B Preferred Shares Converted in Connection with Initial Public Offering </U></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The following represents the historical Series B preferred share transactions of the Company from January&nbsp;1, 2015 through the completion of our initial
public offering: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">On August&nbsp;14, 2015, the Company issued an aggregate of 5,334,892 Series B preferred shares at a purchase price of $12.37 per share to certain third-party investors for $62.5&nbsp;million of net proceeds.
</TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Upon the completion of the initial public offering on November&nbsp;16, 2015, all of the outstanding Series B preferred shares of the Company automatically converted into 5,334,892 of the Company&#146;s ordinary shares.
</TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Prior to the conversion of the Series B preferred shares into ordinary shares, the Series B preferred shares had a liquidation preference
over the Series A preferred shareholders and ordinary shareholders equal to the original per share amount paid of $12.37 per share, plus any declared plus unpaid dividends, if any. Additionally, the holders of Series B preferred shares were entitled
to voting rights, however, the Series B preferred shareholders were not entitled to any preferential dividends and their shares were not redeemable. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>7. SHARE-BASED COMPENSATION </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In December 2014, the
Company&#146;s board of directors adopted the Wave Life Sciences Ltd. 2014 Equity Incentive Plan (the &#147;2014 Plan&#148;), and reserved 1,763,714 ordinary shares for issuance under this plan, which was increased to 5,064,544 in 2015 and to
6,064,544&nbsp;in 2017. The 2014 Plan authorizes the board of directors or a committee of the board to grant incentive share options, <FONT STYLE="white-space:nowrap">non-qualified</FONT> share options, share appreciation rights and restricted share
awards to eligible employees and <FONT STYLE="white-space:nowrap">non-employees</FONT> of the Company. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As of December&nbsp;31, 2017, 1,716,110 ordinary
shares remained available for future grant under the 2014 Plan. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-21 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B><I>Wave Life Sciences Ltd. and its Subsidiaries </I></B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B><I>Consolidated Financial Statements </I></B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B><I>Year ended December&nbsp;31, 2017 </I></B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Share option activity under the 2014 Plan is summarized as follows: </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="59%"></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Number of</B><br><B>Shares</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Weighted-</B><br><B>Average</B><br><B>Exercise<BR>Price</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Weighted-<BR>Average</B><br><B>Remaining<BR>Contractual</B><br><B>Term<BR>(in&nbsp;years)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" NOWRAP ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Aggregate</B><br><B>Intrinsic Value</B><br><B>(in&nbsp;thousands)<SUP STYLE="font-size:85%; vertical-align:top">(1)</SUP></B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Outstanding as of January&nbsp;1, 2017</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,577,766</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">10.58</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Granted</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">522,750</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">26.33</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Exercised</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(137,493</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6.74</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Forfeited or cancelled</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(195,893</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">14.71</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Outstanding as of December&nbsp;31, 2017</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,767,130</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">12.69</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7.81</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">84,675</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Options exercisable as of December&nbsp;31, 2017</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,257,455</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">7.64</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7.43</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">62,060</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Options unvested as of December&nbsp;31, 2017</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,509,675</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">20.23</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">8.37</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">22,614</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE> <P STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:10%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><SUP STYLE="font-size:85%; vertical-align:top">(1)</SUP>&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">The aggregate intrinsic value of options is calculated as the difference between the exercise price of the share options and the fair value of the Company&#146;s ordinary shares for those share options that had exercise
prices lower than the fair value of the ordinary shares as of the end of the period. </TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Options generally vest over a period of three or four
years, and options that are forfeited or cancelled are available to be granted again. The contractual life of options is generally five or ten years from the grant date. Share-based compensation expense related to options is included in research and
development expenses or general and administrative expenses on the consolidated statements of operations. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The assumptions used in the Black-Scholes
option pricing model to determine the fair value of share options granted to employees during the period were as follows: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="84%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="37%"></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="10" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>For the Year Ended December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2017</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2016</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2015</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Risk-free interest rate</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1.49%&nbsp;-&nbsp;2.23%</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1.15%&nbsp;-&nbsp;2.18%</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="white-space:nowrap">1.56%&nbsp;-&nbsp;1.89%</FONT></TD>
<TD NOWRAP VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Expected term (in years)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="white-space:nowrap">3.00&nbsp;-&nbsp;6.25</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="white-space:nowrap">3.00&nbsp;-&nbsp;6.25</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="white-space:nowrap">5.52&nbsp;-&nbsp;6.12</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Expected volatility</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="white-space:nowrap">68.95%&nbsp;-&nbsp;72.24%</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="white-space:nowrap">60.89%&nbsp;-&nbsp;68.76%</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="white-space:nowrap">62.14%&nbsp;-&nbsp;71.02%</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Expected dividend yield</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0%</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0%</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0%</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The assumptions used in the Black-Scholes option pricing model to determine the fair value of share options granted to <FONT
STYLE="white-space:nowrap">non-employees</FONT> during the period were as follows: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="68%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="72%"></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Year Ended</B><br><B>December&nbsp;31, 2015</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Risk-free interest rate</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="white-space:nowrap">2.06%&nbsp;-&nbsp;2.35%</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Expected term (in years)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="white-space:nowrap">9.19&nbsp;-&nbsp;10.00</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Expected volatility</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="white-space:nowrap">62.65%&nbsp;-&nbsp;69.80%</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Expected dividend yield</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0%</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">There were no options granted to <FONT STYLE="white-space:nowrap">non-employees</FONT> in 2017 or 2016. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-22 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B><I>Wave Life Sciences Ltd. and its Subsidiaries </I></B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B><I>Consolidated Financial Statements </I></B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B><I>Year ended December&nbsp;31, 2017 </I></B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">RSU activity for the years ended December&nbsp;31, 2017 and 2016 is summarized as follows: </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="76%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="68%"></TD>
<TD VALIGN="bottom" WIDTH="9%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="8%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>RSUs</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Average&nbsp;Grant<BR>Date Fair<BR>Value (in<BR>dollars per<BR>share)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Outstanding as of January&nbsp;1, 2017</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">22,750</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">21.69</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Granted</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">170,859</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">29.05</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Vested</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(22,750</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">21.69</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Forfeited</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(16,400</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">29.05</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">RSUs Outstanding at December&nbsp;31, 2017</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">154,459</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">29.05</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">There were no RSUs granted in 2015. The RSUs granted in 2016 fully vested upon the first anniversary of the grant date and the
RSUs granted in 2017 vest annually over a period four years. RSUs that are forfeited are available to be granted again. Share-based compensation expense related to the RSUs is included in research and development expenses or general and
administrative expenses on the consolidated statements of operations. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As of December&nbsp;31, 2017, the unrecognized compensation cost related to
outstanding options was $16.9&nbsp;million for employees and $1.0&nbsp;million for <FONT STYLE="white-space:nowrap">non-employees.</FONT> The unrecognized compensation cost related to outstanding options for employees and <FONT
STYLE="white-space:nowrap">non-employees</FONT> is expected to be recognized over a weighted-average period of approximately 2.6 years. For the years ended December&nbsp;31, 2017 and 2016, the weighted-average grant date fair value per granted
option was $16.58 and $30.23, respectively. The aggregate fair value of options that vested during the year ended December&nbsp;31, 2017 was $11.5&nbsp;million.&nbsp;The unrecognized compensation costs related to outstanding RSUs was
$3.5&nbsp;million as of December&nbsp;31, 2017, and is expected to be recognized over a weighted-average period of approximately 3.11 years. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In March
2015, the Company granted 190,856 fully-vested ordinary shares to an executive of the Company and the Company recorded compensation expense in the amount of $0.9&nbsp;million. Share-based compensation expense related to these fully-vested ordinary
shares is included in general and administrative expenses on the consolidated statements of operations. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Share-based compensation expense for the years
ended December&nbsp;31, 2017, 2016 and 2015 is classified in the consolidated statements of operations as follows: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="84%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" ALIGN="center">


<TR>
<TD WIDTH="69%"></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="10" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>For the Year Ended December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2017</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2016</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2015</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="10" ALIGN="center"><B></B>(in thousands)<B></B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Research and development expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">7,670</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">4,936</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">2,268</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">General and administrative expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,473</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,911</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,756</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total share-based compensation expense</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">12,143</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">6,847</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">4,024</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Of the total share-based compensation expense recorded for the years ended December&nbsp;31, 2017, 2016 and 2015,
$2.9&nbsp;million, $2.7&nbsp;million and $1.6&nbsp;million related to options granted to <FONT STYLE="white-space:nowrap">non-employees,</FONT> respectively, all of which is included in research and development expenses on the consolidated
statements of operations.</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-23 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B><I>Wave Life Sciences Ltd. and its Subsidiaries </I></B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B><I>Consolidated Financial Statements </I></B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B><I>Year ended December&nbsp;31, 2017 </I></B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>8. COMMITMENTS AND CONTINGENCIES </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><U>Lease Arrangements </U></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company enters into lease
arrangements for its facilities as well as certain equipment. A summary of the arrangements are as follows: </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Operating Leases </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On September&nbsp;26, 2016, and as amended on December&nbsp;31, 2016,&nbsp;the Company entered into a 10 year and 9 month lease, which includes two successive
five year renewal options, for its facility in Lexington, Massachusetts, which the Company uses primarily for its cGMP manufacturing, as well as for additional laboratory and office space. Throughout the term of the lease, the Company is responsible
for paying certain costs and expenses, in addition to the rent, as specified in the lease, including a proportionate share of applicable taxes, operating expenses and utilities. In connection with the lease agreement, the Company issued the lessor a
letter of credit in the amount of $2.6&nbsp;million, which is included in restricted cash at December&nbsp;31, 2017. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In connection with the lease
agreement, the Company is entitled to receive $11.5&nbsp;million of tenant improvement allowances. The Company has received $3.6&nbsp;million as of December&nbsp;31, 2017, which is amortized over the period from the commencement of tenant
improvement construction through to the end of the lease term. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In April 2015, the Company entered into a lease agreement for an office and laboratory
facility in Cambridge, Massachusetts, which commenced in October 2015 with a term of 7.5 years with a five-year renewal option to extend the lease. In connection with the lease, the Company issued the lessor a letter of credit in the amount of
$1.0&nbsp;million, which is recorded as restricted cash on the consolidated balance sheets at December&nbsp;31, 2017 and 2016. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Previously, the Company
leased its corporate office space in Boston, Massachusetts under a <FONT STYLE="white-space:nowrap">non-cancellable</FONT> operating sublease with SNBL, a related party. On September&nbsp;22, 2015, the Company terminated its sublease with SNBL and
exited the premises on October&nbsp;2, 2015. As a result of the termination of the sublease, the Company recorded approximately $0.2&nbsp;million of additional depreciation and $0.1&nbsp;million of exit costs during the year ended December&nbsp;31,
2015. In connection with the termination, the Company agreed to guarantee SNBL certain obligations of an unrelated third party who entered into a sublease agreement with SNBL effective October&nbsp;2, 2015. The guarantee provides that in the event
the <FONT STYLE="white-space:nowrap">sub-lessee</FONT> does not meet its lease obligations to SNBL, the Company will make the required payments. The guarantee agreement is effective through August 2019, when the final lease payments are due, and
coincides with the original expiration of the lease. The Company simultaneously entered into an indemnification agreement with the <FONT STYLE="white-space:nowrap">sub-lessee</FONT> to indemnify the Company for any costs incurred under the guarantee
made by the Company to SNBL. The maximum amount of the guarantee over the three year and six month <FONT STYLE="white-space:nowrap">sub-lease</FONT> period is $0.6&nbsp;million, exclusive of any indemnification from the <FONT
STYLE="white-space:nowrap">sub-lessee.</FONT> </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-24 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B><I>Wave Life Sciences Ltd. and its Subsidiaries </I></B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B><I>Consolidated Financial Statements </I></B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B><I>Year ended December&nbsp;31, 2017 </I></B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Future minimum lease payments under the Company&#146;s <FONT STYLE="white-space:nowrap">non-cancelable</FONT>
operating leases as of December&nbsp;31, 2017, are as follows: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="68%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="80%"></TD>
<TD VALIGN="bottom" WIDTH="11%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; width:116.90pt; display:inline; font-size:8pt; font-family:Times New Roman; "><B>For the Year Ended December&nbsp;31,</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Amount</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><B></B>(in&nbsp;thousands)<B></B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">2018</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,666</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">2019</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5,675</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">2020</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5,846</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">2021</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6,021</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">2022</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6,201</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Thereafter</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">26,163</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">54,572</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company recorded rent expense of $5.6&nbsp;million, $1.5&nbsp;million and $0.5&nbsp;million for the years ended
December&nbsp;31, 2017, 2016 and 2015, respectively. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Capital Lease </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In April 2015, the Company entered into a three year lease to acquire laboratory equipment, which has been accounted for as a capital lease. The capital asset
was valued at $0.3&nbsp;million and is included in property and equipment, net, along with accumulated amortization of $0.1&nbsp;million as of December&nbsp;31, 2017 and 2016. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><U>Unasserted Claims </U></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In the ordinary course of
business, the Company may be subject to legal proceedings, claims and litigation as the Company operates in an industry susceptible to patent and other legal claims. The Company accounts for estimated losses with respect to legal proceedings and
claims when such losses are probable and estimable. Legal costs associated with these matters are expensed when incurred. The Company is not currently a party to any material legal proceedings. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>9. NET LOSS PER ORDINARY SHARE </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Basic loss per share is
computed by dividing net loss attributable to ordinary shareholders by the weighted-average number of ordinary shares outstanding: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="65%"></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="10" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Year Ended December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2017</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2016</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2015</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="10" ALIGN="center">(in&nbsp;thousands&nbsp;except&nbsp;share&nbsp;and&nbsp;per&nbsp;share&nbsp;data)</TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Numerator:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net loss attributable to ordinary shareholders</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(102,035</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(55,401</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(19,200</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Denominator:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Weighted-average ordinary shares outstanding</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">26,513,382</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">22,800,628</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">10,501,455</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net loss per share, basic and diluted</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(3.85</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(2.43</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(1.83</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company&#146;s potentially dilutive shares, which include outstanding share options to purchase ordinary shares and
restricted share units, are considered to be ordinary share equivalents and are only included in the calculation of diluted net loss per share when their effect is dilutive. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-25 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B><I>Wave Life Sciences Ltd. and its Subsidiaries </I></B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B><I>Consolidated Financial Statements </I></B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B><I>Year ended December&nbsp;31, 2017 </I></B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The following potential ordinary shares, presented based on amounts outstanding at each period end, were
excluded from the calculation of diluted net loss per share attributable to ordinary shareholders for the periods indicated because including them would have had an anti-dilutive effect: </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="76%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="70%"></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>As of December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2017</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2016</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Options to purchase ordinary shares</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,767,130</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,577,766</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Restricted share units</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">154,459</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">22,750</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Series A preferred shares</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,901,348</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,901,348</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>10. INCOME TAXES </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The
components of loss before income taxes were as follows: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="84%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" ALIGN="center">


<TR>
<TD WIDTH="61%"></TD>
<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="10" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Year Ended December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2017</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2016</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2015</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="10" ALIGN="center"><B></B>(in thousands)<B></B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Singapore</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(76,885</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(53,387</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(16,534</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Rest of world</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(24,442</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(1,398</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(2,622</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Loss before income taxes</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(101,327</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(54,785</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(19,156</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">During the years ended December&nbsp;31, 2017, 2016, and 2015, the Company recorded a tax provision of $0.7&nbsp;million,
$0.6&nbsp;million and less than $0.1&nbsp;million, respectively. The 2017 tax provision was due to the Company&#146;s establishment of a valuation allowance against the Company&#146;s U.S. deferred tax assets and U.S. income generated under research
and management services arrangements between the Company&#146;s U.S. and Singapore entities which is taxed in the U.S. The 2016 and 2015 tax provisions were primarily the result of U.S. income generated under research and management services
arrangements between the Company&#146;s U.S. and Singapore entities which is taxed in the U.S. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On October&nbsp;1, 2017, the Company made changes to its
corporate entity operating structure, including transferring intellectual property from the Japanese subsidiary to the Singapore parent company, as well as transferring intellectual property from the Singapore parent company to the U.S. and UK
subsidiaries, primarily to align the Company&#146;s intellectual property holding and management structure with its business functions. The transfer of assets occurred between wholly-owned legal entities within the Wave group that are all based in
different tax jurisdictions. As the impact of the transfer was the result of an intra-entity transaction, any resulting gain or loss and immediate tax impact on the transfer is eliminated and not recognized in the consolidated financial statements
under U.S. GAAP. The recipient entities will receive a tax benefit associated with the future amortization of the intellectual property received in accordance with the applicable tax laws. As discussed in Note 2, the Company will adopt ASU <FONT
STYLE="white-space:nowrap">2016-16</FONT> in the first quarter of 2018 and the Company estimates that there will be a cumulative-effect increase of approximately $0.4&nbsp;million to the Company&#146;s accumulated deficit. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">During the years ended December&nbsp;31, 2017, 2016 and 2015, the Company recorded no income tax benefit for the net operating losses incurred in Singapore
and Japan, due to uncertainty regarding future taxable income in those jurisdictions. In May 2016, the Company established a wholly-owned subsidiary in Ireland, however no income tax expense or benefit has been recorded during the years ended
December&nbsp;31, 2017 and 2016. In April 2017, the Company established a wholly-owned subsidiary in the UK, however, during the year ended December&nbsp;31, 2017 no income tax benefit was recorded related to the net operating losses incurred in the
UK due to uncertainty regarding future taxable income in that jurisdiction. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-26 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B><I>Wave Life Sciences Ltd. and its Subsidiaries </I></B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B><I>Consolidated Financial Statements </I></B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B><I>Year ended December&nbsp;31, 2017 </I></B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Tax Cuts and Jobs Act (the &#147;Tax Act&#148;) was enacted on December&nbsp;22, 2017 and includes
significant changes to the U.S. corporate tax system. Effective January&nbsp;1, 2018, the Tax Act reduced the U.S. federal corporate tax rate from 35% to 21% and transitioned the U.S. federal tax system from a worldwide tax system to a territorial
tax system. On December&nbsp;22, 2017, the SEC issued Staff Accounting Bulletin 118 (&#147;SAB 118&#148;) that provides additional guidance allowing companies to apply a measurement period of up to twelve months to account for the impacts of the Tax
Act in their financial statements. As of December&nbsp;31, 2017, the Company has accounted for the impacts of the Tax Act to the extent a reasonable estimate could be made. The Company recognized a $0.8&nbsp;million provisional charge related to the
remeasurement of the Company&#146;s deferred tax assets and liabilities, which was included as a component of the Company&#146;s provision for income taxes and was fully offset by a corresponding amount in the Company&#146;s valuation allowance. The
Company will continue to refine its estimates throughout the measurement period or until the accounting is complete as allowed under SAB 118. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The
components of the benefit (provision) for income taxes were as follows: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="84%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="71%"></TD>
<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="10" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Year Ended December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2017</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2016</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2015</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="10" ALIGN="center"><B></B>(in thousands)<B></B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Current benefit (provision) for income taxes:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Singapore taxes</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">199</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Rest of world taxes</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(133</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(1,180</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(8</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total current benefit (provision) for income taxes</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">66</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(1,180</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(8</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Deferred benefit (provision) for income taxes:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Singapore taxes</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Rest of world taxes</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(774</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">564</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(36</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total deferred benefit (provision) for income taxes</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(774</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">564</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(36</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total benefit (provision) for income taxes</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(708</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(616</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(44</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">A reconciliation of the Singapore statutory income tax rate to the Company&#146;s effective income tax rate is as follows:
</P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="84%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="75%"></TD>
<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="10" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Year Ended December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2017</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2016</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2015</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Singapore statutory income tax rate</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">17.0</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">17.0</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">17.0</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Federal and state tax credits</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5.7</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3.1</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2.3</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Permanent differences</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(2.6</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(0.9</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5.5</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Changes in reserves for uncertain tax positions</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(3.5</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(3.6</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(1.2</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Foreign rate differential</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2.8</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(0.1</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1.2</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Tax rate change</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(0.9</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0.5</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(0.9</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0.2</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Change in deferred tax asset valuation allowance</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(19.7</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(15.7</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(25.2</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Effective income tax rate</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(0.7</TD>
<TD NOWRAP VALIGN="bottom">)%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(1.1</TD>
<TD NOWRAP VALIGN="bottom">)%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(0.2</TD>
<TD NOWRAP VALIGN="bottom">)%&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-27 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B><I>Wave Life Sciences Ltd. and its Subsidiaries </I></B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B><I>Consolidated Financial Statements </I></B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B><I>Year ended December&nbsp;31, 2017 </I></B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The components of the Company&#146;s deferred tax assets as of December&nbsp;31, 2017 and 2016 are as
follows: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="76%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="71%"></TD>
<TD VALIGN="bottom" WIDTH="8%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2017</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2016</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center"><B></B>(in thousands)<B></B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Deferred tax assets:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net operating loss carryforwards</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">28,913</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">16,046</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Federal and state tax credits</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,522</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">449</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Accrued expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,903</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">242</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Share-based compensation</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,921</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,024</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">176</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">102</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total deferred tax assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">37,435</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">17,863</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Valuation allowance</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(36,069</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(15,999</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net deferred tax assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,366</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,864</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Deferred tax liabilities:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Depreciation</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(1,366</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(1,090</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total deferred tax liabilities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(1,366</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(1,090</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net deferred tax assets (liabilities)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">774</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">A roll-forward of the valuation allowance for the years ended December&nbsp;31, 2017 and 2016 is as follows: </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="76%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="71%"></TD>
<TD VALIGN="bottom" WIDTH="8%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Year&nbsp;Ended&nbsp;December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2017</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2016</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center"><B></B>(in thousands)<B></B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Balance at beginning of year</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">15,999</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">7,466</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Increase in valuation allowance</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">20,595</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">8,774</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Reversal of valuation allowance</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(598</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(282</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Effect of foreign currency translation</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">73</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">41</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Balance at end of year</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">36,069</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">15,999</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As of December&nbsp;31, 2017 and 2016, the Company has U.S. federal research and development tax credit carryforwards of
approximately $2.8&nbsp;million and $0.2&nbsp;million, respectively, available to offset future U.S. federal income taxes. As of December&nbsp;31, 2017 and 2016, the Company has state research and development tax credit carryforwards of
approximately $1.1&nbsp;million and $0.3&nbsp;million, respectively, available to offset future state income taxes. The U.S. federal and state research and development tax credits will begin to expire in 2032. As of December&nbsp;31, 2017, the
Company had a U.S. orphan drug credit carryforward of $0.4&nbsp;million, which will begin to expire in 2037. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As of December&nbsp;31, 2017 and 2016, the
Company has net operating loss carryforwards in Japan of $4.1&nbsp;million and $5.3&nbsp;million, respectively, which may be available to offset future income tax liabilities and begin to expire in 2021. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As of December&nbsp;31, 2017 and 2016, the Company has net operating loss carryforwards in Singapore of $149.2&nbsp;million and $84.0&nbsp;million,
respectively, which may be available to offset future income tax liabilities and can be carried forward indefinitely. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-28 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B><I>Wave Life Sciences Ltd. and its Subsidiaries </I></B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B><I>Consolidated Financial Statements </I></B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B><I>Year ended December&nbsp;31, 2017 </I></B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As of December&nbsp;31, 2017, the Company has net operating loss carryforwards in the UK of
$10.5&nbsp;million, which may be available to offset future income tax liabilities and can be carried forward indefinitely. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company has evaluated the
positive and negative evidence bearing upon its ability to realize its deferred tax assets. As of December&nbsp;31, 2016, management has considered the Company&#146;s history of cumulative net losses incurred since inception and its lack of
commercialization of any products or generation of any revenue from product sales since inception and has concluded that it is more likely than not that the Company will not realize the benefits of the deferred tax assets in Japan and Singapore.
Accordingly, a full valuation allowance has been established against those deferred tax assets as of December&nbsp;31, 2016. Additionally as of December&nbsp;31, 2016, management has considered the Company&#146;s expected utilization of
U.S.<B></B>&nbsp;research and development credit carryforwards and has concluded that it is more likely than not that the Company will not realize the benefits of the U.S. state<B></B>&nbsp;research and development tax credit carryforward. As of
December&nbsp;31, 2016, there was a $0.8&nbsp;million deferred tax asset in the U.S. As of December&nbsp;31, 2017, management has considered the Company&#146;s history of cumulative net losses incurred since inception and its lack of
commercialization of any products or generation of any revenue from product sales since inception, as well as the corporate entity restructuring,&nbsp;and has concluded that it is more likely than not that the Company will not realize the benefits
of the deferred tax assets in Singapore, the U.S., Japan and the UK. Accordingly, a full valuation allowance has been established against those deferred tax assets as of December&nbsp;31, 2017. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The valuation allowance increased by approximately $20.1&nbsp;million in 2017, $8.5&nbsp;million in 2016 and $4.8&nbsp;million in 2015 primarily as a result
of operating losses generated with no corresponding financial statement benefit. The Company may release this valuation allowance when management determines that it is <FONT STYLE="white-space:nowrap">more-likely-than-not</FONT> that the deferred
tax assets will be realized. Any release of valuation allowance will be recorded as a tax benefit either increasing net income or decreasing net loss. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company&#146;s reserves related to taxes and its accounting for uncertain tax positions are based on a determination of whether and how much of a tax
benefit taken by the Company in its tax filings or positions is <FONT STYLE="white-space:nowrap">more-likely-than-not</FONT> to be realized following resolution of any potential contingencies present related to the tax benefit. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">A summary of activity in the Company&#146;s unrecognized tax benefits is as follows: </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="84%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="68%"></TD>
<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2017</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2016</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2015</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="10" ALIGN="center"><B></B>(in thousands)<B></B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Unrecognized tax benefit at the beginning of the year</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">2,343</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1,280</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1,025</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Tax positions released related to prior years</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(1,066</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Tax positions related to the current year</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,864</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,129</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">255</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Unrecognized tax benefit at the end of the year</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">6,207</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">2,343</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1,280</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As of December&nbsp;31, 2017, 2016 and 2015, the total amount of gross unrecognized tax benefits, which excludes interest and
penalties, was $6.2&nbsp;million, $2.3&nbsp;million and $1.3&nbsp;million, respectively. At December&nbsp;31, 2017, $4.2&nbsp;million of the net unrecognized tax benefits would affect the Company&#146;s annual effective tax rate if recognized. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company does not expect to record any material reductions in the measurement of its unrecognized tax benefits within the next twelve months. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-29 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B><I>Wave Life Sciences Ltd. and its Subsidiaries </I></B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B><I>Consolidated Financial Statements </I></B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B><I>Year ended December&nbsp;31, 2017 </I></B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company&#146;s policy is to record interest and penalties related to uncertain tax positions as part of
its income tax provision. As of December&nbsp;31, 2017 and 2016, the Company had incurred less than $0.1&nbsp;million and zero, respectively, of interest or penalties related to uncertain tax positions. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company files income tax returns as prescribed by the tax laws of the jurisdictions in which it operates. In the normal course of business, the Company is
subject to examination by various taxing authorities in the U.S., Japan, and Singapore. There are currently no pending income tax examinations. Tax years from 2012 to the present are still open to examination in the U.S., from 2008 to the present in
Japan, and from 2012 to the present in Singapore. To the extent that the Company has tax attribute carryforwards, the tax years in which the attribute was generated may still be adjusted upon examination by the tax authorities to the extent utilized
in a future period. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As of December&nbsp;31, 2017 and 2016, $48.8&nbsp;million and $1.7&nbsp;million, respectively, of cash was held by the subsidiaries
outside of Singapore. The Company does not provide for Singapore income tax or foreign withholding taxes on foreign unrepatriated earnings, as the Company intends to permanently reinvest undistributed earnings in its foreign subsidiaries. If the
Company decides to change this assertion in the future to repatriate any additional foreign earnings, the Company may be required to accrue and pay taxes. Because of the complexity of Singapore and foreign tax rules applicable to the distribution of
earnings from foreign subsidiaries to Singapore, the determination of the unrecognized deferred tax liability on these earnings is not practicable. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Utilization of the net operating loss carryforwards and research and development tax credit carryforwards in the U.S. may be subject to a substantial annual
limitation under Section&nbsp;382 of the Internal Revenue Code of 1986, as amended (the &#147;Code&#148;), due to ownership changes that have occurred previously or that could occur in the future. These ownership changes may limit the amount of
carryforwards that can be utilized annually to offset future taxable income. In general, an ownership change, as defined by Section&nbsp;382, results from transactions increasing the ownership of certain shareholders or public groups in the shares
of a corporation by more than 50% over a three-year period. In 2015, the Company completed a study to assess whether an ownership change has occurred or whether there have been multiple ownership changes since its formation. The results of this
study indicated that the Company experienced ownership changes as defined by Section&nbsp;382 of the Code. Based on the results of the study, management has determined that the limitations will not have a material impact on the Company&#146;s
ability to utilize its research and development credit carryforwards to offset future tax liabilities. Should an ownership change have occurred after December&nbsp;31, 2015 or occur in the future, the Company&#146;s ability to utilize research and
development tax credit carryforwards may be limited. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>11. EMPLOYEE BENEFIT PLANS </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company has a 401(k) retirement and savings plan (the &#147;401(k) Plan&#148;) covering all U.S.-based employees. The 401(k) Plan allows employees to make
contributions up to the maximum allowable amount set by the IRS. Under the 401(k) Plan, the Company may make discretionary contributions as approved by the board of directors. The Company made contributions of $0.4&nbsp;million in the year ended
December&nbsp;31, 2017. The Company did not make contributions to the 401(k) Plan during the years ended December&nbsp;31, 2016 or 2015. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-30 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B><I>Wave Life Sciences Ltd. and its Subsidiaries </I></B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B><I>Consolidated Financial Statements </I></B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B><I>Year ended December&nbsp;31, 2017 </I></B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>12. RELATED PARTIES </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company had the following related party transactions for the periods presented in the accompanying consolidated financial statements, which have not
otherwise been discussed in these notes to the consolidated financial statements: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">The Company held cash of $0.1&nbsp;million in depository accounts with Kagoshima Bank, Ltd., an affiliate of one of the Company&#146;s shareholders,&nbsp;Kagoshima Shinsangyo Sousei Investment Limited Partnership, as of
December&nbsp;31, 2017 and 2016. </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Pursuant to the terms of various service agreements with SNBL, the Company paid SNBL $0.5&nbsp;million, $0.4&nbsp;million and $0.1&nbsp;million for the years ended December&nbsp;31, 2017, 2016 and 2015, respectively,
for contract research services provided to the Company and its affiliates. </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">In 2012, the Company entered into a consulting agreement for scientific services with Dr.&nbsp;Gregory&nbsp;L. Verdine, one of the Company&#146;s founders and a member of the Company&#146;s board of directors. The
consulting agreement does not have a specific term and may be terminated by either party upon 14 days&#146; prior written notice. Pursuant to the consulting agreement, the Company pays Dr.&nbsp;Verdine approximately $13&nbsp;thousand per month, plus
reimbursement for certain expenses. </TD></TR></TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>13. GEOGRAPHIC DATA </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company&#146;s long-lived assets consist of property and equipment, net, and are located in the following geographical areas: </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="76%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="65%"></TD>
<TD VALIGN="bottom" WIDTH="11%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="11%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>December&nbsp;31,<BR>2017</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>December&nbsp;31,<BR>2016</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center">(in thousands)</TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Japan</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">14</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">136</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">United States</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">27,320</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">8,471</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total long-lived assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">27,334</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">8,607</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-31 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B><I>Wave Life Sciences Ltd. and its Subsidiaries </I></B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B><I>Consolidated Financial Statements </I></B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B><I>Year ended December&nbsp;31, 2017 </I></B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>14. SELECTED QUARTERLY FINANCIAL INFORMATION (UNAUDITED) </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Selected quarterly results from operations for the years ended December&nbsp;31, 2017 and 2016 are as follows: </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="92%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="51%"></TD>
<TD VALIGN="bottom" WIDTH="8%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="14" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2017 Quarter Ended</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>March&nbsp;31</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>June&nbsp;30</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>September&nbsp;30</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>December&nbsp;31</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="14" ALIGN="center">(in thousands, except for per share data)</TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Revenues</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">676</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">676</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">676</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1,676</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Operating expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">20,590</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">25,770</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">27,668</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">32,256</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Loss from operations</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(19,914</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(25,094</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(26,992</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(30,580</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net loss</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(20,996</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(24,693</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(26,135</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(30,211</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Basic and diluted net loss per ordinary share</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(0.89</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(0.92</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(0.94</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(1.09</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
</TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="92%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="51%"></TD>
<TD VALIGN="bottom" WIDTH="8%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="14" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2016 Quarter Ended</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>March&nbsp;31</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>June&nbsp;30</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>September&nbsp;30</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>December&nbsp;31</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="14" ALIGN="center">(in thousands, except for per share data)</TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Revenues</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">417</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">392</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">676</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Operating expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7,952</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">12,055</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">17,625</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">19,180</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Loss from operations</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(7,952</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(11,638</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(17,233</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(18,504</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net loss</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(7,847</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(11,565</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(17,535</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(18,454</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Basic and diluted net loss per ordinary share</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(0.36</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(0.51</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(0.75</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(0.79</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>15. SUBSEQUENT EVENTS </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Takeda Collaboration and License Agreement </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In February
2018, two of the Company&#146;s subsidiaries entered into a global strategic collaboration (the &#147;Takeda Collaboration&#148;) that provides Takeda Pharmaceutical Company Limited (&#147;Takeda&#148;) with the option to <FONT
STYLE="white-space:nowrap">co-develop</FONT> and <FONT STYLE="white-space:nowrap">co-commercialize</FONT> the Company&#146;s CNS development programs in Huntington&#146;s disease, amyotrophic lateral sclerosis and frontotemporal dementia, as well as
a discovery stage program targeting ATXN3 for the treatment of spinocerebellar ataxia type 3. In addition, Takeda has the right to license multiple preclinical programs for CNS indications including Alzheimer&#146;s disease and Parkinson&#146;s
disease. Subject to customary closing conditions, including the expiration or early termination of the applicable waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976 (the &#147;HSR Act&#148;), the Takeda Collaboration is
expected to become effective during the first quarter of 2018. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Simultaneously with the Company&#146;s entry into the Takeda Collaboration Agreement, the
Company entered into a share purchase agreement with Takeda pursuant to which the Company agreed to sell to Takeda 1,096,892 of its ordinary shares at a purchase price of $54.70 per share, for an aggregate purchase price of approximately
$60.0&nbsp;million (the &#147;Takeda Equity Investment&#148;). Subject to customary closing conditions, including the expiration or early termination of the applicable waiting period under the HSR Act, the Takeda Equity Investment is expected to
close during the first quarter of 2018. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-32 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B></B><B><I>Wave Life Sciences Ltd.</I></B><B> </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B></B><B><I>Supplementary Financial Information</I></B><B> </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B></B><B><I>Year ended December&nbsp;31, 2017</I></B><B> </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="appa589845_4"></A>Supplementary Financial Information of Wave Life Sciences Ltd. (Parent Company) </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>WAVE LIFE SCIENCES LTD. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>BALANCE SHEETS </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><I>(In
thousands, except share amounts) </I></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="78%"></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>December&nbsp;31,<BR>2017</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>December&nbsp;31,<BR>2016</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Assets</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Current assets:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Cash and cash equivalents</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">93,680</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">148,636</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Intercompany receivables</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5,920</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,133</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Prepaid expenses and other current assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,931</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,026</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total current assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">101,531</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">154,795</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Long-term assets:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Intercompany loans to subsidiaries</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">14,295</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Investment in subsidiary&#151;Wave USA</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">42,713</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,509</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Investment in subsidiary&#151;Wave UK</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">10,736</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Investment in subsidiary&#151;Wave Japan</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,037</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total long-term assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">56,486</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">15,804</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">158,017</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">170,599</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Liabilities, Series A preferred shares and shareholders&#146; equity</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Current liabilities:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Accounts payable</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">248</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">757</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Intercompany accounts payable</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">11,714</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">12,545</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Accrued expenses and other current liabilities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">492</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">461</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Current portion of deferred revenue</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,705</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,705</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total current liabilities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">15,159</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">16,468</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Long-term liabilities:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Deferred revenue, net of current portion</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5,607</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">8,311</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total long-term liabilities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5,607</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">8,311</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total liabilities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">20,766</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">24,779</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Series A preferred shares, no par value; 3,901,348 shares issued and outstanding</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">7,874</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">7,874</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Shareholders&#146; equity:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Ordinary shares, no par value; 27,829,079 and 23,502,169 shares issued and outstanding at
December&nbsp;31, 2017 and 2016, respectively</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">310,038</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">215,602</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Additional <FONT STYLE="white-space:nowrap">paid-in</FONT> capital</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">8,450</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,401</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Accumulated deficit</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(189,111</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(82,057</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total shareholders&#146; equity</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">129,377</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">137,946</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total liabilities, Series A preferred shares and shareholders&#146; equity</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">158,017</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">170,599</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><I>The accompanying notes are an integral part of the supplementary financial information. </I></P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-33 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B><I>Wave Life Sciences Ltd. </I></B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B><I>Notes to Supplementary Financial Information </I></B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B><I>Year ended December&nbsp;31, 2017 </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Wave Life Sciences Ltd. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Notes to Supplementary Financial Information </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>1. DOMICILE AND ACTIVITIES </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Wave Life Sciences Ltd. (the
&#147;Parent&#148;), formerly Wave Life Sciences Pte. Ltd., registration number 201218209G, is a company incorporated in the Republic of Singapore on July&nbsp;23, 2012. The Parent&#146;s registered office is located at 7 Straits View <FONT
STYLE="white-space:nowrap">#12-00,</FONT> Marina One East Tower, Singapore 018936. The Parent was incorporated with the purpose of combining two commonly held companies, Wave Life Sciences USA, Inc. (&#147;Wave USA&#148;), a Delaware corporation
(formerly Ontorii, Inc.), and Wave Life Sciences (Japan) (&#147;Wave Japan&#148;), a company organized under the laws of Japan (formerly Chiralgen., Ltd.), which occurred on September&nbsp;13, 2012. On May&nbsp;31, 2016, Wave Life Sciences Ireland
Limited (&#147;Wave Ireland&#148;) was formed as a wholly-owned subsidiary of Wave Life Sciences Ltd. On April&nbsp;3, 2017, Wave Life Sciences UK Limited (&#147;Wave UK&#148;) was formed as a wholly-owned subsidiary of Wave Life Sciences Ltd. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On November&nbsp;5, 2015, the Parent converted from a Singapore private company limited by shares to a Singapore public company limited by shares. In
connection with this conversion, the Parent changed its name from &#147;Wave Life Sciences Pte. Ltd.&#148; to &#147;Wave Life Sciences Ltd.&#148; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Wave
Life Sciences Ltd. (together with its subsidiaries, &#147;Wave&#148; or the &#147;Company&#148;) is a biotechnology company with an innovative and proprietary synthetic chemistry drug development platform that the Company is using to rationally
design, develop and commercialize a broad pipeline of <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">first-in-class</FONT></FONT> or <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">best-in-class</FONT></FONT>
nucleic acid therapeutic candidates for genetically defined diseases. Nucleic acid therapeutics are a growing and innovative class of drugs that have the potential to address diseases that have historically been difficult to treat with small
molecule drugs or biologics. Nucleic acid therapeutics, or oligonucleotides, are comprised of a sequence of nucleotides that are linked together by a backbone of chemical bonds. The Company is initially developing oligonucleotides that target
genetic defects to either reduce the expression of disease-promoting proteins or transform the production of dysfunctional mutant proteins into the production of functional proteins. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company&#146;s primary activities since inception have been developing an innovative and proprietary synthetic chemistry drug development platform to
design, develop and commercialize nucleic acid therapeutic programs, advancing the Company&#146;s neurology franchise, expanding the Company&#146;s research and development activities into additional therapeutic areas including ophthalmology and
hepatic, advancing programs into the clinic, furthering clinical development of such clinical-stage programs, building the Company&#146;s intellectual property, recruiting personnel and assuring adequate capital to support these activities. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>2. SIGNIFICANT ACCOUNTING POLICIES </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Basis of
preparation </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In order to comply with the requirements of the Singapore Companies Act (&#147;the Act&#148;), the Parent must present supplementary
balance sheets comprised solely from the standalone accounts of Wave Life Sciences Ltd., the Parent company. This supplementary financial information is presented on page F-29. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Parent applied to the Accounting and Corporate Regulatory Authority of Singapore (&#147;ACRA&#148;) for an exemption from preparing its 2017 Singapore
Statutory Financial Statements in accordance with Singapore Financial Reporting Standards. The Parent applied for this exemption because it is listed on the Nasdaq and therefore is required to prepare its audited annual consolidated financial
statements in accordance with the Generally Accepted Accounting Principles of the United States (&#147;U.S. GAAP&#148;) in order to maintain its listing on </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-34 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B><I>Wave Life Sciences Ltd. </I></B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B><I>Notes to Supplementary Financial Information </I></B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B><I>Year ended December&nbsp;31, 2017 </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>2. SIGNIFICANT ACCOUNTING POLICIES&nbsp;(CONTINUED) </B></P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
Nasdaq. These U.S. GAAP annual consolidated financial statements (&#147;U.S. GAAP consolidated financials&#148;) were included in the Form <FONT STYLE="white-space:nowrap">10-K,</FONT> which was
filed with the Securities and Exchange Commission (&#147;SEC&#148;) on March&nbsp;12, 2018. The Parent received the exemption from ACRA and therefore the Singapore Statutory Financial Statements were prepared in accordance with U.S. GAAP, except as
noted in the paragraph entitled &#147;Investment in Subsidiaries.&#148; The U.S. GAAP consolidated financials are included in these Singapore Statutory Financial Statements on pages <FONT STYLE="white-space:nowrap">F-1</FONT> to F-28. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Functional and presentation currency </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">This supplementary
financial information is presented in U.S. dollars, which is the Parent&#146;s functional currency. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Investment in Subsidiaries </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">For the purposes of the supplementary financial information provided as a part of the Singapore Statutory Financial Statements, the Parent did not consolidate
its investments in subsidiaries and reported these investments as separate lines in the Parent&#146;s standalone balance sheet. The Parent&#146;s investment in each subsidiary is accounted for by either increasing its initial investment in each
subsidiary by that subsidiary&#146;s net income for each financial year or by decreasing its initial investment in each subsidiary by that subsidiaries net loss for each financial year to the extent of the initial investment of the subsidiary. U.S.
GAAP requires that a Parent&#146;s investments in subsidiaries be consolidated. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Cash Equivalents </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Parent considers all highly liquid securities with original final maturities of three months or less from the date of purchase to be cash equivalents. Cash
equivalents are comprised of funds in money market accounts. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Use of Estimates </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of
assets and liabilities and the disclosure of contingent assets and liabilities at the date of the supplementary financial information. Significant estimates and assumptions reflected in the supplementary financial information include the assumptions
used to determine the fair value of share-based awards, the period over which revenue is recognized under the Pfizer Collaboration Agreement (as defined in Note 5), the evaluation of progress to completion of external research and development costs
which can result in prepaid or accrued expenses and the valuation allowance required for the Parent&#146;s deferred tax assets and determining uncertain tax positions and the related liabilities. Estimates are periodically reviewed in light of
changes in circumstances, facts and experience. Actual results could differ from the Parent&#146;s estimates. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Fair Value of Financial Instruments
</I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Parent is required to disclose information on all assets and liabilities reported at fair value that enables an assessment of the inputs used
in determining the reported fair values. The fair value hierarchy is a hierarchy of inputs used in measuring fair value that maximizes the use of observable inputs and minimizes the use of unobservable inputs by requiring that the observable inputs
be used when available. Observable inputs are inputs that market participants would use in pricing the financial instrument based on market data obtained from sources independent of the Parent. Unobservable inputs are inputs that reflect the
Parent&#146;s assumptions about the inputs </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-35 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B><I>Wave Life Sciences Ltd. </I></B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B><I>Notes to Supplementary Financial Information </I></B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B><I>Year ended December&nbsp;31, 2017 </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>2. SIGNIFICANT ACCOUNTING POLICIES&nbsp;(CONTINUED) </B></P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
that market participants would use in pricing the financial instrument and are developed based on the information available in the circumstances. The fair value hierarchy applies only to the
valuation inputs used in determining the reported fair value of the investments and is not a measure of the investment credit quality. The hierarchy defines three levels of valuation inputs: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">Level 1&#151;Unadjusted quoted prices in active markets that are accessible at the measurement date of identical, unrestricted assets. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">Level 2&#151;Quoted prices for similar assets, or inputs that are observable, either directly or indirectly, for substantially the full term
through corroboration with observable market data. Level&nbsp;2 includes investments valued at quoted prices adjusted for legal or contractual restrictions specific to the security. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">Level 3&#151;Pricing inputs are unobservable for the asset, that is, inputs that reflect the reporting entity&#146;s own assumptions about the
assumptions market participants would use in pricing the asset. Level&nbsp;3 includes private investments that are supported by little or no market activity. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Cash and cash equivalents are Level&nbsp;1 assets which are comprised of funds held in readily available checking and money market accounts. The Parent&#146;s
cash and cash equivalents were recorded at fair value as of December&nbsp;31, 2017 and 2016, totaling $93.7&nbsp;million and $148.6&nbsp;million, respectively. The carrying amounts of accounts receivable, accounts payable and accrued expenses
approximate their fair values due to their short-term maturities. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Given their related party nature, intercompany receivables, intercompany loans to
subsidiaries and intercompany payables were transacted based upon terms and amounts set forth between the Parent and its subsidiaries. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Concentration of Credit Risk </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Cash and cash
equivalents are financial instruments that potentially subject the Parent to concentration of credit risk. The Parent uses high quality, accredited financial institutions to maintain its cash and cash equivalents and, accordingly, such funds are
subject to minimal credit risk. The Parent has not experienced any losses in such accounts and management believes that the Parent is not exposed to significant credit risk due to the financial position of the depository institutions in which those
deposits are held. The Parent has no financial instruments with <FONT STYLE="white-space:nowrap">off-balance</FONT> sheet risk of loss. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Revenue
Recognition </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As of December&nbsp;31, 2017, the Parent&#146;s only significant source of revenue is derived from the Pfizer Collaboration Agreement
pursuant to which the Parent and Pfizer (as defined in Note 5) have agreed to collaborate on the discovery, development and commercialization of stereopure oligonucleotide therapeutics for the Pfizer Programs (as defined in Note 5), each directed at
a genetically-defined hepatic target selected by Pfizer. The Parent entered into the Pfizer Collaboration Agreement in May 2016. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Parent presents
revenue from the Pfizer Collaboration Agreement under Financial Accounting Standards Board (&#147;FASB&#148;), Accounting Standards Codification (&#147;ASC&#148;) Topic 808,&nbsp;Collaborative Arrangements (&#147;ASC 808&#148;).&nbsp;In addition,
the Parent recognizes revenue in accordance with ASC Topic 605, Revenue Recognition&nbsp;(&#147;ASC 605&#148;). Accordingly, revenue is recognized for each unit of accounting when all of the following criteria are met: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">persuasive evidence of an arrangement exists; </TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-36 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B><I>Wave Life Sciences Ltd. </I></B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B><I>Notes to Supplementary Financial Information </I></B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B><I>Year ended December&nbsp;31, 2017 </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>2. SIGNIFICANT ACCOUNTING POLICIES&nbsp;(CONTINUED) </B></P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">delivery has occurred or services have been rendered; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the seller&#146;s price to the buyer is fixed or determinable; and </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">collectability is reasonably assured. </TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Amounts received prior to satisfying the revenue recognition criteria
are recorded as deferred revenue. Amounts expected to be recognized as revenue within the 12&nbsp;months following the balance sheet date are classified as current portion of deferred revenue in the accompanying consolidated balance sheets. Amounts
not expected to be recognized as revenue within the 12&nbsp;months following the balance sheet date are classified as deferred revenue, net of current portion. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Pursuant to the accounting guidance in ASC <FONT STYLE="white-space:nowrap">605-25,</FONT> the Parent evaluates
<FONT STYLE="white-space:nowrap">multiple-element</FONT> arrangements to determine (1)&nbsp;the deliverables included in the arrangement and (2)&nbsp;whether the individual deliverables represent separate units of accounting or whether they must be
accounted for as a combined unit of accounting. This evaluation involves subjective determinations and requires the Parent to make judgments about the individual deliverables and whether such deliverables are separable from the other aspects of the
contractual relationship. Deliverables are considered separate units of accounting provided that the delivered item has value to the customer on a standalone basis and, if the arrangement includes a general right of return relative to the delivered
item, delivery or performance of the undelivered item is considered probable and substantially in the Parent&#146;s control. In assessing whether an item has standalone value, the Parent considers factors such as the research, development,
manufacturing and commercialization capabilities of the collaboration partner and the availability of the associated expertise in the general marketplace. In addition, the Parent considers whether the collaboration partner can use a deliverable for
its intended purpose without the receipt of the remaining deliverable, whether the value of the deliverable is dependent on the undelivered item and whether there are other vendors that can provide the undelivered items. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Under the Pfizer Collaboration Agreement, the Parent and Pfizer agreed to collaborate on the discovery, development and commercialization of up to five Pfizer
Programs, two of the five targets were declared upon initiation of the agreement in May 2016.&nbsp;The Pfizer Collaboration Agreement provides Pfizer with certain options to nominate up to three remaining programs and the Parent is required to
consider whether such options are substantive.&nbsp;Options are considered substantive if, at the inception of the arrangement, the Parent is at risk as to whether the collaboration partner will choose to exercise the option. Factors that the Parent
considers in evaluating whether an option is substantive include whether the optional elements are essential to the functionality of other programs nominated, whether economic factors compel Pfizer to purchase the optional elements, the cost to
exercise the option, the overall objective of the arrangement and, the benefit Pfizer might obtain from the arrangement without exercising the option. In August 2016, Pfizer nominated the third hepatic target under the Collaboration and pursuant to
the terms of the Pfizer Collaboration Agreement, Pfizer had the option to nominate two additional targets by November&nbsp;5, 2017. On November&nbsp;5, 2017, the Parent amended its Pfizer Collaboration Agreement to extend the target nomination
period from November&nbsp;5, 2017 to May&nbsp;5, 2018. This amendment provides Pfizer with an additional six months to nominate the two remaining hepatic targets under the Pfizer Collaboration Agreement. Pfizer nominated the fourth and fifth hepatic
targets in March 2018 and April 2018, respectively. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">When an option is considered substantive and there is no significant incremental discount, the option
is not considered a deliverable in the arrangement and no consideration is allocated to it. Conversely, when an option is not considered substantive or it is considered substantive but is priced at an incremental discount, it is analyzed
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-37 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B><I>Wave Life Sciences Ltd. </I></B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B><I>Notes to Supplementary Financial Information </I></B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B><I>Year ended December&nbsp;31, 2017 </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>2. SIGNIFICANT ACCOUNTING POLICIES&nbsp;(CONTINUED) </B></P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
to determine if it should be combined with other deliverables in the arrangement. Options that are substantive and priced at a significant and incremental discount are further assessed to
determine whether a portion of the upfront payment should be allocated to the option and other deliverables in the arrangement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">At the inception of an
arrangement that includes milestone payments, the Parent evaluates whether each milestone is substantive and at risk to both parties on the basis of the contingent nature of the milestone. This evaluation includes an assessment of whether:
(1)&nbsp;the consideration is commensurate with either the Parent&#146;s performance to achieve the milestone or the enhancement of the value of the delivered item(s) as a result of a specific outcome resulting from its performance to achieve the
milestone, (2)&nbsp;the consideration relates solely to past performance and (3)&nbsp;the consideration is reasonable relative to all of the deliverables and payment terms within the arrangement. The Parent evaluates factors such as the scientific,
clinical, regulatory, commercial, and other risks that must be overcome to achieve the particular milestone and the level of effort and investment required to achieve the particular milestone in making this assessment. There is considerable judgment
involved in determining whether a milestone satisfies all of the criteria required to conclude that a milestone is substantive. Revenue from substantive milestones will be recognized in its entirety upon successful accomplishment of the milestone.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Aside from the program nomination payments, which relate to the options described above, the remaining milestone payments required under the Pfizer
Collaboration Agreement are contingent upon the Parent&#146;s performance under the Pfizer Collaboration Agreement, including in certain instances, regulatory approval.&nbsp;The Parent views these milestones as substantive and has excluded the
amounts as allocable consideration at the outset of the arrangement. All commercial milestones will be accounted for in the same manner as royalties and recorded as revenue upon achievement of the milestone, assuming all other revenue recognition
criteria are met. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Parent recognizes arrangement consideration allocated to each unit of accounting when all of the revenue recognition criteria in
ASC 605 are satisfied for that particular unit of accounting. In the event that a deliverable does not represent a separate unit of accounting, the Parent recognizes revenue from the combined unit of accounting over the Parent&#146;s contractual or
estimated performance period for the undelivered elements, which is typically the term of the Parent&#146;s research and development obligations. If there is no discernible pattern of performance or objectively measurable performance measures do not
exist, then the Parent recognizes revenue under the arrangement on a <FONT STYLE="white-space:nowrap">straight-line</FONT> basis over the period the Parent is expected to complete its performance obligations. Conversely, if the pattern of
performance in which the service is provided to the customer can be determined and objectively measurable performance measures exist, then the Parent recognizes revenue under the arrangement using the proportional performance method. Revenue
recognized is limited to the lesser of the cumulative amount of payments received or the cumulative amount of revenue earned, as determined using the <FONT STYLE="white-space:nowrap">straight-line</FONT> method or proportional performance method, as
applicable, as of the period ending date. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Parent has concluded that the deliverables under the Pfizer Collaboration Agreement relate primarily to the
research and development required by the Parent for each of the programs nominated by Pfizer.&nbsp;The remaining deliverables, including sample supplies provided by each party to fulfill its obligation as a licensee, participation on a joint
steering committee to oversee the research and development activities, and regulatory responsibilities related to filings and obtaining approvals related to the products that may result from each program do not represent separate units of accounting
based on their dependence on the research and development efforts. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Because there is no discernible pattern of performance given the nature of the
research and development efforts, the Parent recognizes the allocated revenue for each deliverable under the Pfizer Collaboration Agreement on a </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-38 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B><I>Wave Life Sciences Ltd. </I></B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B><I>Notes to Supplementary Financial Information </I></B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B><I>Year ended December&nbsp;31, 2017 </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>2. SIGNIFICANT ACCOUNTING POLICIES&nbsp;(CONTINUED) </B></P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
straight<B><FONT STYLE="white-space:nowrap">-</FONT></B>line basis over the period the Parent is expected to complete its performance obligations for each deliverable, or unit of accounting. For
the first two Pfizer Programs, this period is expected to be from the initiation date of the Pfizer Collaboration Agreement, which was May&nbsp;5, 2016, and for the other Pfizer Programs, the period is expected to be from the date that work
commences on those programs through the earlier of (a)&nbsp;the termination of the research and development performance obligations under the Pfizer Collaboration Agreement, which is May&nbsp;5, 2020 (the &#147;Research Term&#148;), or (b)&nbsp;the
estimated date the Parent expects to meet its research and development performance obligations under the Pfizer Collaboration Agreement. Given the uncertainty as to when the research and development performance obligations will be completed, the
Parent has used the Research Term for purposes of applying the straight-line method for revenue recognition for the year ended December&nbsp;31, 2017. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Product Revenue </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Parent has had no product
revenue to date. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Share-Based Compensation </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Parent measures and recognizes share-based compensation expense, for both employee and director option awards, based on the grant date fair value of the
awards. The Parent calculates the fair value of restricted share unit awards based on the grant date fair value of the underlying ordinary shares. The Parent recognizes share-based compensation expense on a straight-line basis over the requisite
service period of the awards, which is generally the vesting period. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Parent determines the fair value of share-based awards granted to <FONT
STYLE="white-space:nowrap">non-employees</FONT> as either the fair value of the consideration received or the fair value of the equity instruments issued, whichever is more reliably measurable. All issuances of equity instruments issued to <FONT
STYLE="white-space:nowrap">non-employees</FONT> as consideration for goods or services received by the Parent are accounted for based on the fair value of the equity instruments issued. These awards are recorded in expense and additional <FONT
STYLE="white-space:nowrap">paid-in</FONT> capital in shareholders&#146; equity over the applicable service periods based on the fair value of the options at the end of each period. The Parent accounts for the expense from share-based awards to <FONT
STYLE="white-space:nowrap">non-employees</FONT> by <FONT STYLE="white-space:nowrap">re-measuring</FONT> the awards at fair value over the vesting period. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The additional <FONT STYLE="white-space:nowrap">paid-in</FONT> capital presented on the Parent&#146;s balance sheets presented as the supplementary financial
information only reflects share-based compensation expense for <FONT STYLE="white-space:nowrap">non-employee</FONT> option awards and share-based compensation expense for option awards granted to outside directors, which are accounted for as
employee option awards. The remainder of the consolidated share-based compensation expense was recorded by the Parent&#146;s subsidiaries as the expense relates to option awards and restricted share units granted to employees of the subsidiaries.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">After the closing of the Parent&#146;s initial public offering (&#147;IPO&#148;) in November 2015, the fair value of the ordinary shares underlying the
Company&#146;s share-based awards is based on the closing price of the Parent&#146;s ordinary shares as reported by the Nasdaq Global Market on the date of grant. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The fair value of each share option grant was determined using the methods and assumptions discussed below. Each of these inputs is subjective and generally
requires significant judgment and estimation by management. </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"><I>Fair Value of Ordinary Shares</I>. Following the completion of the Parent&#146;s IPO, the fair value of the ordinary shares underlying the Company&#146;s share-based awards is based on the closing price of the
Parent&#146;s ordinary shares as reported by the Nasdaq Global Market on the date of grant. </TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-39 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B><I>Wave Life Sciences Ltd. </I></B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B><I>Notes to Supplementary Financial Information </I></B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B><I>Year ended December&nbsp;31, 2017 </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>2. SIGNIFICANT ACCOUNTING POLICIES&nbsp;(CONTINUED) </B></P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"><I>Expected Term</I>. The expected term of share options represents the weighted-average period that the share options are expected to remain outstanding. The Company estimated the expected term using the simplified
method, which is an average of the contractual term of the option and the vesting period. </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"><I>Expected Volatility</I>. Since there is limited historical data for the Parent&#146;s ordinary shares and limited company-specific historical volatility, it has determined the share price volatility for options
granted based on an analysis of the volatility used by a peer group of publicly traded companies. In evaluating similarity, the Parent considers factors such as industry, stage of life cycle and size. </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"><I>Risk-free Interest Rate</I>. The risk-free interest rate is based on the U.S. Treasury yield in effect at the time of the grant for <FONT STYLE="white-space:nowrap">zero-coupon</FONT> U.S. Treasury notes with
remaining terms similar to the expected term of the options. </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"><I>Dividend Rate</I>. The expected dividend was assumed to be zero as the Parent has never paid dividends and has no current plans to do so. </TD></TR></TABLE>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Income Taxes </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Parent accounts for income taxes
using an asset and liability approach, which requires recognition of deferred tax assets and liabilities for the expected future tax consequences of events that have been recognized in the consolidated financial statements, but have not been
reflected in taxable income. A valuation allowance is established to reduce deferred tax assets to their estimated realizable value. Therefore, the Parent provides a valuation allowance to the extent that it is more likely than not that all or a
portion of the deferred tax assets will not be realized in the future. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Parent accounts for uncertainty in income taxes recognized in the financial
statements by applying a <FONT STYLE="white-space:nowrap">two-step</FONT> process to determine the amount of tax benefit to be recognized. First, the tax position must be evaluated to determine the likelihood that it will be sustained upon external
examination by the taxing authorities. If the tax position is deemed <FONT STYLE="white-space:nowrap">more-likely-than-not</FONT> to be sustained, the tax position is then assessed to determine the amount of benefit to recognize in the financial
statements. The amount of the benefit that may be recognized is the largest amount that has a greater than 50% likelihood of being realized upon ultimate settlement. The provision for income taxes includes the effects of any resulting tax reserves,
or unrecognized tax benefits, that are considered appropriate as well as the related net interest and penalties. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Parent recognizes interest and
penalties related to uncertain tax positions in the income tax provision on the consolidated statements of operations. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Parent has certain research
and management services agreements in place with Wave USA, it&#146;s U.S. subsidiary, which include transfer pricing assumptions.&nbsp;The determination of the appropriate level of transfer pricing requires judgment based on transfer pricing
analyses of comparable companies.&nbsp;The Parent monitors the nature of its service agreements for changes in its operations as well as economic conditions.&nbsp;The Parent also periodically reviews the transfer pricing analyses for changes in the
composition in the pool of comparable companies as well the related ongoing results of the comparable companies. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Unasserted Claims </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In the ordinary course of business, the Parent may be subject to legal proceedings, claims and litigation as the Parent operates in an industry susceptible to
patent legal claims. The Parent accounts for estimated losses with respect to legal proceedings and claims when such losses are probable and estimable. Legal costs associated with these matters are expensed when incurred. The Parent is not currently
a party to any legal proceedings. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-40 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B><I>Wave Life Sciences Ltd. </I></B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B><I>Notes to Supplementary Financial Information </I></B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B><I>Year ended December&nbsp;31, 2017 </I></B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>3. INTERCOMPANY BALANCES </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The intercompany balances presented on the Parent&#146;s balance sheets are the result of intercompany transactions between the Parent and its subsidiaries.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On October&nbsp;1, 2017, the Company made changes to its corporate entity operating structure, including transferring intellectual property from Wave
Japan to the Parent, as well as transferring intellectual property from the Parent to Wave USA and Wave UK, primarily to align the Company&#146;s intellectual property holding and management structure with its business functions. As a result of the
changes in the Company&#146;s corporate entity structure that were made in October 2017, the Parent made capital contributions to its subsidiaries, which increased the investment in subsidiaries and all of the outstanding intercompany loans to Wave
USA and Wave Japan were repaid in full. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">During 2016, the Parent entered into multiple intercompany loan agreements with two of its subsidiaries; Wave USA
and Wave Japan. As of December&nbsp;31, 2016, intercompany loans to subsidiaries amounted to $14.3&nbsp;million. These intercompany loans entered into in 2016 were unsecured and the interest rate per annum was 0.56%. The $14.3&nbsp;million of
outstanding intercompany loans at December&nbsp;31, 2016 would have matured on December&nbsp;31, 2017. Even though these loans would have matured in 2017, they were classified on the Parent&#146;s balance sheet as long term as of December&nbsp;31,
2016 because the Parent did not believe that it was likely that its subsidiaries would be able to repay the loan amounts in 2017 as the subsidiaries had no commercial revenue or other sources of income. As of December&nbsp;31, 2016, the Parent
determined that if its subsidiaries were unable to repay the intercompany loan when the loans matured that it would enter into new intercompany loan agreements with its subsidiaries for the full amount outstanding at the time of maturity. In 2017
all of the outstanding intercompany loans to subsidiaries were repaid in full prior to the maturity date as a result of the October 2017 changes in the Company&#146;s corporate entity operating structure. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As of December&nbsp;31, 2017, intercompany accounts receivable were made up of amounts receivable from Wave USA related to certain expenses that were paid for
on behalf of Wave USA by the Parent as well as other amounts receivable from Wave USA related to proceeds from the exercise of share options by Wave USA&#146;s employees. The Parent issues options to purchase its shares to employees of its
subsidiaries as a part of the compensation package. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As of December&nbsp;31, 2016, intercompany interest receivable related to the intercompany loan
agreements amounted to $0.1&nbsp;million and was included in the intercompany receivables. The remainder of the intercompany accounts receivables as of December&nbsp;31, 2016 were mainly made up of amounts receivable from Wave USA related to certain
expenses that were paid for on behalf of Wave USA by the Parent as well as other amounts receivable from Wave USA related to proceeds from the exercise of share options by Wave USA&#146;s employees. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As of December&nbsp;31, 2017, intercompany accounts payable totaled $11.7&nbsp;million and related to amounts payable to Wave USA and Wave Japan. The majority
of the intercompany accounts payable related to amounts payable to Wave USA under the intercompany research and management services agreements. There were also intercompany amounts payable to Wave Japan related to the October 2017 transfer of
intellectual property from Wave Japan to the Parent, as well as additional amounts payable to Wave USA and Wave Japan related to the reimbursement of certain expenses that were paid for by subsidiaries on behalf of the Parent. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As of December&nbsp;31, 2016, the intercompany accounts payable totaled $12.5&nbsp;million and related to amounts payable to Wave USA under the intercompany
research and management services agreements as well as additional amounts payable to Wave USA related to the reimbursement of certain expenses that were paid for by Wave USA on behalf of the Parent. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-41 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B><I>Wave Life Sciences Ltd. </I></B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B><I>Notes to Supplementary Financial Information </I></B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B><I>Year ended December&nbsp;31, 2017 </I></B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>4. INCOME TAXES </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The components of the Parent&#146;s deferred tax assets and liabilities as of December&nbsp;31, 2017 and 2016 are as follows: </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="76%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="65%"></TD>
<TD VALIGN="bottom" WIDTH="11%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="10%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>December&nbsp;31,<BR>2017</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>December&nbsp;31,<BR>2016</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center">(in thousands)</TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Deferred tax assets:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net operating loss carryforwards</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">25,893</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">14,175</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Intangible assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">265</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total deferred tax assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">25,893</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">14,440</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Valuation allowance</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(25,776</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(14,336</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net deferred tax assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">117</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">104</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Deferred tax liability:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Interest income</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(117</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(104</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total deferred tax liability</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(117</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(104</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net deferred tax asset (liability)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As of December&nbsp;31, 2017, the Parent has net operating loss carryforwards in Singapore of $149.2&nbsp;million, which may
be available to offset future income tax liabilities and can be carried forward indefinitely provided the Parent satisfies the shareholdings test for carry-forward losses. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Parent has evaluated the positive and negative evidence bearing upon its ability to realize its deferred tax assets. Management has considered the
Parent&#146;s history of cumulative net losses incurred since inception and its lack of commercialization of any products or generation of any revenue from product sales since inception and has concluded that it is more likely than not that the
Parent will not realize the benefits of the deferred tax assets in Singapore. Accordingly, a full valuation allowance has been established against those deferred tax assets as of December&nbsp;31, 2017. The valuation allowance increased by
approximately $11.4&nbsp;million in 2017 primarily because of operating losses generated with no corresponding financial statement benefit. The Parent may release this valuation allowance when management determines that it is more likely than not
that the deferred tax assets will be realized. Any release of valuation allowance will be recorded as a tax benefit increasing net income. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The
Parent&#146;s policy is to record interest and penalties related to income taxes as part of its income tax provision. As of December&nbsp;31, 2017 and 2016, the Parent had incurred less than $0.1&nbsp;million and zero, respectively, of interest or
penalties related to income taxes. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Parent files income tax returns as prescribed by the tax laws of the jurisdictions in which it operates. In the
normal course of business, the Parent is subject to examination by various taxing authorities in Singapore. There are currently no pending income tax examinations. Tax years from 2013 to the present are still open to examination in Singapore. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As of December&nbsp;31, 2017 and 2016, $48.8&nbsp;million and $1.7&nbsp;million of cash and cash equivalents, respectively, was held by the Parent&#146;s
subsidiaries outside of Singapore. Additionally, as of December&nbsp;31, 2017 and 2016, the Parent&#146;s subsidiaries held restricted cash of $3.6&nbsp;million outside of Singapore. The Parent does not provide for Singapore income tax or foreign
withholding taxes on foreign unrepatriated earnings, as the Parent intends to permanently reinvest undistributed earnings in its foreign subsidiaries. If the Parent decides to change this </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-42 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B><I>Wave Life Sciences Ltd. </I></B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B><I>Notes to Supplementary Financial Information </I></B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B><I>Year ended December&nbsp;31, 2017 </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>4. INCOME TAXES&nbsp;(CONTINUED) </B></P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
assertion in the future to repatriate any additional foreign earnings, the Parent may be required to accrue and pay taxes. Because of the complexity of Singapore and foreign tax rules applicable
to the distribution of earnings from foreign subsidiaries to Singapore, the determination of the unrecognized deferred tax liability on these earnings is not practicable. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>5. PFIZER COLLABORATION AND SHARE PURCHASE AGREEMENT </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On
May&nbsp;5, 2016, the Parent entered into a Research, License and Option Agreement (the &#147;Pfizer Collaboration Agreement&#148;) with Pfizer Inc. (&#147;Pfizer&#148;).&nbsp;Pursuant to the terms of the Pfizer Collaboration Agreement, the Parent
and Pfizer agreed to collaborate on the discovery, development and commercialization of stereopure oligonucleotide therapeutics for up to five programs (the &#147;Pfizer Programs&#148;), each directed at a genetically-defined hepatic target selected
by Pfizer (the &#147;Pfizer Collaboration&#148;).&nbsp;The Parent received $10.0&nbsp;million as an upfront license fee under the Pfizer Collaboration Agreement.&nbsp;Subject to option exercises by Pfizer, the Parent may earn potential research,
development and commercial milestone payments, plus royalties, tiered up to low double-digits, on sales of any products that may result from the Pfizer Collaboration. None of the payments under the Pfizer Collaboration Agreement are refundable. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Simultaneously with the entry into the Pfizer Collaboration Agreement, the Parent entered into a Share Purchase Agreement (the &#147;Pfizer Equity
Agreement,&#148; and together with the Pfizer Collaboration Agreement, the &#147;Pfizer Agreements&#148;) with C.P. Pharmaceuticals International C.V., an affiliate of Pfizer (the &#147;Pfizer Affiliate&#148;). Pursuant to the terms of the Pfizer
Equity Agreement, the Pfizer Affiliate purchased 1,875,000 of the Parent&#146;s ordinary shares (the &#147;Shares&#148;) at a purchase price of $16.00 per share, for an aggregate purchase price of $30.0&nbsp;million. The Parent did not incur any
material costs in connection with the issuance of the Shares. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Under the Pfizer Collaboration Agreement, the parties agreed to collaborate during the
four-year Research Term. During the Research Term, the Parent is responsible to use its commercially reasonable efforts to advance up to five programs through to the selection of clinical candidates. At that stage, Pfizer may elect to license any of
these Pfizer Programs exclusively and to have exclusive rights to undertake the clinical development of the resulting clinical candidates into products and the potential commercialization of any such products thereafter. In addition, the Parent
receives a <FONT STYLE="white-space:nowrap">non-exclusive,</FONT> royalty-bearing sublicensable license to use Pfizer&#146;s hepatic targeting technology in any of the Company&#146;s own hepatic programs that are outside the scope of the Pfizer
Collaboration (the &#147;Wave Programs&#148;). If the Company uses this technology on the Wave Programs, Pfizer is eligible to receive potential development and commercial milestone payments from the Company. Pfizer is also eligible to receive
tiered royalties on sales of any products that include Pfizer&#146;s hepatic targeting technology. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Pfizer nominated two hepatic targets upon entry into
the Pfizer Collaboration in May 2016. In August 2016, Pfizer nominated the third hepatic target under the Pfizer Collaboration for which the Parent received a $2.5&nbsp;million milestone payment in 2016. On November&nbsp;5, 2017, the Parent amended
its Pfizer Collaboration Agreement to extend the target nomination period from November&nbsp;5, 2017 to May&nbsp;5, 2018. This amendment provides Pfizer with an additional six months to nominate the two remaining hepatic targets under the Pfizer
Collaboration Agreement. Pfizer nominated the fourth and fifth hepatic targets in March 2018 and April 2018, respectively. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Parent has determined that
the options held by Pfizer under the Pfizer Collaboration Agreement are substantive and priced at a significant incremental discount. Accordingly, $3.0&nbsp;million of the upfront payment was allocated to the options to nominate the three remaining
targets upon inception. The amount allocated to the </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-43 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B><I>Wave Life Sciences Ltd. </I></B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B><I>Notes to Supplementary Financial Information </I></B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B><I>Year ended December&nbsp;31, 2017 </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>5. PFIZER COLLABORATION AND SHARE PURCHASE AGREEMENT&nbsp;(CONTINUED) </B></P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
three options will be recognized as the research and development services are provided commencing from the date that Pfizer exercises each respective option, or immediately as each option expires
unexercised. The portion of the upfront payment allocated to the initial two targets was $7.0&nbsp;million and will be recognized as the research and development services are provided from the inception of the arrangement. Subsequently, in 2016,
Pfizer exercised its option to nominate a third program. The Parent will recognize $3.5&nbsp;million of revenue (which is comprised of $1.0&nbsp;million allocated to the option at inception of the arrangement and $2.5&nbsp;million paid by Pfizer at
the time of exercising the option) as the research and development services are provided. In November 2017, the Parent achieved a milestone under the Pfizer Collaboration Agreement and the revenue related to this milestone was recognized in full
during the year ended December&nbsp;31, 2017.</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Pfizer Collaboration is managed by a joint steering committee in which both parties are represented
equally, which will oversee the scientific progression of each Pfizer Program up to the clinical candidate stage. During the four-year Research Term and for a period of two years thereafter, the Parent has agreed to work exclusively with Pfizer with
respect to using any of the Company&#146;s stereopure oligonucleotide technology that is specific for the applicable hepatic target which is the basis of any Pfizer Program.</P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The stated term of the Pfizer Collaboration Agreement commenced on May&nbsp;5, 2016 and terminates on the date of the last to expire payment obligation with
respect to each Pfizer Program and with respect to each Wave Program, expires on a <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">program-by-program</FONT></FONT> basis accordingly.&nbsp;Pfizer may terminate its rights related to
a Pfizer Program under the Pfizer Collaboration Agreement at its own convenience upon 90 days&#146; notice to the Parent. The Parent may also terminate its rights related to a Wave Program at its own convenience upon 90 days&#146; notice to
Pfizer.&nbsp;The Pfizer Collaboration Agreement may also be terminated by either party in the event of an uncured material breach of the Pfizer Collaboration Agreement by the other party. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">During the year ended December&nbsp;31, 2017, the Parent recognized&nbsp;revenue of $3.7&nbsp;million under the Pfizer Collaboration Agreement. Deferred
revenue amounted to $8.3 million&nbsp;as of December&nbsp;31, 2017, of which $2.7&nbsp;million is included in current liabilities.</P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>6. SHARE CAPITAL
</B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><U>Ordinary Shares </U></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The following represents
the historical ordinary share transactions of the Parent from January&nbsp;1, 2016 through December&nbsp;31, 2017: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">In May 2016, the Parent granted 1,875,000 ordinary shares to Pfizer under the Pfizer Agreements at a purchase price of $16.00 per share, for an aggregate purchase price of $30.0&nbsp;million. </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">In April 2017, the Parent closed a <FONT STYLE="white-space:nowrap">follow-on</FONT> underwritten public offering of 4,166,667 ordinary shares for gross proceeds of $100.0&nbsp;million.&nbsp;The net proceeds from this
issuance were $93.5&nbsp;million after deducting underwriting discounts and commissions and other estimated offering expenses. </TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-44 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B><I>Wave Life Sciences Ltd. </I></B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B><I>Notes to Supplementary Financial Information </I></B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B><I>Year ended December&nbsp;31, 2017 </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>6. SHARE CAPITAL&nbsp;(CONTINUED) </B></P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Features of the Ordinary Shares </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The ordinary shares have no par value and there is no concept of authorized share capital under Singapore law. The rights, preferences, and privileges of
ordinary shares are as follows: </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>New Share Offering </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Prior to the closing of the Parent&#146;s initial public offering, any new ordinary shares or securities convertible into ordinary shares were required to be
offered in the first instance to all the then holders of any class of shares, other than the Series A preferred shares, prior to issuance and each shareholder had the right of <FONT STYLE="white-space:nowrap">pre-emption</FONT> with respect to any
issuance of new ordinary shares or securities convertible into ordinary shares. This right of <FONT STYLE="white-space:nowrap">pre-emption</FONT> did not apply to shares sold in the Parent&#146;s initial public offering and terminated immediately
prior to the closing of the Parent&#146;s initial public offering. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Voting </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The holders of ordinary shares are entitled to one vote for each ordinary share held at all meetings of shareholders and written actions in lieu of meetings.
</P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Dividends </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">All dividends, if any, shall be
declared and paid pro rata according to the number of shares held by each member entitled to receive dividends. The Parent&#146;s board of directors may deduct from any dividend all sums of money presently payable by the member to the Parent on
account of calls. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Liquidation </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In the event
of a liquidation, dissolution or winding up of, or a return of capital by the Parent, the ordinary shares will rank equally with the Series A preferred shares after the payment of the liquidation preference of $10.00 for Series A preferred shares.
</P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><U>Series A Preferred Shares </U></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Series A
preferred shares are classified as temporary shareholders&#146; equity since the holders of the Series A preferred shares are entitled to a liquidation preference upon a deemed liquidation event, which is outside the control of the Parent. In the
event a deemed liquidation event were to occur, the Parent would adjust the carrying value of the Series A preferred shares to their liquidation value, which amounts to $10.00 in the aggregate. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Series A preferred shares have no par value and there is no authorized share capital under Singapore law. The Series A preferred shares are not
redeemable. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>7. SHARE-BASED COMPENSATION </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In December
2014, the Parent&#146;s board of directors adopted the Wave Life Sciences Ltd. 2014 Equity Incentive Plan (the &#147;2014 Plan&#148;) and reserved 1,763,714 ordinary shares for issuance under this plan, which was increased to 5,064,544 in 2015 and
to 6,064,544&nbsp;in 2017. The 2014 Plan authorizes the board of directors or a committee of the board to grant incentive share options, <FONT STYLE="white-space:nowrap">non-qualified</FONT> share options, share appreciation rights, restricted
awards, which includes restricted shares and restricted share units (&#147;RSUs&#148;), and performance awards to eligible employees, <FONT STYLE="white-space:nowrap">non-employees</FONT> and directors of the Company. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-45 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B><I>Wave Life Sciences Ltd. </I></B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B><I>Notes to Supplementary Financial Information </I></B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B><I>Year ended December&nbsp;31, 2017 </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>7. SHARE-BASED COMPENSATION&nbsp;(CONTINUED) </B></P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As of December&nbsp;31, 2017, 1,716,110 ordinary shares remained available for future grant under the 2014
Plan. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Share option activity for the year ended December&nbsp;31, 2017 is summarized as follows: </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="92%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="49%"></TD>
<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Number of</B><br><B>Shares</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Weighted-</B><br><B>Average</B><br><B>Exercise</B><br><B>Price</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Weighted-<BR>Average</B><br><B>Remaining<BR>Contractual</B><br><B>Term<BR>(in&nbsp;years)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Aggregate</B><br><B>Intrinsic</B><br><B>Value</B><br><B>(in&nbsp;thousands)<SUP STYLE="font-size:85%; vertical-align:top">(1)</SUP></B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Outstanding as of January&nbsp;1, 2017</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,577,766</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">10.58</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Granted<SUP STYLE="font-size:85%; vertical-align:top">(2)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">522,750</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">26.33</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Exercised</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(137,493</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6.74</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Forfeited or cancelled</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(195,893</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">14.71</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Outstanding as of December&nbsp;31, 2017</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,767,130</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">12.69</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7.81</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">84,675</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Options exercisable as of December&nbsp;31, 2017</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,257,455</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">7.64</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7.43</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">62,060</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Options unvested as of December&nbsp;31, 2017</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,509,675</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">20.23</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">8.37</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">22,614</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE> <P STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:10%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><SUP STYLE="font-size:85%; vertical-align:top">(1)</SUP>&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">The aggregate intrinsic value of options is calculated as the difference between the exercise price of the share options and the fair value of the Parent&#146;s ordinary shares for those share options that had exercise
prices lower than the fair value of the ordinary shares as of the end of the period. </TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><SUP STYLE="font-size:85%; vertical-align:top">(2)</SUP>&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Includes 72,000 options granted by the Parent to outside directors during 2017; these options are treated as options granted to employees. </TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Options granted to employees of the Parent&#146;s subsidiaries generally vest over a period of three or four years, and options that are forfeited or
cancelled are available to be granted again. The options granted by the Parent to outside directors and <FONT STYLE="white-space:nowrap">non-employees</FONT> generally vest over periods of one to four years, and options that are forfeited or
cancelled are available to be granted again. The contractual life of options granted to employees of the Parent&#146;s subsidiaries is generally ten years from the grant date. The contractual life of options granted by the Parent to outside
directors and <FONT STYLE="white-space:nowrap">non-employees</FONT> is generally five and ten years, respectively, from the grant date. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The assumptions
used in the Black-Scholes option pricing model to determine the fair value of share options granted to employees during the years ended December&nbsp;31, 2017 and 2016 were as follows: </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="76%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="52%"></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>For&nbsp;the&nbsp;Year&nbsp;Ended&nbsp;December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2017</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2016</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Risk-free interest rate</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1.49%&nbsp;-&nbsp;2.23%</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="white-space:nowrap">1.15%&nbsp;-&nbsp;2.18%</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Expected term (in years)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="white-space:nowrap">3.00&nbsp;-&nbsp;6.25</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="white-space:nowrap">3.00&nbsp;-&nbsp;6.25</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Expected volatility</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="white-space:nowrap">68.95%&nbsp;-&nbsp;72.24%</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="white-space:nowrap">60.89%&nbsp;-&nbsp;68.76%</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Expected dividend yield</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0%</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0%</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">There were no options granted to <FONT STYLE="white-space:nowrap">non-employees</FONT> in 2017 or 2016. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As of December&nbsp;31, 2017, the unrecognized compensation cost related to outstanding options was $16.9&nbsp;million for employees and $1.0&nbsp;million for
<FONT STYLE="white-space:nowrap">non-employees.</FONT> Of the total unrecognized compensation cost of $17.9&nbsp;million, $1.8&nbsp;million related to the Parent, which included $0.8&nbsp;million of the unrecognized compensation
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-46 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B><I>Wave Life Sciences Ltd. </I></B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B><I>Notes to Supplementary Financial Information </I></B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B><I>Year ended December&nbsp;31, 2017 </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>7. SHARE-BASED COMPENSATION&nbsp;(CONTINUED) </B></P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
cost for employees and the $1.0&nbsp;million of unrecognized compensation cost for <FONT STYLE="white-space:nowrap">non-employees.</FONT> The unrecognized compensation cost related to outstanding
options for employees and <FONT STYLE="white-space:nowrap">non-employees</FONT> is expected to be recognized over a weighted-average period of approximately 2.6 years. For the years ended December&nbsp;31, 2017 and 2016, the weighted-average grant
date fair value per granted option was $16.58 and $30.23, respectively. The aggregate fair value of options that vested during the year ended December&nbsp;31, 2017 was $11.5&nbsp;million. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">RSU activity for the year ended December&nbsp;31, 2017 is summarized as follows: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="76%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="72%"></TD>
<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>RSUs</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Average<BR>Grant&nbsp;Date<BR>Fair Value<BR>(in dollars<BR>per share)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Outstanding as of January&nbsp;1, 2017</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">22,750</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">21.69</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Granted</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">170,859</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">29.05</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Vested</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(22,750</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">21.69</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Forfeited</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(16,400</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">29.05</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">RSUs Outstanding at December&nbsp;31, 2017</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">154,459</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">29.05</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">RSUs were first granted in 2016 and, to date, RSUs have only been granted to employees of the Parent&#146;s subsidiaries. The
RSUs granted in 2016 fully vested upon the first anniversary of the grant date and the RSUs granted in 2017 vest annually over a period of four years. RSUs that are forfeited are available to be granted again. Share-based compensation expense
related to the RSUs is included in research and development expenses or general and administrative expenses on the consolidated statements of operations. The unrecognized compensation costs related to outstanding RSUs was $3.5&nbsp;million as of
December&nbsp;31, 2017, and is expected to be recognized over a weighted-average period of approximately 3.11 years. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company recorded share-based
compensation expense of $12.1&nbsp;million and $6.8&nbsp;million for the years ended December&nbsp;31, 2017, and 2016, respectively, of which $2.9&nbsp;million and $2.7&nbsp;million related to options granted to
<FONT STYLE="white-space:nowrap">non-employees.</FONT> Of the total share-based compensation expense recorded, the Parent recorded share-based compensation expense of $4.0&nbsp;million and $2.8&nbsp;million for the years ended December&nbsp;31, 2017
and 2016, respectively. The Parent records the share-based compensation expense related to options granted to <FONT STYLE="white-space:nowrap">non-employees</FONT> and outside directors. The options granted to outside directors are treated as
options granted to employees. The Parent&#146;s subsidiaries record share-based compensation expense related to options and RSUs granted to employees of the subsidiaries, as well as shares issued to employees of the subsidiaries. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>8. RELATED PARTIES </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Parent had the following related
party transactions for the periods presented in the accompanying supplementary financial information, which have not otherwise been discussed in these notes to the supplementary financial information: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">The Parent held cash of $0.1&nbsp;million in depository accounts with Kagoshima Bank, Ltd., an affiliate of one of the Company&#146;s shareholders,&nbsp;Kagoshima Shinsangyo Sousei Investment Limited Partnership, as of
December&nbsp;31, 2017 and 2016. </TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-47 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B><I>Wave Life Sciences Ltd. </I></B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B><I>Notes to Supplementary Financial Information </I></B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B><I>Year ended December&nbsp;31, 2017 </I></B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>9. SUBSEQUENT EVENTS </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Takeda&nbsp;Collaboration and Equity Investment </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In
February 2018, Wave USA and Wave UK entered into a global strategic collaboration with Takeda Pharmaceutical Company Limited (&#147;Takeda&#148;) (the &#147;Takeda Collaboration&#148;), pursuant to which Wave USA, Wave UK and Takeda agreed to
collaborate on the research, development and commercialization of oligonucleotide therapeutics for disorders of the central nervous system (&#147;CNS&#148;). The Takeda Collaboration provides the Company with at least $230.0&nbsp;million in
committed cash and Takeda with the option to <FONT STYLE="white-space:nowrap">co-develop</FONT> and <FONT STYLE="white-space:nowrap">co-commercialize</FONT> Wave&#146;s CNS development programs in HD, ALS and FTD, as well as Wave&#146;s
discovery-stage program targeting ATXN3 for the treatment of spinocerebellar ataxia 3. In addition, Takeda will have the right to exclusively license multiple preclinical programs for CNS disorders, including Alzheimer&#146;s disease and
Parkinson&#146;s disease. In April 2018, the Takeda Collaboration became effective and Takeda paid the Company $110.0&nbsp;million as an upfront payment. Takeda also agreed to fund the Company&#146;s research and preclinical activities in the amount
of $60.0&nbsp;million during the four-year research term and to reimburse the Company for any collaboration-budgeted research and preclinical expenses incurred by us that exceed that amount. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Simultaneously with Wave USA and Wave UK&#146;s entry into the collaboration and license agreement with Takeda (the &#147;Takeda Collaboration
Agreement&#148;), the Parent entered into a share purchase agreement with Takeda pursuant to which the Parent agreed to sell to Takeda 1,096,892 of its ordinary shares at a purchase price of $54.70 per share (the &#147;Takeda Equity
Investment&#148;). In April 2018, the Parent closed the Takeda Equity Investment and received aggregate cash proceeds of $60.0&nbsp;million. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-48 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g589845img1.jpg" ALT="LOGO">
 </P> <P STYLE="font-family:Times New Roman; font-size:0.5pt"><FONT COLOR="#FFFFFF">VOTE PROCESSING C/O BROADRIDGE 51 MERCEDES WAY EDGEWOOD, NY 11717 VOTE BY MAIL Mark, sign and date your proxy card and return it in the
postage-paid envelope we have provided or return it to Vote Processing, c/o Broadridge, 51 Mercedes Way, Edgewood, NY 11717. TO VOTE, MARK BLOCKS BELOW IN BLUE OR BLACK INK AS FOLLOWS: E49628-Z72944 KEEP THIS PORTION FOR YOUR RECORDS THIS PROXY CARD
IS VALID ONLY WHEN SIGNED AND DATED. DETACH AND RETURN THIS PORTION ONLY WAVE LIFE SCIENCES LTD. The Board of Directors recommends a vote FOR all the director nominees listed in Proposal 1 and FOR Proposals 2, 3, and 4. 1. The Election of the
Nominees for Director Nominees: For Against Abstain 1a. Paul B. Bolno, M.D. 1b. Christian Henry 1c. Peter Kolchinsky, Ph.D. 1d. Koji Miura 1e. Adrian Rawcliffe 1f. Ken Takanashi 1g. Gregory L. Verdine, Ph.D. For address changes and/or comments,
please check this box and write them on the back where indicated. Please indicate if you plan to attend the 2018 Annual General Meeting. Yes No Please sign exactly as your name(s) appear(s) hereon. When signing as attorney, executor, administrator,
or other fiduciary, please give full title as such. Joint owners should each sign personally. All holders must sign. If a corporation or partnership, please sign in full corporate or partnership name by authorized officer. 2. To approve the
re-appointment of KPMG LLP to serve For Against Abstain as our independent registered public accounting firm and independent Singapore auditor for the year ending December 31, 2018, and to authorize the Audit Committee of the Board of Directors to
fix KPMG LLP&#146;s remuneration for services provided through the date of our 2019 Annual General Meeting of Shareholders 3. To approve the compensation to be paid to the non-employee members of the Board of Directors for service on the Board and
its committees, as described under &#147;Proposal 3: Non-Employee Directors&#146; Compensation&#148; 4. To authorize the Board of Directors to allot and issue Ordinary Shares of Wave Life Sciences Ltd. 5. To transact such other business as may
properly come before the 2018 Annual General Meeting of Shareholders and all adjournments or postponements thereof Signature [PLEASE SIGN WITHIN BOX] Date Signature (Joint Owners) Date </FONT></P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g589845img2.jpg" ALT="LOGO">
 </P> <P STYLE="font-family:Times New Roman; font-size:0.5pt"><FONT COLOR="#FFFFFF">Wave Life Sciences Ltd. 2018 Annual General Meeting of Shareholders Tuesday, August 7, 2018, 11:00 a.m., Eastern Time Wave Life Sciences
Ltd. 733 Concord Avenue, Cambridge, MA 02138 Upon arrival, please present this admission ticket and photo identification at the registration desk. IMPORTANT NOTICE REGARDING THE AVAILABILITY OF PROXY MATERIALS FOR THE 2018 ANNUAL GENERAL MEETING OF
SHAREHOLDERS: The notice, proxy statement and our 2017 annual report to shareholders are available for viewing, printing and downloading at https://materials.proxyvote.com/. Vote by Mail Whether or not you expect to attend the 2018 Annual General
Meeting of Shareholders, please mark, sign and date your proxy card and return it in the postage-paid envelope we have provided or return it to Vote Processing, c/o Broadridge, 51 Mercedes Way, Edgewood, NY 11717. YOUR PROXY CARD MUST BE RECEIVED AT
THE ADDRESS ABOVE NOT LESS THAN 48 HOURS BEFORE THE TIME APPOINTED FOR HOLDING THE 2018 ANNUAL GENERAL MEETING OF SHAREHOLDERS (OR WITHIN SUCH OTHER TIME AS MAY BE REQUIRED BY THE SINGAPORE COMPANIES ACT). E49629-Z72944 Proxy - WAVE LIFE SCIENCES
LTD. (Incorporated in the Republic of Singapore; Company Registration Number 201218209G) 2018 Annual General Meeting of Shareholders August 7, 2018 This proxy is solicited by the Board of Directors Paul B. Bolno, M.D., and in his absence, Linda
Rockett, Esq., each with the power of substitution and each with the full power to act alone, are hereby authorized as Proxies to represent and vote the ordinary shares of Wave Life Sciences Ltd. owned by the undersigned, with all the powers which
the undersigned would possess if personally present, at the 2018 Annual General Meeting of Shareholders of Wave Life Sciences Ltd. to be held on August 7, 2018 or at any postponement or adjournment thereof. Shares represented by this proxy will be
voted by the Proxies as directed herein by the shareholder. If no such directions are indicated, the Proxies will have authority to vote FOR the director nominees listed in Proposal 1, FOR Proposal 2, FOR Proposal 3 and FOR Proposal 4. In their
discretion, the Proxies are authorized to vote upon such other business as may properly come before 2018 Annual General Meeting of Shareholders or at any adjournment or postponement thereof. Address Changes/Comments: (If you noted any Address
Changes/Comments above, please mark corresponding box on the reverse side.) Continued and to be signed on reverse side </FONT></P>
</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>2
<FILENAME>g589845g51v37.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g589845g51v37.jpg
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M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! ?_  !$( #
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MMMKHV?[?<%UC.#@T R),]([E"M\DWC8\AW:O;72'35+\Y65<4'L*\+OC["8
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0;?+;Z]BPWTIY*VGHL7__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>g589845g65t06.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g589845g65t06.jpg
M_]C_X  02D9)1@ ! 0$#P /   #_[16T4&AO=&]S:&]P(#,N,  X0DE-! 0
M     " < 5H  QLE1QP!6@ #&R5'' (   +_/AP"4  $1V5N83A"24T$)0
M    $-,\K0+^5H4,XQU"?,%3=CHX0DE-!#H      /<    0     0
M"W!R:6YT3W5T<'5T    !0    !0<W138F]O; $     26YT965N=6T
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M8VMG3V)J8P    $       !21T)#     P    !29" @9&]U8D!OX
M     $=R;B!D;W5B0&_@            0FP@(&1O=6) ;^            !"
M<F1456YT1B-2;'0               !";&0@56YT1B-2;'0
M  !2<VQT56YT1B-0>&Q 6$DD@         IV96-T;W)$871A8F]O; $
M4&=0<V5N=6T     4&=0<P    !09U!#     $QE9G15;G1&(U)L=
M         %1O<"!5;G1&(U)L=                %-C;"!5;G1&(U!R8T!9
M            $&-R;W!7:&5N4')I;G1I;F=B;V]L      YC<F]P4F5C=$)O
M='1O;6QO;F<         #&-R;W!296-T3&5F=&QO;F<         #6-R;W!2
M96-T4FEG:'1L;VYG          MC<F]P4F5C=%1O<&QO;F<      #A"24T#
M[0      $ /      0 " \     !  (X0DE-!"8       X
M/X   #A"24T#\@      "@  ________   X0DE-! T       0   !X.$))
M3009       $    'CA"24T#\P      "0           0 X0DE-)Q
M  H  0         ".$))30/T       2 #4    ! "T    &       !.$))
M30/W       <  #_____________________________ ^@  #A"24T$"
M    $     $   )    "0      X0DE-!!X       0     .$))300:
M  ,U    !@              ,P   +           0
M       !              "P    ,P                     !
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M;&]N9P   #,     4F=H=&QO;F<   "P     W5R;%1%6%0    !
M;G5L;%1%6%0    !        37-G951%6%0    !       &86QT5&%G5$58
M5     $       YC96QL5&5X=$ES2%1-3&)O;VP!    "&-E;&Q497AT5$58
M5     $       EH;W)Z06QI9VYE;G5M    #T53;&EC94AO<GI!;&EG;@
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M       ! 0 X0DE-!!0       0    ".$))300,      O,     0   *
M   N   !X   5D    NP !@  ?_8_^T #$%D;V)E7T--  /_[@ .061O8F4
M9(     !_]L A  ," @("0@,"0D,$0L*"Q$5#PP,#Q48$Q,5$Q,8$0P,# P,
M#!$,# P,# P,# P,# P,# P,# P,# P,# P,# P, 0T+"PT.#1 .#A 4#@X.
M%!0.#@X.%!$,# P,#!$1# P,# P,$0P,# P,# P,# P,# P,# P,# P,# P,
M# P,# S_P  1"  N * # 2(  A$! Q$!_]T !  *_\0!/P   04! 0$! 0$
M         P ! @0%!@<("0H+ 0 !!0$! 0$! 0         !  (#! 4&!P@)
M"@L0  $$ 0,"! (%!P8(!0,,,P$  A$#!"$2,05!46$3(G&!,@84D:&Q0B,D
M%5+!8C,T<H+10P<EDE/PX?%C<S46HK*#)D235&1%PJ-T-A?25>)E\K.$P]-U
MX_-&)Y2DA;25Q-3D]*6UQ=7E]59F=H:6IK;&UN;V-T=79W>'EZ>WQ]?G]Q$
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M&/\ ]JETJ9)3E8OU4^KN(&>E@5.-;&U,-H]4AC=&M:;_ %-O"U6M:UH:T -
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M '     3 $$ 9 !O &( 90 @ %  : !O '0 ;P!S &@ ;P!P "  0P!3 #8
M   ! #A"24T$(@     !0DU- "H    (  @!$@ #     0 !   !&@ %
M 0   &X!&P %     0   '8!*  #     0 "   !,0 "    '@   'X!,@ "
M    %    )P!.P "    !0   +"':0 $     0   +@   #D  [2I0  )Q
M#M*E   G$$%D;V)E(%!H;W1O<VAO<"!#4S8@*%=I;F1O=W,I #(P,3<Z,#<Z
M,#8@,3 Z,#0Z-3< 1V5N80       Z !  ,    !__\  * "  0    !
ML* #  0    !    ,P         & 0,  P    $ !@   1H !0    $   $R
M 1L !0    $   $Z 2@  P    $  @   @$ !     $   %" @( !     $
M             $@    !    2     $X0DE- _T       @          /_A
M 41-30 J    "  ( 1(  P    $      1H !0    $   !N 1L !0    $
M  !V 2@  P    $  @   3$  @   !X   !^ 3(  @   !0   "< 3L  @
M  4   "PAVD !     $   "X    Y    \     !   #P     %!9&]B92!0
M:&]T;W-H;W @0U,V("A7:6YD;W=S*0 R,#$W.C W.C V(#$P.C T.C4W $=E
M;F$       .@ 0 #     ?__  "@ @ $     0   +"@ P $     0   #,
M        !@$#  ,    !  8   $:  4    !   !,@$;  4    !   !.@$H
M  ,    !  (   (!  0    !   !0@("  0    !              /
M 0   \     !_^% Y6AT=' Z+R]N<RYA9&]B92YC;VTO>&%P+S$N,"\ /#]X
M<&%C:V5T(&)E9VEN/2+ON[\B(&ED/2)7-4TP37!#96AI2'IR95-Z3E1C>FMC
M.60B/SX\>#IX;7!M971A('AM;&YS.G@](F%D;V)E.FYS.FUE=&$O(B!X.GAM
M<'1K/2)!9&]B92!835 @0V]R92 U+C,M8S Q,2 V-BXQ-#4V-C$L(#(P,3(O
M,#(O,#8M,30Z-38Z,C<@(" @(" @("(^"B @(#QR9&8Z4D1&('AM;&YS.G)D
M9CTB:'1T<#HO+W=W=RYW,RYO<F<O,3DY.2\P,B\R,BUR9&8M<WEN=&%X+6YS
M(R(^"B @(" @(#QR9&8Z1&5S8W)I<'1I;VX@<F1F.F%B;W5T/2(B"B @(" @
M(" @(" @('AM;&YS.G!D9CTB:'1T<#HO+VYS+F%D;V)E+F-O;2]P9&8O,2XS
M+R(^"B @(" @(" @(#QP9&8Z4')O9'5C97(^36EC<F]S;V9TPJX@3V9F:6-E
M(%=O<F0@,C P-SPO<&1F.E!R;V1U8V5R/@H@(" @(" \+W)D9CI$97-C<FEP
M=&EO;CX*(" @(" @/')D9CI$97-C<FEP=&EO;B!R9&8Z86)O=70](B(*(" @
M(" @(" @(" @>&UL;G,Z>&UP/2)H='1P.B\O;G,N861O8F4N8V]M+WAA<"\Q
M+C O(CX*(" @(" @(" @/'AM<#I#<F5A=&]R5&]O;#Y!9&]B92!0:&]T;W-H
M;W @0U,V("A7:6YD;W=S*3PO>&UP.D-R96%T;W)4;V]L/@H@(" @(" @(" \
M>&UP.D-R96%T941A=&4^,C Q-RTP-RTP-E0P.3HU,CHP-"LP-3HS,#PO>&UP
M.D-R96%T941A=&4^"B @(" @(" @(#QX;7 Z36]D:69Y1&%T93XR,#$W+3 W
M+3 V5#$P.C T.C4W*S U.C,P/"]X;7 Z36]D:69Y1&%T93X*(" @(" @(" @
M/'AM<#I-971A9&%T841A=&4^,C Q-RTP-RTP-E0Q,#HP-#HU-RLP-3HS,#PO
M>&UP.DUE=&%D871A1&%T93X*(" @(" @/"]R9&8Z1&5S8W)I<'1I;VX^"B @
M(" @(#QR9&8Z1&5S8W)I<'1I;VX@<F1F.F%B;W5T/2(B"B @(" @(" @(" @
M('AM;&YS.GAM<$U-/2)H='1P.B\O;G,N861O8F4N8V]M+WAA<"\Q+C O;6TO
M(@H@(" @(" @(" @("!X;6QN<SIS=$5V=#TB:'1T<#HO+VYS+F%D;V)E+F-O
M;2]X87 O,2XP+W-4>7!E+U)E<V]U<F-E179E;G0C(@H@(" @(" @(" @("!X
M;6QN<SIS=%)E9CTB:'1T<#HO+VYS+F%D;V)E+F-O;2]X87 O,2XP+W-4>7!E
M+U)E<V]U<F-E4F5F(R(^"B @(" @(" @(#QX;7!-33I$;V-U;65N=$E$/G5U
M:60Z-S8Y139!1D8M-C4T-RTT,44V+3DT1#4M,3="0C-!-$5%-4(V/"]X;7!-
M33I$;V-U;65N=$E$/@H@(" @(" @(" \>&UP34TZ26YS=&%N8V5)1#YX;7 N
M:6ED.C(W,3!!138X0S<V,44W,3$X0D,P1D%#-3<R0C-!-C1#/"]X;7!-33I)
M;G-T86YC94E$/@H@(" @(" @(" \>&UP34TZ3W)I9VEN86Q$;V-U;65N=$E$
M/G5U:60Z-S8Y139!1D8M-C4T-RTT,44V+3DT1#4M,3="0C-!-$5%-4(V/"]X
M;7!-33I/<FEG:6YA;$1O8W5M96YT240^"B @(" @(" @(#QX;7!-33I(:7-T
M;W)Y/@H@(" @(" @(" @(" \<F1F.E-E<3X*(" @(" @(" @(" @(" @/')D
M9CIL:2!R9&8Z<&%R<V54>7!E/2)297-O=7)C92(^"B @(" @(" @(" @(" @
M(" @(#QS=$5V=#IA8W1I;VX^<V%V960\+W-T179T.F%C=&EO;CX*(" @(" @
M(" @(" @(" @(" @/'-T179T.FEN<W1A;F-E240^>&UP+FEI9#HR,S$P044V
M.$,W-C%%-S$Q.$)#,$9!0S4W,D(S038T0SPO<W1%=G0Z:6YS=&%N8V5)1#X*
M(" @(" @(" @(" @(" @(" @/'-T179T.G=H96X^,C Q-RTP-RTP-E0P.3HU
M-#HU.2LP-3HS,#PO<W1%=G0Z=VAE;CX*(" @(" @(" @(" @(" @(" @/'-T
M179T.G-O9G1W87)E06=E;G0^061O8F4@4&AO=&]S:&]P($-3-B H5VEN9&]W
M<RD\+W-T179T.G-O9G1W87)E06=E;G0^"B @(" @(" @(" @(" @(" @(#QS
M=$5V=#IC:&%N9V5D/B\\+W-T179T.F-H86YG960^"B @(" @(" @(" @(" @
M(#PO<F1F.FQI/@H@(" @(" @(" @(" @(" \<F1F.FQI(')D9CIP87)S951Y
M<&4](E)E<V]U<F-E(CX*(" @(" @(" @(" @(" @(" @/'-T179T.F%C=&EO
M;CYS879E9#PO<W1%=G0Z86-T:6]N/@H@(" @(" @(" @(" @(" @(" \<W1%
M=G0Z:6YS=&%N8V5)1#YX;7 N:6ED.C(V,3!!138X0S<V,44W,3$X0D,P1D%#
M-3<R0C-!-C1#/"]S=$5V=#II;G-T86YC94E$/@H@(" @(" @(" @(" @(" @
M(" \<W1%=G0Z=VAE;CXR,#$W+3 W+3 V5#$P.C T.C4W*S U.C,P/"]S=$5V
M=#IW:&5N/@H@(" @(" @(" @(" @(" @(" \<W1%=G0Z<V]F='=A<F5!9V5N
M=#Y!9&]B92!0:&]T;W-H;W @0U,V("A7:6YD;W=S*3PO<W1%=G0Z<V]F='=A
M<F5!9V5N=#X*(" @(" @(" @(" @(" @(" @/'-T179T.F-H86YG960^+SPO
M<W1%=G0Z8VAA;F=E9#X*(" @(" @(" @(" @(" @/"]R9&8Z;&D^"B @(" @
M(" @(" @(" @(#QR9&8Z;&D@<F1F.G!A<G-E5'EP93TB4F5S;W5R8V4B/@H@
M(" @(" @(" @(" @(" @(" \<W1%=G0Z86-T:6]N/F-O;G9E<G1E9#PO<W1%
M=G0Z86-T:6]N/@H@(" @(" @(" @(" @(" @(" \<W1%=G0Z<&%R86UE=&5R
M<SYF<F]M(&%P<&QI8V%T:6]N+W9N9"YA9&]B92YP:&]T;W-H;W @=&\@:6UA
M9V4O97!S9CPO<W1%=G0Z<&%R86UE=&5R<SX*(" @(" @(" @(" @(" @/"]R
M9&8Z;&D^"B @(" @(" @(" @(" @(#QR9&8Z;&D@<F1F.G!A<G-E5'EP93TB
M4F5S;W5R8V4B/@H@(" @(" @(" @(" @(" @(" \<W1%=G0Z86-T:6]N/F1E
M<FEV960\+W-T179T.F%C=&EO;CX*(" @(" @(" @(" @(" @(" @/'-T179T
M.G!A<F%M971E<G,^8V]N=F5R=&5D(&9R;VT@87!P;&EC871I;VXO=FYD+F%D
M;V)E+G!H;W1O<VAO<"!T;R!I;6%G92]E<'-F/"]S=$5V=#IP87)A;65T97)S
M/@H@(" @(" @(" @(" @(" \+W)D9CIL:3X*(" @(" @(" @(" @(" @/')D
M9CIL:2!R9&8Z<&%R<V54>7!E/2)297-O=7)C92(^"B @(" @(" @(" @(" @
M(" @(#QS=$5V=#IA8W1I;VX^<V%V960\+W-T179T.F%C=&EO;CX*(" @(" @
M(" @(" @(" @(" @/'-T179T.FEN<W1A;F-E240^>&UP+FEI9#HR-S$P044V
M.$,W-C%%-S$Q.$)#,$9!0S4W,D(S038T0SPO<W1%=G0Z:6YS=&%N8V5)1#X*
M(" @(" @(" @(" @(" @(" @/'-T179T.G=H96X^,C Q-RTP-RTP-E0Q,#HP
M-#HU-RLP-3HS,#PO<W1%=G0Z=VAE;CX*(" @(" @(" @(" @(" @(" @/'-T
M179T.G-O9G1W87)E06=E;G0^061O8F4@4&AO=&]S:&]P($-3-B H5VEN9&]W
M<RD\+W-T179T.G-O9G1W87)E06=E;G0^"B @(" @(" @(" @(" @(" @(#QS
M=$5V=#IC:&%N9V5D/B\\+W-T179T.F-H86YG960^"B @(" @(" @(" @(" @
M(#PO<F1F.FQI/@H@(" @(" @(" @(" \+W)D9CI397$^"B @(" @(" @(#PO
M>&UP34TZ2&ES=&]R>3X*(" @(" @(" @/'AM<$U-.D1E<FEV961&<F]M(')D
M9CIP87)S951Y<&4](E)E<V]U<F-E(CX*(" @(" @(" @(" @/'-T4F5F.FEN
M<W1A;F-E240^>&UP+FEI9#HR-C$P044V.$,W-C%%-S$Q.$)#,$9!0S4W,D(S
M038T0SPO<W12968Z:6YS=&%N8V5)1#X*(" @(" @(" @(" @/'-T4F5F.F1O
M8W5M96YT240^=75I9#HW-CE%-D%&1BTV-30W+30Q138M.31$-2TQ-T)",T$T
M144U0C8\+W-T4F5F.F1O8W5M96YT240^"B @(" @(" @(" @(#QS=%)E9CIO
M<FEG:6YA;$1O8W5M96YT240^=75I9#HW-CE%-D%&1BTV-30W+30Q138M.31$
M-2TQ-T)",T$T144U0C8\+W-T4F5F.F]R:6=I;F%L1&]C=6UE;G1)1#X*(" @
M(" @(" @/"]X;7!-33I$97)I=F5D1G)O;3X*(" @(" @/"]R9&8Z1&5S8W)I
M<'1I;VX^"B @(" @(#QR9&8Z1&5S8W)I<'1I;VX@<F1F.F%B;W5T/2(B"B @
M(" @(" @(" @('AM;&YS.G!D9F%I9#TB:'1T<#HO+W=W=RYA:6EM+F]R9R]P
M9&9A+VYS+VED+R(^"B @(" @(" @(#QP9&9A:60Z<&%R=#XQ/"]P9&9A:60Z
M<&%R=#X*(" @(" @(" @/'!D9F%I9#IC;VYF;W)M86YC93Y"/"]P9&9A:60Z
M8V]N9F]R;6%N8V4^"B @(" @(#PO<F1F.D1E<V-R:7!T:6]N/@H@(" @(" \
M<F1F.D1E<V-R:7!T:6]N(')D9CIA8F]U=#TB(@H@(" @(" @(" @("!X;6QN
M<SID8STB:'1T<#HO+W!U<FPN;W)G+V1C+V5L96UE;G1S+S$N,2\B/@H@(" @
M(" @(" \9&,Z8W)E871O<CX*(" @(" @(" @(" @/')D9CI397$^"B @(" @
M(" @(" @(" @(#QR9&8Z;&D^1V5N83PO<F1F.FQI/@H@(" @(" @(" @(" \
M+W)D9CI397$^"B @(" @(" @(#PO9&,Z8W)E871O<CX*(" @(" @(" @/&1C
M.F9O<FUA=#YI;6%G92]E<'-F/"]D8SIF;W)M870^"B @(" @(#PO<F1F.D1E
M<V-R:7!T:6]N/@H@(" @(" \<F1F.D1E<V-R:7!T:6]N(')D9CIA8F]U=#TB
M(@H@(" @(" @(" @("!X;6QN<SIP:&]T;W-H;W ](FAT=' Z+R]N<RYA9&]B
M92YC;VTO<&AO=&]S:&]P+S$N,"\B/@H@(" @(" @(" \<&AO=&]S:&]P.D-O
M;&]R36]D93XQ/"]P:&]T;W-H;W Z0V]L;W)-;V1E/@H@(" @(" @(" \<&AO
M=&]S:&]P.D1O8W5M96YT06YC97-T;W)S/@H@(" @(" @(" @(" \<F1F.D)A
M9SX*(" @(" @(" @(" @(" @/')D9CIL:3YU=6ED.C<V.44V049&+38U-#<M
M-#%%-BTY-$0U+3$W0D(S031%135"-CPO<F1F.FQI/@H@(" @(" @(" @(" \
M+W)D9CI"86<^"B @(" @(" @(#PO<&AO=&]S:&]P.D1O8W5M96YT06YC97-T
M;W)S/@H@(" @(" \+W)D9CI$97-C<FEP=&EO;CX*(" @/"]R9&8Z4D1&/@H\
M+W@Z>&UP;65T83X*(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" *
M/#]X<&%C:V5T(&5N9#TB=R(_/O_; $,  0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! ?_;
M $,! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! ?_  !$( #( K@,!$0 "$0$#$0'_Q  =
M  $  @(# 0$             !P@&"0,$!0(*_\0 +Q    <  @$$ @(! @<
M     0(#! 4&!P ($0D2$Q05(18Q(A<8&2,D)C-!4?_$ !0! 0
M          #_Q  4$0$                     _]H # ,!  (1 Q$ /P#]
M_' <!P' KING:K$^O)(IEH%I47N5F44:TK+J=%25XU>^2"9?<:/IF<U9M*6N
MPKIE$%7:C",5;1S4%'TBNU8H+N$P@H\KWQ[!&9&KL75NC.8O" H]F;DSKNW]
MI91FL @4L%4&,@[P?() "BFZ:RUOE=^7]IC,9K-(=Z10$0[BOI\9[:&: [%O
M_=[9[&0XG<VF0[E;WAI7_@X*)$<YYU!N/6_%T@;G !0599DT<E\ )W"A@]W
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MVNKE\("4[TD]8U7R\<NH!C I^')&I& Q@%+P/C@64X#@!$  1$? !^Q$?T
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'#@. X'__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>4
<FILENAME>g589845img1.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g589845img1.jpg
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M1CX@/"]X.GAM<&UE=&$^(#P_>'!A8VME="!E;F0](G(B/S[_[@ .061O8F4
M9,     !_]L A  ! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! @(" @(" @(" @(# P,# P,# P,# 0$! 0$! 0(! 0(" @$"
M @,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,#
M P,# P/_P  1" -P K,# 1$  A$! Q$!_\0 M0 !  $$ P$!
M  <%!@@* P0) @$! 0$! 0$                ! @,$$  !! ,!   $ @0)
M"04#!1$% @,$!@ !!P@1$A,)%!4A%ED*(M35%Y<8F!EY,2,T5L:WUU@Z03(S
M)-A1)7=AL4*T-;6VUI%R=29VEC=X.1IQ@6*G$0$!  $# @4#!0$  @,!
M 1$A A(Q05%QD5(#82(3\(&A0C.QX3+!T?%#_]H # ,!  (1 Q$ /P#?XP&
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MZ4#7W7=$$&?/DTCM>]?2_"$8Z/C]5#NM$W;<,[\,F P& P& P& P& P& P&
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M4E<N4I*4KFDIKZWIY2>XE.M*?DNNN[UK6MJ^&M:P)!P& P& P& P& P& P&
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MXDMUKYT?!7TW5I^/RJWK8=C 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8#
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M%7>%UY/>KZ1@Q?U22.><E14)0XM*6%(K-LX:>-[ZMF?#D8# 8# 8# 8# 8#
M8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8#
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M2.H>U[[Y4Y'3.&' G,VN7SS9&X^DE4_OEY#WKBXONMBF\5\WQ.4V0IT-RBU
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MSB,.)#VE]UMAA6I4AYMC>GGWD(1OYOX2UZUK].]8%5P& P& P& P& P& P&
MP& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P&
MP& P,??3O*OYY.0EJ6S60%J).V"BE1P^Q1AC\-K\EO-<*E9+;A5IV-'?0!B2
MDZWKX*<2K;>OC\_PV67%8Y!N#W$7TH'&@\J@!R@/TS9NN.>@H).IMQYG)"<
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M/#*6S<-6C8^+=;F%1:>=E@*Q!20XVI3T,NB,VXVMS"W=F8655O-W;*3TJU]
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M5(E&:THXQ"KL4@.VP]])]%.7_EZA4Y@FP+D:,0R,$DZ5(ORVIQA)J,N0\_\
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MLE3'YC<Z! C<COUSF"W1+4=IQQ<Y$=IW3Z=-*4I*]))9)TN43W7TQZWKMPM
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M.?,7$]W_ %EMYKF6.UOWJ^7_ ,@$/*UZ($!HAY5CMG&+S8[V$ACH[D>?^?\
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M="?H/R.9'5(1.G,QB-DGB*YV0G8"D,+$<5(<CP8TB6\AO:6FUKVE.QQV^/\
MT];![C"NE%N?/?(_4?1]I9#N1&+=S;L7%^5D.52*Y9!EA"R8:^LWJG/R"1]^
M1)8=7!1*CR1B9,&>A<64IET;<=[AB167?4P-?-QXW[??L,'%YQ92<JFDU>K/
M!\W=2 6I#(ZP5I32N@3'B]2U#UIS;4AN421]+7T9&E;^&S7V^,]*] N@$[WY
MKH]>$>>?,5V]$()VVVD#-?JG2.34<A6]V@N:N9,^1*]@N5-A%HLZPEWF6F8K
MTB0UI:?BG3:?FT9F+UN&!K17T!#JA2HL?:@]&+#D^1U_BTEC?K/QSN4Y1ZM/
ML101$:EK[II3)/4RT2MKE?'3B]*1K?Z$:PUC;G_VGI66M_H5DY6#YYU;F?#^
MM]TMU2L9FP ?/HCI_&:I'H]DZLS=)G0KHNT7XM5!9B8.W=2 ]V+L_,AJ1+2N
M)%5MI#R#,Q=+<1C 1N/IR37AP,1]KKTK4YP/I=JZ[7;96O5/BB/:0-]NANW&
MK*5B2B79"@N?%*MWHK =A$(DR$X-EJCK:4E*-I-8V^Z>E9"R..ZJ'$ G4*_Y
MRZG<>WQ8G,+A(XZOKW-F>G:O@?J!_IIAXCTPW;('*Y-F:LG23[IV2P42.*C7
MWX$?2HRV6-F<ZXSHQ<.S/01V("9W]J_TP*GU0E>SM2/"/6OC:,:K%BZ#U$+V
M T?$R'^V2HWYA'N@%E4=,AE^-J"MZ$ZT]%?>:6:QM]T]*R&<\^P[QYBO-BOW
MGCK\KKM]YWUF!;N.&^R\S7UNS'KG8J^27O74JI:(G(0UTEN<X /@I\(C#' (
M\:,PWJ,EA3:#.=>NB,RG2O2AR9*E&?M-=W*-S^5D^,$1\KU%XW_+9_/S#K+A
M,3*C-=U:^9V8EC2%/I4ES3>]ZUO7QPN-ONGI4P\;XV0MW/Y72NS\.[,)ZH 4
M\. \Q[+UOD/2+05J])J%VK52JB+-S@U-YNY7[5#Z(60]LG+40F2WT2"\EW;+
M*VR6XN)=$/(ZEZG=IG-*5,^U?Z,F">5SZ,6JRR'J[QM,+H(<^:8;KCI@JKN:
MGS+K"6$ZD+=VI4E6MJ<4I6][V:QMZ\IZ5+W&..R^SQ;D5[QY\[#P8+NXWTL&
MX9?^Q<IZ#29QCJE7*B[_ -#K^^.6:U213IK5Q--:A3R^F8<Z?+F0X;#KJ']&
M;<=+EBN]#] 2DFH]J^V-ZFZ3+*M&PQ*SVWUIXM65-@)]!G\LBP'?RGKP".S
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M*9.(>=0',+&=M+%XZ5>*]6G!-O@=3A?DD9+^YTQ3+O\ FM:^7:A-EOHD ?\
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MO]KIYE_L7TG^0L:G+XO;?4_J?_O%?[73S+_8OI/\A8U.7Q>V^I_4_P#WBO\
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MJ&-KB2'%')$20Z6<<3./UW67Z.J7H"9*.M>8:_[= >:5G_ R1 ZQB_<,^PQ
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MZ-B##D8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8#
M8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# UX.SZU_\
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MQ0\*;DUHQ/3: >X0FQPD*<F "<K4[Z$ W$;3M3L5U2'V]:WM2=:PF*[XJY5
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M;):A0T3#!J5"'1ERYCZ&FM+<3MQU:4I^*MZU@ZH:_K@^2?\ FD\Z?TW<T_\
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MQ==4Z (MFV4Q?S&;'_"Z3*6YJ8)\EBFU_P 3<EA=5A\6$=KYE8+_ ,9]S/\
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MI,;-=W\/ ? -1X]2U1[/9C=?I\JU-L6>)#F2G8'U'OP+^T)_]X:-3?>TT_\
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MO*G-^ K[F$A0C[A!_P!/4ZUTV7;&R*%:C/%B<GZ4YJ:K\Z6.<RD:[_:/] '
M_?Z<#[1RB51>V] JML/0NDU)?1[]<#(OG/4:>?Z?9>M6&J2[B"L9&T7 ,?AU
MN,HA #NBYL004%1B>]123?-/HSKXYX?LE(\]>H>-=#N]:Z.:]$289/=B)@9T
M^%#.1/+/#N$Z-'XAN7/E&27ZZ\D=L"7_ *FGD_B6OX7UV]N[,W=K+.R"_4GV
MX^T=M\J>4_-M,ZUS@ O@_'(G/++9K!3GY,YZ]U_F50IM&ZOSXTW#)V:K3J>;
MKLR2F%#E#)4Q!%M2B36X?T91=NZ3=:BNW_:"ND]%E.5KI/.E6JYV#K-MZ>/L
M@&VNU;OKEE]]47UUS[GG9UPR[A(YSH1S2MD:+-:VB1MF,8>5&8W$6_"?B\_U
M^V$S4_[91V'YV\D<+M-_""V//WL?IWI^TKY'/Z;S"/+K]^*>EC WGG,[+5K@
M&Z#2MUA[ND&,W,030IZ&+=:5K2)'R:J7?K;/!0I?VU^PRIS/+M]3YFGSA5?4
M_=?8U'(*K-J>[Q,Z-V01UQ^%S^YF9)>16IM2JUV[,2DRCB-NF#82+'&.L1U*
MD3'1RG7OC"T>??:3NW/_ !AZH\DQ>T!C#GH7EOG^J!^DV")<C]SJMDYIQR@\
MPN,"=:#E@(V<GS1@C0OS&EBDRT?JLP4D0F-)CMLIT7G.4O@KW5/L^U$J5Z:4
MY#91]=W9>5T8+7==((]!Z*6-=/8]+VSOW?;!U*TE[5(L%E#>HJ^:8I]K?;>_
M,E@794=*EQ%)AJ$WZ:L8QOVH/1O\_P!2([QOF@2C5<!S>_0.F!HM@1%\_G87
MO#IGIHQQ?Q^$4<T1JD2L\[DP:>U-*0XT)T"6<2VA$9#@;9><Q^O#NK<G[-/;
MM\\N588ZUR-=H>_FDC5.P?E=Q0"NE[Y==>N6U'K'TC2#\:XU7MO;[#%Z8R-*
M5\K%DA"<6!\7"#3B1JA4/R1*._M6=[-=ZNG8;?VWF$R/:.J\_OA6!5J87HRK
MM$YMZ7@]KJ\RP0*EL*T$MHVA)?JS)'4HP3;=4N>DAK4C<1BISF,2,^OM\>8+
MGY!\[Q.*7&PU ZD/<K44J,6G"DM1ZM1B;T7]7*F=M[P2MF^K6@4Q&6J;:B\!
M@P66]K<Q3[S:I3YG=>5RS@PR8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8#
M8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# UX_WGC_\ EA;_ /XIO+_^
M\J)DKK\/_O\ M6PRW_X:/_R$_P#S:RN=ZOO"->#L_P#U-WC?_##['_O4N6'6
M?XWS;#^')KO_ +P%_IGVC_\ %I\P_P"T6.[K\?\ ;R;$&'(P/,'T%QWUD?\
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M>>_6 E+*,@HH"!$#W0P1(S%']#52&@^N?&(\YMC3CT&4-F-2$MN0Y*6ABJO
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M2#<^8@L+CLK1 E31L>2XQO:I*) Y7.6<N&3 8# 8# 8# 8# 8# 8# 8# 8#
M8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8#
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M2'XL./O6E2I\EAKYD)4I:2R9=NM>CN7V0V,JRYQRMV\M"I4R+5+;5SX$WO\
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M-#T#G&H;;K"7--2Y:'QRJM3O(_%2-6ET^8'-.A)AIFQ+1JR%FI31N)SXES2
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M:?B2OI[&;W3M9>4P _(.$P!77A]2C^?5THN"Z5;((DX&., >;G>8-2K*B0;
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M]#$+F36V-2IK<F')2OY6QRO@]*,,& P& P& P& P& P& P->#L__ %-WC?\
MPP^Q_P"]2Y8=9_C?-L/X<FN_^\!?Z9]H_P#Q:?,/^T6.[K\?]O)L08<C 8#
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M &:[\;M! W.FIY7S035054&\>0RAOXSI,Z02WOX,ML?%TMLFWC-=7HUA@P&
MP&!C[Z!X=%[:.I;._P!7XY.E'+D=$%#8=!22,G63C73^:P)@5_X:DBYXTS>(
M<_ZS2D+^2#O2=Z<^122RX8T6/P='LP6Q0B16J32Q^+V^2\7FB"4B1JT]':Y\
M/I5F4^J7N2DI0 U/D1HKZ%I?BIE?^44S\5_,PUR2W6.>/3?/W2*-Q>Z41YBT
M6B]E:5+BB8)"C :W>[,NWLU!D5*&G0D6&JM'%QFUI'3845<E+^H4A"-QW#.=
M<U"-;\.FZ^$3,*WT"(LH?0ENNW(='EK+<WK$+H7?;:8%58XZV$0.CHJG88PS
MYXT8;%D(%?YR.W'^BPR:N[*[?)W,0$7G/;&*3=.'%H?1]5T;%WP@UNP5&O3@
MW%*=SO9,E.87'VHS8Y 3\Y6VAEE3<>6TC;DIS2YL@ENL6Y-\-G-1$3X5BI\^
MRNSTR[1LL.*H@=*!#G.%2Q_.;O/3LA/DT<HYQ^1%ELK:EM-1RBEHC.[^LV^.
M2'[!X.Z& J'12[9BM3)JN6=I74*]3#,BIC:#9;2WZ+*C:;5-$*NX9*4,OKLL
M>/.8_6*M15R(6Y#K#B=1FXA>47K5?&5BL-PJO5HUCHP^D&WP-J!T/EQMX-2^
M=_@_YMRXN[<M*R>>E2$V;T)=+U+/LPMUG<]N5]%<Z0TJ3N4.791>F>*H]-Y)
M(@R;3QL94(',P]/L$#H4<H$YUJZSN+E>-DNQD=1=2W)EX:,D84J(XY].=.;6
M\RN:Q)<9E-CEK]55YCY,JLVU"6+!U#GW5&S%@A=?;BN6<+8=]=Y*Z=O)043L
M- A5H<DO KA:\#QPTS.*V6&J'&TPSN&VXB,D9\$\\.Y[5O-%Q=!7*Z<M8MG6
M:;Q&L")JY\8%?;Y:.3<Y@<[)LNPR3:9UBB.M"X\B Y^+D2?GE.L*:3M"5NDM
MNYC[_,]7[H)LT'^>[BM<YF%Z3%JK?-*_T8A;Z12I]C,U ?-I$0N:> / 7.@F
MA?X:+4VF$C!TAW\./2Y^(?3MHN<>:US_ !/YNW!N><G.\QM5KKE^KMP4VW$%
M2Y/F:I5CT%T3K[,6NBXEG@$ T4F"Z".$DQ33$9F4B'#9_A1GV]0QG3-Z.:%X
M>[(Q961I1?."P^Q5KH<F59WE+1 Y+;K&UY@%-V_G T%5:D.;OWYARLV='ZBA
M1#$9Z8EI4U*D/.3QRGZ_=(*_&\H)(%E;_=*'7J\&+A1LL[!;).$^G6^?)ZN#
MI?6>@M%&( U77F;CU80Y!0IPDWLDP\YJ3OZL1F&.7@GOSKP>Q\7Y%=*%"LH2
M-T0K"8U^:,3X]JJ\&R1.?!*<&N#U2C5'GL89LW) H(D1^V9#TUWYUR",Q]UR
M1LEN;GL@6I^-.TU>)-8BW:C-(M1C3A\>B24:@506JP\+LL^358M<I]/!%")F
M?S$U\\=L8!B1W#C;VOK;8?;F%NZ50)_B$D,&W9=TM7) 5=+<X(4@X3_+RCTC
MH[(SF_K,23Z/U-LIJ' (V@HKN<4L28^$[Y/R22XJ6]I<?44<OUZ*^KQ2>N:X
M<J9,Y7!K1<J&M),E6TFYY"VTV8WR]6^&D4_E(2#+X]6(-.?2'_A[;D,MCD*'
MQ/I2ER1R92]XXD#[/^H=>A% E8L'.I%ML((JV%CS+!4&+;Q_J')PQVFK3N.L
M&2!G;5%GQW67&?TB])2I*]-J29EPBWB?E"90>G#NGVF)S81#!5^Q#Z[SNB12
M;M.IIXK7>0UN5>JVX7A"6X5ALD'GQ#9%S4)MYIB<VQI]]6I<F46[LS$?EH\V
M4CKO?3O1%-<KM-:0<X]+OPV0,C%S9,O0>=]:CC*Y96$071Q<;.KW:P9:$N7(
M<TVU'UK\.I#C+J1+9,*'PGS01\Y6HYU7JG2A9477:&ZS-Z"4M$>O1X05BE\S
M$&QMSBDZK'=D5*I[YPY*&SB5HE,0([N_DA1G%R7W1;G2+"N_DOHG5[IU(VR9
MU#HD/J\$KS:D6B9!8#6>JV"J&R77?Q$V57^FC&1%EZM;FC8B1)!RG&9(!K2&
M&DK9E(++)'4"^4Y)#JI!%OZA1+&'K1B@B#58FO))E["'Y]=.=W>D"^AH2  *
M+6<-4"8D>Y*,RSLLR^2U-4N,U+_+VR9T>IN&3 \:XG+??G'>9>A_-'-?//!^
MJTKI_1_5%HHG:CWITUSET<&]/]&Z#TB-JY<QUP6WD6Y_/)O1G8<MN 6D()-0
M4NL+:4_]-HZ9VVRVO3S@O-G^-<,XOR"45:.RN4\GYUS:2;8C+A,&7Z-3P]8>
M*LPW'7EQ&B#@O;R6E+7MO2_EVK?P^.&+<W*6,(8'B^SR3W[RCB_?_)_.O/?!
M>FTKI-R]6SJ+W4YZ<-\_7  >H>D]*Z+"F7#E:>"VPFT2YX]TUR),CP2\A!)(
M_3C#K6W_ )&CIG;;-UNNG\/5/BG/G>2\:Y)RI\F@T]S+F5"Y\\9:C*AMEG:9
M515<<)MQ%.OJBHGK&[=TWM:]HTOY?FW\/CABW-RDW"&!XJIXW[^YIY^[MXVH
M'G[@G1*3T,YZNA4COQOTX;HBH5:]/=&ZA?1YFW<F1P6U%&2G/D]17&FPH)F0
M@EL=\S#[6G]::.F=MLW6^'\/6CDE'7S'E/,N:N$4F%\]Y[2Z.LLF/N(DHNIU
ML: 413$VZ_N*F;L?]73?SK^3YOA\V_A\<,6YN4A81KP=G_ZF[QO_ (8?8_\
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MZWT$+VSM.]+^7>MX,5S6KJ="H]FJE3M]D&5LG=89Z97'34R*+&SU5V=6!TV
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MPAHL,W :G.C'9VI\7<-LDP34%?'N2?J_11.9,HW$6UM7U$R=;:WKY]?+@5/
M8# 8&!-W^YEX[Y_8;U7CUXZ'-3S$Z=K70[93O.OH[H7-*8<JF]IN(\_U6A<G
MLG-X+M)<2M!O>RNT!W&743-LK9=2@U-FZS+.0.8$V$0*/@24$R#.#8)@*8%R
MF)PPL))Q6IHXD.FQEN1ID&=#?0ZRZVI2'&UZ4G>];UO#*I8# P%N?W-_&]#.
MW@(<O?09<;FAX_6>@7.J>=O1M[Y;3S=0?7%ND,[URD<HL',H2:/*9=:..[+;
M9#NL/(F+96RZE!J;-U9V"R@TV,'&0Q"$6$%X,0H**#93,T<2&SX[<N"0@3(R
MW(\N%,BNI<:=;4I#B%:4G>];UO#+O8# P"M_W._&E(-702;OU_DP.<'[!6;Y
M>JSYX]&77DU2,T^8\/NC!OL5.Y0=Y;$C4B?&>8-R=E]Q0[T9]$QQE3#VD&IL
MW5GE GP2L&$4%S8A(82B1IXXC D,S(,^#,91(B384N.MR/*B2H[B5MN(4I"T
M*TI.]ZWK>&7;P->#L_\ U-WC?_##['_O4N6'6?XWS;#^')KO_O 7^F?:/_Q:
M?,/^T6.[K\?]O)L08<C 8# 8'GK7^%7:O6;F9A0BW_J_SGU#Z>ZFH%%/B3?Y
MK6KM6NDJJ)*4BQSR$TA+(ESZ&X*-26)$5R<KY]M(^*D&LS^'H)'=W(CL/J8>
MC*>9:=5&D:0F1'VXA*]L/I:<=;T\UM7RJTE2D_-K?PWO7Z<,L5/7//.M]'J_
M,1G&RKX2PANN#K";),EW0"?U0BT+H0\X(?.1%+*@46K9-D0V4@QYLX,_/;(,
M1W'(J?@:VV3KX,=&0OK2=:"@JG1[AQN@,L\T$4JC1A-3(M .5O-<?&6<?'LC
MI0[6Q/1Z<2_6Q;\AS9%Z=!0G\-]1"HCR"Z)BZ1QZX])\S3*!>ZXCI%S$=-=4
M W;D5@@7FT^N][>15SLDAM,46DK.XS&95+?3]&1):>>0\GZKKK>R2R73HQJ#
MUGV&2N%+L[-%.U:FTZ]+E;K.I=/59Z3SD_05"KW1N7RB<W\H*2 UA'P8HZ1)
M@Q![T%$O\N;8^I#?26\5Y-1/:UXM-T0K70N9TXB0*&(,*&5IDHB%.Q*IW-B)
M7 UB-:GRR5879XE(DZ=CPH<)U;BF4_4C[GJ<'VJ<4,^V9IZQFG:ST(.,AP*Y
M)=HX9\#,CVZY5TYN&W7 5N00<>I@#HP%S1"40B1'!H-W3,:8N7M,S6Q]J^.2
M<S]$48QSX7-:,S:8]>"%LLPT\]12T6F*(7_N\^1%K:V6OQD",[7+$ TM<=3L
MA6D(WIS3BYFG"6RO1;#)@,!@,!@,!@,!@,!@,!@,!@,#S8^YN7'4_G?F;IME
M?V*H')O<GF+H73+:^P^L+0Z(-M) 45N=HEL-.I#U@/,,QM39SWRQH;;OU7EH
M:2M:3>SK9WPCH1Z/X-ZH^XIY6)^;NKTCN0GDWG/V&_TP[S Y$N(&A_K_ &;R
M\/I,6T'0RY0D.1MDFJD_R^(Z\F3*;@2'$-[;:6K0Q=NVYT>MF&# \UON9FQ5
M*IWD_J-JDZ#<\Y-[I\]WSIMQE,O[ T&D,:N%=EW&USFFG6PE8&F+%":ESW_D
MBQ-2-./+0WI2TF]G6SOA']:]%\)]3?<;\X&_.'5:3W$%RCRQZW:Z38N8FXEP
MKU%E="Z!Y58HXVRGPZI0@47MFZ867!ANO)E261TAU+>VVE+T++MVZZ:O6G#!
M@>:OW+; &H@'QWU2X3$ N<<G]U\5NO3;K.;>U7J!37*EU&HJM]M(MM.,@JS$
ML5J'QI$^1MN+%5+0MY:&_F7I6]FN9.N%ATST1PSU)]R+AEC\Y=2I?;ZYRSR!
MZE@=&L_,S46W5NDD^A]7\K*HX:Q6$.J2(&'+6S13#T*"X]J6_'&OO:;^DC:\
M+B[=ESI<O6;#F8$>=7 W:T<_L=>YW8X%3MAAB'!A6 @S/>:'CWB4+5@_"K%R
M8A" 6EUW\6Q!F-+VJ#,=:D?(Y]+Z:BSKJB+R-SRZ\>XO5N4W.KUNOR*FNWN0
MOU*FZD5".,,])O!, !$LS)+AM#@JJOP''EOMZ;^:3I"5K<;=^4;K+<QE!A&'
M/K?C%MZ?'YZ=YT+K>[W2"%[FBK$66*@EQ+Q?DW0*V$;!%I\*6[!)2+(=C(C/
MHTK4"2XF9\JOH?#9K;9.JJU4/VBM<5[-J()*KLDPG=27%J5TWH\@[8P%=?K8
MF,( 7#HPVT%I:YDBUQR<^.M%A?7"AS8\;\Q8^C]1@FF4%4*D>O!T&%6;$Y:2
MP.QW.G_^^E])&L3*'SNN^@.C6*V"SDE=UM=J?.V;CI\0,8T/*G7M*@;COD6]
ML,O.FOM1U4_+_IBG<^:D\_,6BE=&_4OF5)=9,=<(%XC\&E^;;)03\LE\2]E$
MEC1'IJ!SPLM,U,(0F&XSR?H(9>B[A;+U2=&Y+Z1DF9Y>&9O]5IT0BESF_/[?
MU]=B/A8DN^<;DEXUW*(L=IA7$D^"KMM?%HF%2[8Z(6;CH=2\EO\ "U,Q:H/E
M7J\M9*0=V;ZU1*\5M9VQV,$[TZ#T_5')NV[G<NK-")A+N<%BR<S:YP"GC9R)
MR32W2TXA+: H1)B;BESM^B9_47!;CUF_4,K7&K(X+;J;M7.S!/09]9'@ML]X
M\^='T3>!Z.0HL@F[5Z :;AD(L.40BS-1TZ4SK:'FB;;(MJF<G].">YU^:?O5
MQWRFNE"WZM?AK&NUL;J46[=I4S6>C.6+IHJ:9F6&E&ZI] HZ LY5EP>A&Y<)
MQI]V0+9CZK#[%P7M=C]-]"Z#RQP<+.?J;$F5.QS#'/V(00D]PSL/-QLQUMH5
M+ZU M&K998NH&G'=U/</4F4]&DSHL=*2RS&KO.T'UVJTUI-4'6^K<]@]3K%L
MKT6W]<DW"[UJHM%N8P.BT_H9975R(JP CPH59" E#C5UD(613&TL3I*-H&=O
M[ONG<&]!C[_Y\?N\N\7.+1#7,K6?M9GL#YJN"OP/ >D5;IT O5RIER59KJ8[
M-:M$(LV..W':&2FVH\J)'@I'NC,Q<+R[MR;OM^O-[' Y5L75+6.:% BPSIKM
M9HX?GDOE=KK]THIRFPC@XE*O%EODUJ5"-LP9#D1F1'<U/B_@-QWR2R1=O2.;
M$Y?*O/5(#56%TTCR.S<BLMIH4JRU\F6(UFO5DW6Y$Y,R]EX\(RILFY]1MZ;*
M3N5N.XI"UNI^78G6Y0M \^^GP@N&#JEJB\_@1A-R.4ZM5V[RHM3I5H+P?2!R
MAT9;$*% GV6B\VL5[J+"HVV40);0=.M1MPV?PZHN8[%.XUZ%DQI8#H9+K9^O
M6?G=M#@!JNH_JQ+Y->C@QP20)762([C<['T&H'VDI>$RU&CDL3+_ !>FQD)I
MQC3-,SLMV!Q7UGJL0ZT$G]+IA-%;'A%'YO:F9PL?SQKDU-J\&A"1[-KLCT+J
M@+HD.83>LJ8^W'F&G7-%']S=0F!G:S$XK4^A5>U=H%6G5KF46;8XDWG=AN=S
MF';3,A3'3R"H6+'8O%LB#JI6H:![0>=],(8FLNJ21B+EQ=D9QFX_=BQR'BWI
M*BO<AKZM7Z -INN7"T%"/8U6"J!*M5RMM3V<=;J_-MI@E?2G3HSS#U?F/Q9[
M\!B7#0M8E8U3+IJV5=OJ?G7I/IMZD *!#CP^?3*#9J])=U=)$,9;(5FYGU8*
M9$V:O3;DR+;FC[P5K+D1QFLS'?H:6\HLS]+4-1)9)KU62O@'H[\2;JC#]C'!
M#]@N#HDR!ZDZ!H=;Y];C_82MVK5BJ8DS *E+Q<7[3!D0"\>!*?'+D1U)FPE#
M=MR(N9^Z<K=3^SQ_*_,>?4*OGHUVC5JCU:W,2[[-W=ZS#$U-Z,0)C;4,ZE4=
M6,Y'L\&&VZX[9M-KA//R-IFK:3!D5-.64._S.>O4!8QHA<K<5M)1(^)T .,Z
MO)@,E:C  \+<,UZAM_BQ5>IUK/DZQ;689B+H=+8D%E..3&674*8+G:F:A\RZ
MM7/->J8.C$JU?9'8+5<6(16XPK&>@4^R^HS'2-PS-P6HG#+GG.8E-MREJ=E[
M7)4IK;[ZOB^LELS]&/VN:^QH$(=JO[Z-*("H]N#1I=QZM!8=(UR"O=D"V\N@
M=U:U#F.SW,NTL'(@JC$ZG^6.,3HCU:<2^/V7[5\UZ@^M3/::];;8>N-7Y[NU
MECPNOCCP$ZY6P:>I=#+2*OT&'$Z@#KLR+;>:$*_ 95%%W)0=V,\B*Y$6C4R0
M3[<?5Z)89,#7^YW[&\M<&\H^Q^ =F[ISGF/<1W:?N.MN\?N1^.$Z3-5T?O7<
M;ESU02ES-(L%C;O]8MXR8$7 8DH+-3FOPNW5*^7(Z7;NMEDTQ'KEXX &JIY$
M\KU>R"9P&Q5OSAP\ ?!E(SD(F&-!^95@<5$D8;R4NQ)PZ='<9>:5K2FW$;3O
M7QUE8W?^U\V1^$,#7KH_L3RYQ'Q'ZZ\Z=<[ESOG/?!O0ON1B'N+6PXP'ZA,(
M]%[WZ M7/HH:C2M(L5A7?J]<1<L)N!'DI+,SV=Q=N[7K61UNVW=-TFFCV6\H
M C-6\M>:ZS8A<T'8*YP'C@(Z%)1UQ"(<R(YW7!Y,7/BN:TY&FCYL=;3K:M:V
MA:-ZW^G65SW?^U\T_80P-=BI>P?+_'?M\>K/-'4NW\]H/H<:9^Y!57N&V<VR
M*ZO*L/0NZ^B#M $B*#(2FRGY5]#W$5)"Z@QI"2S)!A47;NG$_&.O&W=-TFFC
MV[\TA"U:\Y< KA\;+#':_P 3Y4$-!Y[*H\X46%44# )#9L=?P4Q+@S&%M.(W
M^E*T[U_V97.]:FS"->#L_P#U-WC?_##['_O4N6'6?XWS;#^')KO_ +P%_IGV
MC_\ %I\P_P"T6.[K\?\ ;R;$&'(P& P& P& P& P& P& P& P& P& P& P&
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MO+A(WH73!%;:I ZM\SZ;8S,$Z CUG<S<T+8YGX1QV8W^$2MQ<<8VN\0OGM
M,HR)PRTV2Y6#J<Q\PY7:2.A\Y'48!TFB5%VMI&[Y\?MC,&UT8D6L4>>9+UYY
MEJ.K6I2GT(@8,;5*>#>CN=:\XWZHU7HMHG<V\HBJ-:.:_F<K\JL]ON4^D5YU
MFP091!(URTT<Y"@F)$YW_P U'!PBK;3OS2-MN#2V^:,P+_OGE(6ST.J_G]E>
MI$'J!"GS[N)L=K<ZRB9=^W$"1QVP:H%HCB;6Q+6%EUL?/LHF'^4HCQ&1<[4I
MO30^VZK^40]<MDG[!LE>+U+FTT7-I 69SF2W4Q[X*U]T6@R:9/\ +.4EQG4H
MHY^K1I?UH(9@I'=TY%@K:0IUH:.EUWJGJWE PBV5N-OU%@MHW1K(US[G!(W?
MKZ6#^?'H-./A6*\Q"BTA@[;K=#;E06($M+D5F.[.7):920$DJ\O13WINZ;[K
MSFK+Z-#BGQ?2ZR%%UVC E5-KEKW U$JW<*[T,M5YC<[J![LKGY&X*<(/JU!D
M/_ <PEAHFH3$Q7YZKY]=XY6:/Y4$N5V-G.!V#F D3$I]G@AN7-1J1TEL7T6A
MVX%H%RH<<(%7X8XO6G6-3R;>QRX*HC<7Z3XVV=_%V+QT#V!6+7'J%7!WVU-@
M^@$6X5Q)5*OOB+[S\O+@LI089K'.$AHA>E,RI#R)6RE3;D,HCI:CE7M2TMPD
MVX6049]J6\O"HI^PV6*,@V'SM.F&D49J.0)"$&N"VVVW<%,$<JA4 59*O>'K
M-%GC9UDD-Z C_IJ#2-I_'2J?;-7+?SOL,S7;W1Y4'HA,E-$W.D5X</Y\%8 7
MOG;HKK0,MT6SW@0%B-53J>M#Q;PL?"FB6);RH:F!SS4]U48?:M:P6'V-&Z+^
ML@\=TQM^*-L5*NLC7/G&JWS>OR.N'G*TOEDD5S'H4[I#I2J@:\N;,T#MCT:'
M.DN[<BN;=9@C[<83[6;)ZP%G^<DK^2L-A9.]7EU:RTJD\Z9#A&JEH;2!D&\Q
M+(2H1Q\/3!I)\N5(1#Q$(6(17D(@2$21^QQ GVO07#)@,!@,!@,!@,!@,!@,
M#7@[/_U-WC?_  P^Q_[U+EAUG^-\VP_AR:[_ .\!?Z9]H_\ Q:?,/^T6.[K\
M?]O)L08<C 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8#
M 8# 8# 8# 8# 8# PW]']JZASV^<VK'-*H<.NDY@.=8$*JA$O7C8(U<A%4+0
MH!,1!(3VCU1%2Y!B2G:X$:-$2VZ\\XA7T=FI)>K%SJ'9/6L3D-E#'-D@QL]R
MT\9AW.K<7NLLLY>K%P458J]R.O5T 2EEQQ![H1 G&BDTNJFQU#V(2UZG.)?<
M+),_1,'J+K/8Z_-"\UYI7KG,?.<TFHL,D?7#$UZ0BTU+H8YDE5; $'S23%JH
MARM0WYBW'H#,79*%KXR'9C2&HFV3K51G]$ZIS3S=-*MP;P_T OV#J($+/)@2
M=@<!P7^@]!*UDC88\V"6)1:A+#"HT""XQ#EJ<7.A,1V]:>;<;IB6L>Y_?O1I
M6^<YL5A F!4N/^ AE^2?J??:C70\NXW;RZ'I2SE\41@BB!>WO6LUL?%F*5N*
M^EV*ME>H!-I\N-O1>D#U7Z #5X@9*UZ;;83G.2A)@I&XET$/+&=YE\Y,V.'P
MYFM1URBQ-L%: [41,OY-JD.3T#W'_P 8WM:QQB1BO2/6;;,TS$AP$,PW^^6E
MJN,\H.R'I8CEO5J12N=4/\<LZM_\7T>H3RI9R<AO;\C:6W(+2([#FG2?:MLA
MUOV:)U8K1$K,.U1QK,$J#YPQRXX(E'7C_2>OT:)5]65PV^]&0#K-. &'9.V=
MN+?*+=<VW"?CMM%QM=6J]K]:G! (TB( )"(<%=EDOBN>6:83M;>KGR4#+IAQ
ME]D*W3C V'9;,O;,9B1*2Q AON.?,Q.9=&-J\/.W4^U/7RK<_P"G6 K=DS _
M3F"4Z)SB17"0&R53I=UB?B>BN/161HP%+K<89$KTH:^M$UU+J9#._J1Y*R63
M&8HG/>U>G;M;J975PVA\0]9*POI\Z7R2R#T\;EJB=9*6GE4.61(1H-B?TS31
M$5H\O;[#"IGXC:7$%!K30LD=;J_I'O('JO8*MS2!%M[O/[$S7H5#C<NMA-R%
M49GGD#TZ;U.?<(,_42P$*W>C+4) &']"02CO-PFD?C'V9&BR3"Q[=WKTK.!]
M!"U8\4F)?H':HW([S5N.DM6@\5J--,6D%TNR5,Y%_!0JP\0'.5P8[!4G9 ['
M:<U"=C$XFV1)'89]3=Z*F[*S6YL6PUH=?+I3+4='\;M:&^14FK]5HU.#=2^H
MN4^S?")^JER\R1 8UMJ,[%W(^BB.,(-/CC%:_GZ]BI '+D)HB+;& Z-!:I5&
M^7V<!,Z?&;H/7C]8Z.^],(NDZXBQ%:C6U)%I:1^'T6>B.*W(?BJCC&WH[U?Z
MIZ]M;(=8TE6&PBR?/(D>S#N8GCLD^%OO6I5$L9(NF6NM#Z[8.<5=EXBY$9C.
MQVMM1I$M:F''H^"S;%N ?0OLL[),P7:;7ZX:&@ZG!;"FJ/:W"$Y@RSS2'(ZH
M#",-,NE&&[+9#+4P8X389'Q!_P 5*VZPYM\8VNK?.D>A:]8R1ZT36""*56YF
MJZ)E<6=E%;)*I'?NKU _:^93502L2%U:\<V%UI4(>\MH5-V01ME4=M]M]H3"
M8^_%>XD.K5<%1;7:*W6K'5.)DQ0B-1)A!J)9H7J#FJ+\<)EQ[\=U"Q',2KJ2
M F3(1$<@_56[I;*7\),8U1'+]">SOS*S X-1KT,U6JX0A"&3U$M?U+XB(FR"
M==0! QK>WILIFTCX6G@J"46.@=M]WZGQ?@JV7&U6WN]^G(EMMP,]H35Z<#Z.
M0HMDMRN?V [:J#4Q9HU I_48=5'C-#K$"ZJ)$17I$K<A^*&D&67$,JC1Y*6Q
MB)I\HO=<LMAZMT?KS!,<2N OB^@5?F5XS7A]>@Q>9#2)B*$B%R4UV/&(V4U*
MF28BTIECICSD62M;S.]()<32,T,,F P& P& P& P& P& P& P&!KP=G_ .IN
M\;_X8?8_]ZERPZS_ !OFV'\.37?_ '@+_3/M'_XM/F'_ &BQW=?C_MY-B##D
M8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8#
M8# 8# 8# 8# 8%**@@AW0])L.+,)$E81T4DI BSTC38Q:G!IB!J4T[J(4'N+
MVIB0W\KK2M_%*M;P*K@,!@,!@,#IQAP^&^0E0X,.+)+2FYQ61&C,L/DYK,&(
M,:F$'FD)<FRFAH]B.EQS:EI88;;UOY4)UH.Y@=*"-'#&WVAL"$/:E39I*2W!
MBL1&Y!$E)<F$9[Z([;:79L^8\MUYU6MK=<5M2M[5O>\#NX# 8# 8# 8# 8#
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MKX[WO>_T:UK6!QM/,OZVIEUI[6M_#>VG$.:UO_+\-[1O>M;^&!RX# 8# 8#
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ME6J<%KMOL=N@%9M:L_9ZI9W"LFN<N(6(6TN?Q*>X)U&$D%S69\7\3J"O4A#
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M4;!4'F'3G&'8;U.K/TQ;M6ZI%9W(TZIU).%(;TPJ-MB6Z+-,LO,,F!YK?<L
M"+T \>\IMT71OG'6_=/%J/T^ERWI"0'0*6BI]1MRZ?;(++K39RL3+%5!\F3
M?^>++W%2AY"V]J1LWLTS>^%A4KSOP[RQ]R#AM:\X\PI_$JSU7R#ZD(]'J_-A
M3-5K5U*\ZZOY731C=AKPSZ @@=JC%[,,PIRV?Q;,<D^SISZ2]HP9MV7/B]9L
M,& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P&
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M,K,,F P& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P&
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M(,2F0\=N7,>$V*)<!SGXM&M26%1+?";+I^DM'_O76YF_C(4IS8S75G^<N$E
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MYZYU#LMLK-;[9[+\Y<@Z2Y2+58*+93G-;39ILRU52%<Z@2"VZM1K*R&;BRY
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M&4B/)D_+I4EMEOZFM[1K>#-6=;_)U1L=]J-N$D7:F,"W89T*TB!+EKT0O5D
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M@ !ZZQ:7!-<IL;F5&XL7>(2(34;; S4*$YK3S^VU*&EGU35W?B/4>A=DIMT
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M6Z@PTTVT2EQI.F80S'VWQGU'-D\BKKITY.KS0*:[U*[.==LY&189MX$]5'=
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MYC$BER1Y0B-G_!,5I+OP<=+)67[>JX3?'^Z6/J<"K.G^OD*#4;P-MXSJTZT
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M# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# UX.S_\
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M!,9L[) Y;U3T 6!^D2%J#*MA/BT4G3JV%H^JRT]T3H\8,1Z,0362*HI"*RH
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MUO2DJUOX;UO]&]8!"$-H2VVE*$(2E"$(3I*$(3K6DI2G6M:2E.M?#6M?HUK
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M^.L&CN?E/:_]?N7_ -$EK_XU8-#\I[7_ *_<O_HDM?\ QJP:'Y3VO_7[E_\
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MPPO_ .:1W_U-G!>JK80P& P(HY;_ ./T_P#^*]F_^YX+ E? 8# 8# 8# 8#
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MMJ_NO?TZL_Q/!^6>V']P_P!>_;5_=>_IU9_B>#\L]L/[A_KW[:O[KW].K/\
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(Z]'HMAE__]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>5
<FILENAME>g589845img2.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g589845img2.jpg
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M1CX@/"]X.GAM<&UE=&$^(#P_>'!A8VME="!E;F0](G(B/S[_[@ .061O8F4
M9,     !_]L A  ! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! @(" @(" @(" @(# P,# P,# P,# 0$! 0$! 0(! 0(" @$"
M @,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,#
M P,# P/_P  1" -P L<# 1$  A$! Q$!_\0 Q  !  (" P$! 0
M  <(!08#! D* @$! 0$! 0$                ! @,$$   !@,   0!!@8+
M#00(  \" P0%!@<  0@1$A,)%"$5%M98F"(75Q@9&C$CTY6UU98WEUD*05&Q
M,E(DU%9VUWAY.M*35#E",W.T)76WN#0F=SAQD:(U84-3@S9F)Q$!  (! P($
M!04  @,  @,   $1 B$Q$D%187&1$X&A(F(#\+'!,C/10N'Q4G*"DJ*R_]H
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M0\[755C5$%/,M@?F^%]OE/$A2-SLHUQK<SQ?%&GM\:4!$;+=R-_?!-*P)?\
MZA(G!L?X.'3'*(QF)WZ?%2RK/; ]P:FJX[7)88Q4K_*F8%<\R\5-3X[UQ,-O
MG$$=ZXLGHF?@3-EF1R55E$[<?H_8"="P!E#>L:T#@Q(S5)6]%EC :G/&9CY^
M=._&_;)[GAM,7;:5>U]%F#JVN/<4AG=/&D1F]G5LY%O36[4K7M07' +)EE:1
M"!U]%EUA1;;ZF?2FIJ3-RA:F3B+,5 T!8;*)SQNNE5+BM;V=[_A$<Y 31&./
MM^QB%<:7#0G0D%@\RYJC$X5WIT'.2+9NNX65PZNJ:U*Q7LUK2YW=$+VL0%M<
MI2IR$)B10>5HU/BB,XN>FOB]%.V>+KKG?M,U_P DT8P+)Q:];MW&Y;/'+'LY
MB,=W1/05FU)+7]ID-JJ&5A8GEZ)8H2H(VZ:;DA:\\&C0D ]30-5G'*.?*=M6
MJS:@>K^MNJN9K^NWE.&T]$:UY^[QI.?U](+DKZY@+OQV1^E"JT6"&T,Z%L=6
MN4.$7<R5:41 ](-(@#.V()Q?@ZD3CCC,1.MP\_=>TEU1!N>/; 3H*U2R5[YN
MYGN"F>DJ-JF4<P-LC.L:XVN$I'.UXN^=)599]$35S6MT1-97U8J2HGX3<I*$
MA7;T$\@R-<XN?&7L1^:H3#O:QB?([SS>KZI21FC:\KIPYIMJZ8M\[2=O:UD?
MT?$'.\RXS%HL:^5VA*V8V/"9O:RS%30FVG&E%LL\NL7>?*ZU>2S#[<'?1-&T
MPX3RNT]T0WG?W$E71]4>WO>_22"Y'1!R\.H'*N8_5K]T#-TCE#IA-*XGCR?*
MHXA>#EK4A*\$WSALW0!:C?+&Y\8W;5TE[:G7M^O'6MD1&JXI3J:U%7M0V3#*
M,1V!5AY3\GX\26"IMCGQ4XJ(C-ZI;!1Q3)$&V!2[,;I$USBW)]')A(M#$"D9
MXQ4=K^;-5/[5$^<;4XRFL^H9TU740[>ZJZ?OFO.A[!YKL=6QJK,YG:JYATE8
MHA0=:5]3")/([+8DSB<PLR!44B6Z$XFG;-/, 62<])B]:B-/-'E1^VCUGSP+
MBNP'KE.J^K(]SGKW":[5<IO5FURT-5>M/1_3[M:U-7)62R>HE=9&K6^N2RF)
MS;Q_"KFQO5Z+2>IL!I.19SB;B]Z_9N]8>UWT)&^SWB7VE"K$FT0#W-;_ &1#
M;P@EQ<R1",@9K+CLE D@UB(7.D%77;J^I6!^'!U[2AE8HJH:]$*DQR0! " T
MG...G:EP/9ZY.Z+Y%17;7DXK@NG^8DJ:LFKF2LIS**4LZ^XL%J2RQ=9"*9W!
M2$4C+?.J[*?7XG46W(3G23)R?B=JCP>IH(C.<Q.V[0N:N;^OX,;W7RQ:7)T'
M>*!ZUZJ[6N=GZ!<[KK^0LK)&[M+<'&MBY!1QK$NDSDHV\-:#1^@GZ&C$IT=Y
M-[(V$0F<=)B=8B% ZW]LSL.$PWCU5+.!*)MLZG^#;@X.G-,2ZX*G*C#+:,A7
M0M4B[18W8;*Z,[HV6PE9#D3Z$*8$V2I22][).&+RX;Y8ZZSO?_A[2^V+5G3_
M ##S9R3R;<%21=KC=0\>PULFUJM%I-;^L37RT24]F<JM10M(TB.<6 N)^5U#
M(P.&R!G"^%]#S:]3#GG,993E'=Z@X8,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@
M,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@
M,!@=-Q+7'-Z\EL5$H7(U&J+;UJE+M<G1KAD#"D5*$03THEA*=1L(QE:-+V8'
M6P^8/CXZ#YE)][AW9?);K[GR);?$0[FB/&7)\)EJBSU%)1:IF"I^U)[+Q1QG
MH%<96[H:URY@;HN[(I(\(#CSWMD)T6C4K/5.\^1UC''*M*N?DLE5?1'N(-4N
M[QX\#:--7[T;15/\O793]Y6? 0U7$D+#T"VRQ+8;?-H;5")4BD1E7.,!<7&.
M)$X&\YY(/(1KUH!!&K%4F,=,NBE<X]T+L8K@#VHKL6V\NB,CZMAUQO\ ?TZI
M'GF'WG?KJ^P*"O<GAH:NYK4%*T*NOSES69],'9"W+-L*7240Q)0*1*0RVN&/
M.8[/;?E'K)S?O;6J3L_I>55D<XAYF3W?<LKJ9S3NE=A"R115(Y2KCZ@E>O2A
M4ITS>8!4C*4&@2N83DH!"T7K*YS'U<8[O+GV\/=LNZ40'KYV[(6P";3BO>5F
MSW)Z<B53#C#>L2\P3.(R:0GT>^*FM8K0:LJG7F-)VMT5+O*I$<]$#/UH.M>,
M;RPBXX]Z3C^F]:H]7MP3^T^0+BK N#<-1CW"JU8'.;UE(7>W>?9#(6Z)F&>$
M9>'%-7\T0/KLF_\ A3B,PPQ(> T0BQ^<D%3V]=)ZTV1V]YA%!HWTBLM_DNUZ
MMF_/C3R3.@5VYSBN) Z3>J.Q[325/6\Q3O4:<W%BCCXP/PU GQD4FFGI/A_(
M4<?L7B$>W=5/?Y)[M+W*H[7DJ[6A*2MD![YQE(N;8V\.UB795-)0":J>D(<G
MF;2M*GMD.S8S1=%$T!PBU19^E*]<<#0$*908,(-DC"Z\5-H/[E[_ -9]$>U@
M\5(ODM706SK_ .^*4Z'JTM_B$R8)+*.?*.>E[:E3S>-A<F>9Q!%(R$SPS.K8
M>F L)/+$8 /X16C7"HRO>H2AV-UAT:\]GR+D.AK9(YL@5"\C$=A=$7.R40;T
ME=4C:I#.7Z#PZLZ1J0Q&]H'%2'Z,JUSFL^:'I:8(9"1(ET:+8ADQQCCRG6YI
M$:CWLZAI:E>>TB"Q =I6#8L)O:?NEGSM367!J5SB-%V:Z5_*2G"-7,IA[4EM
M<4H!N/-$7;TI:AZ6-2I2+X(C6Q:6OMS,STCU;997OHQ"/-LQF53<I7'=E6UO
MR!0O=-B6"V2VN(41%>?+Q2R-<!2-@E+R6[NMAQ=%&U S&)-HS:O9"G6E)7HA
MV<2/Q])G6Z;3:GOD\[UETBKI V+Z=(A%9_0M7V+8JNUZLC,L8YAT0WQ!TB:B
M%4$^/Q%LVG#(<BL!F'*W=J2^1F^).T64K^$4^F(_',Q?5O$8]UM=,:[ZBMEK
MYC=HO6G-EN32A"[%M_H&AZ<@5C6W +M<*EEC.SR2;2=&&/QMD:DY#T:ZKR0Z
M4C/$V(2%K@2(O9.&L1>LJ[03W-9#UKTG[8BNJ%DAJV&3GH[O.A^CJP2R:&SN
M+2N44)SXLDS*!MGT8"XL\WAB9U5H7EG=&TU)I2$X.C2P[",O1KCQQF]ZADNZ
M._.F>:O=,YJJR-R.+D<<?BJIF5]-1QSB34J>TJ:^^D9'R^P6 DFQA>WA@:8;
M.Y'%SUA0!>@)-ZNQ:\!"\28XQ.$S_P!E;:F]YFWHYTKW];70CTB=>$ZJHJ:7
M-S/!X;"8ZBG#Q'89U8Y<BQUX#+U:E :^#MRP88X&H!+U1+>E(<"3!F )+V,,
M:G"*B(_M^I6<2>_A11-96,^2*!,:&VH);])4PA@<:Z1H6<5/)7_H-BD<E@#_
M /G0L<G#4D;A[(SPE]%*5C@,DR/GM!A0BE CDNSUL^W-^#3W7WI[3LQTXG'R
M_P VL<W:;NZ_L[E*\$JNW:XD)#+/*K@TGF#M$*GL*.2D$&E2![CB)))VZ7 $
MK9EC( 231)3BH+ 55]N(OE/2VX5I[I3[&TD$KZ&5-T-UK:O0?:'N"T76C5+)
M71D&7L3CRQ*WQ<O9UC^A0Q.,-%2-K,B,(:%BHI8]IVY,':W:Q6+P&3AWFHB(
M^;>HK[SC5:L;YOW1?)MP6O:-VU1=EX3JI$LPK6*N])5KSK9RRF+37O<ED;VF
MC4OD'XT&Y0UL#>WG!V\[*V:(U(7O6\'"KN=%DV3W,:@.]M-C]SF61&;16J7J
MI6FTRH 24VO]@B')'I/&8K"D1256E9ULGDDF<4:!/YCR4P3U0=FFEEA&,).$
M\^'5YY=N>[)T)#.3NYXBT<USOESM:C^<XY=C6R2"P*GGZ&-TI:*Y^AZ&_P",
MRAE4N,9D;M6TI9CD+I'3$^EY#D(@1 5J?>S<-8X1.4:WC,K<VQ-^W*-]I4J9
MT-"+.LCL&.UI#%!++:+M%^A;>)^>IDT%SJ6*@P<$8B]P3.*0-R7.K8U(M)BU
MYJ5.EV$P6A%F&8XSGK_5Y_OWN VP=5'MXS2A.J;)[5?IO[E)M&VW'R:=@/+U
MI/Q0Z%LM]-YFMFN7YJB;/7CI&92B0.B]:M*;#BT0 G[&>46'9YOC%S<5HNDJ
M]X1L#S.VWH70[9&9L@O:ZN=+)J&X>G*&IGZ%6=0CD[M4X9(_/ID]EM-IGKE;
M:7II+84:@Q2%2$Q0%(4 9@3/#6KTIQ,OO1UY,GNGPP'GJV9-!;"XIBW?\]L1
M0\PAA::.YS5/\[C]A/,X;%[N-T>9-7RV#B++:F0+@I>SE.M)/VLHTX(]OQUN
ME#^B??,*O'B/L<VB$CI0=[PSE*+]2U!)X3;U+7:\)ZV=+9@T*<"Y857;O*$E
M4W*R?2=&6Y1%Y)-4IR70&P'FB+.T4MJ/QUE%ZQ=+XG>\4T05FZ#8KJY<N"NK
MPI&0<LQ2'TB"3UM,)3>+OV8O<V#GQ%')"PO^H;%WQ^D#$M)?$SDM"2PA3&&"
M4* A^4SPO:=/^$,WQ[DMK35SIBIFZ'S_ )&Z,JSW1N!:,Z8JU=)81/4+Q3_1
MXW^1,NF2P(R!S8)3 K+C3::6<,HI Y)%* XDPLK80C,+&$1KO%2T66>ZO:U\
MWS[=S]5%;6K1_)5J]OW57>KI>I)7B^-](5I2=47PWR]&]PQ H<IK &<V;PG3
MLSZ5%@,<4;08:(P@0=)S!PB(G_ZIN\#_ +0OS].8S:$P(JQP*98]S!=W6=4H
M&6YJ=FTRL&N:(+1+I-'[%A,/?W=]YXLA[C[HG=FIHD@-[4MVSO,:6I3&I0RR
M?Q3'K29S_> 7HK-Y5J.1\G2BL)IUBP++(@R>Z[UI6L&G\4I\T8HO$5K3(7%Z
M<6.777+6AZ^>PUTB4?/Z)N+T$\05 PDY6>&DS>SVHPP8# 8# 8# 8# 8# 8#
M 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8#
M 8# PLD9=22.OT=$Z/+&%^971EV]1QP$TR%GTZ(3T.W1A=0 ,&V/+?H_U4JC
M01;)/ $>M;\/# \I*,]F+FJC*=M'G0BU^H[0YXN& 6' YQ2=MVHQR.#.)UH.
M*5WEMA!$RP.,R<5JJG).(XI_.<CEI1IPQ:WL6B]@-S^29F]+68Y?X,JKELJW
M7!GF]R6[85YHHBR63;]YS5#-++>HK7D540RNX>2ZM4>C#*W1R$L*U2%&40W@
M-.4JSU*HQ0H-&9LDY3EY(+-]HKG9NJ7DNL:[LGHNGGSB>+S>#T-=59V,R--Q
MM$,LI&4@G\7D#R[PI]B<E:92F2I_6"H9?4(-2E&IAD&AV,1><W,S6J5W7VW.
M;UW"K3[=3<&?QGFQN8X_&ES:P3 P$QDS TS9)/WYKDDN=4#JM7D6)(23]R$0
M $F+DZY24 1(3?P2<IY<NK2+$]HWAZ:2M',H?5+7SV[_ (F;^H*2E<V,<'IU
MJL*LNCH45")PS6$U1Z'[12A2SIDY2]C5&@">V.983M",#YBQ#GEM.KCLWVG>
M7;8C:V*RAQM@IL7\(-/MVGB:9DVHE6J"9I.PRU&M+.,C*D(;$VZ1Q/H;GY=D
M")V,/PNMBT+18SF/6V<NOVO.9[\6]!N,\56=I9TC2-%43-#F&9$,YC#'^;YJ
M\6+4LI@YI+*8>Q3J/S-X^.$L-&J3GF)B0B3^GH83"1G,;=$3C]FOGD\$Y>W"
MY^JWBVIY=M#='KKY?+2C3S:S/=W.<3D,(KR=L!SE7BF#IA@B\I6)%+8H9%+)
MZ8@?#HTVRB]A+[D^%4DVG_:TYRI::4_8$=DETR"54M>G1O14<=9S814H6/EF
M=3P[4+MIPF2U4PE+Y B7(Q&*T96SBAIEQHA[,&7Y2@B<YG3P;]TOP%4_25I0
M._2YW=E!=#UQ%W6!1R]N=)\3 I^IKM[7A=W&NY40\L4MA<WA1CT'2TI"[M"T
M*59XFIQ%#$/8B1E,16\*_,'LZ\[0>(T\SUA;'2U7S^ER+J;F*]8G/X>JMN3L
M/0U@J+5MF.3Y3+ZXE$"E#-(;"4?.R<(V HUJ6!T8A,3[V/SEYS.]4E.;>V-S
MU8:'I-)+9#;[LHZLY2K7CVVW@^;(#'E96-6MDS:V%[:%QL<,VBL%R!/%YKBY
MFA4%JC]@'I.#R[T(G.8KPFW*D]MJIX[=9]VUS;'054+Y&OJ)WM:!0&:15+75
MU/=*1]AB,0>[!:G^!2%]1.J^(QA"U/1L=<F';TA3A KT8+Q'LO.:J:8E\]K7
MG=UI)32+=)KBBJ(GKV1=RQ*?1R8,A=A5]T1(K&?;/')HHL=HD[18UG:9!)%A
M2-M=6ES2@2&Z 8$TP #0CG-WX4_E0^UESI34_J^SV.47;)IK55^=!=*-#W/+
M"3R=9(+4Z;KAMK*UG.8*3H\G5O2!P:&WXM(0$PCX1P.,$$6R?3( )SF>VS>.
MC?;KYWZFFMKSNUP3=6[7%R:NXXE*5EDB9K:T=7JK#,M)(_1X@30J4M5C,<TV
M6J0NGK& 3B(*\"-B!YMDC*8V[HKW[07&)\5.@KA'YNYPQ1Q1!^#C(VHF)B9'
MJH*]G2RS8U*"5C4WMSREMQ//UNW<;\4J!O:X #0D!'K>]EYY7?6[9AV]L2LI
MA5:BM+.OSJ2U71!9-=VW6]M3&?PA+:M+V!51"U-"I%6#I#*SB460K$J=T5@7
M;=&AUT\@6'!</B0C\NASF)TB&5F7MN5Y8%?4M%9;?'33K/J!O,[H2M>@/IO!
MT5R-$\6,SY%W)&,UOK1)6HX>XQ&1JFD;4"-EI@(AZ]/R&Z]79(RF+JJEVJT]
MLWG.J;"J&RXPOLPR14G>G6?0L.+=98@6-AL][-+=2K>)>TI<?3&.$>3!>#OF
M9, PD:'?E]0T_P /E$YS,5W_ (>?73OM4+:TA-",_$E3V+.9I6C%U#"R+#WV
MLKYIE;7$^DK 56M)('8S@RU+*OQH4X]S^2+E9Z1#\TOS,!$1\WJ!FG&&@-QG
M?]MO)>ZAO;M@<=]L*K/;>Z&V@M*(,O/\:J&S53 >[1Y$[NZ$A,Y.#Q$%Y)R5
M]9=L<L+TK95GF+6)QI4YV]!,#L.C,Y3SYQW:9OVA>=7NO.EX7:%F=(W=*.K:
MFC=#V;==LV8T/]PH:<AQZM9%Z]A3VV0QCC$896MR<%"PP8&@Q6XKCQJ5QRD[
MRC"/<FXJHI?2TZ@U951N%2M=EVK4.E2"/(6ZQJ>DS?%[-CFHVXM;@D/8WYS8
MY U%C6Z:@IEA:A I3JT9QQ(R]@,WAF)J;4IKCVG^:ZYW7#H7)KLF<Z@77"[M
MYXM">S]$_3^U^@5]</53F/UH.94:0-KHQ)H0];2)FQL1M25-I.3LL(=Z,]0U
M.<SY53#.7M$\Y&/S++HM8G0]<39CNGJ>ZDLT@5BLK5)!*^S7)E<N@('I6OA;
MJG0P>4CCR,M()(4F?FD!&MHW,DS8AB'.=M*_X;Q2'M<<LT0%G21Q).Y0Q-/&
M"3@LV,SV4)W]B>^?$TWF$[,:WXA,SM:Q?(UZ^<+DBA=H\'JH-@+]/0P[-$2<
MYGUMH2;VCZ4'S]9?+<EO7JR=478-8L%.-,'E]DPY<75U>QB0LTA96> /*"M&
MQ_4K40H\B0A<9$JD#C\W)PD>OX>80B\YNZBTBW-[8?,M\2?H&8SW=D"D?1#!
MSBU/[LP33<?<("^\H/<ADM(6'4[BWMA;E#K BL@DARL2[9RHI0, "QD[)V:4
M:(SF*KI_+58Y[4'.S2-,_2:<7S:%I']2T;UY+[MLBP&IYL^Q+/YP1GME/,LM
M6-L298L36\/:5)J5.QM+2UD!*-,WH6C3##!#G/PJFI0;V;>7Z_M.L+$8Y[T6
M?%Z/NNR[XI:A'BT$#K0E7S"X4,O1V0VQF%*8EMS.BDD'.' [2)P<ENT(C1 1
MF)R#5!1PYS5:,M&O:0HB+TW:O-Z.X>FUG.-E4M8U!,]'.=B119"JBKNS# _.
MR*L7#==@G 5[ C\Z1D.D#N_Z:41HR20: +PT.<W=1:3.B/;CJ3IYFJ."6=95
MZ#IFID]6 W13%+HLVUI8:ZFI&WRF!OD]]:#+9QM[0.K4FTH/9'IE^,3DA).T
M,OQ#LD93&V[T%PR8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8#
M8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8#
M8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8#
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M:I5&%DA&,"9.89O6@ $+09+ 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8#
M8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8#
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MP@!/!X_LX*IR6+9=?U%%%4YL^7L,%AZ)SCK,KDDF<"&MH3NLMD35$HRWFK%
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M;UOQU@<F P& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P&
MP& P& P& P& P& P& P& P& P& P& P/,KW=:NLJU.+7A'4\!?;3EU?WARW=
M@J\BA*97+Y9&J2Z.K&T)DV0]N5GI2':4ZBD76&H47J@,6'E!)+WLT8 B-X3$
M9:O&'JZR;ZW-NQNT*TAO6W-\%O:^_:!YJ@+^*"N]-=&66P1&VIRVWNWP"O9P
MC1RM,C<VFUR69NVYH4X75?HP*<)@ Z&*.D548S4U$MQ9U'=84,6+L0_W- <
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M[C9!9*9)%3UB?1(M;,&*)>&\Q%<ODTR7SOW#[/H-FM6>U-V'6+[U[TC.I(3
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M^"TSE)O@A"1^@+=<\_[2O'ADP& P& P& P& P& P& P& P& P& P& P& P&
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ME)3C?MQG-_$O8W+<CNA0_P!B=PN72TTN*YTL#2,K(W65TNR*&!\=X55I4E5
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M'9I1 1[!HUSUOKI\ECN!."?S, 3E>^2.M9S,);%ZP@0YQ"J[L2#2-[B54H9
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MC3':"/7B$6RCC@#T$6OV-^'RX'6^E<6_UD8/WX;O])P'TKBW^LC!^_#=_I.
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M;/\ L&\H_P!!\!_B3!SS[R?HH_;/^P;RC_0? ?XDP<\^\GZ*/VS_ +!O*/\
M0? ?XDP<\^\GZ*/VS_L&\H_T'P'^),'//O)^BC]L_P"P;RC_ $'P'^),'//O
M)^BC]L_[!O*/]!\!_B3!SS[R?HH_;/\ L&\H_P!!\!_B3!SS[R?HH_;/^P;R
MC_0? ?XDP<\^\GZ*/VS_ +!O*/\ 0? ?XDP<\^\GZ*/VS_L&\H_T'P'^),'/
M/O)^BC]L_P"P;RC_ $'P'^),'//O)^BC]L_[!O*/]!\!_B3!SS[R?HH_;/\
ML&\H_P!!\!_B3!SS[R?HH_;/^P;RC_0? ?XDP<\^\GZ*/VS_ +!O*/\ 0? ?
MXDP<\^\GZ*/VS_L&\H_T'P'^),'//O)^BC]L_P"P;RC_ $'P'^),'//O)^BC
M]L_[!O*/]!\!_B3!SS[R?HH_;/\ L&\H_P!!\!_B3!SS[R?HH_;/^P;RC_0?
M ?XDP<\^\GZ*/VS_ +!O*/\ 0? ?XDP<\^\GZ*/VS_L&\H_T'P'^),'//O)^
MBC]L_P"P;RC_ $'P'^),'//O)^BC]L_[!O*/]!\!_B3!SS[R?HH_;/\ L&\H
M_P!!\!_B3!SS[R?HH_;/^P;RC_0? ?XDP<\^\GZ*/VS_ +!O*/\ 0? ?XDP<
M\^\GZ*/VS_L&\H_T'P'^),'//O)^BC]L_P"P;RC_ $'P'^),'//O)^BC]L_[
M!O*/]!\!_B3!SS[R?HH_;/\ L&\H_P!!\!_B3!SS[R?HH_;/^P;RC_0? ?XD
MP<\^\GZ*/VS_ +!O*/\ 0? ?XDP<\^\GZ*/VS_L&\H_T'P'^),'//O)^BC]L
M_P"P;RC_ $'P'^),'//O*AON9^WAPC3?%5L675'(/.U=6%$WZDW"+S:'5/#H
M_*(\O,ORKT@UK,]-K4G7MJH:5085LPH8!;+,$'>_*+>MJ;PRRG*IF:>^>'(P
M& P& P& P& P& P& P& P& P& P& P& P& P& P/-;F#_P Q#W1?_;\5_P#T
M'=L-Y?TQ^+TIPP8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8
M# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# \U/=]_\O*^?_F=(?_<)
M5.&_Q_WAZ5X8,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,#S6Y@_\
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M8XS7+HM9ADP& P& P/-3W??_ "\KY_\ F=(?_<)5.&_Q_P!X>E>&# 8# 8#
M8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# \UN8/\ S$/=%_\ ;\5__0=VPWE_
M3'XO2G#!@,!@4 ]R^@;-Z6Y@(K"HVMM>)@7T#RC8 D3J\HV%)]&*HZ6JNRIJ
MJTX+]Z3[4H8E%EIQ)/\ CJ30!*!^$/6&L)B)N>SQX>?:;ZJ>+VD3TD9H6SU)
MU%VUT<=V<F,F+<:OE?&P^M(SUE0SBV(TOB)7*) >R/<4<4 O,H1M$L/"8'R
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M2F/ .50:?2&'MTE.&A$ L#[\YJ/P K=;V=)_)'QOY6N)5',W;5L3CVR8C?-
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M;+=-M[\+XF;,;.V3DDY.-N^5:(@0"_EWK>B93CEUZRVJDN NF8-SS[05=/\
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MPB)]7HA+D*R^1V"-RACI^IZOY^?/G6YW&4P6HJG^BK1(DU$V3(*YDCNU+X?
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M/@$:A$H35:VRNL;,=IX^RY\C3A83D:1-+3;7,MO>U#$:SI#E"(MP/3JE(A>
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M29SE5?WG!F65*8Q(%LY+76G9< M&"3*1/#W8#FTB7TF[URVIF5M9D#,V;)3
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M_P"7E?/_ ,SI#_[A*IPW^/\ O#TKPP8# 8# 8# 8# 8# 8# 8# 8# 8# 8#
M8# 8# 8# 8'FMS!_YB'NB_\ M^*__H.[8;R_IC\7I3A@P& P& P& P& P*E]
MQ3:45YS1-)5#I)*(@^)913K9J1PEE2R*7-C/);JKR,28<;8E;:\$NSP?&GA6
M401I*H,,&9K198S/*'9K'655ZW67!.;@AD:CMGWTMYN0WG9CE')<YI'1(]3F
M#Q:FZBD"&-2.;/T71R5; D5Z.<A2(5AQA2IV3HS4'Q*E$7K9A9JNEM4A[IU0
M[1IEL9\EEVI)'#8?[>)S9"BX]MHC;T[V$[1MMZ6')XPFC*8<C/5LCPI"Z$F_
M@1P2;2A.%$<$9FRSQVCQ:8E-O*N*QLV&U!++R4R1H=/<C4N3D\,KG,Y)')V;
MT'!7&DUK4=)(RN(5?.$ DZAZ9R2@GH'4*U0;Y#P@V D:3K-=$QRPRXH;8+A7
M#W..B1<\-/0* M\L)C22R3643&'_ )O;9''X^GET9CCG+E-?K+Q&HTJ6H2C#
M42X:=K&>4@-VG#$TKQIDX9=]A;]NRF[#D9ED3^8SHN(QR0S92XK:[E#,@?)V
M>U'6'8SQ7\/>W:&MK4SI@;=S&AE$:2(W8 Z2 V-4GI,1RJ$%Q][ZXF=5R:1N
M$WOIB>ZQYBO2:U^B9V%Y;3)E:<!Z N-IJ,Z0ER*#MDGGBEUK.',A?S4XI2A/
MR!Q"K5(Q*#B30-5TOINWA:Y3Z4]3U2EF#[<ZZ<1ON.>JE%>%Q1Z/J"+\]-M!
MW2W53-BEQ,:W'6EO=2W-M,$^:<=+%LC<U36?L>B ID9-L>E4Y.LU\[?[8F\.
MD;[<R8LFU^(S**KZ#15[>H#-J\#=5:O=S261_-,;=FQ>M9'1&Y?/2M<K(/C3
M0V(52?X?2L8EHBJ]6II)KU*^%)D\'FMSJ.A#&:^WZ_("_1Q856U>O, 6K9-4
MD?APG:/$1QK;)/)F-LB[0)K5J3)1$GE<YG;5J" +2"_3\'(HN#LF1IYDJ9D]
MPLS7;E=V%UY6)JVN=MSI5,!C=<3Z+1+GAP3*8Z,U'/GB8%U[(C&1> QZ/.>'
MT@.O22; 22L?#LVN2QF^V:50F.IU]H6T6QR7E.VH\ML=*J<DJ:TWZ#=.-5@$
M'OR)I;26*+&O<6CAR]O ,I$Q&.>_1 E*4E%X-/W:&S77;+!$4;BVOO1=H(GR
MD84GZ.,G!$MKG=-]#2JSJXCHW!')$5<KGZO&9D8WF6*90U1IM<4S,TLR!004
MDTITM4/):B^B)+)FM]2_G6SX[:DIZ&;"5_.'4<=HIO@L)G#XYV_8R6Y;OA4?
M898E<J_(E$U.44NW0_3*G?42+YY:'=<[" 8I)$K2"(B].ZV<F)Z+F,OLMB*F
M=U0B,11A[)?HA]!VS3$!PD$+US<10Z<+Q]&CU+VA;A/DB-;D&S#"7[>CP*@+
M"4XB@DTCY(_=K;O!/8U:O$XFMZPV>2KI3E"+,4&:8>[(::>**G-;5RKGH'H2
MV)FQ4A>ZV.Y24EP4'+P2)O<4*= 3Z2/RA41:BM*I,G8EN6U';CA$6K!IL)M=
M(^JHI^2.36XSI5'I^US>\D,7LEB:X%%8#(HQ+P0FOFI4HD2M_=VP#&A=4JE,
M7H>_BBZF,16K\UW$U[7QSVY7Z)SLR73!/,.Z$ FB<;D3_(PFR65VDZ09&P%.
M;>0H=6V4Q-W;'%'I%ZY*L3AYBQ>)GDT)GZHGIHB&Q8%8T<@6HE);"Z#6U] G
M+VVK=4R8*IY"^-3F?=+XPWJ6D71Y@ KU&&&-1%J>W!C3%#2L1G^<!)3IQ^3)
MT6)UO2]6GFOR^J;3<(')+>Z"A<+GW;]^N-F*FXV5.#L*!*^?5T[KO;3($T?<
M7F-5\N>$R91IS8Q!T!0G+2FGEA$<'5.EZ:0D"J[,NDN65*3<\PN)\-F]-/+>
M\M4?;Y=$9S33$S1&UWINNJPX*T0)3")2Z6%%&IF.4[-,3/L=F:A*W)&M0%0:
MF3DF(K1FY!$G^^KL&0X,$J60^P[)AU1D.TFB[BF#OF+DT!-I6:ZO"I6E0A2C
MOOHUX1QE02:43MY8$H#RP"*)WH,-H1PB;NM1UN7+U=L]*FS SB^S+U4M7S:6
MF)-Z0B$A2G5U' L1$0!I&DTRKC4)T1)+ E?22@'JDQZH CQM5^F]HW+5G5Z6
MW85]0&-M%R1Z.2BH.R8'(8JE>+&<G5N?H-'F9KI]_;4@X$T0FL55C*TBQ;&R
M69Z=53ZT.>S% S3->FCI$1%?!D*XF]\N%OUM&X[8LA9X,U,W.9E4;FJNS32;
M3J?\7:)9=B=SCQ55.##)K#<Y.!Y;C5KS(&EPC"AN;3=)DY)XOG*$U7BR:&:]
M"UA4M:.4T<[PL99->5:ODMEO;XI=(:NC-O6C9-8LTL?'J31: /+U6D>KAD=U
MJA:W-+4:I;FQ.>;I,$WU5A=U*B9TK='*!TO)T8F>?2B7RR"N[-7]M1+5AR=O
MM1D+E$)C/;0B(5!'">I("*RXT*R*F9T9223A9!O>T(RW(2<\1IFS!I^O)9JW
MK]5+:EY#..>;VI%',;3JABNYO$Q/IUGL<0E7.MI3\Z,222_1P]=ZQ;HR-PGY
MX:- <6KT33#AH3@':*)$:SM*%"7_ +%=HE)I3%IA>[B& 4':,@J9&OB):-XG
MY1_1%MP^N)U*V1=$FQ3,[10<U(&QW;6!44 +HY&HU2U -28  2_3U[NI-[*Z
M.2)IJEY-F-]6A'D;O!3JV>YM$W-_4.J=1 Y^/J)")WFS+'USP&OHR7'GJ&:6
M;T6?9RPIA\XFSYP1HAI_VIN[S/NGG^>675=6S*Q%:2G8$FZVA$I>8\0F=+1A
M<^:&$^E:(E.G-C3+PJ'F70^Q$#HF&F2.J9(@:A&^0P[>$B(ZM:DMJ7B\MJB=
MV%+^CJLCMD5#8-P\ZL4)@SP7)2K+?IJ^%5?54TC;=%'A?J61NJ6V)JB(D^%
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M,$44 1IFQBVX8# 8# 8# 8# 8# 8# 8# 8# 8# \U/=]_P#+ROG_ .9TA_\
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MAV0WH#CA[&8 (2RQ"WO6M;PUAAE&5SL^@G#D8# 8# 8# 8# 8# 8# 8# 8#
M8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8#
M8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8#
M8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8#
M8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8#
M8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8#
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MZ9.4(8QBWK00AWO>!QMKNUO#8V/34X(W!H>D:)Q:7)(H+.1.2%R3EJD"M$H
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M)&0@5$J361^ V-CT-G<P%"$)&XA:7I(IV4/P'Z*DL?AX#UO8:NQ6Y5,IE;O
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MO40.3-+\/7X*$Y.D6"WK0/-HMQOUF)_7Q:8B?NWS(7-'Q;+)TEFJ5X9F>_X
M5'NB5SJUM*_HZ-ADDQJUR)C9D?CC7&:=(>424BMMKE;HP+"G).$;DD*5&"L;
M;L\Q:WV_\6]F[FEQS:;[YM]P6.T^]P]'?@6]JD#TY0*3T?!Y,V3)$6\OLH0,
M[,Z$MCW*$1)\@,941@C%*DM*8:--O&$ME-'4B1^6S]C>[B<)LMZ.GT,88O*%
MS]JL$M5'<NR%5$=N,.$6GC1,8#=[<WJM2$TG:\M><-)I9\(/:7(FFWA_+M\:
M2B8&WLOASM)^CG%.GY"I*6SY@OTF:IMH+O=IM8C1.W=A23I"C5)5+B8R^@K
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M+3+(Q,V%$4W.L@2&Q%8G4(]%F$)QA 84<K)- /1>/=+_ #[V_ .B+$4P>)M
MPH%\?F\KALB1R)ED G1@KZ;-L$>C)FQ-0AKZU=GE>\)ES(B<!&'.34(PT7PZ
MA.>E+).,Q#'R7NJ(,!Z=B35],'R=G3&?5Z;"$*N/IG!NF,9N.$TC"VYV7N#B
MF;FU!:DFL9G7M2PP>B0,9QZPWP^&,*V.+=(-U4EDEBBI^3UZ]PZRVEQL1IEK
M2%Z99"Q,RN!Q"K)\D5MC^C&D-?6:81"W6M2A/VC2GE&EJ"%1!!I.];%:7T:O
MR[=T2LJ3R1JJVDG2$Q5[B-=7S/)TYNC$1IVG%_P:.SQG:1-R-4Y/$@D::-'@
M)<UAHR4J("5*0F$<4((4XF*WEJ[KWLDC;2^S*34G.VJN25?4+##Y,2]Q5Q=9
ME+>4T5FO$P9P1<A< ]C;YFQ5"_*8ZM/4C^)VBV!64BV:G$>./J[ZOMIS9TTE
M>)'1<F9HS50("._'C4PC3@?56[*"@>&-,F;$H/4G"R+09_:GV3!1&%E-R5?H
MI"8ZJ"C"M#CXOZD[2K^;2&55G)JRE*-FCMG-_.5Y.#\)E-B\ L*?I)']&8J^
MF?%^5^9)A'-,*S2Y+H:4M%-F<)NPGF+"$8XSNWQ%T<RMM'T/,8-5[ZH47@OC
MD,HVK_BV:/GK4;E&Y#*XTK=G0XX]KBL9259#E3ZH'L*A0F0D^@6G.5[+3C%:
MU+%2[L%KKZSZTJN:QV-HI).]L+.\,S':,<D<MALPD<<E4C;$#C#DZ!*ZGQ(X
MN*#("\FB2;,,4%C+2#)">82(QN+A7:Q^]+*=^=Y[.:SHF71Z5IN3S>F@J7"3
MP1>ZUM!+ :I673;^X,IVUS/(IFY'Q%T=%S 6:80@;VL>C%1RDXA&:7C$3K.E
MK>].=),G,\&3S1Z31EV\4[^XC97BP6"#.[LUQ2/K)&^@AR-X(4J)=(@H4?@0
M@(+++V,P.U"A,5XFZ,Q%M *[.;S9L)NW64E35@GLV(5&MM58],1)1<MGE,Q>
MZXTK30XLT]\418+'+D;>O6#&2H2.9N@@3'IPG*"B\?5K](=-6%<]\0-$J@CW
M7=53_EETO*&('A?%WI1)D3Q/8*AB#TYJ&?1KA&),DBKR(Q<S[./2D <B? \\
MX!H2!,5'C;79A[A;/$52Q(OJ\]J$NL>\H! 3YG9$*A2*=I^;I [1>V90G7.)
MJE(S-^I E1((^E/&)>\JW$&S"424HY6$<64KWMQTELSE(':LE+96+A,>7XO4
ML@+< IY<\%])05CEZ)9.(JY_#FQP^/Z>@Z4IPBV<5X;*\I@P[%@X^K>P]@)G
M&?)8+':NE#M\-^<2XRV1*'F/-C/%HSS=/VZN)0[# -2I<7=QD[\\)A-"$@GS
M&$>L-08G]+P$..EMAY[Z:/O!P):WFL7^L5[U45:7K$$CT^L;^>[UQ: WQ.S[
M=OF(PU/'Y<SK6 P#BW>HJ)*">0(E4?O9P21,4CZG>FIM85VQ&N&Z(G.5:/U9
M7--UUAR=W8D4S126NK[=*I^8/HW'$"-F.82M)=!3&@#\28F,(,.'LX"CSB8B
M(MVY-U<[1ZRY;5L+K2:6M,R9I8C<D;UC]!X?&V1OK&GZ)L5\)2/HT^EVVYU)
MMY(4WZ6$+%AKT<>6<<G;]%&D#CI<[-BM3I.3-5$TG=E-0%/.$]R37G! B9)6
M]$114VPR]Y9#V@*]2,&UI('Y(@E11196AF%$JC-&#]4HH8!B(UJ4(Q[N%TKQ
MHL5]O>'2 F!1ZR.V&^/V4A5Q@TUQ:>:YC9K^&.@AZ,3>I2HB*TAIZ-M<5!^S
MG!>U&:5%D^L0H4%XWMOHG.F^MH];$/MZ1BCGS4X4PD)<9,A8)0RSR/.*%=#0
MS5!J.SAB"4P.SD0CT:A<4H=A&WN28PO>S"!)U)Y)QKXHO;.]!'(8NF?J+F<;
MF]K1&I)I1T&52>*K5L_;+@>/F-L;WUV1J!-4$?84=L*R1$G#6D(VT8349Z\_
MSI@#CVG1L+3VJ6XV!&*K<*R.B4Y5S>5UU,29E.F-BC#--HP"%N*6(PJ6[0J6
MZQY;+HC/FZ0M#66%N6JF09I@BRU)!Z0L<=+Z(O2>X,Y0_GF%W5=4!A47>7YT
MM,]ZA#7;# 5(?H;6LX4QA8]05@=$XW.=.Y:(&AG(RQ)B &E^ U)(E"8H<7C<
MU#?9CWFRP):[R.3U1+TE'M4\OBMQVZF>HTI,U).<:^L^=6.I504:M.])XZ>K
MI]]9FA4 XX]:Y)/,<G2I325!M3CZL]4W=M13PM<FFSE'JQ>B9?!X8TE*)LPR
M^-2=]L=C&^Q9CCDSC^OF5TE! 4ZA&[-P/$;:N3[#YS4YR52>)QF-F%A_="%_
M1-#Y**L=:SBDX@5P3BLI/.9Q#6ML?@TFY%()6W3)5\7MOK<ET2J N36M5J%"
M0YJ ::I$D/+"F,'%JB'W!X6X,ZJ6_,$G5*XRBN%@7PR$O$.E47ETXALWYQAT
M9;H[,5R1F7.1TH=+_8R&E7XMB D*Y=\Y%:$F(& O!)=6]"RT!G9DIO-H405@
MYXD[8>?'B5+1)28]$&KG6N;1DJYC?F-&A4RML7JWM<K(,5$D+=&"$G$25HL(
M,),;5U1[#O<(;Y\0SM<1J1SD4ZD\UKJ(QYC8K ASU% %6G7MFV-'G&2V$V#4
ML[*NC;74SLGDK:F)<5S4HT1L@*XE2G--+Q]&W,W=\*<&;2QS@LL87TQ)7OPL
M86*F12M<7F57+-:,FC0UJT:PU(O!4TN@#@K>%(-[*$S;(5DZ%HW182<90JE]
MQ!IM)HB#O PAAK4;-^>IDX/0'B-3I$YT3:<H?4*]))#64AR2P:?DLS )0Y,8
MC#5Z%,L3C(4&CV?H@O&DFJ.\CVEAB[Q(:!GS<LM6+0"<T;'D<DACF\6'&; M
M>JZD2D.^]N2)M@TKCSI=4;<7- H4*4Y3:N$(E6>>G4$%$X^+ SOW&(O7ACI$
M9C6QK-:\6<+.3SFOW6PX<VMJ1EJV,5O,71PA\N<Q)$LZ<9E'+@CHHZV 2(U:
M]4M-(5:0_"G#T.-^22@S_G[F%JC+[$:T41F-W-7TTL8J1MS;I$O=%5;0=+/&
M&!O?S\I _%/SM#%;J:R-YHM)T>VY61H!(S-!&*G)H[I[BT 1QVOW $,<FJ06
M$U5V02S3N5Q:#L\,L.<D6PN=JTL26JU3BW1Q]KQNI"2#>#"BUNO53)RDP% E
M9.%X2VBP>H'U_P";J4O>GF.0 563<="QK4/7)F(A\7-LRN!A@<MBYRQX&<Q)
MDQH3U16W8@T1/P8=K$AA@=E;&3CK,2P\[[ZC-;UF784PB+6QKV*5VI%K"@SE
M9D812IM.II^)9)NJK= H2A/M8 2#RUJ31!;< 2<XD"H:-2< C8C&YJ&1G7?E
M=P)G6K'6*/\ IV:GFPHN^LRAUCK67&I-$KSA_/T20R1Z<7 AK9FVS9E.F]:V
M+C1^B6Q:/6FZUZ&RA",9EM*'LN+JN:;)Z-!#7UV356YRM@D$0B3DT2$V0OL3
M>"&@PJNY4><SQR8,D@VL3G-CAZB4DXL_0#@IS@'%%#CK3"'=C/J*7HZJ<*,?
MD]P*+58ZY514J<1<Z,MC)(JHF%S-MDK9P,"<G<5+B4 >$JDDI"8XEO*+:8L@
MXDPE6:./7HPB/O5K*1UO)914,PC$!NMH9YG4<M-?(VY">JW<)O 8JOF$O9$J
M@"R#C:F"RVN3B1C&M%N/_$C&84L2FH]#CTZOZL[::12M6W1B(S:3O#^[L4!K
M.'FKH<TQB9OKA<5S5F5+D\CVF5/3*S*T]//+PH4*!J2/H^A3FI$ABP_T3AQ0
MDU>X]^+UID22VXRM5S5MG'2,C>HFID<)87Z*U-5=YR"KVAEB21./T;7FJC30
M?\SMS?OXEU2(1FG'DJ34Y*@O"]MDPBZ-?YM;].Q"&UFM8:3L3HR]JADLY4F1
M-0DLE95=07D&9I'*,!*&^1]K6V7 -@0./J"5.6F0[2@M,0>1I42JB^M-Z=NE
M&&K'IXA$:J1TU2U'3&HZ*G$Z:':/M;5 I!/FV!E1-GCL+-,^<W^*PUGL..;>
M511B82 A?K28A9M,I"4*OSEL$.ZCW(^=+*Z7>JOE$4AD&8++EK*PJW9A<Y?,
MHO6"!Z.<W-.WMZD3:RGOJ^.JRVU.>K&,Q/L@X[9&S1$E$K6D0)O<#9"K$CU7
MO]:J8_,5CM54;E<:.GT57RJ*2:\U&MUDVI8RA"8XRQ$E:W)I62IP0^9%'2G/
MS%F. $BPPDO'KT=RG.V'J352WRZUJQ%%IENCKNOIS8XF^H7MFU&*<FA46,:4
M*Y8<G/T^/I:LLPH)GB0#98]C,#Y@AT)QUTVMFG#M18 V6&L='3%[:F*T:<I-
MB<=R:)-HY=9MS1JN):VI4*(]8:8VQ&),EG(1O#JI$ 8#2% $J57LO6Q#BWA9
MT<G7\SVM<[@R2F"N=8E6RQ3)A9%$8?Y''I34S\^QB1@C+B\HU$3?RC%S&)2V
M*5:8)"A,<4(\@H>S"0"M:9:E[=L*T'7IEGEE<L;,DJ.XWZL80%#)"G+4\94,
M(B<D3*GL)Z;9;,L<!R4'GT(.R@$J  V#SDF",),52M%7]R3IZIZ$R!;SL8LF
M2"A2[^M"(0.7L*-B@U7[>Y+'XV7$SGO1 )'*I05"'<UL90C3D%E-9H5*Y.,:
M8!QJ<==^KT7C$C9YC&H]+HZKTX1^4L;3(V-?HLTG2UG?$"=S;%>BC@%G%:4H
ME0!^480B#YO#>M;PPSF P& P& P& P& P& P& P& P& P& P& P& P& P,%)
MF(,F8'9@&[/K$%V1&H_GB,N9K,_MNS-:\JQI="0C,1+21:UL _*+7]S>MZWO
M6PJ._P#&%<-,&?FZO8[\YSAS6Q][U(IK8L\9W9;*V>VI;<9DW%-XU\:_QZ<C
MFUA/B\+DA2BT(:SX0PD;?_FVC7*>NS]TQQE"(+7[ZPSK9TJE<[:KY9ITZ)9%
M,#TAS%T38"^P9S&T#B^O*V0N.B5JDHD#PM.VZ*!DC/\ ,1ZWH%B<IF?!,%A\
M]5[9*>O"W4<I8U]6Z<"(6_0^5.\:D#6UO4='$Y"R_.R _2DYMD$>'\.I\V_7
M#L #B3"CRP&A)$S#&1GENEH?&RXE'XTM1,)*FBE120<BD"L8#N;@PT%1;^*6
M.)ZH08\& M>CM"'OX_T!?$^KZAGF'*9=&LN4:DJ6;-T[B14O^<X[$Y; 80U/
M,WDCU%J]@<XDD<ELBAT)C"Y>8T,S(H?HFWF$ZV6:>D3I2DA!A:,HI. 3,RPL
MCXOHJ62YPE4@:I2X(W.4RB=JX'].)0DK8<YG%>2*JIK+_H6A<DK7MYE4$E;@
MD6>;0D^SE9RPLHM<::I&.4PZ37Q1332V*DI*ZRE;TH<:B<R)FYV-)'*7-9]%
M*W115Q30O5J343<BCJ5[5I!D 3:*7IU)OQ@3S3!FB+RE*=747$*>7/8X0Z35
M)'790Z*D$!<):ZNL"B)SX]JI&\!AD<7&&E,"98\+33 )P#$G1EF;(2 (3ZT5
MHDS:KTMH.K8C(NB;;OT)9(.G+6Y\A:1=!5DO3&0H,+D$=B% R(4C0B0.43FP
MK+7HUZIW1:2I$2SX L9AP$GQ)A;G2(Z.PYTYRRED<@A;S/IPP6#!W5!8<\M1
MRM-_CDK=G6^&)9 -L$DL12X(4*\^70VKTJ+3(F]';:W-C6:D*2" B-P7/P3'
M4C-S73,CG%85N_,+%)8)7-1G3J,K)6L7+8M7<1AY\!K-Q=A/:]0%"A31:&#*
M,/$9Z@]$Z.4[\QP!F"9F=95C/YQY\J&C[.MVYY))K*@@"NHY\J*C$HELDAK9
M&^DYC8#O*7.M8FUN"C2>7OT%GGS.)6@%O01J%8D.D^EJD1Q;F9J/!(+;#>7+
M]D;[,5XIK#7I/,H% K9J68O,AK5/+IO 2([)ZQ9;/KET5)D,Q6DM4@:%" TC
M9Z9^;#TB90-<D+*3EDUC1J]M\DT)8%.VO$:WD419FRP$)-=W[/7"RGQP&3'4
M]A.-E2Z72!>A>3RW"[F)]?7)2UNKHI2JFU2Y&#&?H@L"818RF)U6BG$-I&W(
M[ X$ID32DVC.9Y[4"F!31/'94R*(DD.1M,NK9>PKRUGPC8U+CD9HDX3T![>J
M.2J0&I3S2AF=80Z107+JR2LU@K+*7R%8LL"+.&C%]UG*&&9W="(4GK1IDKPA
M0O"5ND=F%PA&0VGIO 19@$Y1FTFE!8#M%N=G2E/,O,=D16%0R5[D\ 0.M5(.
M=P0(NVED0>[#JF,"<$\>KR5 CDM5*9@D:_15JT8R%8UX"U:L S=%JEI!@N82
MI;M.T?T#)$[)*I,K#,8M%)I!79K@]C*HM*3:]MA"QCFT*DJ6/.2=Y+CTN(BK
M<H%OP(5 $A+,3'%?A[&2)F&76T91T38CUCNC3,4<:)_#[=6N#U*%R%I0RR P
MF*US&W9>M<'(I(2W(HI#V],8G-%I(>(O8S ",,&(0N90M5L!Y:HRUS#HO)I)
MM\C//+(%K?I=8;_(:VK7G=]G B8+$F)X?7@R*,3"XR*-J-,VMB-6G(VP9?Q
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M!.D1I$Q(0$ITJ9.6$!8 :T$  ZUK6M:PR[> P& P& P& P& P& P& P& P&
MP& P& P& P& P& P& P& P& P&!&UQUFT7+5=@58^'FHV^=Q5XCNW-.#0UK(
ML7)# -<A;?,('D=HZZ:)7)!ZV'9:E. 6MZWK6\+$U-O/)GYKO9$LKZZ[7JZJ
M[XM9]!>2R\*K'*414,2S"RVBJX= 9%!W28Q<;.X-T&K6HRHTJ"K2$J@M\@<3
MDH31#.2JS5QM&D(V<N#[H:8:7%&I)$GQ_P!4?Q4T/TW;W:.H5$PD'+EL/TMF
ME3.!\VALJ,61V7Q-U;TC&N=FQS0'?,A!3JF++T$6%Y1>NVJRKSRY)77AJW:#
MC*9]89A:Y-DN@6J<3&-&G,#[8<Q72)S*3/E81F/12,(C#UAJP@AD;RD[>>HW
MHK8AZV;LS?U6_-B\*QQXE38X0 L#,I#475+4*RYA)I7/[)9+MNMGI&*PJT2)
M#,')\DKH]12-5R>E3JQ.)9[8C2I4J3R$[UHL1EW0";R%<#D[P6;(:.J6!,M4
M1^BX[(>>F:7MI\/Z),JQTE"M2X.C@DCB5C2(("-])<83\\I1*5CB2(#D!N+T
M6:$O*-FV.7(TYE]\N\^EL#>4L!FKC3LZ9HS%)W5$>_%2KJR"#8%%5.[B&O7.
M>AC+H]$JCM?1*0I&Y<5)W(I02G#ZIJX<M*ZL!&^9.AX\VUF=&J_9V:05A/\
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M1G(LUTA1U?5Q&T50'1BV2F;GVGXZY&'+)5!7V:)-+GYC5M*CX5Z:/ *+>RM
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M6B$1Q8"F6%1&%,AC$3Z^P)S](O5,'HS0S!^77A6)3?A# 8# 8# 8# 8# 8#
M8# 8# 8# 8# @?INZF_GNC+"M=:8@TLC[4G01A,Z'>@W.<YE#DBBL#:5YVA
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M6R95$Z(#-OV\*C@$O:K(D5K.W4C'9?+BB7UZH9ZI70J35_8/3L)K*0O?,"E
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M 8# 8# 8# 8# 8&LR.&QB7'QA3)69(\&PV3))E&=K-&# TR= W.C4A>220F
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M*(9;T<N(N-S!GG:)6ZHTC6)D.5>F6,OTTA>R1]6_66>A?0W/-+L[G(A4%9M
M,CI0RV>0LV1Q"-M@+%J3G6"K7M)$X>RL4V?U44?(C E)RY!%7U/'7/:4]2=I
M+ZA3CL@5,^KDD:#C_EB8QZ3HH5.(J^$50EG+:GA$EL J,&PBN'6L:29$3O#"
M)VBASRX,*:VF=$A*6MZCTFX@7E&'20D.#66AVM:?(EE/EI2"V*CN-D.C%<]-
MM#A-6MX=(*1>-?<G25\C%V0E,?4MLMCU,V6/NYJS3>U3!,A2K"5QYB0&P'*=
MX6(RC;P^;-N)]&QN2P^5"Y.Z':;'O@;[$&VKV68Q9N!*HY :51M"I\DL-:>C
MTU)*69'6)!3,D^+-,=A#2E@ GULLDW":SUALTO3\6RGG]PZ6?:E-D$3IBA+E
MHU6SBCKHSV=$ZR$G(A=P4,M8'-T85Z%V"JA@&L]&M4E^B>1ZA"D!9VU!@^JZ
M?FLYMS2QR:$1M57%KPF8Q*ZY)5#>&Y)$\3IRK*V)S43#)$# Z3!TM"RF\ANM
M>LUR0#&)$XKFE2L,TC\4[DH"0:*GX)'J(FC&^A9:[4'2#_)ZRD+DX18F)1U/
M'A'VHP1=*V4Z2ZQ4=@S=G9G&N0Q2,%)&D:IP1)%+$A 8B*&G-3[/$W>NZ(>8
M)!S.Z22HIS6]/754+O?\2?)C7*.72]S#'95$X+7-81T<L=8/&[EG$*2+386O
M9&].<Y("W<T: 0C A$6$X9<KUNG=.L+FRQ9_%6..\Y3NU)8ZVW->B?BVIJA*
M,J)V;0$_)Y4<K:=SYM9<3UIQ;%L= F0!;0+CSFM-Z^TP1_@[)4Q'Z\V?LV!<
M[P^W:UC#%2ME2RW5['9$Y:&^FIVYP%6U04^VV2<61(Y<O76[5K!(&!5;=BIU
MPVLTYS5'JUIGH(]DZ-\!%UX-:@EE\>Q#H<VKHTR6'&Y[>4RZ:C:K3F]S]35+
MK.H3)XM(+<1_,KA-7."Q=_GK]/A+FLU.V(S70PI>$L19N_2/$Q-6X=37EN>M
M-616 <]S6WWAGKIZBD.KR+-S VN<!J&J;>9& @Z0.TXL&&P^/QQ1:5%-VV4M
M2ZC<G8UDV).2:6G6^D76-;;A>IG)5:$J;.NJG=)G[KT=2U!9R=7'D#U(%C1'
MM.RZ,N%HIVU]6,S7'J9T^*3G&0)#S_FC6BC *3-%)!!)'*=(Z.@R6/SMS5<4
M_AK1 [>3KSUU!0^U;PDLI>+(C+,LL5?(62C8Q(Y99-IR2RTS&6]O2E,4)(VF
M,;4I>-#4&D:/-,T*F8MHT'?^2GRQZ\M -"6C$&6V)K*;%HRQY=M>GI*Q+.,C
M;])SY_$:J3V0[M<'L2P(F@<WEG>WR(Q]S?B]G*$Z@Q4I#HXOU53:JK[$HR+T
M\W!@U,6_"F-IC'/\H@%5G,L)#)I5#.K+ W"J@?HF839;K%2T,CFRX\E44Z/+
M>L;=EF"5$D@V5L9)QF]6^ KGF^LZLE-U617$M@K>2GB,MEY=ORZ26?83$74L
M]#.:X842PNP;5.TG:I\D3N3)'V!Q/2J'%04 M*)2;LG!<S-.DXS:JH]\]=*6
M7SA:%:RU$_5_]$S9.CACS/K)FLK:GFI( RPJ)0&S)F+4U4()NH8RTSJ4V'(R
MGDS9NRB?BS21KM"-9UT3R_5+U.;NMZD;'K6VJ\EE2JY@T/,?97R:)D=V!#14
M/MA *"SJ50&30_YA1K&QV<&]P5JV]"QGE*2-&IDY8A$3.D;,E."^,^;[BI-B
M+B<S99T]U@_JH1^+:4V"3%&VL^98=)YVRH9NS,\[;(RYM#>R+G5+'"'%$X!5
M;T<F+T$@D7ICZIAKR/I+DZ+4]'Y>\4=9$,;>;8+6#_6E6ND39GV<)J[OR*2"
M%05Q@#-%9O+6"4()!$&E]1JD@W$U<A3-2[XL@G96MC+4WNSL;CG"\3O.*<YL
M<(6*)-;O-DK<J\4.+M-)=5X*1DBL2*0U=5[C()6],=;D2EF;#5X&"/IFM*M9
M6@9I>A%-^@DD^JK\4)DR+AI_C=8)HS4/0=@JEH:V;ZSC**Q[ %*M-_2T!>Y"
MW1DA[G%\L2%)%5</H?8GAI6.H&HLQ GT$DXT>MX6LKZ+"M[%0-A6]$(3'^>+
M1C\HI*"PB)/CE!I6W53'*(8):@2V'%:LF#=7US1?Z4I"BV1&H&D9$$F9TIAI
M0-G:T([02:U;;.A!<LT8RU\?9$0<4::6VW-&V.N$*,?DC]%Y+?XY..W[%7/C
M"_LK_%H<85*7!=(G4E0$EMT>6>$(#2TVP".4[=G92/M45$^36@:CI.R;@>%:
M<J;W8DC3DS2L](*>HM,J%=:MBWK9C"IELJDL<8=%D-VW-V=P,J(CSD$HMH_4
M&LZRK=+6JD?I.XTG+^8>D)Y)J4H4E Y39%*XC$R9IS@D>)LW15@E;A7][QV1
M6E$EYT+<DZ-B>6E:I4'#&:H0%"7GF&%UJ[C=>MMIZ@9S&AOS)#(LY1:R&2H'
MDE8REJ&YL=V.KSD4II9<T%MQR(MK30X_2=6T[2!3[3["7O7^*'6C-RWB;597
MECN=?/4YB;3)76J9J18U=KG(HP9\3FR9C?(V1(6P19A>M+2F61K2-:,T,O\
M;O/Y?. L01$S&S6BN?*7(<YJ\D5W'R72QK-A%R3=:46I+/DEG5N") @\P<!
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MRRN=MT@>9--&5HKAQ4@5N%<11AFCU(&6%5VX'E%;/86=.A:3@IR C3["03H
MN7]C_+U)QI@611NC+TJBJM7"UA48D5AV3+HXSF5U)D,PA!,68I9+WIJAZ".2
M-L3*4Z5J*1IM?#% $6(HL -#E*6&^%Q9JEDFG+<S)4LMF+;&F>3/A>SOBWAL
MAPGP491JM"-$3HIG%)%VRO( ._\ .1>;>_D\"(D:N5J$99TGL1M@!1$A0RU[
ML!K1#D4M4PICG\E*7%2&>QZM%3^?7$=G#U\Z*QJGA"U)W$XU:I,$=LQ0<(9;
MFJ;NHIRL51,@3J(<UFD2JRHS<$A+%M7Y72RX:KAR^,2]1X*=;TYLZNOV8PK0
M?*5XMY?F +7F\PN6KSOFJE+*7N;O+87M2]N\CB4N6R!FDDMB4B^DL$9'F-Q-
MY1R"(OS&]-JUF8)$N1@$F/*T-.J, 9H>A;P7+MBYWIPUM=FI7#"W,A^15DA>
MU;P]R1Z>W8NFG4+[5ZEQD3L\K) L=88]!"K2+3%(EFE =&#-&+6MZ%RD*10R
M+RQ9$G"1LR5V6063@F<14*=G:&QR@MB?8R!Y2>D:6':H+%)EZ;\/0P>FI%^#
MX^&]$1FY<T40[I9>B=*SCJ])/8[:L3F"92%::2_QV[Y 5*[6:EH!+/+\/-9$
M0!6JV#RC":'6RMEZ^3"W+H2/E>@Y2A"WNE>I$Y11%7IDBF/ODHB3HV%4M\]?
MBLTSO44?&5X91PH,C7!1B2'DCT!4, ]C#OPP<I3'%HTU0Z/-,78].6FAD2 0
MH-/#Z^29STG+V(0?C7^2N+N_.I_B+?B:J4G&[_NBWX:PC/X# 8# 8# 8# 8#
M 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8%-[PY;>N@;.->I39TBAE;M
M-,RJK6&.09#7[FYOA]NJ3$EQ+I8"RZUG;4E3*XDP,K8TC;]%*RBSW/U#- 4!
M!AJ)J/&T4MG-M\[>N9#W<NMB)S2"2!Q^7]2LD]ER>S[&KB&.2PJ05U):\(@3
M6SRMNM!A2IQ+2G9]4MK.[.2MR0I@K$J49@N-6W]$\R6;8]F/MP5E)8/'YY':
MI@"*F5\K _&IF6WZ\LJ4S).IDY;,EVHW7\NB\E51YVTE,,6#;G)7H!7F],6"
M)B(J=D7-7!4[;'XAD;K;-B]>&3FD;%?)'%P-:BS)%)J-KH*9H5N:":0N6P90
M?*+N/^EKD:H(5;$<A*T (3#A#)+RBO%F$G#+^0CKN(O4G8+!A]1=GF=)P%XF
MR9 1+T\)D[6_RF:0IP10Z&QF)@6)KHE2U>VIDJ4AJVUEH@F%@/1@V(<NO6DU
M]A4(\WZP4\@:XG7\^1UU="2QI%!;)E<AA4>E;"&KK4@)C<"1QF'SEP0N*1SG
MR5<#0F\PHTM(8 0@[$'"8S2L%?<1657E@47+'B.5#;26M:<C]9$:<K(L.OSZ
MN,9+FE5ALZ2 I$,!F&IW&8+#W] Q->GA2W*UA;$28IV 2DW8"SEIXIDZRXR'
MTS.6N7'.3$W'Q"BK.B-?KG ;H:KCEQOD]J.>5[+EC2G(&T2"'M+A6FP.[>LV
M:6N3G?#[(,+-,V$F.51\6@JN,Y;,)UU*KGD-K!.DZD97QL<;:C5F3@^=5XDE
MO,5>TP^,336;C7B2)25*W2V)+%*18>])3#F]46,PH!H!$;'*HBNCHV/2W3?2
MC[%JFOR/P>!1&-T;=:<FV:J?7">,\VMVRJJDW/IRMPCDAC\)=ZR;&6%V0[/:
M5IV8^%N*A2%/\YE;;1"7EB<8UAWK"YCZ-OE(N76/NG(&_,-'D4U%D42E<PF+
M1)')YM:H;%F\V>5[G!8JMB[7M-3B%,T-12=T/"-8>)2K\ %^(B8AK3U[?4I1
M(KS<($YP!!+^B87WI7UF*GE=*S&YP:>D;#L&R*1?4(]-[B-G>X&KD29M?BD:
M<@A<C5GF>*LUO0>8<MKZ4W=GYSNB'&\_R6NJGH>'NE-RJS%;I 17M9;M&G]!
M/JN0PTJ2I9PNHU2])'=*\)-;.;!-&R!)"]# KT:+9>B7&MVW"2<H3-YX\Z*I
M,Z1Q)ZMKHDBXI-*7@\AXC]=!G5LGK%(V5 227(I"V0EB0B2M1:@0%:\XA-M4
M87LXT16ARCE$](1\FXBDKAS=V)39S765>INC0O;C7M91602N40"JI<IA32UI
M)B*=N47C$M62)VGC,G?SSD;4D"UJ4Y(D81G@&H-+RBXG71Z1,K.UQUG:8^QM
MR)H9&)L0,[.TMJ8I&W-;6V)2D3>W-Z,@("$B)$D( 446 .@%EAT'6M:UAAY\
MQ_AG2^.\11:T]Q*7,O,5-S"!2]"D7R9(6]RM]BU=Q]K>(P<E):U)K8DW%5VS
M-*QIQ^107O18A>/D-\MZZRC")\&S"N9K4#VWPBGK)C5:MM^LC8R/MH6+ 5$0
M)L[JU9>T->&%0V5W,A2=2PQ(XE$L2KAI0;<"/ !QI(]FX.7Z^"TW7E-SNZ8X
MRL%?1" ;EJ MZ50F['ZP)3!I[S[-E2=.D:+!K\N)PI[<Y(-(6(PU:U;=V=(\
M 3@;UOK(E1^RB8S2&0<+R![GT]?I5+F=(SR93T0]1EWC9CEJ90R:6/:]!6E4
MTZ:M*6Y&VEO]>/E.#7&!]79.UGH%AT<0,[01RT:W4O*/1%00UD/=D]+V_*9M
M4SI6'0D%!+IM6,0=50;CN&VHW**RFJ6$RB0-Z1.==[XA7M:UN*$:4-,82M+&
MD$!66<HF>M.:+<$V+)X5#H7=5XR=O:HGR\Y<\B1UPXQF7G/8;0<%BNZUCR_7
M;5DR=#BU;.SQQH9UR?25QTG;%)QVP;5!()$Y:Z=VV5CPV<X2N3SOIM:PVA,7
MNLJ5A)#NUOTO,1"E%8PN70Y[L57%G$#?$OI8\&2'3FW+C42M<TK#3/0.!LDH
MP1)R[.2.\]=&N\<YWJ&QU%2):^YJ<&)X(L"*/\G6RVX%]:PMYB%4Z5P5PAK8
MU5>6)6O2.\A])Z?=#/0[1(]:(4B/)%QK,=4%M/MORR T>=4,(*K![9Y%">)7
M*?QB02B:LC5(+AY>L&"NT_,;9:FB\DD3/!+3@L7^'3 "GW\UNR4*@M&'YP6C
M :YW-SX_-=R2T*Z3OEXRERVZ,TU(B ,KM%DD9?WJT8E#I;!9\W6) U9KI(F2
M#O<M8]26/(5#BF-3(3#2##DQ9NOP#\,7K;7[#K_H:Z8 A)DL:J2N+/JZR*QM
M6KU+18LKL*$2R40%Z^<W=JEP5=809[B\9D[2)0V%GIRW1:BVN^+](P:0!*DL
M3$3X(TE_,=R7?.E5I6FFJN)N(I!S6QME<,<AD$\8D]6T]<AMM6&.02MSA,2%
M()381ZS:)(@"T$-Z%*A+"8H-$K/$46)B-&@-O"%MEHH_N06#"Y$^PMQL2!Q!
MZ6?/^E*3GEMYTN2C:"BS@(QK/$IF+8XVD-XDZC7@G5JE"D90C1 )"(<H;E$N
M! Q4="((U,UU:H*JA"-?,I-#5C=.9W8URMU?HZFCZQY<[UAEFI5E=0N /$F(
M:D1@ C2J'SS)RDH2S-'CENUF%<$6!'F_YD<[+;%PJUJ6.5OSS/CPB<)M%72H
M+HG=BT'*)0C)C;&PF"C,.?VV//:1!HI.[H4ZU/H!25<(H(G*$6(/;PN%'!*H
M;9$72UA.D)3<@GRJ%GS.P(;$I$XT-5=SPB;I6N6HH&_R!N;E4ALY*L9C#&\9
MIZ9$,"H) AZ\2\XO2^JU;Y0=EO=GT#*XW *LIU35Y,$22&T(A:LTD$S75PQI
M% I3SXJC9U:15%8L%=E0_AT*Q^<MEMVCANB9"0Y%%ZV9N*;!=_*+WT+9,F=Y
MA:LJA5<FT<_TE'HU7R>OU[BY-EJJAG72XR?=E5C.4;:I>VYACZ!L,:Q$J4Y*
M-4,9N_B @+$37JU6J*EZHH]Q<) FW55TO-F1JLBK:,DD]E%?+2+/K:&--7*;
M%87E+64VT^,M@0F+M*M<TJ$J$YJ=B%&R%*PI5X$"9B4Q2B$3.)W%:_0;$W(Y
M=I;S?#:\B\$0#4AD+U-81,;7EI:4T9Q!;8F:'K<Y1)BSMG^8H8#AFA 6$(A"
M]*\6V<]P"55-5<"JA_VPK&^M*[KF%,[^U.CBK7/ZF/1!M:Y&M<FI:RH"&).%
M[2F:0E$JEOJ)/*(>R1:]/1)FYM.&$,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,
M!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,
M!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,
M!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,
M!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,
M!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,
M!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,
M!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,
M!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,
M!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,
M!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,
M!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,
M!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,
M!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,
M!@,!@,!@,!@,!@,!@,!@,!@,!@,"&[SZ%I'F:%D6+?UG1*IH,I?6^,$2B:.8
M&EH-D#J0M4MS0!48$0=K5B=N/&6#]D02A?WL+$3.D;JC?I>_;&^V[S__ "U3
M?N6%X9]I6J_.9H'5#_G0?C:A?YO?T;U,/QN_.Q?T)^C&U?P&GSYV\OI_-^UG
M[7Y_#_'^3"5-UU55_2]^V-]MWG_^6J;]RPO#/M*UM.]*T)T%7;I;5*6O#+,K
M5D<7II=IK$W4MR8&]RCJ),XOB)2M $(2U#6A6%&G!\/P0&:W_=PDQ,34[JH!
M]W[VQ!A",';_ #\((PZ$$6ILF\!!%KQUO7[5^QO6\+PS[2LAS_U_S%U7]*M<
MY7?7]R?0?;/J7?05[*>/H]N0:<MLGSGZ80_#_.>F=5Z7C_C>@/\ O82<9C>$
M'RKW4_;G@\HDD*EW8U&QZ60]^=XO)V!SF"=.Y,<A85Y[6\M#@1LO>R5K:XI3
M"30?^B,&]87AGVE(E'=\\9=+30VNJ#Z2JNUYR0QKY,=%H9(R75X+8&Q2@1N#
ML)*6 (M(DBIT3EC'^QH1P=?W<$XY1K,,1;_N,<,4#8#U55S]1U!6UC1TEK/?
M(;*I00W/K62]MB5Y:3%B,8!"*"X-2XD\KQW^$68'?]W!&.4Q<1-,37'N:< V
M_.XQ6-8]:4O-[ FCE\SQ2)1^5D+7I_=-)5*WX%M2!+T(]1\(D-,\NM_XH-[P
M3AE$7,320+[[?Y'Y;D+'$^A^@JSI^229F-D3 RS=_*:%[LQDKC&TUT1$F %L
MU&6O)$5L7^6'>L)&.4[0A1![MWMI.B] UM_:M"*W!T7(VQO1D3-,,]8O<%)2
M-$D(!Z7X9RE4< L&O[HA:UA>&?:5EK]ZFYVY89H_(>B;A@]/,<K=CV&-N<X=
MRVA(\O"5":Y*&Y :8$6CE1* D9H@Z_8 '>\)$3.RKV_=]]L4.MB%V]S]H(=;
MWO>YLF\-:UKQWO?[5^QK6%X9]I6PG'2=#5I3*'H>?6M#8G1[FTQ1];[/>74M
M)$5;/.1-P(@XDN8@[ -+(A.Z7247A^V>N#^_A(B9FHW50_2]^V-]MWG_ /EJ
MF_<L+PS[2M?#^DZ&G]*+.CH7:T-DM%(&64R-;:;4ZEJ8>F8H0:YDRUT-=-!T
M6%''S694%2+P_:]D#_O82IB:G=4_7N^>V*+6MZ[>Y_WK>M;UOZ:IOEUOY=;_
M /587AGVE::@^H.>^I6!]E/.]NPFX([&7H,<D#Q!W8MW0M+X- E= -:TXL(=
M%+!-RTH[0?\ (,UO^[A)B8W5B5^[C[9Z!8L;UG:]!IEK>K5(%J8V:)@FIEB)
M08E5IC0^E^":G4%" +7]P0=X7AGVE.%!]M\E]2OL@C/._0%:W"_Q5I2OLC:8
M._E.ZUF9UJP3>D<5Q18 [)2J%H=E!%_='KPPDXY1O".;$]SCV_JEG,HK.RNM
MJ6A<^A+J8QRR)OTL(1/3 [E$DJ#&]R2"+V).I 2H +8=_P!P6L+&&4ZQ$TSE
M.^XGPYT%/VJJZ4Z@J*S+%?$KJN:(=$Y.0Y/C@D8T!SH[J$J,  B,*;V].,XW
M?C^" .]X)QRC68FF1N_OWB[FR;!K>^>E*JJF=B9&^2!BLRDA+4\;8G8Y<F;7
M7248!"^#6GMIX"Q_^ELH7][!&.4ZQ#0X?[IOMVV!+8Q X5V%1\EF,T?VF+12
M.-,O3J71^D3ZM);6=G;4^B];/7.*]0 HH&OE$,6M8.&4:S$IHZ ["Y?Y5,BI
M71EXU[3ALX"\#B()T]E,XI "/[;=/0FS1@1?$:;-NZ7U?#_%]<']_"1C,[0K
MGOW??;%#K8A=O<_ZUK6][WN:IO#6M?L[_P#587AGVE:^Z.DZ&YU@+9:=Y6M#
M:OKMZ=FEB:IA+G4ML8U[P^H5KFSMR98,(@F*G%O;CSB@^'X0"A;_ +F$B)F:
MC=5']+W[8WVW>?\ ^6J;]RPO#/M*U9_3%!)J'#T^?;,+*Y\%&D\Q#;HW8L,)
MW%U:HI$F?-.WE]/YO.5G +"/P^40M:PE3==55/TO?MC?;=Y__EJF_<L+PS[2
MM;4?2M"7W6SI<--6O#+(J]E6/J!VG,6=2W&/(%L92E+I F4K@!"$LUI2'@,.
MUX?@!%K>$F)B:G=5 'N_>V(8 (P=O\_" ,(1@%J;)MZ$$6M;"+6_2^76];PO
M#/M*R?/W77,O59<J-YRNV 7(7!S&<F7#@KT4\!CQL@ XF,H'/980_#B<P-*G
M97C_ (VB1?WL).,X[Q2"9/[JWMRPR2R*'2KLBBV&41)]=XS)6-QF"<AP99 P
MN"AJ>6E>1LO>R5K:XI#"30;_ ,48-ZPO#*=:E)-&=[<:=,3)37E!=(59;,W1
ML*V3JHQ#)&2ZNY$?;E;>@7.YB4L 1!1)5CJF+&/]C0S@Z_NX)QRC688*V_<<
MX5H6P'VJKDZFI^N+&C(6P;_#93*"&Y]:0O+6C>FL2U&,L0B=+FE>2H+\=_A%
MFAW_ '<$893%Q$TZ%:^YAP)<<\C-85;UE3$ZL&9KS&N*Q&/2LA<]OSB4B5.)
MB-N2!+T(\\"%$<;O6M_XA>]_W,$X91K,33>KZ[CY$Y<DC+#^ANA*RJ"42)CW
M)6-CF\@*:'!T8 KU+7MV1D& %LU%IQ2&D^?_ "P;U_<P1CE.L0AEM]VOVU'A
MR;6=L[4H1<Z.[BA:6Q"GF:8:A<Y.:HE"WHDX/2_#/5K#P%@#_=$+6L'#/M*R
M-_=5<Y\KM4<?.BKC@U.M$O<U;+&7"<O!;.F>W5 C^<%B!O,,"+1ZE,BUZHPZ
M_8!\N$C&9V5@%[OOMB@"(0NWN?M!#K8A;W-DWAH.M>.][_:OV-:UA>&?:5KY
M]TK0E64ZW=!6):\-A]*.S?%'5LLQ\=2T<36MLY^!^B"Q.Y"#L R)#\YI_A=^
M'[9ZP?[^$B)F:C=5+]+W[8WVW>?_ .6J;]RPO#/M*UL7Z5H2;4@KZ3B=KPU_
MH9 Q2>3++6;74L^&IV"&'N::5.QKKH.BPHF%0S*@*1^'[6(@?]["5-UU51U[
MOGMC;UK>NWN?]ZW\NM_35-^QO_\ M87AGVE:BA.G>?NI(\]RSGBW(5<$;C;W
M]&WYZA#L6[H&I^^;T;K\U+#BPAT4L^;G D[R_P"08'?]W"3$QO"KJCW=/;,2
MJ%"11VS0)*E(H/2J21S1-H9*E,:,A02/7I?(,HXL0=Z_N;UA>&?:4[4%VQR;
MU,]2&.\[7]6UPOD3:T3U)6N#OQ3NL96EQ5FH4*]>46 .R4RI82,L O[H@[UA
M)QRC>$9V![GGM]55-Y36UC=<TI#9Y"7A1'Y;%'V6IT;S'WI)H E+8YI1%[$G
M5D!-#L0=_L>.L+PRG6(EL-.>XCP]T)/FRK*2Z?J.S;$>4;JXM</B<F(<GQ>A
M9$8W!W5)T8 !$84WH2Q&F[\?P0:WO!..41<Q-.U=GN!\5<X3DRL[VZ7JBK)\
M4T-K^9$YA)"6MZ RO E06MR$D& 0M)5PD1NBQ?\ I>GO^]@C'*8N(FFEPOW2
M?;PL:81:OX-V!2$HFDV?VJ+1.--$N3J75_D3XL*;VAG;4VB];/7."T\!10-?
MXPQ:U@X91K,2F'H#L?EOE93%T?1EZ5Y3BJ;$.RF)D3E\*9S'].PF-Y3R:VA,
M"+X@#<8[)M&[U_B[.#_?PD8S.T*[_I?/;&^V]S__ "U3?N6%X9]I6ONWI2A>
M;H.UV5>]K0VJH$]O+='FF5S%U+:V9P>W= N=&QL3*AA$$Q6M;FQ0<6'_ -(!
M(M_W,)$3.D*H_I>_;&^V[S__ "U3?N6%X9]I6L7=+4&VT2#IU?;$,2<^FQIN
MF)=N'.I884.+.RE,C;7T+MY?3VW+52PHLL?AX"$9K7]W"5-UU53_ $O?MC?;
M=Y__ ):IOW+"\,^TK751TI0MZ5BXW/4%K0VPZJ:#I G<YY&'4#A'$1\5)^(D
M92A< (0@&S$?A'Z\/P-828F)J=U3@>[][8A@ & [?Y^$ P(1@%J;)MZ$$6M"
M"+6_2_8WK>%X9]I67Y_ZVYIZK32I9SE=4"N1-"%+2DEQ\%>BW@N/J7XE<H9R
M',180_#F.)+8H$5K?^-HH7]["3C,;H$DGNL^W%#Y%((C)^RJ*8Y-%7QVC4C9
M'"8IR%[,_L+@H:GEI7$[+WLE:W.*0PDT&_E",&]87AGVE)]%=X<<].2]= >?
M^C*NMN:-C JE*^-0N1$NSJDCJ)<WMJMX.3%@"(*%.O=DQ0A_W!G!U_=P3CE&
MLPUVV?<>X3HBP'ZJKBZGIZNK&B_S=](8;*)00W/K/\[M:-[;/CD8RQ")^-:7
M A07X[_"*-#O^[@C#*8N(FG5K#W*^"+IGL:JVJ>KZ:GMAS%6H01>'QR5$+WQ
M\6)&]8ZJ4S>D"7H1YI+<WG'"UK?R *%O^Y@G#*(N8FFZWUW+R'R[)F>&=#="
MUE4$JD+%J3LC#-Y 4T.+G']N"MJT[I"# "V:BVXH#B?/_P#U"Q:_N82,<IVA
M#K3[LWML/KLTL3/VC0SB\/KHW,C.W)9DF,5.+L[K2&YL;TI>BO$Q2M7*2RBP
M_P#I#'K6%X9]I6,O_JWG'E9MC3QT7<L%IUKF+BM:(NNG+P6SIWQS;4@%R]$W
MC,"+1ZA*C'HP8=?L!WXX2(F=E8A>[][8@ B&/M_GX(0!V(0MS9-X!"'7CO>_
MVK]C6M87AGVE:^Q.E:$J2H6Z_++M>&PJF79)%ES;9#^ZEHHJM1S;2/<24)W$
M0=@&5(-+R?AM^'[9Z@?[^$J9FHW52_2]^V-]MWG_ /EJF_<L+PS[2M;'NE:$
MEE&J>EXU:\->J"21^1RM3;"!U+.AA$<B*AR229Y,==!T6%"R*6=4!0/P_ $0
M/7]S"5-UU51U[OGMC;^77;W/_AO_ /W5-^Y87AGVE:JANFJ Z@C+S,^>[:A=
MNQ6.OAD:?'Z$NQ;LW-;\4WH78QJ6'EA#HI8!M<B#M@W_ /RS0[_NX28F-)59
M-]W?VRB#3B#NVZ!+.(--(.+%-4VA%G$F"*-+%KTOD$68#>MZ_OZPO#/M*>J!
M[4Y0ZG=I&Q<ZWY6]Q/$0;D#O)VZ#OQ3NJ9&QT4J$;<M<"RP!V0G6*DIA8!;_
M &1 WK^YA)QRC>$7SWW0/;XJZ;2FN+#Z[I.(3N$/2R.2V*O<M3I'B/OK>+0%
MK4YI1%[$G6)1[UH8-_L;PO#*=8B:;+37N'<0=#3UOJVD.GJDLZPW5 Z.;=#X
ME)B'-\6-[(EVM=E9",  B&2WI->H;O\ ]$/RX)QRC68FG+=/N#\3<YSM16-Y
M],U-5M@)&IL?%,1E\E):WHEH>0GB:G Q(, A!3+PIC-EB_\ 2\F\$8Y3K$33
M4(/[HWMYV5,HK7D"Z^I&5S></[9%HC&&:7)U3M()$\JBT34SMB8)>MJ%R]6:
M$LL&O\86]:P<,HUJ4N7_ -F<K\K+HPV=%WO75.+YHD=%T423E]*9SWY&R'(2
M'90V@,"+9Y3><YIPF[U_B[-#_?PD8S.T*]Z]WKVQ][T'7;O/^]B%H.M?35-\
MHA;UK6O_ %7[.][PO#/M*UEX]+T'S3#6BPK\MB&5/"7YZ11QFDTS=2VII<GU
MQ;E[LA:TJDP(@F+%3:UJ#@!_NEDBW_<PD1,[*I_I>_;&^V[S_P#RU3?N6%X9
M]I6L<^EZ#9:)*Z==;8AB#GTZ.-$N*MQ2ZE@A1D9?U:) S/87;R^GMO<ECB06
M4/P\!#-#K^[A*FZZJI_I>_;&^V[S_P#RU3?N6%X9]I6=@?57.5GTQ)>B:^N2
M"RZCH<AE[G*+09'@M7$6)O@"$]SFBMQ<PAT @F-($IAJO>]?M8 ;WA)B8FIW
M3Z,LLS7E,  P/CX^48="UXZ_8WX"UO7C\N$<7PB7_P ,G_[DO_LX'+Z9?D]/
MTP>GX>'I^4/D\/[WE\/+X8'%\(E_\,G_ .Y+_P"S@<H"RRP[  L  ;\=[" (
M0AWX_)OQ#K6M?+K XOA$O_AD_P#W)?\ V<#D+***\?2*++\WAYO3 $'CX>/A
MX^76O'P\<#\;2IA;V(2<C>][WO>]DE[WO>_EWO>]A\=[WO _0"""]^8LDHL7
MAX>8!8 [\-_LZ\0ZUOP^3 _@TZ<P6Q#()&+?AXB&4 0M^&O#7CO8=[WX:U@
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M)@24Y6B]F&FA-'LSE73LN'ADP&!'EL6S6U%5O,K?N":,%=UE7S(JD<RFDG7
M;V1A9TGE"8I5J!:$,9AQQ@"2""@F'J5!@"20#-&  BQ$S-1N\$S/[3/Q0[GJ
ME59<Y^X+<\.+5*$K;8U:<LN3G"I#I,:(H:IC6NTI9G,Y*+8?'7KI$YNO'P$
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MYK2UY)U9 TD&N+4Q/K!P1-4V?'6:M5?/[C&)E)V2)L46<I<?"F%\:5!)SX)
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MB3KD29UPP4L@DS$XL$ E\EIQSB[-6B.7H"&V-*VB-.ZPIL+<"2R$0B2=&A"
MOPUJL1/U7XO!]5S;[GUE>S7-O:XE7"$=KR2QKBF,T_!K;_.UJ"6M=AV+!':
M(D+(*'MS>@/B*22-*)>LTM5N9J=)M)HD>QB. +1N\8SYQ-ZK&QKVF&^W?<>E
MUV=B\STY<G/)7 /,=.P,5DIX189;3>E<NBW4V VQ1?M>XM)J1H4:*"Z:) 2I
M+%L #!:WO61.=8UC.MH$LO@.\67W+>U>E9-[3E&=]5S<\QYP?J!G%A7G1L%>
MJB#4]71^-21<Q,4]CLH>F\]=)$1)@=$A1"\6<H6O/H1>PU>4<(BZF'O[UNFF
M#CSS8+9#.;(=UP\O*)I:%W.<]EL3A<5LF.NCXV(Y8T.,CG#.^1$@Q!'CE*M.
M6O3"3JE"8!6Q%^?1@#GCOO3YN:J]E'H6SN9/<SIQ?!(S[?E6=0R.BYOR#R>E
MM\WH**T!:-).)4P<I^]/;$)1'8\T6I+&](2M:F,2H"5%X[],6TB0L4=9_)$3
M$[S"_DY>_=9Z=Y)Z'Y-O?@."U_-; Y&O6MS[YB'6-9R:NIQ;#I6+S'H87$Z_
M-9VV;,+384D5 ]03N8E*9"C-[-,.T'*S]&.491/50JV/;,Z5W<'M]6!-_;GI
MWOBNZ']J:J^3[-INR[GIR)L<9OR//"9<Y/#<=/FV4-C[]&4"8],0M2)!%'!<
M![*/UY1:$:C.*F+J9E=B9>W9.NENNZBEEM\Y16IN49)[0$_XMM6K&2?0N2@J
M*:32?QIV::MB@64A"!Y106.-FA-CXW(2D"=0A($5Z8P@UHS&58S$3]7*WG?4
M/LI=_3_E_P!PZJ^D)M#6#H:<]&<OW'S!>:J0M\HCMF/W(,=21.OYI8S2P&.3
MY'RINP1=$!S I(^-)5+1J/0-V6(H<;]S&,HF-JU^+TINQ=[HW9G&75_*MP>W
M]#J3G-B<DVO#&>TH[UI6$Y@DXN=R8DC+'&.(Q8IM;I5&XW*U"Q4J^,?#TVFD
ML@!1HCQ#]358CACE$Q-Z]FL^WESG</,=/61&4GLT\]T+9Z#E9DB;G-([?U%N
MX>Q[,AK*D:0P2QA1*#?%QAJL!Q4KW%0YO G-(F&J,": X0]B$,IB9OEI?HP'
MMA\'WW2?>=Y].)N38I[;O,-@T:WP==R+"[Y8KE9[(O(4U32!1=8(]!"@UK6R
M9ECY!S802WZ)/-"HV+1)8#C]:+GE$XQ%WEW2?T]4O<U:>[(P=S<W<FL_4=="
MX-#S,Z,ZCH>NJ-<FR8J[P<['4K=&3-"]*5R)&THTH/P$F@&#5_(;K90@[G5(
MG'AQF:FTMU?SMT@[^[.D[CG]7-E>5M+?; @M(R1K+L.,3!SAM^#NPNQI+6^M
MM(DJJ1-T<:CS"POQ"4IN6C+\2_+L6@ZJ3,<./6U!XC0ONYT')?=#K+GKE&FU
M[=W%V'>-P5ETY9_2L8:(I6L)M)F:8>CD#O4$9CTFGK\^-;6U[<$Z7U$VM*#
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M;U= X3*Y-[WDX]Q^YJ>B]DQEV9.>J<E=;N\+1L*%Z+V@:9O*RU91!Z\ME">
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M:WH98UUB5HTDHC2]FU(D,B8EL?WK>]/J1V0*&;>@FZ(%O3F2H&BWK1^_)O\
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M"'7CO^[@?O 8# 8'X+,+.+ :48 THP.AEF%B",L81:\0B ,.]A$'>OV-Z^3
M_> P& P& P& P/P686:'SE& ,!YA@\Q8@C#YRQB+,#Y@[WKS%F V$6OV="UO
M6_EP/W@?C9A>C %;&#1I@1C 7L0=&# 7L&C!@!O?F$$O9@="WKY->;7C^SK
M_> P/QZA>C-$[,!HT0!&!*\P?4$6 00B,T#Q\VP!$/6M[\/#6]Z_OX'[P& P
M& P& P/P TLSSZ+, 9LL>RC- &$7IF!UH0BQ^7>_(/6A:WO6_E\-X'[P& P/
MP686:'SE& ,!YA@\Y8@C#YBQB+,#Y@[WKS ,#L.]?W-ZWK?RX'[P& P& P&
MP&!^ &EF^?TS &>F,11GD&$?D,!_CEC\N]^48?'Y=;^76!^\!@?C9A>C E;,
M!HT8!C 7L0=&# 7L 3!A!X^80"Q&!T+>M>&MBUX_LZP/W@?@)I8QF%A, (PK
MR^J6$8=C+\^O,#U ZWY@></RZ\?#QU@?O 8# 8# 8'Y&,!0!F&#"666$0S#!
MBT    UL0AC$+>@A"$.O'>]_)K6!UT*]"Z(TKBVK$KBWK2"U*)<A4$JT:M,<
M'0RE"54G&80H(-!O6PC +81:WXZW@=K _ #2S="V68 S0!C*'L PCT$PL6PF
M%BV'>_*, M>&];^76_V<#]X# 8# 8# 8'Y&,!0!F&#"666$0S#!BT    UL0
MQC&+>@A"$.O'>]_)K6!_=;UO6MZWK>MZ\=;U\NMZW^QO6_[NMX']P/P88646
M,TT8"BBPB&888(("RP!UL0AC&+>@A"'6O'>]_)K6!^\!@,#\ -+-\_IF ,],
M8BC/(,(_(8#P\Y8_+O?E&'Q^76_EU@?O _!9@#0 -*& PLP 3"S"Q:& P ]:
M$ 8!AWL(@"#OQUO7R;U@?O Z25R;EQRY.B7HEA[8ITB<B$JHA0<WK-D$JM)%
MQ91@QI%.TR@LSTS-!'Z8PB\/ 6M[#G&H3EC],9Y(!Z]'Q ,T 1Z^(,$2G_!V
M+6_V\T&P@_RA:WK7CO6!S8# 8# 8# T>S?YMK!_V'EG\ K\+&[Y5?;-_Z43H
M/_A&]RW^#+XR.N?^T><+7_VC[^:'VZ/^:IRA_AF>5/Q;SY/HSPY&!Y0]QQ"6
MV1TS2<!BM=N]H+E_,74+HS-*6ZGRDFJ%2\B?\SLT<M)=(6!:4[?&183X<20<
M@2K7-(!6:-,5O>Q:V;QVGSC^76C_ $S<41M.CZZ*F;E<$4!/T?)]J31?5[%&
M(FY7;"N?IE*9P[Q>;++"33J52XNQ:\/$N)1Q@YB*3J5*+X@M4D$HP5%=FC=#
M])2BS.4JV:WE1$OB+T]OMQZ.F:9H*.)5D2ULF'):-*-A+&ZJAH(J(^VW<L11
MNE!FQE$:T?K90]&%B*R^/_*Q/N",4@ESEQU#6"*-U@[DW2[ZG<Z]?K/E511F
M8H6KESH]_)0R*8P]AE+LG1-;JTIG$DGYN5EF+$9.]A"((3 &<>L^"3N GQW>
MN4*S^DD@>)%)61PLV&R%2^/"J2JFU]@5KS>%O$2;Y@O<GA?/([ E[(-C:Y H
M4G*7QM;R%RC83U!@ C+^SS<[#'-V[J#I6S&TE2@CU-L/";RMME!<<TC<RI&/
M+K"L)5.EE=4^WM^H?:RB8,R<*->TKW9M"Z -"2(AP$ M&<:QJHCKJMJAZ7N_
MYTBULJI%7RJLI=VE)N2 4<1%U)$S9VAHM^84@BF.IS](CU*JP$KU$MRES;1M
MFF\J,&'$@"$Y/\X&DJ-NM6JY45]=!0;EU(XUY)*^9X-RWP;R]>9D<?H4X2%Z
MLQSE+3:BV71%WD()0V%1EA-CE:$E(%2-*8L)7J]G&;,))VG/+,1RUZRM"OZ9
MNX#C)K<32&OR:RBG:+!R0.BQQ92HFSNT.=PQ:C5<P#./I$2J(L)2]2;4J;FT
M#9MO,BX"B1A$<?\ .!1*C;K5K==6N2MJY:Z4=FQ8I1+VN@[D7H5Z!4>C6(ER
M"O9&>G4I%J0TE2D5I5).A ,+& PL8=;#O0M:WAG'>/-XU639D\(X.G7%14\F
MHK4KZE[ =WNQ4\G?"+('R= J(!<<)LPR7$+4\C*>),)U8*X5/&U&U2AZ"Z*0
MF[.)$+1TBN7+I_+T%ZX2$RVD^68T]JG%0T3?H[E5@F"-&].S28_LCP]HSG-H
M=%C.N0KSV]T$7KUR=F^0\.O >A!WO6&(TF6Q\S ;X5T%U!2D E#_ "*F*Z:*
M.=F=J?96]S=-5MKS9+8F[&JQCDTF<7I\(;B8PPQ5_P#F,U:86S&O^]D%D$*R
MB0"=8B9W73?Y"RQ9A?91('),UQ^,M+F^O[JI%OX5K:69$<XNBY5LL(QA)1(4
MXS1^&M[T$._DPR\>D?:O19HYJR,1J!8HE$9Y&G],RVVJH;H$$N-='=3MM#N+
MBIKZ)6Q(Y0KB?T8<P.30![&PO8%99A:D)H1?YN;XQ^_[);!>O2!EL-_+/XP8
M(GF0K^FT'47HHK;Y5D"BO-%7]"H69+7VI6!B_&.ZK[.^;MJ-*O@]LK*K5@2:
M4"_:145;'TG-'=E]KV[9^Z@@4W?F!G]P:3N11"16YUG+7=BNOHMP6%;;#7(2
MY3#'U8C$$:3:T1GP9NRO7%O7J;$_WKR9@?0?0:6;R>3@D%=$U7">SJAY;(K8
MB#K]/+W#[18Z70*Y8MFXY0(;=*HW+;7V<B(3H-H36YOV2> 9RD)R85%>-6D3
MHEHLY^ZYY@:JLFS!7KP?1'7ACC*GR)BFYB-O)E'*6TY#5'!O+$@4*E+N)-ZQ
MB@_80(PG +#HTPLTHD5QF^\?RK;'NE^B;*BZRPJMK^+E2]YH?B:S;1<H!#$\
MKL=%$;%:K^73PZ#QF43-B;9\HBS[&DGS*T*5859+:O<1D@<5_P ,D.+41IXR
MN5870[$BYNK.R(58:M]<[N3UFRT]*8;6HI6\61(I\VIWULW%J\>'Z.(6Y:_1
MM&N7>5X<4B)D(*,.6CV!,8 1(C6IZ*"5Q:5^WI?%2JTM@0>I+49Z1[[KZ2/\
ML@S._*G+="]8TW 6]2*"L-EKXLVJE?P*8V3Z1OSB0D%ZI2,PC9Y9J4U,1$>%
MQ^S9%_?%UQ:NXGT=9,>31BM)YR<3;M0Q&/1'3Y%K6MU#SY*K?EM9/MB'2$R4
MU\^@71E2KCVCFC36[1Q&(85ISB:-*E)QBZ\6QHNB>U$;&S-;RV-+0;8%L<T0
MJ%VU8%4-4:;#B[>7S5';;6PP.)W1,#'Q/ 6R/-SE'EZE>G K"\ 2J]J!)C5!
MHK'Y-JAU_=%V!9;=S&384 B<X993TRED%TFUYIQ.F,=HMTI)/&VN+5ZJE29D
M;YB[HKU2'OIPE*I,0G9S1I4I?QX!(!41%N>K.E^G[%O]Q;FF N3]4$9Z'L;G
MV:DD0>.M3-'(Y6K6^LZNW3+%56<)^-D;Q8+,E/TQ:CVT^F%X) 2(PXC:X\3$
M1'C2P'?CNY,W&/1+RQ.S@SN:&N'-0WN[,X*FUQ1'A4H]!4(G% <0J2G!UO>M
M#+&$6O']G$LX_P!H1]V=>,MI%V<))!H_!7&6QGCCK:T(P[RUI7K3TDDKZ3\W
MIV5D,6-[F@4DPY]4ROU'A.5KUU D2419A>R=Z,+C%[[7"-YE?G2L L]5SDX3
MZMW>6S&Q^<&&,W(?72AF109ANU@Z%?9,C5P<,N6-TA=6Y3SJH;XV:<M)"-7(
MD@%@%8DH_C"U%7T01!+MM&!LG0L+C$Z+?[X=NM.HY#ZE8U,QS)OD$4IB'U,S
MR.1OB.=6I"(=7++'W:2,*5_"I?1J!N2L:1O\HM^<@LQ$UVJ%BNEK%D5R>V_7
M-G)V4C<@ND/"\E71)HECM$6QS%;%Z4 I?(2"8-GQCLTQY]22,]K/4AT>+:$\
M?G ;H0@B)$1&==-4'<[V/;K2X-7.\.=T-)26QND^D$#O%YBOD5V@YE8:4K^L
MW NEZ]=9@Z,_TV<K5#(4U@-*H[9;6@C;XL"E0>5.5Z19B-YUT3)1/1U_=&V"
M?5B*:UM73A4#+(7&PY8UP=1)BKQ7QKI&[J$ Y5FS/$N+*BU>'IJ,.7.AOQ#J
ML3.#ZG1DJ  2;/6DF(B+5QJ#L.<570G63NU,C$A*YG>>GGV,UQ)$:LZ;6LOE
M_5-J 8KH3+"W5N:D]!1IT.4M0]I33%ZQP;W$"T]HVE)+4EG&YCQI(TPL?MAQ
M1UTR2*02&J"4?87/<9:+&?:QCD5<K=A4U2./TOA[K XW;,I3MS9&Y*WB )1M
M<$MU;UB8G96S4QZA0*Q^2VG'SI:CC(.MM69:&[!0L?5$QBT(1','S+]#V!!$
MX0XD1]"<)]=O7:P:>@:)(T G19H#3?PMJ-Z 9RK2NR&NWXP]SOI'DF%-]:H[
MB;%]>]4/;G7;W;DDJ&.JU#*.@DK;(UKM'FI[VYN3'I[/3I23DV] "X'#"8#>
MMZ&7':986_NI;GYC?[?U)$+5'HZTU>\+>6(HKBH'FN;!,BE>1=S?54NM=#*=
MRMGE5<OACRX.S*J;&PE;$&OXIO4J3BUIJ81C&2Q=$S^XR^A+QH6U[!@%E)JT
MJKGZ?L<GB\.,@TD"XVR_7@TO[7,&,N3R-K3%$CK-(:T:(V49M&?O1VSC-;.&
M28BKA:2:R<,.ADPEX6]2]?1*,O\ (A,[?OQ7.8F)I5.NVM)X -WI8MTF],O7
ME%OSCU\F_P!C#+R@K/L7I%961=AVJS/4?B=N5=4LBJ><-=-Q]0:CNNXI&Q-D
M7IFMX8W7,_+;8:W]JE*8QK=W(]G*1B1J%3D=I.:$E*;F(NH9JF>G.D;QFK=0
M&I+'*IG$?>.EMRNPI+7L;?)-(&VCYG5,78HVW0B.66^P%KEFR[8(/DQZ9V<B
M$Q20C1"=,8X[^;Q,1&K'U5/KCJ^?3R1)9)#UE833W*9M33I7XHHLV^*D<]3-
MJ(V9 FHY!L3:],TS)"80A A-1C:0C*,$-2: ].)J8\:6$ZGZ-M>FYZ"NH:EA
M1CU=E5IV/FE5)D:]0DUT>&S(_!'!#+B43JA/>HBB8+299$8B3;2JM-<<>1Z4
M>7PV02(B8M!K-UK-;I?Z>-11N"E,9=IT14[TN>HXL>5\(Z4?Z<NV:70C9-B?
M$9:9QJL),=;2RQA$/1BQP*,'O8@;++5(FY__ #FK 4\,*Q7RS+;,D'-W:[F^
MVM*Z^,D;CIG3VUS$E9VLN-&2\A(Z. '8@D*A8H5Z\&_0R2B@&[ >66:UTTN%
MI;CN2TK%]KB1W]#9234EI2;E5-:OT@CB!0X%QM[5P5/)'HJ,A4.J-:A\QHCB
MD*H:@P]'H0#=^H,'@(S$5G72T(RF97O35Q]EV>Q3F$KF^L">-E$\:7*"*-J+
M67+HND8)N I45* E5TA4,2_2ALTF"X&$.0O$\1J8K9!QK28B/-+U"=(=,6U=
MQ:G=?.YU%N5M]&5>^B.@\?8&BLVBE958$(B<K*GHK.=)'+I+*I77ND;LU&1]
M*!,8]E>AZ13<<<N),1$>+I=%]'7Y#)WUX; 9I5$=B7(G/%7W^7$9/$UKT_V8
MID)%S.LBB;\^ E;7N*QUX;:M @:5R)(:K [*A#'ZQ2?:50(B*B^LNL;TQ?+B
M!3;C=*:[9H"I[$(Y$04FZPY2=,VU,Y6ZFH1+.'25ZE!2H=@(),N!,#6<*$+>
M.)%[3>.CQ?.814;=:M%Y/N.64U-35/9'&X>*#Q:G72N[;;$B1Q3/R/OY'%I?
M+"ZE8UACNH()COK5NI9 (S"#%I[K)FD.CP[\0'#ATZ_PVVONH>O)3:SJW?07
MZ01"L[>'0ULE,<!96R'MX(M6;0YSVXRI\[VGJ3(E94_=BUK<PZ8CBSXP842
M9RLX*T#J3CC2>*ZO:WXYP LZQMHV+6#8!W.*KI0$2A$?60^,MY1M1(K 15VW
MC5.TF=ER9*L),+,=#A[/-T>(6B A  O"3$<JC:U/.M;%Z*34??%*2NXJTF"R
MQ^()U>Z*=P>O#&@B*I&)_AL0F<)TR"FKL2]02R&BP_+''(]4!<2!L<-'B7^8
M/HFL8B[\7H;<Q-U5AS^R-M!L3.^RV+&0AH>DT1AL=1+$L$0J4B6;N]65FYR6
M.P]3)D+068:U,BEU(2ZUX@+VI- 4F4&(J9U535]R2 5.='65$)3"I:S5=3W-
MTWK67NT7<XP"6+K;;%B9T<9-%U;RF6M)CE)D!B4AK\4RA L 8D,V,XL6M&N.
ML0CBJ+7N*L'B<25AE]</]?R;W-[BH%54IC$L^DWJV19+NF(D9TY3O9ZI!*(U
M(7 IV4-X6HU)]$R3A;#\1L*D F(GSI_ 77TM,EW/,+D=Q*:PO*/];P&*]#UF
M;5#:UIFMIE](V=,$$99G%EL-W99]4D@6Q-6>QNX%JDY6$HOXP!*] >E"6L=>
MU-DA]E7&Z6U2;Y%)?'H/7^HQ[G#E(:>CD,.^CLQ>Z7Z@9XJQOC@IW)@GZD#F
M6Z%JCU&B#! 6G. RPATX; 02HKQT8F_NJ+DDW-"34)G<<KR<3[VO[ ZS72N.
M-1ZM]CTP94E+F$*HJ2*1IS&AD<$TZ=R4IXAG')E "3@&CVG& P1C%Z]Z2"^W
M';;%T(LH...U<L4YGL^I*MGJ]U%>C&L4:)YOMJX9$Z*8S]*@-3E*7H5=[;HX
MA.4;2MR92I/,TM^%T2<*BKZ..'7YU#;$^CM&1Z<UA$)"PNO8L6G=N%5NX2-%
M+W#G":4)'88]PZ'*IFF;F/3N&XC$<H2'+EVDSFUK"$9I._(,D5$1?DGDCII6
MLXHK#H20K"X;-+7KNGS6E)%8>ML(T=IW"&,LL>C$-AAKTT*9 H=YA(RTC>2J
M<""2@F!-5GA)+.,T2OJKHJW6G3G4UKS"(4BE?XM7DH#;O3-=3B<RNNF!WF1+
M-3D-J291125#(C9TBKYLF"DZT2T+GH#HM1#(3B. 2E/'\.26L8U\D06KTW?]
M]\H])+ RNJ*R0UU[>2NS[%0ND3<ES;9TIL9FZ$B,DVV/"R7)%D @3:13Y^FX
M907%8!T<=@4''%(=DK"Q$1,>:^?2UUSRG*NYV9JT:W%5*KGL2'5,E=D$9;9@
MZQE!NKYQ8CHYM47>91#69ZD:UNKPQN0%*W I.4J6A/&6JT3\(>9B+N^BJUN=
MF](U[2RIZ<&1WC][U#5MIW79M?\ XI(FK876K8A-YC'ZNGUEO3Q=S:SU*R6\
MP5^N4?,[0Z/LB2*1*1$E&%H?24%C&)GP9N\[$MZZ.5O<!L 4PB3'7D%A_8--
MLE-IXH(Z0:6U?'I7#DDDGD\.>]N+6]R)^;M/)*)(W%)R6!:D!X'G#VJV(B(F
M(ZZ+C4G,;>3W);%,6U*HI.E$6KBF+58I)&8>?"MHB[1>+=C3W#U#<9(9 !P;
M6)TJCXAN6"&!4-,OV4H]49.CC"3$5<*EF]SV5&9DR,LSU D4<HNRK$C';3\:
MU.;<&'PR06.NKKFB6QP9CXH+CY4O;G)KE#IM6!8'306HT5HOQ": O&/79%,D
MN;HF?M+<YM4@BE%V3()%[8TIDS]'H*L6R%5&.ANA)ZW$5A+-+I4A&N01.,J6
M](J*\P-*S-N9 M:*6Z] M1'C&K?*NGUQ5A8-AR1%)(@JJ^9^Y7,*:<J^-BJL
M;ZJ0V D96\R8!FXG[0FY[99B !A"(" Q&8U ,*,V)0: ].2:F/&EEKY<K33]
M<<M,L;LTR.5J^5WT>X3JO@,'QR>:'19OKPU(:K<MOB(*=2D(?1:1CVE.VC'Z
MH]:'ZV] )%<9[J$U_P!+=#\N<B\\+G9P@MBIIAP?7LVK^/MT*6MGXMY$R2;E
MFGF$+BY&S)*9/(T%HZ#3.3KI2:T&C4LINBE*1.KUI*:J,LI\WI=S',.@):QV
M4UW3&7MA5QR4D-U;SJ3P^.0IVG,:<8FR.9[H[P&-SN;H&U9%Y>J7MVQ@6IRG
M!*G)-"46(0Q",3713CAZ5SJN4]&U^^/,-DYW0%L]_P MGDK2P<F)2!\D%=7*
MX)VHX]0D?7#3LZJSC5YQQZK9Y_P(2$P/*6C]09K*IN>U(4;[9>;R=H=;$@-9
M3'6;H_:D=5!L; :2Q*"@>XIT,W(5+8 U:X#^&5-Z$H6A>L8$SQV+6_+O6M%J
MM//]H>B%Y6!<QW1%44)5=AU[6"6<4C>EINTGEL.,F\@&ZU;+:1C["VQMD,E,
M9;E#2;JS5)SSLP0S@I20!(&28/URS,1%7*GC-VUT%9]-V/>\;=*NK%%S[RI4
M70<K@3]&'*0);;?YQ6;[:<@2I9*IDS2X0JKG-M8!M$<<$Z=:M,<-J%)XCRTO
MP1Q>,1-=Y;6M[ML]DES%'WYLA;.BJ:V96;UL>]-SFW+(;S_,I7$V#GN4(-?.
M^T\:>'&.7&QO[RI5_%)=HXH_ +**\2QD#C'KLT=O[/[%GST$JMJL4OCG':YJ
M"YMP)B@+,O3S>-]!36Q'V&124S&36I%U-<[CM+1A$D$Y)6]P";*OC3C@Z3)=
M-YI>.,+Z<Q3FW;-4W3+K#?XB9%6F\KEJJMXA&(PJ;5;-':AM>;0,E]D\D7/C
MD<_R&2)V@K9Q9*9&D3:(#L 1",,WHS-0M;AEH]F_S;6#_L/+/X!7X6-WRJ^V
M;_THG0?_  C>Y;_!E\9'7/\ VCSA:_\ M'W\T/MT?\U3E#_#,\J?BWGR?1GA
MR,#7U#'%S)0U294ULHIDC8WN/,SX>E1[D*>.NZYB=)"SMRX8?CP-+@XL#:>K
M)+%Z1AJ1.,>M[+!O01T5SO1)%AGVR54D #92AX#(QS7Z,->W\$C"UC8QR-,M
M$GV-'(E3*/:,]>5Y%:A+K11I@P!"'1;FJZ,,P\J\UQ@R0FQ^BJL:ARM$YM4A
MVDA3$#3DS/+PWR%T830"1B 5'EK^U)UPV\O0$>UA03M%:,\18+GNV^UJDJ*X
M&% S7- X5/HXPO!,D;$4Y9FQX;6=\)0KV@IY1Z<RC"D*_38\*DOJ@V$0B%1I
M6][ 8(.Q$S&S+LE9UU&C(B9&X+$8^* 1MSAT&"QQYJ:2H?$WHUD/=HW&B&]*
MG)9&-Q.C3>(Y*G"62,2(G>P_M8? ERBR953R\[7;")3/*WJEXOE\0&K()()'
M$61TFRU'5QI#F%8TN:UO4* F051* 'I3?.$U"8LV,C81#%O"ZUX-N34#2:*S
M#KE257!4]J*#5"HV=DQQM!(A."QJ PK'?2X)&A@?5K 6% <O#K2PY '289HB
M=>3!<U71DTU-U*C8G>+I*U@Z:-R"',]>OC"1&&<IH=X)'D[LD88<XMX$FDJR
M-,Z5^6EID1@1)R0*SM #K1@O$7+&**!I-79A-S*:K@I]J$&D*BIV;'&T<B"X
M)6D3 D>-KMD>8;ZD8![;R5XM;6E(-[3 -T1O9>"YJNC]5W2-?UM3[;1K8V&O
MT 1L3U'W)#,#2Y&IE263J');+5$M.5D!(>UDL7O*P]QV,K1:@Q49X@T$7EP3
M,S-]656U!5+DJ=ESA6\'6K7ZN2Z@>UJJ+LQZMVJDHQR.*K=Q4F(Q'+(.6<\J
MQA:S!"1Z$I-WZ?B,7B+EH%L51S.=%WHZX*\K)5%97)*J;7T<IC+6K0/,I12!
MFA%/E+=&(S1'NC9(7I$@9S-_A)33P!+$#7RZ$3/1O3-3%11R),\"CM8P)@A,
M?D#1+&2),D38VF.M<I87M))6>2(F= B3H"'UND2$E>4KT#U]+"PG>;U->;!<
M[OS7%2Q"KXW(HNPDK'!!+9O8U@R8^0GE.RU\D=HRYZF,H,<3!)R2#D7QCX-(
ME3^GHM.W$$)]:V O7B)FT8,](<G4^ZQF)LE6U/"GBQG5N:8LUI8HTIULC<*T
M,46PP-+>9\&88)/ #XL-Y:TWG"G:QHM&)0E" '6"\I2+-J*INQT#RVSFLX9)
MTD@DS5-'G3HPH3E"^8,;"DBK1*3EH2@+=2%NBZ IM)6!,"H W@^&T/T=[!L1
M,QLS+15=9Q^OCZF8J_AK+5ZEJ?6,^O&J.-+?"S664&N!TC:1QI*D*9]MSZ:[
M*A*R?1],_:@S8];\XO$7-WU=D5;U\,M:2*%1813C,6>PUY>V-NV!;.X^-D,8
MIBJ#M/X'R5G'&F_:9:+Q4$[1$; +7I \".G+76M8TY,\WF!\;;GEH6-=?,<C
M<2DPW9J56_*HE'&V,(EFBS5R N>2Y*S)_1UL!:I20GV/Q],.PEU:B_<U4!)H
MZ")O500%5'"V^*M &@J.H$*0#3!T[ZCB#2$+>4E$%KCB.4.1*1-X^B22X*"P
MA\AQ@1"YAG9Q5=0R6N"X%.8-#5U81E$TJ44:7LR$B-QA'#"BCV%4RHR"B28]
M]%R4(-HC$GH#1A*UZ6P:U@B9O3=&PN6^2I]#HB0&C:=?X4F;71SA6DL*C^FQ
M,SV"H1R*1&LAJ5$3LELG:@!2ET 7O13MX^*H)NA;UL7E$^+>_P W^D=SA'9(
MJK@PYPW,GT<;9"9'F\Q6V,GS$;%MH&TH9(DC>7N+GF-FQ$E@'MM,&EV+T!"+
MV+G9J%6TYR_'M2B+U175;-A< L1BU(V5A8$1:>(6-'HPRR6,%%)1D;(9G*/1
M29(E#<!+H!2%,O#HC1>A"#@F9G=M,TYVHJQ6\]LFU3020I5$K63LS:V/(-*P
MS1R;2V5SE1#@G*)<$T@<V4K2-2K+- <H1^)!@A%;V#8N88]RY\HQ#)'RTB(1
M%H=/#XVM;%]H,J-O8I,V( 1443^?-O0BMI@.S-$R@HR7!2 TTA"2 G8_0!HO
M!<[=&L5"U<L6-0:&BZND=4WE1L1@3#4;BPM$KB=KQY3%$$<2LZ!CEYK6M=T#
M@>Z,J4(SOBM>97YA&;UOS;W@FXFYTEM4>YDYZBC(OC<=I>MVIA=6^3-+DTIX
MHTB0KFJ::CFI<V*2#DQ@3FZ2_0]J^.(WXE*=MR?9@1;*!X"Y9&S8#1S^A="+
M6B4$<TEDK(+"G4<G:6XXR5.+,^KUU;,IRLXGXE2O8I*]*%#-X#T:B6J!FIQ%
MF"V+!$ST:P=R-R^>QL<:'054:8(V\O$A96HJ%,9"-&\R-,A229?LHE(7I4;*
M4[8F"ZZ.]0+I\.7M5H[8 [T+E+)T"@@HBSP=1$HSN#QD$4VQ18UG;OHVQ%P%
M>TN\+^;6D1'S>W@B+DP(E+?Z8 Z1G)"AE>418=Z)<[]6FR^AJ-LQ,\F3"L8)
M*RY<[QZ5O#@L8FX]6\/\;91L$8DXG<@L"X3VT1L\2!(N+.TH+;S!)PF>B+8-
MEN8=!XYGY]?D-?MKG3E>&(:I3 0UJG31AL;@P=M 8A.$SQH3:0D&U,B@YK3#
M.1%;"D/&F*$86+98-Z%RV532]0K/@_BZQ@:H+>CL%M1@411D.*);+86FN5H-
M>BC$0BQM=AN)XE#TF%K9#F?O1B@)@]:WHERU%#RYSPVP!PJQ%3\&3UZZ/K3)
MEL4"S$B:S)"P'-BA@>2P#V(U,X,!K*C^ -*& 2(*8H)/D" .M%Y3=]1\YHIY
M]G[+9@XJG:I6V60R6R[*V+TFLF;SJ+0"4UM%'F=D$D;W(SHQ'I8<)'LP0!@4
MI4A@A#^%*"$7-4SUJ4'2MXZ8=7!5L(L@46$Z"C9LOCS>]'L6WPI(0\Z:5"LD
MP] !V)0$!4A+$$)VB2_/K?D#X")F-G03\X4*FD[E,P5% 39.\1@Z%N+NLC;<
MX'J8HJ8V^,KX_LM<2H3%-;I'6E*A6%  $*Q(G+*/]0  AT+G9&]?\?417%@S
ME^A\/AC8P2F,T<B45NCC32%I9Y)2<WL:<0N?#&(1RI0^E.<N3@0F&EZV@"Q)
MM)QZ"#0"Q,S,:ILK&K8O4S1(6B+_ #B:&5V!8%FR%P>%FE[FZ2NR9:ZR]^4G
MJ0DIR])$JIT^#0DA $"1N3)TX?$)6M[$S;047)O-+:PS&+-U'UNAC4^/;%,K
M8$<8;TS.YGLKP=(F4PIN)* D:Q,LB/&X(_@P$?"KQ;4%>0[\/!<M974!Q^\*
MD=$JJGJ4:^.IS;;;X0FB[:A7M )(>HB+A.T9R%*F5)%DE-:S4*Y6 [1[@$L0
M%&S [WXB\MTY@K*NRR0)P0>*A(+F15B *TQ-OIAGI P&$S/0?A_#Z3EF%A%I
M=_\ A.A:UOS^.$N7:DT.@L@<(I)Y?&XP[N=;O"N5PM^D#6VK%<(?5+"[1I=(
M8\Y+R1FL#D?&WU:B-4D#*,$D5&E[%Y!BUL,2VU'5C-YOFFNH4V>>Q'>W!_ 1
MIH2>>TY!I?I]L4?H) >::O&G53\2Y[_SP_X@SSF;\XO$MRZ,1I^H*V7E+87
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M25U5OLA>5)28LL!SF]O2\]6J/%K9AZ@X9@][$+>]D9G T>S?YMK!_P!AY9_
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MU'G&D3735?3FF:2JT>;9%>3M.WIC27LIL.X*P>I V)AZK&G9.6H+I!6FC[B
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MTB"Q&#WK6_* .Q;^36]X1@DLK0.#L4WHD:U<T'QX<A*F*7YO4PTT!3A\")K
M[E+QF#=M:UL_R:)V3H@.Q;,\VO+@8]H;*[:W"3V*RDQ=*X30AG4RR9(CF_0I
M DC#<H1,ACH\@,V6J1LC:(X)'F'Z9(!&;UX>8>]EUV;2:ZM1!*)6>Y-Y*=R-
M2IVY2:L3%DKSUNO,B(1'#,T!4:KUOQ*"#8MF?^CK>$:'9=K1.K&UJ<)(8H4C
M>)E6D+2-;5\$I=]+[2LB,5?'7,Q I6HS LB22RI,)6H#YME$ ,$ )@PZ+$6(
MM)0Q@+ (PP00  '8AC&+00!"'7CL0A"WK00ZU^SO>$?D1A.MC ,PO6PE^J8
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M3",H/8 AWLS8= ^36]CWK0?PMZ#K6_-\GX0M^&O[^\#' >F8UN->"W9L,:"
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MO80^(M"(F4G-LA9G5K$\(W%&) 23ZJT[:M-L+;L"8M6>0Y#+.&4B4)"#="-
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MY_'1GX/AYODP.V!S;#EQK66X(37-.G*6'MP%:<:XA*<+82%1J0)FU!2<T>O
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M3R%*W9WPQ!Q*G?IB"(6A!,_!WKQ^3 [/SDV[5DMWQZ':Y4D&N3H?BB-JU"$
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M&?')C.:G5&HE"9B^)+$QF.Z1V;43@TKW=)Y4.T:E9H].F>- 5 .2A,+'YA;
M+R##OPV$/T2HK>'GS+G6OD<F)%1 HX&1N,D5"=5,@=[22+[#62(^0*EZISD#
M_('-S5KG=4H+)$8XJC!!UO0OD+-[RL+A&CV;_-M8/^P\L_@%?A8W?*K[9O\
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MRZ/-!M/R:.E+5*MI/+$]+>O>DK"2-^@('!6=HPZ%S-K7Z%L/IZ*6!#L6C0C
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M;2ECU2Q28$V@A>%Q)RU*X+")1%%4UA._@0'*@*)@E,$$)!)A@"8S4>,*TM5
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MG6M(KN5*B::D;[#B5/2F%!(F'/B*4:B+K"9RSR4MD=GP"]N,3.3:C6(EZ8!
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MSY/HSPY& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P&
MP& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P&
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MNF9-$ZID_-/3,I9J#"WQE'%K-F=<.]1"65<A$\*BDTHGUN)WL"9M6#)4O#"
M@S3:'05:C6QC4X3IK:#>"O<IZ<M^Y?;U.FG0]0W\D[]AU_R6XN8X#7D7C4GX
M455=&CY4T^+VQOBV=F,\??R0PQ]!-2AJ5;R<$U&,D>MIL+EA$1.E5U[IG]PS
MO/K/E+I^6\X0AWCJ]X[0J&GH_P"W"H<8.@6$Q'ILVX66I+O8Y,HT ()BTQB$
M3UKL#TW#>P$HFU61X^EORZ)CCC,7/2=5<+-]S;J^%6?><O2= U>!UY_]Q>K.
M'(U[=CC6T1W:_0E;2205K$UMQ$24*]/9Z*<6.TS5?+H\<S(@Q=$UM>RCDRH.
MCCBXU&$3&W2[0*?V7U_RB1[J3R5U6Y6[/&'W*ZBYY2,TX8*NVJH6N+4;Z10F
M=#-C%-)5&(I$XFE8Y"".LB!V7LT )>QEN*T[Q/6:&7CCE6G2WNK[=5R](V_2
MEW;Z14,K^Z0"WII#*YL!#)>?7F4S:M0Q&,2)E46FT\R6)9521*T&%<_JD*](
MVKDY1R4E(KTE(^(V'=<LHB)T?+GSQ4]VU![&TQZQ@\(JZO$=NU]6<:G72]"S
M>Y'/KUTY[<.M4#5T4_S].X-9$8C>X_525>,I='%JM8E1IQ';V7HO8@':9B?R
M5/\ XV7LL!DX_I?K*KH?[64PBHZYL7V_>Z7_ +0B5"64KL.KA5?&Z0 LYVMN
MQ]HI%(V5HL]PM15M$WO:@TI\=DRA2$TPXO6]Y&?JG&>>]Q2+?8)B:Z =0\Y)
MI8UM-!JK2]I*KK8@<3KVR)?/(=VLBD<NC>Y3>]EAEIC0VQ6\JN&F2$*V-K;%
M8@)9"8H^=#TV@@V7\LQ51W35[@$BM]N[+]VFOYQU>\&54H]FB<V!!^>7]OC#
M='9$TOL3Z08G..PI L6!.&ZPQTCWSRYOS>F&Z+R3BD:\?PB4G6JF-<<9B->6
M[6"^]NX>&Z+ED.'8<!O<B/>SCRYV%3: =1M$3244Z2&T8?SZ^H!!9Y$2LL"N
M()$7C4C4*GU<6>,QI-V<J3)## DEXXY3V^J8>O\ [8-]=0V^IZ$CW0$B9K%B
M4(=*N<J<L\Z2<HKK*?VJ<1)<X2U@L>+\A6S:=9,!;&]M9:I@5^= H<VAS!ZI
M9AB<9PSGG$1L\-:XZWM[KKJCV@K5NSI*II3*)EWYV%O?'<<A46CDVY5_%35_
M1=:L[$ZNB!W43IXWM@3EZ>1R)/ZJA>O3F(QE$:&4,Z3C$1-1TW2KQ7V/V%+X
M3[;M341(:<J>%2KV_>@^N;&KVL>?H.0FERNA^DVQE3UE4L4:C&QB@.K/;W?;
M*I4)R% $>EQZL@@2[9)A9,HQN9G>Z86H_=O]Q;?+EO\ 5RM+![E9%'!UB]((
MXPXJ>84(Z5NMAF,-:VYKAU;49=,SZ#DM$0YBERXN1ZG30W21 X,985"A,)48
MF*BSACRX^*7>DK#Z$*=/:6E2#W;FFQ(?8_8BN*V)<4 AE'16JP/#YSI,Y]'V
M>4)8>Y%0UX:22D@TC6R2 U0(>WI*M,]5:D2FB)%?5]/1DJB]S[J>5V]0$X=[
MTJIV57K[DMC\23#VVDE>1I+:-&U7%918D8!:BN6I77=M&36"L4)12J0JG-+]
M&E+4[Z+3D)=>@<8)PBI\(NWH[[/5S=3=/\OI>GNE;AB4^+M5^F;/7L&AM9LD
M(;Z_9ZJMFT:X7.CG(&Y>K6RZ03L+"E4*0B*2HVX*0LM.5L8SS3*QG&,34/,O
MF/W$>_'%PX:N2R[9AMS07KNW?<+IH?/$8I^*P]>E_-;8K^D=7NT:GC6H4R-R
MGT@<Z=+;%I @?-AJ987HM*%26-0:;G#'6(WBFF5#[K/6RZ(T382CI^E;_>>L
M>'^T>C)S2\'K"(,KCP1.J$IM=9,,"L4L[TY2=RB39,PAA;NEG!8UJQ[*T,@T
MO]M2!A.&.L553ZM/DG>GNAL=:S:4C[#K+;BV>S16ONTD#(YDK\(6R4*Q.R5=
M1+9H]Z-),K*4%(='N+NM J>RE =:0'(RA;!IJ<<.W_:D@V/W9T3';@ZF>:(-
MHJI+*M+JSV3:E-F_XG8R]N2MHZYHAG.EGXQ' )[;(;),C@WCTF$:Y:%4W("M
M)4YI98M[P1C$Q%[5+(3KW)^XZS:91S^[VBGF$PBONJRSBAYZJ8*^Y[A<M35>
M@YJCO0400@C%N2V <Q1ZV)<^/PF%&M?%J1L/2I3/12'N!A !TC#&=?"Z=">>
MY+[D.FKE2HG)YB%6V;/:8ZSL1SMR#.O$$H9KDE-(7!NN:P:#7^T^A&OFZ.(!
M1,U.\V&SQ:3.LB1K##2FW25,0:87#ACK/33NL36G?_79/<O)L'ZFFT1KFL^E
M8#1K'7=5<WJ.>+PCKG?,EYX<[,MZ+WF^DS!]O*#L8WH&G6&R*,DJXJI8 I/B
MU9FU6S]U)QCC/'HC#W>YAJONN^H9TF9(-)'*(_V?;KM_31^QHJR3J$O06_HV
MLSM-TOADA)4,LHC*DS6M*4*LL:8\/X(];P8U.%3MR_A)\7ZXZD-[G8^69=>S
M=4\#OFI]1OBIKHF <YVA%VN0QOD]EL29J[[8%[T=>E56)"I0M&YLR0UK3PEP
M:RTJ/9FQ'>?8XQQN(UB=?5YP<P]^]F1#D3VYZKBO3C_-Y#T6W=7RN;7"M*YB
M?[-@4QJ%T:RHYS>OD_4UIP*M%C\Y.$@6R=Z,D;F9+S6<O25K( 43L\F-3CCR
MF:VIO78??W7=ITA>=37K??//(@63V;2[[FL'T@K.SHMV!9=PIK9KN<1ZLK')
MF;R@W!4[='$A#9J'.;@M(>) G]90K)*^'-ICC$3$Q$S]7H](.HYX;6GLN<5R
M-!&ZZE'F![54? T6?"([8<4 GDUH\[1X:\N/2-.I:0R!I(<=J&E<$/KMSB42
MJ(V$TH&]&(USGXH.0=W=T);EU9+C>\#<*11^^;(?;%+H,--Q5,8XU$\OBMG;
M92YV>4OU*2Y]#U!Q/P 4H"$Z@D@7QH%(S?$LO'&JK7C;;O>MK5WNCLOVL:E9
M:8A_1"Z9-G>H4M-V#;LBI*%R%:U4[7:Y!(G>=Q9EDCXVJ($I#IV2Z2HC%)AZ
M?0"C"!BT:$?CF(QF=MD35O9WN0\=2!WY+7WVRW5OV]_:N@G6%E1O4$-L2>=(
MV@6^=&-R.GF2QI2O+FS9"EY$5:&_;R:E5OQQ+"1I.42<M4[T6>.7U55S2-E/
MNH]?0.J9Z^QKK2E^OWJ:^TE;O?!4CKNJX$TI.1+EA">%GQ:$NR&).[XB>Z\F
M*Z8+&I"WRG0Y'IQ8C!&'F!V<26.$7K%?53BE/NW]?4Y';^,CG1E$]B)=<0\M
M]-IK8B]8Q]LA'($ZOJ_(]3,R:YRWU[)#MR6OH/#9$IF"9(]*@/I:=E,TM/\
MAMFC!#AC-:3&J49;WGWFT$=B4=1W4=%=2*N?9)QY)FOKE*W<]UFYN$)NE/-G
MF[Z2AVG^4-O+,EZ&B46A9+S&2'!0E3#:G,0%Q9J@LDPP<<=)F*N]/UJB?IWW
MGK$:>=H%;_+_ $M8+K(()Q3 >IY:@N"D.5ZW8;.(E]C2^*,6K)2RV>M4P<GB
M6C@3BW#9:B0*BT(@EK0+S JDR?8C"+J8Z^/Z]7J;[9J],Z]D^\F[D%DE">.M
M*"=SBBC"S1%#=>**#< DF&@"#9NR@*=!"+>M>8.M;\->.7JQE_6$/U#!F2@O
M?=ZI>WZWK"E#7-O;;;+[F;U<,_"ZL\&1J>H)4B^9HRC$2T1J"5C (E'"$J).
M0F*T4028>J./4&GGF%F;_''G_"8/>SG\9FWLM]>6174P:Y#$);2L2DL/F\5?
M *&1^C[[.X*J:'QCD#4H])6T.Z!4 PE2G-V T@S0@"WH6O%*8:?DB)WMY@VI
MSNQ<_P L]M;GGL:!\Z\W\+71?/0DKON.<_V7;B7G&R[=;Z0@_P";)'.@YM9:
M2'N9)4F>FMX&%F5F!8'-<W)"Q[.'XAU&XF[G&YR^?BJ#U$1#$E7>Y51W([PW
MSGA".]Q^U+&:.C2>PY$XT*UWM85I1\CI*EZWG;>HD7S762U0H8]2!$S#5I&1
M6XJ )TVAB$2(U&^,Y:95/_A[8>Q2S&0]C[[KMY__ .:S.O>W9E%Y+R,S2V23
M>M^7$J*%P\,7;:BE$P4_2*1UY;C#HN4I7 :%F3''+32B&]-H@?GKG^2;JM=-
MWO-AS:/9O\VU@_[#RS^ 5^%C=\JOMF_]*)T'_P (WN6_P9?&1US_ -H\X6O_
M +1]_-#[='_-4Y0_PS/*GXMY\GT9X<C I_U/;_!]>+*Y9NTI[RY%%;BZJI'5
M2#I%WK)OV-Z8CF]*LD$*!8Q@0)W%H.<TP#%B3R&$;/+UL8?-K"Q&4_UM,;;4
ME#/<<0?,]95$[Q%X@1<0;/FV%PU?''2KWA47(BHN@^%;36Q; G1::!<%$7YF
MX\T6CM $+>A8+GXN[/Z1I>UR8\GM*H:OLHB(J=+(H1/X!%)B3&%F@D@TKCQ<
MB:7$#*IT!.7K1B;10O  =>/X.O 1,QL[:ZH*E<Y^R6PY5=73A:<:0'-4<LM=
M"8TKG\?:U"=2D4-K),E#89(FI >E6'%#)(4EEB+-&'>MZ$+6Q<U71U8M2-+P
M=>0ZPJHJPA[FE>9-(TSC%H#%(^O3R&:$(DLQ?B%C2TI%!3S+$S:F+<U01:/7
MEIRPGB'H =:%S.[IL= 41&$4Y;8W2E21YNL\2D=E(&.MX<THK#$M >6L%.4J
M!F3D2T2LM4:$W:\*CU-&"T+QT+?B+E&484<A]-*[NAS-%*GM<ZJI,1S9>3&_
M5DW.*5I>86D8)^@JQ_)E48+0R!CCA4G0.21.3M8UISU&AD[T<$?E'U0Z-!=&
M\07:7***YFN#FZRDE9LPV245-3TJK^0-D2C!QQK*:B4PV*J3V])%QJ1C1C]-
M/\#Z@MD[WYM^78F,HUFV0G,4XMYDJYUEEA0_FNBJ;CHHD2\O<BBE;5]7K,-M
MEWSC!BUZE4VMC"B$VSM[^):]#\OH.JO9I'E/,V+8CE,Z7:)IAT1[8DY@D<[$
MGMJ\7S2 P64#B4+Z.E;Y4,E:HQ-6]2%:*,0RR'8:XQNE256+1VD3<J"L"9^'
MH'CK>\+6<3QUM(,DZKX67U-#>I99?'-#C2R-^/:H)?#[.:\7P5LE+^A7L*UK
MCD^7+CFQJD3HW[5(5*<A04J,*]4@P/AYP8..5\:FV^TJZ<M6Y#8/8O/*JB+%
M@450/D5KF9U%N!R:,19M6Z2D26,1![B6E;?'TJG28@"]"D,)"+TP!.+_  0Z
MT2;C2=T#<_3+VP[B<IM7W,+QQ%8+R%ED+?84&IK5)O;J;&I"ZI1RQ++(O$RC
M5JF/O;VE(VXA5$"2J599?K>8S0<+/.-9M:]RI>G7F8Q:Q'BIZT=; @Z ;5"I
MRY02++IC#VLQ.H2#;8M)E34:]1] -(K-*V2D/)+V68,/AX"WK9+EU8?1-'UZ
M4J)@%-U5!R5Z!Y:EQ4/KR(QDI8UR-<6YR%M5%LK.B"H0/SD4%0M)'K9:H\.C
M#="'K6\%S+75G+7,CA'H?$7#G.B%T4KQ<N<X!&%E15^ICT&<G1>-T<G"'LIT
M>&VQE<XN9@E)YJ(H@PX\6S![V/>]X+GNV"1T/1TQE?T[EU,U1*IQ\VHV?Z92
M.NX@^2OYH;ER=T;VKZ1.;.J=_FU YI"E!)'K>D4>6 P(=##K>A<[(F<C.6/;
M\JBPK =C6ZFZQE5RN-BV-)E6YA*37VY.BK):VI;(7@X(91(UCI-+ E*-*'RA
MVF1@,*+ $A(2'18URGQ8R[)?P?R1HJW;\7\Q4 =-;")D!-A6 BKF"NDMM-(Q
M.J8J0EO[DE0N;].4,95K0;7:,-7$(#3];,"2(SQ+'++2+26DK;F2[ZO2 1U_
M1=MTQ8B_5FHB28E IS6DW=9"8)V^GY!&F]SC$B<GHY2)3MTT$XY0,S8]F"WO
M>\)<Q/BD=37=?K84"MED&ARNNBVM&QEP%3&64^% 96[T/F]H!%C40V(+6A^&
M+]%/HCTBO3#Y0Z\NO E]>K)O,5C$C"S D,<87X$<>VZ2QX#RSM[H%AD;/ZNF
MA_9@KDY^FM[:]'#^&5$>0\CSB\@@^.\" *]7\H=%3N66U!HW5]BV=05ES6@)
M%9:JN4/T^KRQ:^-3IYI!&Z8R.-I)$GTRFNP F#;U T!OK;],T>O-A9Y1%=$6
M5=T5[:MQ*WN+5!;?'%A*J?.D=XR%CA4EJ-[_ !9*DS@:1++==$C:><5$%9#H
M]&:<'TS2<P)RH?K'^)@O$LQE&LVQ,"L[VNNLXBL8J\DW$W04'YW1J) ='V/5
M-V''*::DQ9J@^1I&,)#D@A3+HM&,>G @E.E'HK>PF;\N_ 3&>.]Q;<>>;=]O
M3H"RYA8_+D\Y'MFY0LR,,]F]+N]32JTQ1T04;>@W*Y!$C%4P,8MA3)TY0E9N
MTW[666'?X(=:$QE$5E=-@G72O#S7?L0I^S+LYH;>F(VK3[@4 G4VKA'<#"XS
MIK("E!#V>0+RY2V.,P9CB@@ B" YP3B"'6C [UK!$95<1-)S)J2J4S4I84]8
MUZ0QK9>"P5C,3"XV4U*YZ6XIG<N;J6X#:%&?+P.R,E5IR&#:W2@H!GJ><(1:
M,W+LIJOK1$X(G9'7<&2.K;)W^;-SFFB3 0X()G*TYZ24RY$L*;P*4LGDJ528
M4X+RQ!5K"S!!.,'H6];#(.,'A3PZKWUVA\6='MUBRF#NCPXQ]I6NKE"EJDQ8
MLAZ]P4I#5:R+*U9PS36\P8DAA@MB$7L6][P-(=>>J"?ES.YOE'T^\N4>B94"
M8'!UK2%N*YC@Q'I:(A;.K6,IQ[9$R?0!Y&XD0$8?('P+^36%N6]?0^'$2I18
M&HM&RIN:PAC2J:@8FP,L.C!"S;F7'CI$%+\\FL12_P 5 4FSMD:._#T#S?+A
M/! 7-YO(]Q,B+KKFB)U0ZD76A<U.KOB-:-L2E]@H$;ZK:703X_+8RP35R*"_
M,1@!A</E&81H?AO7E%LL\H^F7]CP.,^A+'LAVC*#G"Y[9J9U2U;:[RVM-<SR
M?0!X:' M\1U_-78M*YOS K:W9K K+;59I>R%*?1FBPF%ZWH?5$=:2@?1U**9
MFML933]6J+"<ES YN,\/K^)FS->Y14>C(NX+908T">U2Z-CUXH#3#Q&(]_*3
ML&"YVZ/V.DJ8,ECG/3*BK <Z>W:-O[S-!P&*"ECL^PW2@,0>G.1[:=O"]VBF
ME9NFU2:<,Y#HT?H"!YM^(N=NCD?J8IZ51Z51&3U/6DCBDZ>S9+-HP_02+O$>
MF,C/TD"=()4RN#4H;9"]G:0$:$K5E''BT27XB_ #X"Y99MK:NF;Z&_-$!A35
M^+E"N:Z]^;8LQ(?H(V.B,IN<VZ&_"H"OHNA<6\@!!Y*'T"SB0! /6PZUK"7+
M"OM(TQ*(P[PB35%6$BAD@D:B8OT1?8#%'>,/<N5KOG17*G=@<&E0U.4C5.7^
M<&+CBAJAG_MFQ['\N%N5?^?.,H_2-Y]"]+2*Q99<5W]#CB; \S27,,!C@8=4
M]<FOHZWJ2(-%?Q:+H"X_%M215LY<LTK=70W99BI09LDO02SE<1'2%G)57->S
MIPB;M-H'#)BZ0)^(E4&<I5%V20N$+DZ78-II'$UCNA5J(Z_)]EA]-8C$2H!Y
M=> ]>&&;F&-C%/U+")7*IW"ZNKJ(SB=&>M-YE&(3&F"5S$[1OKZ-E4A:FQ([
MR$S1_P"'YE9QV_/\O[.%N=NC8'F&0^1NT:?Y#%(T^OL,6JW&'O3RQ-;H[11P
M7I?@5R^-.2Y*>L8EJU%^TFFI1E#,*_ %O8?DPC7EE/5(XV$WVXX5;7*^UVA!
MMK:;.60B,JK";&P19A0FYOFA[8.2(D BC1!V26I"7L(MZ\/#>\+<U71Q.-+T
MZ[OLOE+M4]:.DFL&.$0Z>R-Q@D76OLWB*70=)HK+W=2U&N$ECB?0->FA6F')
M0>&O &O#!<LG :RK:J8T5"ZNKZ#UM#B#U2HF)P&)L,.C1*E=O6UJ@IBCJ!N:
MRSUFPZV:/16A&;U^%O>"9F=V688A$XK'$D.C$7CL<B*!*>A0Q9A96UGCB-$J
M,.-4HTC(WID[8G2J#5!@C"P%: ,1@M[UO8M^)&FP>BJ1K%ODC16U.577K5,A
MG&2]L@]>Q&)M\J,4E'$*!R1$PM"!,^#/)4F 'M4$W8PF"UOQT+?B6YG=G6^L
MZW:5<07M=?0AM75\RJHW 5C?%&%&KA$=7)TR-:P1!0G0%G1IE6)$9)1J5%LD
M@PLH 1!V$(=:)<NE*Z@J:=OK;*)Q5]=S*3,[*_1IHD4KA,:D3ZU1R4H5#9)V
M!M=W=L6."%ED;:K-3KTI1@2%A!HRS0C"+>MBY9,NO( 2K"O*@T.*7 AQ=> 6
MEQEE K! "C-G%08*@*+1P8<6=O8PMFM_!:%OQT7XX+8NMZ@J6FVM<QU#5U=5
M4RNC@-V<V>MX3&H.UN+J8 )1CFN;XPV-:16X&% T$1Q@!&;#K6M[\-869F=V
M.1411[9,U]C-M-52WV$ZO09(Z3M%7<023-RD04"UK"_KY00SEO:QZ"V.2A-I
M48>(_1!YA?F\@Q:V+G;HSK!6%:110QK(M7D&C2N,,2^+QI4P1)@9U$>C+HX%
M.SG'6,]N;TQK2Q.+J0!2>D3[+3G* !,&#8]:WA+86-492<+D<NF$.IZK(G+K
M +4%3R4QJOHDQ2.;%*SOB%14N>VMH2N<D+4G_AF!6&G:&/Y=^._EPMS+!)^8
M^;$<)55HDY[H]+7"Z3 FBVOT]3P(B$K)B4(@1<L510I@"Q*),6)*5L*\9&U6
MMEA\!_@Z\!<W=ZMJ1T]4C=83A;C?5M<H;7=T 6IULY'"(REL)S:PEEDA;7":
M$-@)(M0!**"'1)BD1>@AUKP\-:P7-5T;3&XO&H:S)(Y$(ZQ12/(!JQH6*-M*
M!C9D0UZQ0XKAI&MK3I4*<:UP5FGF[ #6S#C1C%XB%O>R,"WU=6;2",EM5=01
ML+A3H\OD-+;XC'T0(D]2/3AJ0O$9 F;RPL+H_:=E7QJA+Z1JKXDWU1"]0?B+
M8AEHVDXTZ3E[CE/5:P/5GE*B+*=V6OHDU.EAD+0F@6$SE>A:"%<L*5@/'HT*
M\:C1FABT+Q\=X6Y9$VI:J4)SDA]95\<D404BKU"4V&1PQ.?6:;8]IJ[.)&V[
M+-@J?9@O(T"UMO!YM^!6O'>$N7\,J2J35!JLVLJ],5'ND1>SU)D+C8U!SS $
MQ:.!NYIPFW9ACI"490"FA1O>S6TL.@IQ%AUK6"Y<+[3=0RAEE\:DU55O(H[8
M+H!\GK ^P:,.[+-WHLA$F+>)>U.#6H0R5T F;4Q>E"TLXW0$Y8?-X #K1;E@
MGOG/GN306/5=(Z(IJ05G$C2SXI73W5\(=8+&3RA'#*.CT17L9\?932QJ#-A$
MF3E;UL8MZ_QM^(N=[U95MI&EV:=%VBT5#5[59A+&DC!-B-L BB&=%1I @):D
M,>+ER5I*D &-$UIBTQ232C2<M.6$L(- #K6A<[=&=D-<5Y+E2]=*X'#).M=8
MLO@SHKD,78WI4Y0EU5$KG2'KU#DA4FK(LY+4Y9RAO,V)(<: (QE[$'6]$N6'
M9J7IV.SISM&/U-6C%9CTVIF9XL5F@D6;)T[-"-,E1(VISER)J(D"]M2HT)!1
M9!J@90"B0!"'00!UHMSMT:XY<S\WO,=D,0=^?J1=8E+I:9/Y9%W*J8(NCLGG
M9I0"#9K(614PFMCU+3"2P@$Y*2C5FPAUK9GAK!<]V3D% 41+2XB3*J4J23%5
M^V'LL#*D%;PYY+A+.I0!:U+3$0.+,I#&VQ0V!TF&0BT24,C6B]AV#Y,%RW%Q
M@L(>(ZWQ!VAT5=(DTB8Q-47<8\T+8ZV"C"A&KC0F]D4HS6Q$*/*V].:AV64'
MX0P@L17DV .]$MT/Q85KL/D_%Y!O)]./QG>3Z),'E_&5ZOK_ (PO+\W^'TX]
M;\/YV_\ P_S?+ZOC@MG%\6C+J^,$G=(XQ.4DB@74,7D*]H;UCY&POJ4M$^!8
M'90G,7LX7E$2 E7I.87\04#0#/,'6M8 F+1E/)%LR(CC$1+W)I1,#C*B6AO+
MDB]B;5*I:W,JU\ G"YJFEO6+CSB$QAHB2C3AB"'0ABWL*MW9P[0%N\]=(\[L
M<*C%*,74D&E<)LZ64W"H3#I:X;EK8L:ULE4*DL?$A>I&E+7F#*/<25?X8M[%
MH6M[ULU&4Q,3V2U5_/E.5##UD,A%;P-E;W]I;6R=*&R%19G4V0<@90,1KO/]
M-#0A(E;JY(=#"H-6 -V9HT8=_@BWK"3,RZGYL/-?XO1U'^;S1OXJ3'D,B,K'
M\4T"_%Z.0!'Z@7T<+^8/HV)Y"/\ "TJVF]?6_E\V"YN[U9A_H*BI6HCRN4TK
M4LD5Q&.+(=%%3_7$.>%$8B+BC$W.$6CQSBS*3&6.+F\6R#D*;928TG>P"!L/
MR8+EO++$HI&UCVXQV,QYA<),K1KY(N965M:UD@7-[:E9D"U[4H4Q![JK0LZ$
MA(28>(P928D!0=Z  (=$:39E'5/;\>L&-6#!V5[16G6C[3D]<2"SF24R"KY*
MG7IGJ$'3-@.:Y<C8%A;HH%Z*=:3HLTX1A>PF;\V%B9C9G":OKDJNVRHQPB+K
M:O9XVRP]O@+JRH'B)DQ>.)$2%B8ALCJ2L0J6YK2MQ "2S0#T'T0[_9UK>$N;
MOJR4O@T)L&-+X7/8?%IO#G4DM,Z1.7Q]IDL:<DY0P&%$+V)Y2+6M826,L.PA
M,*$'6PZWK7R8+E@6^G*B:8:T5RU577#97K O;W1A@C?!XPCAK(YM#B6\-3BT
M1=,UELC:O;'8D"I.<20 PE2'1@-A'K0L%SOU;,V1&*,KY(I,SQB/-,DF VLR
M6R%L96U ^2DQD2";V4<B=DJ8I>]C:$ ]D)=J3#=IR=[ 7Y0[\,#8<#1[-_FV
ML'_8>6?P"OPL;OE5]LW_ *43H/\ X1O<M_@R^,CKG_M'G"U_]H^_FA]NC_FJ
M<H?X9GE3\6\^3Z,\.1@?/U[F_.UV]$>X_P +Q.HU[!"D3QRCWI"YA:M@T,Y7
MS6D49IHDI=I5,[I']26%QM-+I"A$=\S"<G/T=F)C=[2*R]&%Y'7"8C"9GO"J
MR3E?L?G.6];49RA:_5+^W>W[[:?.33PW"UK^^M536OT*JJV^(B^R-U8#4Y4$
ML*5(_ADZDB.:-,:$[PH0&*TXQIT0RJMQ,1,Q&LZJLVC>?0,"YM[1F/*-Y^X&
MLIF+>V6P2VVK*Z8<+X9IK6_N!_C;@B%,V53)KN9X_)V*;+(2K?-RMHC9GT31
M" CT4$D0P@'%B(F8N(N_DD-TLOLC3!V>?QK8'N(3GF)'".#C[5G%IL]T.G1,
M)GSU;ZQ/W*9RXFMB.D3O4O:*']-8[((TC.:V9Q&,3*268!. -*QTY5>O_BW:
ML*9WTJI7J];2/3/6\9XAAO3W-;WRY(K\;^W%-C=%)T=239YZ3YL;;;A\74=E
MPFDY'-4+7IKE2@H0"'PDYN3J1IS_ $]PTN+B.5>'_I@.RNG>NWN$ULZ5G3W;
MW,EUUIQSR3:=7Q9WLKM6U95+Y(^2;YWLR+CBU>L)U+3Y\K)A+&WSYYMA0M>7
M-,>23\W)SPZ$8,<<;UF)BY[/;SVU8Y(XC:_NSN<IC,ECS=(?<AL"51U4]1UY
M;B9+&AT+0R8+_&MJT)6Y$RG*T"@DM2BT>28<086$6Q@$'5<\]L?)YI<O=B4/
M/^U;_P#</NJ#V9RA6_,7)]N55S]3\@Y:NVOW)+SE W=MM6W[UMV:G5JT5>ED
MLX71M(FA\)2NZE8D1%B#Z8UZK8=1O+&8QC&-9F5[/>B32#H/VK'=95$;G#DY
MV5.N-)9&&E' W9ZFK0V//15,R,MV=H!I M< *8LU';6N2-41Z:8"8T*KRE@,
MWJL_CTSU\5<^D*@L'E7K?VX>C.K'*8]<<[4>V=9L,^M"%<UMPRJ5M^WBH.=4
MUM2:AZ&C#T$IK01QB<H[J1H&I4J0'J0G*!%>L$>RQ,3C,1I+SUN"D[5N</0]
MU\]5-8]/4#T_[RWMO3'G-/)*'E.ADJZ_9R8E=_6SEST_((V]-E;RZ:"2N!XG
MI.R@>"&P9ZH9(#M&[C43$5$ZS&,_^GLW[+->R2IH9VU7MKQ1Y9>BF_N^ZWV\
MIAJ'K8+6USN4B2QHVO[CI:+EM3=&(]74OK1$U@TWMIJ[X-U2K J5)IXMBRL?
MDFZK:GCIR#P!T,P^W8A[>D,SDD.M?F?B_P!RR-\J4E6M#OU57U'9C;SI;2;Y
M[L>Q/GYPL>R)&2M:BET3;T+0R@2&K$QY03S0A,-C<Y1SXUI,PFZPV>VJ>_-2
M:NI[]]S$/-%A\,O]S/=G5')^@7VTGOW')K]"EAT'GB^EF-;.H6Q1Z'AV."P]
M0G11+3MI44J)4':,"*I%3=5=_)6&R+UZL,>8E"^V[J[TK2XDWLJ5I9Z6O^7U
M5S(WH[MUPM>WF.KGBQ8K0K2Z@9;+E#>A:R%B1>4CC:YX+.2..]Z3IR0QJH_Z
MU7+Y)%O>RN_DK79H^C)AW?!>S$/&G&SC[=D(YI9K;#4UA=/N=5H5E]I+'9ZR
MCJVIY7-PWX(;?*FV?F::6Z+BV-&6 C>C]$B,>E<;F_)8G\=75%5][=*+GIKZ
M3[.>W/GZY)Z97],2OJ6I6;DJ45[S;'EX*#;X9((X7RA:37:EEEJ2(3,&0USE
M(7I7ZOIJO2V =2HG&*J-?#_VH([/_3UL<^=F05,AZ-L6H9- O;#MR QR1INS
M;80M-MD]QQ=!=#?")GU:Q_C2D+NP1QK3CE0&XA*PEG(1*B$:4!9^]1JHN-KU
M[=GTM^Z1:L?KJC&]I47C.>=)G,UC^CA-HP;CY][(7%&-[ H"]1 <(;H!/&EC
M42]*YE$$*%ND0E(BQ$DF[WY]:KEA%SM?QI7+E539W,7L,0-6BY9M>-VI6O'\
MH4$<T0"02EAN4V0'$R(S1S"\K4C_ #2&3:2Z</I%LDM(K<V)0K$G3IC#TQ9&
MRY5/Y-]+>/<;G?;<@K[H&"UA:/7[;7DAZ8]I=75\[ACAV4].;!%;AM*5Q/JD
MVL;%ZF:E-TOD,0M[(F%(!KP?,*1248H E3)3MA'&ZQWFKJ>R:+07]25$=;5,
M2:RN[2^(*O\ =XA$9LJRV&1] S6^V+CN7<J,$YT@CUOL)3U>[]2P.CW0I([.
MC*L6+6X@P:4*@ ?4#HD5.NG*OF])_8MCKZPT'UR>[MUT)F^3^XMU3+86\]!1
MB412V)K 7LZ$FP^<2Q%,6=C?USC)&@H!QBU0G <J-T,1W[?ZNM5G\F\>3QWJ
M[A;L5^]B)W2('&<6"3(SD#\NX@%0\0KJR%%:P#M]18%M0)+,_FUFM.P7*S*W
MC:\29H>C/27E+0)R CT,C0HW.4>Y_/P6YN.00;M#K"D[;XFHFU&""\Y<+]SQ
M'HZPW7GBRJ ;#X_:%( BU+<K)FF=0J$N,\F$?L5)IX"S-:5>D90H]B 8$9N@
M[)'TQ,93O,?^T9>S50MMTOT[Q&^])162OBF8>T+!8_S;-V:EG*I&JF=()!$W
MNY><KX(0HUILDM-&D(9E[2]2%8A./3)UQ13<4I$;O%'Y)BIB/_I)UT^W;9G=
MGN4>YG7C_+4U0\W2M/[;S].9"Y4(=+)U98:QB[M+$S30-QO[^S1VMG1G=V':
M-[<43>^K2 K"P:TF'KP,$91CA$[SJTB?M/;B:LNV;X#:_=HVY/[KDPH281V&
M/EC+)!5'MIMUVQ=^L.<<T5Z0VJ7U=(A-I_I)Y,S)W%U0Q;2DEF$262/S".-Q
M&FWS0E9EXWK%($VEQ.[N]&3A*3>[US#6O/EF.;C>A75$WYPD?/=@.'344BBJ
M6-(NA; J9NL) /<?/<T:YX%I,>)O$>-(E$ M1>T<N/PMLD4L7I,4-KP-DV1W
MXD]JD_W"^I&D-SMH>CB.J%O,394$;4<UES:6,['OJU'SZZWT;(4A;SLLIX4)
M"$)2Y0!*(O8A4=*YTU"7VEW!'J:X]L2=S7K^TDC';W2+34''[BIZWIGI7JWG
MYVOZ.,7-%LSBY*)B@?FJZ8%7 C#M1^RA(4#PQ&_'.)>CQ'&"%8W,:=-5D%M]
M=.OWNFUZNA\<ZAK9J1]^2.B;EK>12'K6PX:[<YGUC-6=@L:2,#NSD\:5Y5D[
MD#0@=HMN-?&/9*@7KGN8]B5%A=4J.'3;]>*WG <=ZTA'L,5E%N=H,!GZ[34U
M9K-6,4M@"FOOH]-7ZW9VE;WN0)I0A3FMQT=:W03NF(6$!*6#3DEB_:SO-E9R
MKW-=D!>RO7=A\AWO[A-<V1S1-*&KLZ:<CM2"52"7G6PNEMK.]3PJ&."\V3QF
M()2;,>+0EK^HDLBDZ/\ ^&M+HX*$RT16R3# 1?R:Q$Q-[OICRN1@,!@,!@,!
M@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!
M@,!@:/9O\VU@_P"P\L_@%?A8W?*K[9O_ $HG0?\ PC>Y;_!E\9'7/_:/.%K_
M .T??S0^W1_S5.4/\,SRI^+>?)]&>'(P& P(FO2CJOZ4J2=47=,8!,ZLLIF^
M8)I%S'1Y90/33\6E7?""=(\X-+TBU\4C+%YTZDHS\'P\WAO>MEB9B;C=*29,
M2C3)TB<'IITI!28@OS"%Z9)!82B@>8>Q#%Y0!UKQWO>]_P!W".? 8# PDCC4
M<F+&YQB71]DE4:>DPD3Q'I&U('QC=D8Q!$)(YM+F0J0+TPA UO99I8P[WK7R
M?)@9D(0@"$  A   =!"$.M!"$(=> 0A#KPT$(=:\-:U^Q@?K 8# 8# B!)0U
M4H;X>^F$L5 5=LBJQBI9YFOSJ]C,65I&I0\S-DC6V0;D*.D@1220*U/Q):0"
MP>S?(,T180A"6YJNB7\(8# 8# 8# 8# 8# 8# B&UZ'JF\%E4K[/BH).KI&V
M(Y>%8FC=7MLW&;0B3<^-,?DX ,SDW@<QMZ"1K"_A5FE",SUO$90A!!L)8F8V
MZI>PA@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@
M,!@,!@,!@,!@,!@,!@,!@,!@,#1[-_FVL'_8>6?P"OPL;OE5]LW_ *43H/\
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MX@1!/G4(UQ2<L8SI?=8(OKR@!,$FD!TP=D 8G)HI#G2.N]?V,S3Y5)9[I..
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M#$>>BV$ SP*=;*$7CXZ720W/N2(D+7R0L5?3.4T5"Y97D'G]\M:Z*D1F-/\
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M )JG*'^&9Y4_%O/D^C/#D8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8#
M8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8#
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M.5_R&0+][!_N^"Y/S,.5_P AD"_>P?[O@N3\S#E?\AD"_>P?[O@N3\S#E?\
M(9 OWL'^[X+D_,PY7_(9 OWL'^[X+D_,PY7_ "&0+][!_N^"Y/S,.5_R&0+]
M[!_N^"Y/S,.5_P AD"_>P?[O@N3\S#E?\AD"_>P?[O@N3\S#E?\ (9 OWL'^
M[X+D_,PY7_(9 OWL'^[X+D_,PY7_ "&0+][!_N^"Y/S,.5_R&0+][!_N^"Y1
MC)Z$IVI+DY4?ZSK]AA+PZ7/+&!S7Q\M0A.<611S=?3F<U+] 4;+6(!N32E4>
MD8$0-'IRQZUH0 [T6)N)\EZL,F P& P-'LW^;:P?]AY9_ *_"QN^57VS?^E$
MZ#_X1O<M_@R^,CKG_M'G"U_]H^_FA]NC_FJ<H?X9GE3\6\^3Z,\.1@,!@,!@
M,"L79_\ ^:S=_P#L.M_]Y287'=9W"& P& P& P& P& P& P& P& P& P& P&
M P& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P&
M P& P& P& P& P&!7.[/YS>1?_R_2;_[8.B\DM1M/E_,+&963 8# 8&CV;_-
MM8/^P\L_@%?A8W?*K[9O_2B=!_\ "-[EO\&7QD=<_P#:/.%K_P"T??S0^W1_
MS5.4/\,SRI^+>?)]&>'(P& P& P&!6+L_P#_ #6;O_V'6_\ O*3"X[JZ^ZG=
M5B5;R_J"TFEL%=>W3-A0_G2K2JF*2FV8T?3<]4Y6=.84-:YLB)OD5=TO'Y&\
MMZQ0M1IT[FD2^<\O8@[PN$1,Z[0\0)O[D'2T1X]#S-,)B?2EC5U5/N#TS;]M
M]21&3O=L3J:T+ HLY\OUNV.,'L5F2-%^]&TE:K;)0O*9T?E!SJT+/F],O-":
M'4=8PB[\MOFS6^RKYF%G<*T ]65'8:VU7TS[;\>;*BVTS\'0-PP*1\:H;4E7
M0,IGY<Y+;7VIW2PI$IC2Y >Q'(AKFH6E+@%PWI,.IQB+\I_=)1_NJ^X,SUAQ
MK,'V,\[IY#T_0QO1[?MXCZ*K*Z>'4Z3US&V?EM%,[BZ+AH4$W%'GEP?5CH@
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MH&P[ I'K8/ 2@.P!WH>_PM>&OE^3 YC"RSBQE&@ :48$0#"S A&6, M> @#
M+6PB"+6_#>M_)O _H0  $(  "   A"  0Z"$ 0Z\H0A#K6M!"'6O#6M?L:P/
MR6445K>BBBR]"&,P6BP!!K9A@MC,'O0=:UL8QBWO>_V=[WX[P*XWSR72'3*F
M-"NADE<K9XT80/<*36A9T8K>6$I'QIDJ)!9-;127LD%LYL1/[&E5%)G]O<2
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M_P"7Z3?_ &P=%Y):C:?+^86,RLF P& P-'LW^;:P?]AY9_ *_"QN^57VS?\
MI1.@_P#A&]RW^#+XR.N?^T><+7_VC[^:'VZ/^:IRA_AF>5/Q;SY/HSPY& P&
M P& P*Q=G_\ YK-W_P"PZW_WE)A<=UG<(8# 8# 8# 8# 8# 8# 8# 8# 8#
M8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8#
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M?)]&>'(P& P& P&!6+L__P#-9N__ &'6_P#O*3"X[K.X0P& P& P& P& P&
MP& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P&
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M4NRQ2I)T:0J3>NJ >.3*R_C[Z=7";:4HM21.R%*_H'N.Q5<WG+2&%.EE=+S
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M-#[='_-4Y0_PS/*GXMY\GT9X<C 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8#
M8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8#
M8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# T>S?YMK!_V'EG\ K\+&[Y5?;-_Z
M43H/_A&]RW^#+XR.N?\ M'G"U_\ :/OYH?;H_P":IRA_AF>5/Q;SY/HSPY&
MP& P& P& P& P& P& P& P& P& P& P& P& P.%0H(2)SU2HXM.F3$FJ%"@X
M82R2""0",..-,%O00%E%AV(6][\-:UXX'E3RS[@%]=>FLEW5IRE&(QP0_229
MM[+T7:70:")69)()#3I V'W2QT@EKEY;$E=N3ZP#+2@=)4WN1J ?QHB"R]:
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M=JKYKD^WCR1;'*+%T\INFPJ_L6?=+=:V9U$[KZSBCW#8HQ'V7'H.WJHN@9Y
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M@/RB$O3$DD!=4]S2NKW^PYF P& P& P& P& P& P& P& P& P& P& P& P&
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B)S".+'0K<?"5IOW&SHZ8)$)+Y/2$G%L&]>&\KG<W?5__V0$!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
